```
=> d his

     (FILE 'HOME' ENTERED AT 09:22:58 ON 05 OCT 2006)

     FILE 'HCAPLUS' ENTERED AT 09:23:29 ON 05 OCT 2006
                E US20040235780/PN
L1              1 S US20040235780/PN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 09:24:00 ON 05 OCT 2006
L2              8 S E1-8
                E 220750-46-9/RN
L3              1 S 220750-46-9/RN
L4              1 S 92562-88-4/RN
L5              1 S 25526-93-6/RN
                E THYAMINE/CN
                E THYMINE/CN
L6              1 S THYMINE/CN
                E CYTOSINE/CN
L7              1 S CYTOSINE/CN
                E ADENINE/CN
L8              1 S ADENINE/CN
                E GUANINE/CN
L9              1 S GUANINE/CN
                E INOSINE/CN
L10             1 S INOSINE/CN
                E URACIL/CN
L11             1 S URACIL/CN
                E 5-ETHYLURIACIL/CN
                E 5-ETHYLURACIL/CN
L12             1 S 5-ETHYLURACIL/CN
                E 2,6-DIAMINOPURINE/CN
L13             1 S 2,6-DIAMINOPURINE/CN

     FILE 'LREGISTRY' ENTERED AT 09:52:02 ON 05 OCT 2006

     FILE 'REGISTRY' ENTERED AT 09:53:10 ON 05 OCT 2006
                E 16.138.1/RID

     FILE 'LREGISTRY' ENTERED AT 09:54:28 ON 05 OCT 2006
L14             STR 92562-88-4

     FILE 'REGISTRY' ENTERED AT 09:55:22 ON 05 OCT 2006
L15            50 S L14

     FILE 'LREGISTRY' ENTERED AT 09:55:51 ON 05 OCT 2006
L16             STR L14

     FILE 'REGISTRY' ENTERED AT 09:56:48 ON 05 OCT 2006
L17            50 S L16
L18          1733 S L16 FUL
                SAV L18 KHA250/A

     FILE 'LREGISTRY' ENTERED AT 10:01:06 ON 05 OCT 2006
L19             STR 65-71-4
L20             STR L19

     FILE 'REGISTRY' ENTERED AT 10:30:06 ON 05 OCT 2006
L21            50 S L20 SSS SAM SUB=L18
L22             0 S L19 SSS SAM SUB=L18
L23          1142 S L20 SSS FUL SUB=L18
                SAV L23 KHA250A/A
L24             2 S L19 SSS FUL SUB=L18
                SAV L24 KHA250B/A
L25             4 S L2 AND L23
L26             4 S L2 NOT L25
```

```
L27          54 S L23 AND ?CYTIDIN?/CNS
L28          36 S L27 AND 1/F NOT (1-5/CL OR 1-5/BR OR 2-5/F)
L29           9 S L28 AND 3/N AND 3/O
L30           2 S L29 AND  C9H12FN3O3/MF
L31           6 S L23 AND ?FLUOROADENOSIN?/CNS
L32           1 S L31 AND C10 H12 F N5 O2/MF

     FILE 'HCAPLUS' ENTERED AT 10:49:37 ON 05 OCT 2006
L33           4 S L3
L34          49 S L4
L35         292 S L5
L36          39 S L30
L37          35 S L32
L38         338 S L33-L37
L39         315 S L25
L40           1 S L24
L41         697 S L23
L42         835 S L18
L43         697 S L38-L41

     FILE 'REGISTRY' ENTERED AT 10:56:23 ON 05 OCT 2006
L44           1 S  129618-40-2/RN

     FILE 'HCAPLUS' ENTERED AT 10:56:51 ON 05 OCT 2006
L45        1501 S L44
L46          33 S L45 AND L42
L47          33 S L45 AND L43
L48          30 S L45 AND L38
L49          33 S L46-L48
L50             QUE PHARMAC?/SC,SX
L51          33 S L49 AND L50
L52       57456 S ANTIVIRAL OR ANTI(N)VIRAL
L53          24 S L51 AND L52
L54           9 S L51 NOT L53
                E HIV/CT
                E HUMAN IMMUNODEFICIENCY VIRUS/CT
L55       35862 S HUMAN IMMUNODEFICIENCY VIRUS?/CT
L56          20 S L55 AND L51
L57             QUE HUMAN()IMMUNODEFICIEN?()VIRUS? OR HIV OR AIDS
L58          32 S L51 AND L57
L59          33 S L51 OR L53 OR L56 OR L58
L60          24 S L59 AND 1907-2003/PY,PRY

     FILE 'BIOSIS' ENTERED AT 11:15:27 ON 05 OCT 2006
L61         145 S L43
L62         133 S L38
L63         147 S L42
L64         147 S L61-L63
L65        1381 S L44
L66           2 S L65 AND L64
L67           2 S L66 AND (L52 OR L57)

     FILE 'EMBASE' ENTERED AT 11:20:37 ON 05 OCT 2006
L68         274 S L42
L69        5710 S L44
L70          30 S L68 AND L69
L71          30 S L70 AND (L52 OR L57)
L72          17 S L71 AND 1907-2003/PY

     FILE 'MEDLINE' ENTERED AT 11:22:53 ON 05 OCT 2006

     FILE 'EMBASE' ENTERED AT 11:23:47 ON 05 OCT 2006

     FILE 'MEDLINE' ENTERED AT 11:25:37 ON 05 OCT 2006
L73         125 S L38
L74         155 S L42
L75         155 S L73-L74
```

```
L76         1183 S L44
L77            1 S L75 AND L76

     FILE 'HCAPLUS, BIOSIS, EMBASE
     OCT 2006

     FILE 'HCAPLUS' ENTERED AT 11

     FILE 'HCAPLUS, BIOSIS, EMBASE
     OCT 2006
L78           43 DUP REM L60 L67 L

     FILE 'BIOSIS' ENTERED AT 11:
L79            2 S L78

     FILE 'EMBASE' ENTERED AT 11:
L80           16 S L78

     FILE 'MEDLINE' ENTERED AT 11
L81            1 S L78

     FILE 'HCAPLUS' ENTERED AT 11
L82           24 S L78

=> d que stat l82
L2             8 SEA FILE=REGISTRY
                 144114-21-6/BI OR
                 52350-85-3/BI OR
                 92562-88-4/BI)
L3             1 SEA FILE=REGISTRY
L4             1 SEA FILE=REGISTRY
L5             1 SEA FILE=REGISTRY
L16              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L18         1733 SEA FILE=REGISTRY
L19              STR
```

E, MEDLINE' ENTERED AT 11:27:48 ON 05

:28:47 ON 05 OCT 2006

E, MEDLINE' ENTERED AT 11:29:25 ON 05

72 L77 (1 DUPLICATE REMOVED)

29:55 ON 05 OCT 2006

30:06 ON 05 OCT 2006

:30:16 ON 05 OCT 2006

:30:24 ON 05 OCT 2006

ABB=ON PLU=ON (129618-40-2/BI OR
220750-46-9/BI OR 25526-93-6/BI OR
770723-01-8/BI OR 9068-38-6/BI OR

ABB=ON PLU=ON 220750-46-9/RN
ABB=ON PLU=ON 92562-88-4/RN
ABB=ON PLU=ON 25526-93-6/RN



Page 1-A

7

Page 1-B



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE
L20 STR



Page 1-A



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE

L23	1142	SEA FILE=REGISTRY SUB=L18 SSS FUL L20
L24	2	SEA FILE=REGISTRY SUB=L18 SSS FUL L19
L25	4	SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND L23
L27	54	SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?CYTIDIN?/CNS
L28	36	SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND 1/F NOT (1-5/CL OR 1-5/BR OR 2-5/F)
L29	9	SEA FILE=REGISTRY ABB=ON PLU=ON L28 AND 3/N AND 3/O
L30	2	SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND C9H12FN3O3/MF
L31	6	SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?FLUOROADENOSIN?/CNS
L32	1	SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND C10 H12 F N5 O2/MF
L33	4	SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L34	49	SEA FILE=HCAPLUS ABB=ON PLU=ON L4
L35	292	SEA FILE=HCAPLUS ABB=ON PLU=ON L5
L36	39	SEA FILE=HCAPLUS ABB=ON PLU=ON L30
L37	35	SEA FILE=HCAPLUS ABB=ON PLU=ON L32
L38	338	SEA FILE=HCAPLUS ABB=ON PLU=ON (L33 OR L34 OR L35 OR L36 OR L37)
L39	315	SEA FILE=HCAPLUS ABB=ON PLU=ON L25
L40	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L24

```
L41          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23
L42          835 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18
L43          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L44            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  129618-40-2/RN
L45         1501 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L44
L46           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L42
L47           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L43
L48           30 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L38
L49           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L46 OR L47 OR L48)
L50              QUE  ABB=ON  PLU=ON  PHARMAC?/SC,SX
L51           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L49 AND L50
L52        57456 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ANTIVIRAL OR ANTI(A)VI
                 RAL
L53           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L52
L55        35862 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HUMAN IMMUNODEFICIENCY
                  VIRUS?/CT
L56           20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 AND L51
L57              QUE  ABB=ON  PLU=ON  HUMAN(W)IMMUNODEFICIEN?(W)VIRUS? O
                 R HIV OR AIDS
L58           32 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L57
L59           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 OR L53 OR L56 OR
                 L58
L60           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L59 AND 1907-2003/PY,P
                 RY
L61          145 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L62          133 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L63          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  L18
L64          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L61 OR L62 OR L63)
L65         1381 SEA FILE=BIOSIS ABB=ON  PLU=ON  L44
L66            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L65 AND L64
L67            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L66 AND (L52 OR L57)
L68          274 SEA FILE=EMBASE ABB=ON  PLU=ON  L18
L69         5710 SEA FILE=EMBASE ABB=ON  PLU=ON  L44
L70           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L68 AND L69
L71           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L70 AND (L52 OR L57)
L72           17 SEA FILE=EMBASE ABB=ON  PLU=ON  L71 AND 1907-2003/PY
L73          125 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L74          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  L18
L75          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L73 OR L74)
L76         1183 SEA FILE=MEDLINE ABB=ON  PLU=ON  L44
L77            1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L75 AND L76
L78           43 DUP REM L60 L67 L72 L77 (1 DUPLICATE REMOVED)
L82           24 SEA FILE=HCAPLUS L78


=> d 182 1-24 ibib abs hitstr hitind

L82  ANSWER 1 OF 24  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:641882  HCAPLUS  Full-text
DOCUMENT NUMBER:         143:153711
TITLE:                   Preparation of amino acid hydrazide
                         derivatives as HIV protease
                         inhibitors
INVENTOR(S):             Randolph, John T.; Chen, Hui-ju; Degoey, David
                         A.; Flentge, Charles A.; Flosi, William J.;
                         Grampovnik, David J.; Huang, Peggy P.;
                         Hutchinson, Douglas K.; Kempf, Dale J.; Klein,
                         Larry L.; Yeung, Ming C.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 155 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005159469	A1	20050721	US 2004-10177 <--	2004 1210
PRIORITY APPLN. INFO.:			US 2003-528679P P <--	2003 1211

OTHER SOURCE(S): MARPAT 143:153711
GI



I

AB The invention relates to amino acid hydrazide derivs. I [X-Y is CH2(CH2)1-2, CH:CH or C(:Z')(CH2)1-2; Z, Z' are O, S or NH; R1, R2, R5 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, etc.; R3 is H, alkyl, aryl, etc.; R4 is an amino acid or acyl residue of defined structure], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having **HIV** protease inhibitory activity. Thus, hydrazide I [X-Y is CH2CH2; Z is O; R1 is CMeEt; R2 is PhCH2; R3 is 4-(2-pyridyl)benzyl; R4 is N-carbomethoxy-tert- leucine (all-S stereo)] was prepared by a multistep sequence involving peptide coupling in the final step. Compds. of the invention showed EC50 values 1-100 nM against wild-type **HIV**.

IT **25526-93-6 92562-88-4 129618-40-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-4178
ICS A61K031-4166; C07D043-02
INCL 514389000; 548316400; 548317100; 548311100
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): **1**, 7, **63**
ST amino acid hydrazide peptide isostere prepn inhibitor **HIV** protease
IT Amino acids, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(hydrazides; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT **Antiviral** agents
Human
Human immunodeficiency virus
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT Hydrazides
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(pseudopeptides; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT 134379-77-4, DOC 817
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Reverset, DPC 817; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)
IT 857901-33-8P 857901-34-9P 857901-35-0P 857901-36-1P

857901-37-2P 857901-38-3P 857901-39-4P 857901-40-7P
857901-41-8P 857901-42-9P 857901-43-0P 857901-44-1P
857901-45-2P 857901-46-3P 857901-47-4P 857901-48-5P
857901-49-6P 857901-50-9P 857901-51-0P 857901-52-1P
857901-53-2P 857901-54-3P 857901-55-4P 857901-56-5P
857901-58-7P 857901-59-8P 857901-60-1P 857901-61-2P
857901-62-3P 857901-63-4P 857901-64-5P 857901-65-6P
857901-66-7P 857901-67-8P 857901-68-9P 857901-69-0P
857901-70-3P 857901-71-4P 857901-72-5P 857901-73-6P
857901-74-7P 857901-75-8P 857901-76-9P 857901-77-0P
857901-79-2P 857901-81-6P 857901-82-7P 857901-83-8P
857901-84-9P 857901-85-0P 857901-86-1P 857901-87-2P
857901-88-3P 857901-89-4P 857901-90-7P 857901-91-8P
857901-92-9P 857901-93-0P 857901-94-1P 857901-95-2P
857901-96-3P 857901-97-4P 857901-98-5P 857901-99-6P
857902-00-2P 857902-01-3P 857902-02-4P 857902-03-5P
857902-04-6P 857902-05-7P 857902-06-8P 857902-07-9P
857902-08-0P 857902-09-1P 857902-10-4P 857902-11-5P
857902-12-6P 857902-13-7P 857902-14-8P 857902-15-9P
857902-16-0P 857902-18-2P 857902-20-6P 857902-22-8P
857902-24-0P 857902-26-2P 857902-28-4P 857902-30-8P
857902-32-0P 857902-34-2P 857902-36-4P 857902-37-5P
857902-38-6P 857902-40-0P 857902-42-2P 857902-44-4P
857902-46-6P 857902-48-8P 857902-50-2P 857902-52-4P
857902-54-6P 857902-56-8P 857902-58-0P 857902-60-4P
857902-62-6P 857902-63-7P 857902-64-8P 857902-65-9P
857902-66-0P 857902-67-1P 857902-68-2P 857902-69-3P
857902-70-6P 857902-71-7P 857902-72-8P 857902-73-9P
857902-74-0P 857902-75-1P 857902-76-2P 857902-77-3P
857902-78-4P 857902-79-5P 857902-80-8P 857902-81-9P
857902-82-0P 857902-83-1P 857902-84-2P 857902-85-3P
857902-86-4P 857902-87-5P 857902-88-6P 857902-89-7P
857902-90-0P 857902-91-1P 857902-92-2P 857902-93-3P
857902-94-4P 857902-95-5P 857902-96-6P 857902-97-7P
857902-98-8P 857902-99-9P 857903-00-5P 857903-02-7P
857903-04-9P 857903-06-1P 857903-08-3P 857903-10-7P
857903-12-9P 857903-14-1P 857903-16-3P 857903-18-5P
857903-20-9P 857903-22-1P 857903-23-2P 857903-25-4P
857903-27-6P 857903-28-7P 857903-30-1P 857903-31-2P
857903-33-4P 857903-35-6P 857903-36-7P 857903-37-8P
857903-38-9P 857903-39-0P 857903-40-3P 857903-41-4P
857903-43-6P 857903-45-8P 857903-47-0P 857903-49-2P
857903-51-6P 857903-52-7P 857903-53-8P 857903-54-9P
857903-55-0P 857903-57-2P 857903-58-3P 857903-59-4P
857903-61-8P 857903-62-9P 857903-63-0P 857903-65-2P
857903-66-3P 857903-67-4P 857903-68-5P 857903-70-9P
857903-72-1P 857903-74-3P 857903-75-4P 857903-76-5P
857903-77-6P 857903-78-7P 857903-79-8P 857903-80-1P
857903-81-2P 857903-82-3P 857903-83-4P 857903-84-5P
857903-85-6P 857903-86-7P 857903-87-8P 857903-88-9P
857903-89-0P 857903-90-3P 857903-91-4P 857903-92-5P
857903-93-6P 857903-94-7P 857903-95-8P 857903-96-9P
857903-97-0P 857903-98-1P 857903-99-2P 857904-53-1P
857904-54-2P 857904-55-3P 857904-56-4P 857904-57-5P
857904-58-6P 857904-59-7P 857904-60-0P 857904-61-1P
857904-62-2P 857904-63-3P 857904-64-4P 857904-65-5P
857904-66-6P 857904-67-7P 857904-68-8P 857904-69-9P
857904-70-2P 857904-71-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 857904-72-4P 857904-73-5P 857904-74-6P 857904-75-7P
857904-76-8P 857904-77-9P 857904-78-0P 857904-79-1P
857904-80-4P 857904-81-5P 857904-82-6P 857904-83-7P
857904-84-8P 857904-85-9P 857904-86-0P 857904-87-1P

857904-88-2P 857904-89-3P 857904-90-6P 857904-91-7P
857904-92-8P 857904-93-9P 857904-94-0P 857904-95-1P
857904-96-2P 857904-97-3P 857904-98-4P 857904-99-5P
857905-00-1P 857905-01-2P 857905-02-3P 857905-03-4P
857905-04-5P 857905-05-6P 857905-06-7P 857905-07-8P
857905-08-9P 857905-09-0P 857905-10-3P 857905-11-4P
857905-12-5P 857905-13-6P 857905-14-7P 857905-15-8P
857905-16-9P 857905-17-0P 857905-18-1P 857905-19-2P
857905-20-5P 857905-21-6P 857905-22-7P 857905-23-8P
857905-24-9P 857905-25-0P 857905-26-1P 857905-27-2P
857905-28-3P 857905-29-4P 857905-30-7P 857905-31-8P
857905-32-9P 857905-33-0P 857905-34-1P 857905-35-2P
857905-36-3P 857905-37-4P 857905-38-5P 857905-39-6P
857905-40-9P 857905-41-0P 857905-42-1P 857905-43-2P
857905-44-3P 857905-45-4P 857905-46-5P 857905-47-6P
857905-48-7P 857905-49-8P 857905-50-1P 857905-51-2P
857905-52-3P 857905-53-4P 857905-54-5P 857905-55-6P
857905-56-7P 857905-57-8P 857905-58-9P 857905-59-0P
857905-60-3P 857905-62-5P 857905-65-8P 857905-66-9P
857905-67-0P 857905-68-1P 857905-69-2P 857905-70-5P
857905-71-6P 857905-72-7P 857905-73-8P 857905-75-0P
857905-77-2P 857905-79-4P 857905-80-7P 857905-81-8P
857905-82-9P 857905-83-0P 857905-84-1P 857905-85-2P
857905-86-3P 857905-87-4P 857905-88-5P 857905-89-6P
857905-90-9P 857905-91-0P 857905-92-1P 857905-93-2P
857905-94-3P 857905-95-4P 857905-96-5P 857905-97-6P
857905-98-7P 857905-99-8P 857906-00-4P 857906-01-5P
857906-02-6P 857906-03-7P 857906-04-8P 857906-05-9P
857906-06-0P 857906-07-1P 857906-08-2P 857906-09-3P
857906-10-6P 857906-11-7P 857906-12-8P 857906-13-9P
857906-14-0P 857906-15-1P 857906-16-2P 857906-17-3P
857906-18-4P 857906-19-5P 857906-20-8P 857906-21-9P
857906-22-0P 857906-23-1P 857906-24-2P 857906-25-3P
857906-26-4P 857906-27-5P 857906-28-6P 857906-29-7P
857906-30-0P 857906-31-1P 857906-32-2P 857906-33-3P
857906-34-4P 857906-35-5P 857906-36-6P 857906-37-7P
857906-38-8P 857906-39-9P 857906-40-2P 857906-41-3P
857906-42-4P 857906-43-5P 857906-44-6P 857906-45-7P
857906-46-8P 857906-47-9P 858036-89-2P 858036-90-5P
858036-91-6P 858036-92-7P 858036-93-8P 858036-94-9P
858036-95-0P 858036-96-1P 858036-97-2P 858036-98-3P
858036-99-4P 858037-00-0P 858037-01-1P 858037-02-2P
858037-03-3P 858037-04-4P 858037-05-5P 858037-06-6P
858037-07-7P 858037-08-8P 858037-09-9P 858037-10-2P
858037-11-3P 858037-12-4P 858037-13-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 66-99-9, 2-Naphthalenecarboxaldehyde 70-23-5 73-32-5, L-Isoleucine, reactions 78-84-2 97-96-1 98-03-3, 2-Thiophenecarboxaldehyde 98-79-3 104-87-0 104-88-1, reactions 105-07-7 106-23-0 108-10-1 108-94-1, Cyclohexanone, reactions 120-14-9 120-57-0, 1,3-Benzodioxole-5-carboxaldehyde 121-33-5 122-03-2 122-78-1, Benzeneacetaldehyde 122-85-0 123-08-0 123-11-5, reactions 302-01-2, Hydrazine, reactions 351-54-2 407-25-0 455-19-6 459-57-4 587-04-2 590-86-3 591-31-1 620-23-5 630-19-3 645-36-3 870-46-2 939-97-9 1122-72-1 1122-91-4 1452-77-3, 2-Pyridinecarboxamide 1489-69-6, Cyclopropanecarboxaldehyde 1571-08-0 1846-68-0, 2-Octynal 2043-61-0, Cyclohexanecarboxaldehyde 2196-13-6, 4-Pyridinecarbothioamide 2916-68-9 2987-16-8 3012-80-4 4021-50-5 4070-48-8 4595-59-9 4748-78-1 4766-51-2 5398-77-6 5470-96-2, 2-Quinolinecarboxaldehyde 5779-95-3 5973-71-7 6287-38-3 6654-36-0 10040-98-9 10111-08-7,

1H-Imidazole-2-carboxaldehyde 18962-05-5 20570-96-1
20859-02-3 23074-10-4 25714-71-0 29668-44-8 32723-67-4
36880-33-8 39238-07-8 39515-51-0 52480-43-0 54751-01-8
55745-70-5 56881-90-4 62373-80-2 63038-27-7 66605-57-0
69770-20-3 74124-79-1 77358-26-0 79124-75-7 82911-69-1
83902-00-5 87199-16-4 98737-29-2 127406-56-8 128018-44-0
132509-34-3 133047-46-8 854754-13-5 854754-25-9
854754-39-5 854754-69-1 854754-74-8 854755-33-2
854756-65-3 854757-66-7 857900-62-0 857900-63-1
857900-64-2 857900-65-3 857900-66-4 857900-69-7
857900-70-0 857900-71-1 857900-75-5 857900-77-7
857900-78-8 857900-79-9 857900-81-3 857900-83-5
857900-87-9 857900-88-0 857900-89-1 857900-90-4
857900-91-5 857900-92-6 857900-93-7 857900-94-8
857900-95-9 857900-96-0 857900-97-1 857900-98-2
857900-99-3 857901-00-9 857901-01-0 857901-03-2
857901-07-6 857901-10-1 857901-12-3 857901-14-5
857901-16-7 857901-19-0 857901-21-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 2913-97-5P 21278-85-3P 72155-45-4P 74761-39-0P 74761-42-5P
78269-85-9P 107202-43-7P 154876-20-7P 161772-80-1P
162537-11-3P 173838-60-3P 175277-28-8P 198084-12-7P
198904-77-7P 198904-85-7P 198904-86-8P 198905-12-3P
437713-06-9P 533885-37-9P 853893-93-3P 853894-11-8P
853894-13-0P 854739-73-4P 854739-74-5P 854745-36-1P
854745-37-2P 854745-38-3P 854745-39-4P 854745-40-7P
854745-41-8P 854745-42-9P 854745-43-0P 854745-44-1P
854754-44-2P 854754-55-5P 854757-53-2P 857900-54-0P
857900-55-1P 857900-56-2P 857900-57-3P 857900-58-4P
857900-59-5P 857900-61-9P 857900-68-6P 857900-72-2P
857900-74-4P 857900-86-8P 857901-25-8P 857901-30-5P
857901-31-6P 857901-32-7P 857904-00-8P 857904-01-9P
857904-02-0P 857904-03-1P 857904-04-2P 857904-05-3P
857904-06-4P 857904-07-5P 857904-08-6P 857904-09-7P
857904-10-0P 857904-11-1P 857904-14-4P 857904-15-5P
857904-16-6P 857904-17-7P 857904-18-8P 857904-19-9P
857904-20-2P 857904-21-3P 857904-22-4P 857904-23-5P
857904-24-6P 857904-25-7P 857904-26-8P 857904-27-9P
857904-28-0P 857904-29-1P 857904-33-7P 857904-34-8P
857904-35-9P 857904-36-0P 857904-37-1P 857904-38-2P
857904-39-3P 857904-40-6P 857904-42-8P 857904-43-9P
857904-44-0P 857904-45-1P 857904-46-2P 857904-47-3P
857904-48-4P 857904-49-5P 857904-50-8P 857904-51-9P
857904-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 3056-17-5 7481-89-2 **25526-93-6** 29321-75-3
30516-87-1 69655-05-6 **92562-88-4** 127779-20-8
129618-40-2 134678-17-4 136470-78-5 136817-59-9
142632-32-4 143491-54-7 143491-57-0 145514-04-1
147127-20-6 147318-81-8 149950-60-7 150378-17-9
154598-52-4 155148-31-5 155213-67-5 159519-65-0
159989-64-7 160707-69-7 161814-49-9 170020-61-8
171345-51-0 174022-42-5 174391-92-5 174484-41-4
178979-85-6 181785-84-2 186538-00-1 192725-17-0
198904-31-3 206361-99-1 206362-00-7 214287-88-4
214287-99-7 216863-66-0 226700-79-4 231957-54-3
251562-00-2 269055-15-4 280571-30-4 284661-68-3
284661-73-0 357263-13-9 370893-06-4 376348-65-1
383198-58-1, PRO 542 394728-76-8, TMC 120 394730-30-4, SCH-D
410544-95-5 410545-90-3 461443-59-4 674782-26-4, PRO 140
854908-06-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

L82 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:588945 HCAPLUS Full-text
DOCUMENT NUMBER: 143:133695
TITLE: Preparation of amino acid hydrazide derivatives as **HIV** protease inhibitors
INVENTOR(S): Randolph, John T.; Chen, Hui-Ju; Degoey, David A.; Flentge, Charles A.; Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Hutchinson, Douglas K.; Kempf, Dale J.; Klein, Larry L.; Yeung, Ming C.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 281 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061487	A1	20050707	WO 2004-US37711	2004 1110
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2549228	AA	20050707	CA 2004-2549228	2004 1110
			<--	
EP 1697348	A1	20060906	EP 2004-810778	2004 1110
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:			US 2003-733227	A 2003 1211
			<--	
			WO 2004-US37711	W 2004 1110

OTHER SOURCE(S): MARPAT 143:133695
GI



I

AB The invention relates to amino acid hydrazide derivs. I [X-Y is CH2(CH2)1-2, CH:CH or C(:Z')(CH2)1-2; Z, Z' are O, S or NH; R1, R2, R5 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, etc.; R3 is H, alkyl, aryl, etc.; R4 is an amino acid or acyl residue of defined structure], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having **HIV** protease inhibitory activity. Thus, hydrazide I [X-Y is CH2CH2; Z is O; R1 is CMeEt; R2 is PhCH2; R3 is 4-(2-pyridyl)benzyl; R4 is N-carbomethoxy-tert- leucine (all-S stereo)] was prepared by a multistep sequence involving peptide coupling in the final step. Compds. of the invention showed EC50 values 1-100 nM against wild-type **HIV**.

IT **25526-93-6**, Alovudine **92562-88-4**, MIV-210
129618-40-2, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D401-14
ICS C07D417-14; C07D401-06; C07D417-06; C07D403-06; C07D409-14; C07D405-14; C07D413-14; A61K031-4178; A61P031-18; C07C243-24

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): **1**, 7, **63**

ST amino acid hydrazide peptide isostere prepn inhibitor **HIV** protease

IT Amino acids, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(hydrazides; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT **Antiviral** agents
Human
Human immunodeficiency virus
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT Hydrazides
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(pseudopeptides; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 134379-77-4, D-D4FC
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Reverset, DPC 817; preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 144114-21-6, **Hiv** protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 857901-33-8P 857901-34-9P 857901-35-0P 857901-36-1P
857901-37-2P 857901-38-3P 857901-39-4P 857901-40-7P
857901-41-8P 857901-42-9P 857901-43-0P 857901-44-1P
857901-45-2P 857901-46-3P 857901-47-4P 857901-48-5P
857901-49-6P 857901-50-9P 857901-51-0P 857901-52-1P
857901-53-2P 857901-54-3P 857901-55-4P 857901-56-5P
857901-58-7P 857901-59-8P 857901-60-1P 857901-61-2P
857901-62-3P 857901-63-4P 857901-64-5P 857901-65-6P
857901-66-7P 857901-67-8P 857901-68-9P 857901-69-0P
857901-70-3P 857901-71-4P 857901-72-5P 857901-73-6P
857901-74-7P 857901-75-8P 857901-76-9P 857901-77-0P
857901-79-2P 857901-81-6P 857901-82-7P 857901-83-8P
857901-84-9P 857901-85-0P 857901-86-1P 857901-87-2P
857901-88-3P 857901-89-4P 857901-90-7P 857901-91-8P
857901-92-9P 857901-93-0P 857901-94-1P 857901-95-2P
857901-96-3P 857901-97-4P 857901-98-5P 857901-99-6P
857902-00-2P 857902-01-3P 857902-02-4P 857902-03-5P
857902-04-6P 857902-05-7P 857902-06-8P 857902-07-9P

857902-08-0P 857902-09-1P 857902-10-4P 857902-11-5P
857902-12-6P 857902-13-7P 857902-14-8P 857902-15-9P
857902-16-0P 857902-18-2P 857902-20-6P 857902-22-8P
857902-24-0P 857902-26-2P 857902-28-4P 857902-30-8P
857902-32-0P 857902-34-2P 857902-36-4P 857902-37-5P
857902-38-6P 857902-40-0P 857902-42-2P 857902-44-4P
857902-46-6P 857902-48-8P 857902-50-2P 857902-52-4P
857902-54-6P 857902-56-8P 857902-58-0P 857902-60-4P
857902-62-6P 857902-63-7P 857902-64-8P 857902-65-9P
857902-66-0P 857902-67-1P 857902-68-2P 857902-69-3P
857902-70-6P 857902-71-7P 857902-72-8P 857902-73-9P
857902-74-0P 857902-75-1P 857902-76-2P 857902-77-3P
857902-78-4P 857902-79-5P 857902-80-8P 857902-81-9P
857902-82-0P 857902-83-1P 857902-84-2P 857902-85-3P
857902-86-4P 857902-87-5P 857902-88-6P 857902-89-7P
857902-90-0P 857902-91-1P 857902-92-2P 857902-93-3P
857902-94-4P 857902-95-5P 857902-96-6P 857902-97-7P
857902-98-8P 857902-99-9P 857903-00-5P 857903-02-7P
857903-04-9P 857903-06-1P 857903-08-3P 857903-10-7P
857903-12-9P 857903-14-1P 857903-16-3P 857903-18-5P
857903-20-9P 857903-22-1P 857903-23-2P 857903-25-4P
857903-27-6P 857903-28-7P 857903-30-1P 857903-31-2P
857903-33-4P 857903-35-6P 857903-36-7P 857903-37-8P
857903-38-9P 857903-39-0P 857903-40-3P 857903-41-4P
857903-43-6P 857903-45-8P 857903-47-0P 857903-49-2P
857903-51-6P 857903-52-7P 857903-53-8P 857903-54-9P
857903-55-0P 857903-57-2P 857903-58-3P 857903-59-4P
857903-61-8P 857903-62-9P 857903-63-0P 857903-65-2P
857903-66-3P 857903-67-4P 857903-68-5P 857903-70-9P
857903-72-1P 857903-74-3P 857903-75-4P 857903-76-5P
857903-77-6P 857903-78-7P 857903-79-8P 857903-80-1P
857903-81-2P 857903-82-3P 857903-83-4P 857903-84-5P
857903-85-6P 857903-86-7P 857903-87-8P 857903-88-9P
857903-89-0P 857903-90-3P 857903-91-4P 857903-92-5P
857903-93-6P 857903-94-7P 857903-95-8P 857903-96-9P
857903-97-0P 857903-98-1P 857903-99-2P 857904-53-1P
857904-54-2P 857904-55-3P 857904-56-4P 857904-57-5P
857904-58-6P 857904-59-7P 857904-60-0P 857904-61-1P
857904-62-2P 857904-63-3P 857904-64-4P 857904-65-5P
857904-66-6P 857904-67-7P 857904-68-8P 857904-69-9P
857904-70-2P 857904-71-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 857904-72-4P 857904-73-5P 857904-74-6P 857904-75-7P
857904-76-8P 857904-77-9P 857904-78-0P 857904-79-1P
857904-80-4P 857904-81-5P 857904-82-6P 857904-83-7P
857904-84-8P 857904-85-9P 857904-86-0P 857904-87-1P
857904-88-2P 857904-89-3P 857904-90-6P 857904-91-7P
857904-92-8P 857904-93-9P 857904-94-0P 857904-95-1P
857904-96-2P 857904-97-3P 857904-98-4P 857904-99-5P
857905-00-1P 857905-01-2P 857905-02-3P 857905-03-4P
857905-04-5P 857905-05-6P 857905-06-7P 857905-07-8P
857905-08-9P 857905-09-0P 857905-10-3P 857905-11-4P
857905-12-5P 857905-13-6P 857905-14-7P 857905-15-8P
857905-16-9P 857905-17-0P 857905-18-1P 857905-19-2P
857905-20-5P 857905-21-6P 857905-22-7P 857905-23-8P
857905-24-9P 857905-25-0P 857905-26-1P 857905-27-2P
857905-28-3P 857905-29-4P 857905-30-7P 857905-31-8P
857905-32-9P 857905-33-0P 857905-34-1P 857905-35-2P
857905-36-3P 857905-37-4P 857905-38-5P 857905-39-6P
857905-40-9P 857905-41-0P 857905-42-1P 857905-43-2P
857905-44-3P 857905-45-4P 857905-46-5P 857905-47-6P
857905-48-7P 857905-49-8P 857905-50-1P 857905-51-2P
857905-52-3P 857905-53-4P 857905-54-5P 857905-55-6P

857905-56-7P 857905-57-8P 857905-58-9P 857905-59-0P
857905-60-3P 857905-62-5P 857905-65-8P 857905-66-9P
857905-67-0P 857905-68-1P 857905-69-2P 857905-70-5P
857905-71-6P 857905-72-7P 857905-73-8P 857905-75-0P
857905-77-2P 857905-79-4P 857905-80-7P 857905-81-8P
857905-82-9P 857905-83-0P 857905-84-1P 857905-85-2P
857905-86-3P 857905-87-4P 857905-88-5P 857905-89-6P
857905-90-9P 857905-91-0P 857905-92-1P 857905-93-2P
857905-94-3P 857905-95-4P 857905-96-5P 857905-97-6P
857905-98-7P 857905-99-8P 857906-00-4P 857906-01-5P
857906-02-6P 857906-03-7P 857906-04-8P 857906-05-9P
857906-06-0P 857906-07-1P 857906-08-2P 857906-09-3P
857906-10-6P 857906-11-7P 857906-12-8P 857906-13-9P
857906-14-0P 857906-15-1P 857906-16-2P 857906-17-3P
857906-18-4P 857906-19-5P 857906-20-8P 857906-21-9P
857906-22-0P 857906-23-1P 857906-24-2P 857906-25-3P
857906-26-4P 857906-27-5P 857906-28-6P 857906-29-7P
857906-30-0P 857906-31-1P 857906-32-2P 857906-33-3P
857906-34-4P 857906-35-5P 857906-36-6P 857906-37-7P
857906-38-8P 857906-39-9P 857906-40-2P 857906-41-3P
857906-42-4P 857906-43-5P 857906-44-6P 857906-45-7P
857906-46-8P 857906-47-9P 858036-89-2P 858036-90-5P
858036-91-6P 858036-92-7P 858036-93-8P 858036-94-9P
858036-95-0P 858036-96-1P 858036-97-2P 858036-98-3P
858036-99-4P 858037-00-0P 858037-01-1P 858037-02-2P
858037-03-3P 858037-04-4P 858037-05-5P 858037-06-6P
858037-07-7P 858037-08-8P 858037-09-9P 858037-10-2P
858037-11-3P 858037-12-4P 858037-13-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 66-99-9, 2-Naphthalenecarboxaldehyde 70-23-5 73-32-5, L-Isoleucine, reactions 78-84-2 97-96-1 98-03-3, 2-Thiophenecarboxaldehyde 98-79-3, L-Pyroglutamic acid 104-87-0 104-88-1, reactions 105-07-7 106-23-0 108-10-1 108-94-1, Cyclohexanone, reactions 120-14-9 120-57-0, 1,3-Benzodioxole-5-carboxaldehyde 121-33-5 122-03-2 122-78-1, Benzeneacetaldehyde 122-85-0 123-08-0 123-11-5, p-Anisaldehyde, reactions 302-01-2, Hydrazine, reactions 351-54-2 407-25-0, Trifluoroacetic anhydride 455-19-6 459-57-4 587-04-2 590-86-3, Isovaleraldehyde 591-31-1 620-23-5 630-19-3 645-36-3, Aminoacetaldehyde diethylacetal 870-46-2, tert-Butyl carbazate 939-97-9 1122-72-1 1122-91-4 1452-77-3, 2-Pyridinecarboxamide 1489-69-6, Cyclopropanecarboxaldehyde 1571-08-0 1846-68-0, 2-Octynal 2043-61-0, Cyclohexanecarboxaldehyde 2196-13-6, Iso-thionicotinamide 2916-68-9 2987-16-8 3012-80-4 4021-50-5 4070-48-8 4595-59-9 4748-78-1 4766-51-2, Phthalimide diethylacetal 5398-77-6 5470-96-2, 2-Quinolinecarboxaldehyde 5779-95-3 5973-71-7 6287-38-3 6654-36-0 10040-98-9 10111-08-7, 1H-Imidazole-2-carboxaldehyde 18962-05-5 20570-96-1 20859-02-3 23074-10-4 25714-71-0 29668-44-8 32723-67-4 36880-33-8 39238-07-8 39515-51-0 52480-43-0 54751-01-8, 4-Bromomethylpyridine 55745-70-5 56881-90-4 62373-80-2 63038-27-7 66605-57-0 69770-20-3 74124-79-1 77358-26-0 79124-75-7 82911-69-1 83902-00-5 87199-16-4, 3-Formylphenyl boronic acid 98737-29-2 127406-56-8 128018-44-0 132509-34-3 133047-46-8 854754-13-5 854754-25-9 854754-39-5 854754-69-1 854754-74-8 854755-33-2 854756-65-3 854757-66-7 857900-62-0 857900-63-1 857900-64-2 857900-65-3 857900-66-4 857900-69-7 857900-70-0 857900-71-1 857900-75-5 857900-77-7 857900-78-8 857900-79-9 857900-81-3 857900-83-5 857900-87-9 857900-88-0 857900-89-1 857900-90-4 857900-91-5 857900-92-6 857900-93-7

857900-94-8 857900-95-9 857900-96-0 857900-97-1
857900-98-2 857900-99-3 857901-00-9 857901-01-0
857901-03-2 857901-07-6 857901-10-1 857901-12-3
857901-14-5 857901-16-7 857901-19-0 857901-21-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 2913-97-5P 21278-85-3P 72155-45-4P 74761-39-0P 74761-42-5P
78269-85-9P 107202-43-7P 154876-20-7P 161772-80-1P
162537-11-3P 173838-60-3P 175277-28-8P 198084-12-7P
198904-77-7P 198904-85-7P 198904-86-8P 198905-12-3P
437713-06-9P 533885-37-9P 853893-93-3P 853894-11-8P
853894-13-0P 854739-73-4P 854739-74-5P 854745-36-1P
854745-37-2P 854745-38-3P 854745-39-4P 854745-40-7P
854745-41-8P 854745-42-9P 854745-43-0P 854745-44-1P
854754-44-2P 854754-55-5P 854757-53-2P 857900-54-0P
857900-55-1P 857900-56-2P 857900-57-3P 857900-58-4P
857900-59-5P 857900-61-9P 857900-68-6P 857900-72-2P
857900-74-4P 857900-86-8P 857901-25-8P 857901-30-5P
857901-31-6P 857901-32-7P 857904-00-8P 857904-01-9P
857904-02-0P 857904-03-1P 857904-04-2P 857904-05-3P
857904-06-4P 857904-07-5P 857904-08-6P 857904-09-7P
857904-10-0P 857904-11-1P 857904-14-4P 857904-15-5P
857904-16-6P 857904-17-7P 857904-18-8P 857904-19-9P
857904-20-2P 857904-21-3P 857904-22-4P 857904-23-5P
857904-24-6P 857904-25-7P 857904-26-8P 857904-27-9P
857904-28-0P 857904-29-1P 857904-33-7P 857904-34-8P
857904-35-9P 857904-36-0P 857904-37-1P 857904-38-2P
857904-39-3P 857904-40-6P 857904-42-8P 857904-43-9P
857904-44-0P 857904-45-1P 857904-46-2P 857904-47-3P
857904-48-4P 857904-49-5P 857904-50-8P 857904-51-9P
857904-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

IT 3056-17-5, Stavudine 7481-89-2, Zalcitabine **25526-93-6**, Alovudine 29321-75-3, PRO 2000 30516-87-1, Zidovudine 69655-05-6, Didanosine **92562-88-4**, MIV-210 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142632-32-4, Calanolide A 143491-54-7, Racivir 143491-57-0, Emtricitabine 145514-04-1, Amdoxovir 147127-20-6, Tenofovir 147318-81-8, KNI-272 149950-60-7, Emivirine 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159519-65-0, Enfuvirtide 159989-64-7, Nelfinavir 160707-69-7, SPD754 161814-49-9, Amprenavir 170020-61-8, FP21399 171345-51-0, Zintevir 174022-42-5, PA-457 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 181785-84-2, Elvucitabine 186538-00-1, JE-2147 192725-17-0, Lopinavir 198904-31-3, Atazanavir 206361-99-1, TMC-114 206362-00-7, TMC-126 214287-88-4, DPC-961 214287-99-7, Dpc 083 216863-66-0, L-756423 226700-79-4, Fosamprenavir 231957-54-3, MIV-150 251562-00-2, T-1249 269055-15-4, TMC-125 280571-30-4, S-1360 284661-68-3, DPC-681 284661-73-0, DPC-684 357263-13-9, BMS-806 370893-06-4, Schering C 376348-65-1, UK-427857 383198-58-1, PRO 542 394728-76-8, TMC 120 394730-30-4, SCH-D 410544-95-5, L-870810 410545-90-3, L-870812 461443-59-4, GW873140 674782-26-4, PRO 140 854908-06-8, GW 5634
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid hydrazide derivs. as **HIV** protease inhibitors)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:588404 HCAPLUS Full-text
DOCUMENT NUMBER: 143:133693
TITLE: Preparation of amino acid derivatives as **HIV** protease inhibitors
INVENTOR(S): Degoey, David A.; Flentge, Charles A.; Flosi, William J.; Grampovnik, David J.; Kempf, Dale J.; Klein, Larry L.; Yeung, Ming C.; Randolph, John T.; Wang, Xiu C.; Yu, Su
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 279 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005148623	A1	20050707	US 2004-8713 <--	2004 1209
PRIORITY APPLN. INFO.:			US 2003-528974P <--	P 2003 1211

OTHER SOURCE(S): MARPAT 143:133693
AB The invention relates to amino acid derivs. A- NHCHR6CHR5CHR4CHR3NHCOCHR2NHCO2R1 [A is an amino acid or acyl residue of defined structure; R1, R2, R3, R6 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl or heteroaryl; R4, R5 are H (not both), OH or substituted hydroxyl], including pharmaceutically-acceptable salts, prodrugs or stereoisomers, having **HIV** protease inhibitory activity. Thus, Me (1S,4R,6S,7S,10S)-7-benzyl-1,10-di- tert-butyl-6-hydroxy-2,9,12-trioxo-4-[4-(2-pyridinyl)benzyl]-13- oxa-3,8,11-triazatetradec-1-ylcarbamate was prepared by a multistep procedure, which includes the reaction of intermediate tert-Bu (1S,2S,4R)-4-amino-1-benzyl-2-hydroxy-5-[4-(2-pyridinyl)phenyl]pentylcarbamate with N-protected L-tert-leucine. Compds. of the invention showed EC50 values in the range 0.7 nM to >3.2 μM against wild-type **HIV**.
IT **25526-93-6 92562-88-4**, MIV 210
129618-40-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-4745
ICS C07D471-02; C07D498-02; A61K031-4439; C07D043-02
INCL 514303000; 514341000; 546272700; 514314000; 514340000; 546118000; 546159000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): **1**, 7, **63**
ST amino acid peptide isostere prepn inhibitor **HIV** protease
IT **Antiviral** agents
Human
Human immunodeficiency virus
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT Amino acids, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(pseudopeptides; preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 854754-19-1P 854754-23-7P 854755-08-1P 854755-09-2P
854755-10-5P 854755-12-7P 854755-25-2P 854755-36-5P
854755-37-6P 854755-46-7P 854755-47-8P 854755-48-9P
854755-49-0P 854755-50-3P 854755-84-3P 854756-41-5P
854756-43-7P 854757-60-1P 854757-85-0P 854758-79-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 192725-55-6P 854754-01-1P 854754-05-5P 854754-12-4P

854754-28-2P 854754-31-7P 854754-34-0P 854754-36-2P
854754-42-0P 854754-48-6P 854754-49-7P 854754-53-3P
854754-60-2P 854754-64-6P 854754-65-7P 854754-71-5P
854754-72-6P 854754-76-0P 854754-79-3P 854754-80-6P
854754-82-8P 854755-01-4P 854755-03-6P 854755-04-7P
854755-06-9P 854755-14-9P 854755-21-8P 854755-26-3P
854755-30-9P 854755-31-0P 854755-35-4P 854755-38-7P
854755-45-6P 854755-51-4P 854755-54-7P 854755-57-0P
854755-61-6P 854755-65-0P 854755-69-4P 854755-72-9P
854755-73-0P 854755-74-1P 854755-75-2P 854755-76-3P
854755-77-4P 854755-81-0P 854755-82-1P 854755-86-5P
854755-91-2P 854755-99-0P 854756-01-7P 854756-05-1P
854756-09-5P 854756-11-9P 854756-21-1P 854756-33-5P
854756-35-7P 854756-37-9P 854756-39-1P 854756-45-9P
854756-56-2P 854756-58-4P 854756-63-1P 854756-68-6P
854756-70-0P 854756-75-5P 854756-80-2P 854756-88-0P
854756-94-8P 854757-02-1P 854757-04-3P 854757-06-5P
854757-08-7P 854757-10-1P 854757-32-7P 854757-34-9P
854757-38-3P 854757-40-7P 854757-49-6P 854757-56-5P
854757-62-3P 854757-68-9P 854757-70-3P 854757-72-5P
854757-76-9P 854757-82-7P 854757-87-2P 854758-00-2P
854758-04-6P 854758-13-7P 854758-17-1P 854758-29-5P
854758-32-0P 854758-41-1P 854758-48-8P 854758-49-9P
854758-54-6P 854758-57-9P 854758-58-0P 854758-61-5P
854758-64-8P 854758-67-1P 854758-71-7P 854758-78-4P
854758-85-3P 854758-86-4P 854758-90-0P 854758-93-3P
854758-96-6P 854758-97-7P 854758-98-8P 854758-99-9P
854759-00-5P 854759-01-6P 854759-02-7P 854759-03-8P
854759-04-9P 854759-05-0P 854759-06-1P 854759-07-2P
854759-08-3P 854759-09-4P 854759-10-7P 854759-11-8P
854759-12-9P 854759-13-0P 854759-14-1P 854759-15-2P
854759-16-3P 854759-17-4P 854759-18-5P 854759-19-6P
854759-20-9P 854759-21-0P 854759-22-1P 854759-23-2P
854759-24-3P 854759-25-4P 854759-26-5P 854759-27-6P
854759-28-7P 854759-29-8P 854759-30-1P 854759-33-4P
854759-35-6P 854759-38-9P 854759-40-3P 854759-42-5P
854759-46-9P 854759-47-0P 854759-48-1P 854759-49-2P
854759-51-6P 854759-52-7P 854759-53-8P 854759-54-9P
854759-55-0P 854759-56-1P 854759-57-2P 854759-58-3P
854759-59-4P 854759-60-7P 854759-61-8P 854759-62-9P
854759-63-0P 854759-64-1P 854759-65-2P 854759-67-4P
854759-69-6P 854759-72-1P 854759-77-6P 854759-79-8P
854759-81-2P 854759-83-4P 854759-85-6P 854759-87-8P
854759-89-0P 854759-90-3P 854759-92-5P 854759-93-6P
854759-94-7P 854759-95-8P 854759-97-0P 854759-98-1P
854760-00-2P 854760-01-3P 854760-03-5P 854760-05-7P
854760-06-8P 854760-07-9P 854760-09-1P 854760-10-4P
854760-13-7P 854760-17-1P 854760-19-3P 854760-22-8P
854760-24-0P 854760-25-1P 854760-26-2P 854760-27-3P
854760-28-4P 854760-29-5P 854760-30-8P 854760-31-9P
854760-32-0P 854760-33-1P 854760-34-2P 854760-35-3P
854760-36-4P 854760-37-5P 854760-38-6P 854760-39-7P
854760-40-0P 854760-42-2P 854760-43-3P 854760-44-4P
854760-45-5P 854760-46-6P 854760-47-7P 854760-48-8P
854760-49-9P 854760-50-2P 854760-51-3P 854760-52-4P
854760-53-5P 854760-54-6P 854760-55-7P 854760-56-8P
854760-57-9P 854760-61-5P 854760-65-9P 854760-66-0P
854760-67-1P 854760-68-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 854760-69-3P 854760-70-6P 854760-71-7P 854760-72-8P
854760-73-9P 854760-74-0P 854760-75-1P 854760-76-2P
854760-77-3P 854760-78-4P 854760-79-5P 854892-38-9P
854892-41-4P 854892-42-5P 854892-43-6P 854892-44-7P

854892-45-8P 854892-46-9P 854892-47-0P 854892-48-1P
854892-49-2P 854892-50-5P 858033-46-2P 858033-47-3P
858033-48-4P 858033-49-5P 858033-50-8P 858033-51-9P
858033-52-0P 858033-53-1P 858033-54-2P 858033-55-3P
858033-56-4P 858033-57-5P 858033-58-6P 858033-59-7P
858033-60-0P 858033-61-1P 858033-62-2P 858033-63-3P
858033-64-4P 858033-65-5P 858033-66-6P 858033-67-7P
858033-68-8P 858033-69-9P 858033-70-2P 858033-71-3P
858033-72-4P 858033-73-5P 858033-74-6P 858033-75-7P
858033-76-8P 858033-77-9P 858033-78-0P 858033-79-1P
858033-80-4P 858033-81-5P 858033-82-6P 858033-83-7P
858033-84-8P 858033-85-9P 858033-86-0P 858033-87-1P
858033-88-2P 858033-89-3P 858033-90-6P 858033-91-7P
858033-92-8P 858033-93-9P 858033-94-0P 858033-95-1P
858033-96-2P 858033-97-3P 858033-98-4P 858033-99-5P
858034-00-1P 858034-01-2P 858034-02-3P 858034-03-4P
858034-04-5P 858034-05-6P 858034-06-7P 858034-07-8P
858034-08-9P 858034-09-0P 858034-10-3P 858034-11-4P
858034-12-5P 858034-13-6P 858034-14-7P 858034-15-8P
858034-16-9P 858034-17-0P 858034-18-1P 858034-19-2P
858034-92-1P 858034-93-2P 858034-94-3P 858034-95-4P
858034-96-5P 858034-97-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 52-90-4, L-Cysteine, reactions 60-18-4, L-Tyrosine, reactions 62-55-5, Ethanethioamide 70-23-5 73-32-5, L-Isoleucine, reactions 88-13-1, 3-Thiophenecarboxylic acid 90-02-8, o-Hydroxybenzaldehyde, reactions 98-80-6 99-61-6 100-52-7, Benzaldehyde, reactions 100-83-4, m-Hydroxybenzaldehyde 105-36-2 105-53-3 118-90-1, o-Toluic acid 123-08-0, p-Hydroxybenzaldehyde 135-02-4 138-41-0 274-47-5, Imidazo[1,5-a]pyridine 298-12-4, Glyoxylic acid 447-61-0, o-Trifluoromethylbenzaldehyde 454-89-7, m-Trifluoromethylbenzaldehyde 455-19-6, p-Trifluoromethylbenzaldehyde 456-48-4, 3-Fluorobenzaldehyde 459-57-4, 4-Fluorobenzaldehyde 500-22-1, 3-Pyridinecarboxaldehyde 527-72-0, 2-Thiophenecarboxylic acid 529-20-4 534-07-6 552-89-6 563-83-7 589-15-1 591-31-1 598-55-0, Methyl carbamate 599-04-2 603-80-5 620-23-5 630-19-3 636-76-0 701-99-5 1113-41-3 1121-60-4, 2-Pyridinecarboxaldehyde 1122-71-0 1122-72-1, 6-Methyl-2-pyridinecarboxaldehyde 1189-71-5, Sulfuryl chloride isocyanate 1452-77-3, 2-Pyridinecarboxamide 1483-07-4 1589-82-8 1730-25-2 1918-79-2 2018-66-8 2491-06-7, Dimethylglycine hydrochloride 2510-36-3, 3,5-Dimethylisoxazole-4-carboxylic acid 3012-80-4 3430-13-5 3510-66-5 4363-93-3, 4-Quinolinecarboxaldehyde 4467-06-5, 2-p-Tolylpyridine 4530-20-5 4621-66-3, 3-Pyridinecarbothioamide 4926-28-7 5315-25-3 5453-67-8 5470-70-2 6245-57-4 6436-59-5 6973-60-0 7499-07-2, 4-Chloro-o-toluic acid 7499-08-3 13335-71-2 13831-31-7, Acetoxyacetyl chloride 15761-38-3 17153-20-7 17997-47-6 20859-02-3 21641-92-9 23806-24-8 24015-97-2 24250-84-8 31556-74-8 32939-32-5 37535-51-6 37595-74-7 40473-07-2 55135-66-5, 9-Bromo-9-phenylfluorene 65719-09-7 67746-43-4 69320-89-4 76497-39-7 78795-02-5 78902-09-7 80866-76-8 98760-08-8 119433-80-6 119483-45-3 121359-48-6, 2-(Tributylstannyl)thiazole 124252-41-1, 4-Tributylstannylpyridine 129460-09-9 132388-59-1 139665-79-5 146255-30-3 156732-12-6 162119-33-7 373638-50-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 2913-97-5P 5346-38-3P, 2-Pyridinecarbothioamide 5858-27-5P,

3-Methyl-2-nitrobenzaldehyde 13515-65-6P 15536-75-1P
19550-89-1P 20949-84-2P 39067-28-2P 39238-07-8P
39977-44-1P 52199-24-3P 53014-84-9P 56671-66-0P,
Imidazo[1,5-a]pyridine-3-carboxaldehyde 60032-57-7P
69950-65-8P 74761-39-0P 110599-27-4P 120230-41-3P
120230-42-4P 133047-44-6P 133047-45-7P 133047-46-8P
133333-27-4P 138745-99-0P 143291-14-9P 143688-72-6P
144163-81-5P 144163-85-9P 144163-88-2P 157717-56-1P
157717-57-2P 157717-58-3P 161772-80-1P 162537-11-3P
163116-17-4P 164014-94-2P 167556-64-1P 169870-02-4P
173838-60-3P 177748-39-9P 183182-30-1P 184679-13-8P
189195-41-3P 191481-72-8P 192725-57-8P 198958-58-6P
259807-95-9P 266306-18-7P 301652-23-3P 338462-91-2P
431896-84-3P 431896-85-4P 431896-94-5P 760938-66-7P
854739-74-5P 854741-49-4P 854745-36-1P 854745-37-2P
854745-39-4P 854745-40-7P 854745-41-8P 854745-42-9P
854745-75-8P 854745-76-9P 854745-77-0P 854745-79-2P
854753-93-8P 854753-94-9P 854753-96-1P 854753-97-2P
854753-98-3P 854753-99-4P 854754-00-0P 854754-02-2P
854754-03-3P 854754-04-4P 854754-06-6P 854754-07-7P
854754-08-8P 854754-09-9P 854754-11-3P 854754-14-6P
854754-15-7P 854754-16-8P 854754-17-9P 854754-20-4P
854754-21-5P 854754-22-6P 854754-24-8P 854754-26-0P
854754-27-1P 854754-29-3P 854754-30-6P 854754-32-8P
854754-33-9P 854754-35-1P 854754-37-3P 854754-38-4P
854754-40-8P 854754-41-9P 854754-43-1P 854754-45-3P
854754-46-4P 854754-47-5P 854754-50-0P 854754-52-2P
854754-54-4P 854754-56-6P 854754-58-8P 854754-59-9P
854754-61-3P 854754-63-5P 854754-66-8P 854754-67-9P
854754-68-0P 854754-69-1P 854754-70-4P 854754-73-7P
854754-75-9P 854754-78-2P 854754-81-7P 854754-83-9P
854754-84-0P 854754-85-1P 854754-86-2P 854754-87-3P
854754-88-4P 854754-89-5P 854754-90-8P 854754-91-9P
854754-92-0P 854754-93-1P 854754-94-2P 854754-95-3P
854754-96-4P 854754-97-5P 854754-98-6P 854754-99-7P
854755-00-3P 854755-02-5P 854755-05-8P 854755-07-0P
854755-23-0P 854755-27-4P 854755-29-6P 854755-32-1P
854755-34-3P 854755-39-8P 854755-40-1P 854755-41-2P
854755-42-3P 854755-44-5P 854755-52-5P 854755-53-6P
854755-55-8P 854755-56-9P 854755-58-1P 854755-60-5P
854755-62-7P 854755-64-9P 854755-66-1P 854755-68-3P
854755-70-7P 854755-71-8P 854755-78-5P 854755-79-6P
854755-80-9P 854755-83-2P 854755-85-4P 854755-87-6P
854755-88-7P 854755-89-8P 854755-90-1P 854755-92-3P
854755-93-4P 854755-95-6P 854755-97-8P 854756-03-9P
854756-07-3P 854756-13-1P 854756-15-3P 854756-17-5P
854756-19-7P 854756-25-5P 854756-27-7P 854756-29-9P
854756-31-3P 854756-48-2P 854756-50-6P 854756-52-8P
854756-54-0P 854756-61-9P 854756-66-4P 854756-73-3P
854756-78-8P 854756-82-4P 854756-84-6P 854756-86-8P
854756-90-4P 854756-92-6P 854756-96-0P 854756-98-2P
854757-00-9P 854757-12-3P 854757-14-5P 854757-16-7P
854757-18-9P 854757-20-3P 854757-22-5P 854757-24-7P
854757-26-9P 854757-28-1P 854757-30-5P 854757-36-1P
854757-42-9P 854757-44-1P 854757-47-4P 854757-51-0P
854757-54-3P 854757-58-7P 854757-64-5P 854757-66-7P
854757-74-7P 854757-78-1P 854757-80-5P 854757-90-7P
854757-91-8P 854757-93-0P 854757-94-1P 854757-95-2P
854757-97-4P 854757-99-6P 854758-02-4P 854758-09-1P
854758-11-5P 854758-15-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 854758-20-6P 854758-22-8P 854758-23-9P 854758-24-0P
854758-25-1P 854758-26-2P 854758-27-3P 854758-28-4P
854758-30-8P 854758-31-9P 854758-33-1P 854758-34-2P

854758-35-3P 854758-36-4P 854758-37-5P 854758-38-6P
854758-40-0P 854758-42-2P 854758-43-3P 854758-44-4P
854758-45-5P 854758-47-7P 854758-50-2P 854758-51-3P
854758-52-4P 854758-53-5P 854758-55-7P 854758-56-8P
854758-59-1P 854758-60-4P 854758-62-6P 854758-63-7P
854758-65-9P 854758-66-0P 854758-68-2P 854758-69-3P
854758-70-6P 854758-72-8P 854758-73-9P 854758-74-0P
854758-75-1P 854758-76-2P 854758-77-3P 854758-80-8P
854758-81-9P 854758-82-0P 854758-83-1P 854758-84-2P
854758-87-5P 854758-88-6P 854758-91-1P 854758-92-2P
854758-94-4P 854758-95-5P 854760-81-9P 854760-84-2P
854760-85-3P 854892-39-0P 854892-40-3P 858033-35-9P
858033-36-0P 858033-37-1P 858033-38-2P 858033-39-3P
858033-40-6P 858033-41-7P 858033-42-8P 858033-43-9P
858033-44-0P 858033-45-1P 858034-20-5P 858034-21-6P
858034-22-7P 858034-23-8P 858034-24-9P 858034-25-0P
858034-26-1P 858034-27-2P 858034-28-3P 858034-29-4P
858034-30-7P 858034-31-8P 858034-32-9P 858034-33-0P
858034-34-1P 858034-35-2P 858034-36-3P 858034-37-4P
858034-38-5P 858034-39-6P 858034-40-9P 858034-41-0P
858034-42-1P 858034-43-2P 858034-44-3P 858034-45-4P
858034-46-5P 858034-47-6P 858034-48-7P 858034-49-8P
858034-50-1P 858034-51-2P 858034-52-3P 858034-53-4P
858034-54-5P 858034-55-6P 858034-56-7P 858034-57-8P
858034-58-9P 858034-59-0P 858034-60-3P 858034-61-4P
858034-62-5P 858034-63-6P 858034-64-7P 858034-65-8P
858034-66-9P 858034-67-0P 858034-68-1P 858034-69-2P
858034-70-5P 858034-71-6P 858034-72-7P 858034-73-8P
858034-74-9P 858034-75-0P 858034-76-1P 858034-77-2P
858034-78-3P 858034-79-4P 858034-80-7P 858034-81-8P
858034-82-9P 858034-83-0P 858034-84-1P 858034-85-2P
858034-86-3P 858034-87-4P 858034-88-5P 858034-89-6P
858034-90-9P 858034-91-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 3056-17-5 7481-89-2 **25526-93-6** 29321-75-3
30516-87-1 69655-05-6 **92562-88-4**, MIV 210
127779-20-8 **129618-40-2** 134379-77-4 134678-17-4
136470-78-5 136817-59-9 142632-32-4 143491-54-7
143491-57-0 145514-04-1 147127-20-6 147318-81-8
149950-60-7 150378-17-9 154598-52-4 155148-31-5
155213-67-5 159519-65-0 159989-64-7 160707-69-7
161814-49-9 170020-61-8 171345-51-0 174022-42-5
174391-92-5 174484-41-4 178979-85-6 181785-84-2
186538-00-1 192725-17-0 198904-31-3 206361-99-1
206362-00-7 214287-88-4 214287-99-7 216863-66-0
226700-79-4 231957-54-3 251562-00-2 269055-15-4
280571-30-4 284661-68-3 284661-73-0 357263-13-9
370893-06-4 376348-65-1 383198-58-1, PRO 542 394728-76-8, TMC 120 394730-30-4, SCH-D 410544-95-5 410545-90-3
461443-59-4 674782-26-4, PRO 140 854908-06-8, GW 5634
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 38870-89-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with ammonium acetate in preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 631-61-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with methoxyacetyl chloride in preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 7529-22-8
RL: RGT (Reagent); RACT (Reactant or reagent)
(sulfide oxidant; preparation of amino acid derivs. as **HIV**

protease inhibitors)

L82 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:527407 HCAPLUS Full-text
DOCUMENT NUMBER: 143:59982
TITLE: Preparation of **HIV** protease inhibitors, in particular imidazolidine derivatives
INVENTOR(S): Flentge, Charles A.; Chen, Hui-Ju; Degoey, David A.; Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Kempf, Dale J.; Klein, Larry L.; Krueger, Allan C.; Madigan, Darold L.; Randolph, John T.; Sun, Minghua; Yeung, Ming C.; Zhao, Chen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 287 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131042	A1	20050616	US 2003-733915	2003 1211
CA 2549389	AA	20050707	CA 2004-2549389	2004 1110
			<--	
WO 2005061450	A2	20050707	WO 2004-US37745	2004 1110
			<--	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:			US 2003-733915	A 2003 1211
			<--	
			WO 2004-US37745	W 2004 1110

OTHER SOURCE(S): MARPAT 143:59982
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
*

AB Title compds. of formula ANH(CHR)(CHR1)(CHR2)NR3S(O2)R4 (I) [wherein A = alkylcarbonyl, arylsulfonyl, 1,3-substituted 2-oxoimidazolidinyl, 2,4-dioxoimidazolidinyl, etc.; X, Y

= independently O, S, NH; R = (un)substituted alk(en)yl, cycloalk(en)yl, hetero/arylalkyl, etc.; R1 = OH and derivs., OPO3H and derivs., OSO2H and derivs., etc.; R2 = H; R3 = halo/alkyl, halo/alkenyl, (un)substituted cycloalk(en)yl, aryl; R4 = (un)substituted cycloalk(en)yl, heterocyclyl, hetero/aryl] were prepared as **HIV** protease inhibitors. For example, II was prepared, in 62% yield, by coupling acid III (preparation given) with amine IV (preparation given). I showed **antiviral** activity against Wild-Type **HIV** with EC50 in the range of 1 nM to 100 nM.

IT **25526-93-6**, Alovudine **129618-40-2**, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-4168
ICS A61K031-277; A61K031-195; A61K031-175; A61K031-18
INCL 514389000; 514602000; 514522000; 514562000; 514591000; 548316400; 548316700; 558410000; 562429000; 564038000
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, **63**
ST imidazolidine prepn **HIV** protease inhibitor
IT Anti-**AIDS** agents
Anti-infective agents
Antiviral agents
Human
Human immunodeficiency virus 1
(preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 9068-38-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**HIV**, combination therapy; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 853894-05-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-formylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-07-2P 854739-68-7P 854739-90-5P 854739-95-0P 854740-18-4P 854740-98-0P,

(2R,3S)-N-[(1S,2R)-1-Benzyl-3-[(cyclopentylmethyl)[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl]amino]-2-hydroxypropyl]-2-[3-[[2-[(isopropylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanamide 854741-06-3P 854741-19-8P 854741-25-6P 854741-33-6P 854741-48-3P 854741-61-0P 854741-62-1P 854741-68-7P 854741-70-1P 854742-58-8P 854742-87-3P 854743-24-1P 854743-61-6P 854743-96-7P 854744-02-8P 854744-22-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(3-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-29-9P 854744-57-3P 854744-64-2P 854744-65-3P 854744-66-4P 854744-77-7P 854744-87-9P, (2S,3S)-N-[(1S,2R)-1-Benzyl-3-[[(4-cyanophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[2-oxo-3-[(3-pyridinyl)methyl]-1-imidazolidinyl]pentanamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**antiviral** agent; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 853893-95-5P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853893-96-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[4-(formylamino)phenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853893-99-9P, 4-[[[(2R,3S)-2-Hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]benzoic acid 853894-00-5P, (2S)-N-[(1S,2R)-3-[[(4-Acetylphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-01-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-cyanophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-02-7P, 4-[[[(2R,3S)-2-Hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]benzamide 853894-03-8P, (2S)-N-[(1S,2R)-3-[[[4-[(Amino)(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxoimidazolidin-1-yl]butanamide 853894-04-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-vinylphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-06-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-(hydroxymethyl)phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-09-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[3-(hydroxymethyl)phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854739-69-8P, (2S)-2-[3-[2-(Anilino)-2-oxoethyl]-2,4-dioxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methylbutanamide 854739-70-1P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-vinylphenyl)sulfonyl]amino]propyl]carbamate 854739-71-2P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]carbamate 854739-77-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxoimidazolidin-1-yl]-3-methylbutanamide 854739-78-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3,3-dimethyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxoimidazolidin-1-yl]butanamide 854739-79-0P 854739-80-3P 854739-81-4P 854739-82-5P 854739-83-6P 854739-84-7P

854739-85-8P 854739-86-9P 854739-87-0P 854739-88-1P
854739-89-2P 854739-91-6P 854739-92-7P 854739-93-8P
854739-94-9P 854739-96-1P 854739-97-2P 854739-98-3P
854739-99-4P 854740-00-4P 854740-01-5P 854740-02-6P
854740-04-8P 854740-05-9P 854740-06-0P 854740-07-1P
854740-08-2P 854740-09-3P 854740-10-6P 854740-11-7P
854740-12-8P 854740-13-9P 854740-14-0P 854740-15-1P
854740-16-2P 854740-17-3P 854740-19-5P 854740-20-8P
854740-21-9P 854740-22-0P 854740-23-1P 854740-24-2P
854740-25-3P 854740-26-4P 854740-27-5P 854740-28-6P
854740-29-7P 854740-30-0P 854740-31-1P 854740-32-2P
854740-33-3P 854740-34-4P 854740-35-5P 854740-36-6P
854740-37-7P 854740-38-8P 854740-40-2P 854740-41-3P
854740-42-4P 854740-43-5P 854740-44-6P 854740-45-7P
854740-46-8P 854740-47-9P 854740-48-0P 854740-49-1P
854740-50-4P 854740-51-5P 854740-52-6P 854740-53-7P
854740-54-8P 854740-55-9P 854740-56-0P 854740-57-1P
854740-58-2P 854740-59-3P 854740-60-6P 854740-61-7P
854740-62-8P 854740-63-9P 854740-64-0P 854740-65-1P
854740-66-2P 854740-67-3P 854740-68-4P 854740-69-5P
854740-70-8P 854740-71-9P 854740-72-0P 854740-73-1P
854740-74-2P 854740-75-3P 854740-76-4P 854740-77-5P
854740-78-6P 854740-79-7P 854740-80-0P 854740-81-1P
854740-82-2P 854740-83-3P 854740-84-4P 854740-85-5P
854740-86-6P 854740-87-7P 854740-88-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[[2-[(methylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxoimidazolidin-1-yl]butanamide 854740-89-9P 854740-90-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-imidazol-1-yl]butanamide 854740-91-3P, (2S)-2-[3-(3-Aminobenzyl)-2-oxoimidazolidin-1-yl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylbutanamide 854740-92-4P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(1-oxido-3-pyridinyl)methyl]-2-oxo-1-imidazolidinyl]pentanamide 854740-93-5P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(1-oxidopyridin-4-yl)methyl]-2-oxoimidazolidin-1-yl]pentanamide 854740-94-6P, (2S,3S)-2-[3-[[2-(Aminomethyl)-1,3-thiazol-4-yl]methyl]-2-oxoimidazolidin-1-yl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylpentanamide 854740-95-7P, (2S,3S)-2-[3-[[2-(Aminomethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-3-[(cyclobutylmethyl)[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl]amino]-2-hydroxypropyl]-3-methylpentanamide 854740-96-8P 854740-97-9P 854740-99-1P 854741-00-7P, (2S,3S)-2-[3-[3-[(Amino)(hydroxyimino)methyl]benzyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylpentanamide 854741-01-8P 854741-02-9P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[[6-[(hydroxyimino)methyl]-2-pyridinyl]methyl]-2-oxo-1-imidazolidinyl]-2,3-dimethylpentanamide 854741-03-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[[6-(1-hydroxyethyl)-2-pyridinyl]methyl]-2-oxo-1-imidazolidinyl]-3,3-dimethylbutanamide 854741-05-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854741-07-4P
854741-08-5P 854741-09-6P 854741-10-9P 854741-11-0P
854741-12-1P 854741-13-2P 854741-14-3P 854741-15-4P

854741-16-5P 854741-17-6P 854741-18-7P 854741-20-1P
854741-21-2P 854741-22-3P 854741-23-4P 854741-24-5P
854741-26-7P 854741-27-8P 854741-28-9P 854741-29-0P
854741-30-3P 854741-31-4P 854741-32-5P 854741-34-7P
854741-35-8P 854741-36-9P 854741-37-0P 854741-38-1P
854741-39-2P 854741-40-5P 854741-41-6P 854741-42-7P
854741-43-8P 854741-44-9P, (2S)-2-[3-(3-Aminobenzyl)-2,4-dioxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylbutanamide 854741-45-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[3-(N-hydroxyethanimidoyl)benzyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854741-46-1P, (2S)-2-[3-[3-(Aminomethyl)benzyl]-2,4-dioxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylbutanamide 854741-47-2P, (2S,3S)-2-[3-(3-Aminobenzyl)-2,4-dioxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylpentanamide 854741-50-7P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[[[methyl(2-pyridinylmethyl)amino]carbonyl]amino]pentanamide 854741-51-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[[[[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)amino]carbonyl]amino]-3-methylbutanamide 854741-52-9P 854741-53-0P
854741-54-1P 854741-55-2P 854741-56-3P 854741-58-5P
854741-59-6P 854741-60-9P 854741-63-2P 854741-64-3P
854741-65-4P 854741-66-5P 854741-67-6P 854741-69-8P
854741-71-2P 854741-72-3P 854741-73-4P 854741-74-5P
854741-76-7P 854741-78-9P 854741-80-3P 854741-82-5P
854741-84-7P 854741-85-8P 854741-86-9P 854741-87-0P
854741-88-1P 854741-89-2P 854741-90-5P, (2S,3S)-2-[[[(3-Aminobenzyl)(methyl)amino]carbonyl]amino]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methylpentanamide 854741-91-6P, (2S,3R)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-hydroxy-2-[[[methyl[(2-methyl-1,3-thiazol-4-yl)methyl]amino]carbonyl]amino]butanamide 854741-92-7P, (2S,3R)-N-[(1S,2R)-1-Benzyl-3-[(cyclobutylmethyl)[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl]amino]-2-hydroxypropyl]-3-hydroxy-2-[[[methyl[(2-methyl-1,3-thiazol-4-yl)methyl]amino]carbonyl]amino]butanamide 854741-93-8P
854741-94-9P 854741-95-0P 854741-96-1P 854741-97-2P
854741-98-3P 854741-99-4P 854742-00-0P, tert-Butyl [(1S)-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]amino]Carbonyl]-2,2-dimethylpropyl]carbamate 854742-01-1P
854742-02-2P 854742-03-3P 854742-04-4P 854742-05-5P
854742-06-6P 854742-07-7P 854742-08-8P 854742-09-9P
854742-10-2P 854742-11-3P 854742-12-4P 854742-13-5P
854742-14-6P 854742-15-7P 854742-16-8P 854742-17-9P
854742-18-0P 854742-19-1P 854742-21-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**antiviral** agent; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 854742-22-6P 854742-23-7P 854742-24-8P 854742-25-9P
854742-26-0P 854742-27-1P 854742-28-2P 854742-30-6P
854742-31-7P 854742-32-8P 854742-33-9P 854742-34-0P
854742-35-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[[[(3-fluorobenzyl)amino]acetyl]amino]-3,3-dimethylbutanamide
854742-36-2P, (2R)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-

(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[[[(3-fluorobenzyl)amino]acetyl]amino]-3,3-dimethylbutanamide 854742-37-3P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[[[(3-fluorobenzyl)amino]acetyl]amino]-3-methylpentanamide 854742-38-4P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[[[[(5-nitro-3-thienyl)methyl]amino]acetyl]amino]pentanamide 854742-39-5P, Benzyl [(1S)-4-[[amino(imino)methyl]amino]-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]amino]carbonyl]butyl]carbamate 854742-40-8P 854742-41-9P 854742-42-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[(2-isopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854742-43-1P 854742-44-2P 854742-45-3P 854742-46-4P 854742-47-5P 854742-48-6P 854742-49-7P 854742-50-0P 854742-51-1P 854742-52-2P 854742-53-3P 854742-54-4P 854742-55-5P 854742-56-6P 854742-57-7P 854742-59-9P 854742-60-2P 854742-61-3P 854742-62-4P 854742-63-5P 854742-64-6P 854742-65-7P 854742-66-8P 854742-67-9P 854742-68-0P 854742-69-1P 854742-70-4P 854742-71-5P 854742-72-6P 854742-73-7P 854742-74-8P 854742-75-9P 854742-76-0P 854742-77-1P 854742-78-2P 854742-79-3P 854742-80-6P 854742-81-7P 854742-82-8P 854742-83-9P 854742-84-0P 854742-85-1P 854742-86-2P 854742-88-4P 854742-89-5P 854742-90-8P 854742-91-9P 854742-92-0P 854742-93-1P 854742-94-2P 854742-95-3P 854742-96-4P 854742-97-5P 854742-98-6P 854742-99-7P 854743-00-3P 854743-01-4P 854743-02-5P 854743-03-6P 854743-04-7P, (2S)-2-[3-[[2-(Aminomethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methylbutanamide 854743-05-8P, (2S)-2-[3-[[2-[(Acetylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methylbutanamide 854743-06-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[[2-(hydroxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854743-07-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854743-08-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[[2-[[(methylsulfonyl)amino]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanamide 854743-09-2P 854743-10-5P, Methyl [4-[[3-[(1S)-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]amino]carbonyl]-2-methylpropyl]-2-oxo-1-imidazolidinyl]methyl]-1,3-thiazol-2-yl](methyl)carbamate 854743-11-6P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[[2-[(methylsulfonyl)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanamide 854743-12-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[[2-[(diethylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854743-13-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[2-(isopropylamino)-2-oxoethyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854743-14-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[[2-[(methylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanamide 854743-15-0P 854743-16-1P, (2S,3S)-2-[3-[[2-(Aminomethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-

imidazolidinyl]-N-[(1S,2R)-1-benzyl-3-[(cyclopentylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-3-methylpentanamide 854743-17-2P, (2S,3S)-2-[3-[3-[(Amino)(hydroxyimino)methyl]benzyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methylpentanamide 854743-18-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-4-hydroxy-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854743-19-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2,4-dioxo-1-imidazolidinyl]butanamide 854743-20-7P 854743-21-8P 854743-22-9P 854743-23-0P 854743-25-2P 854743-26-3P 854743-27-4P 854743-28-5P 854743-29-6P 854743-30-9P 854743-31-0P 854743-32-1P 854743-33-2P 854743-34-3P 854743-35-4P 854743-36-5P 854743-37-6P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[2-(isopropylamino)-2-oxoethyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854743-60-5P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854743-62-7P 854743-63-8P 854743-64-9P 854743-65-0P 854743-66-1P 854743-67-2P 854743-68-3P 854743-69-4P 854743-70-7P 854743-71-8P 854743-72-9P 854743-73-0P 854743-74-1P 854743-75-2P 854743-76-3P 854743-77-4P 854743-78-5P 854743-79-6P 854743-80-9P 854743-81-0P 854743-82-1P 854743-83-2P 854743-84-3P 854743-85-4P 854743-86-5P 854743-87-6P 854743-88-7P 854743-89-8P 854743-90-1P 854743-91-2P 854743-92-3P 854743-93-4P 854743-94-5P 854743-95-6P 854743-97-8P 854743-98-9P 854743-99-0P 854744-00-6P 854744-01-7P 854744-03-9P 854744-04-0P 854744-05-1P 854744-06-2P 854744-07-3P 854744-08-4P 854744-09-5P 854744-10-8P 854744-11-9P 854744-12-0P 854744-14-2P 854744-15-3P 854744-16-4P 854744-17-5P 854744-18-6P 854744-19-7P 854744-20-0P 854744-21-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](neopentyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-23-3P 854744-24-4P 854744-25-5P 854744-26-6P 854744-27-7P 854744-28-8P 854744-30-2P 854744-31-3P 854744-32-4P 854744-33-5P 854744-34-6P 854744-35-7P 854744-36-8P 854744-37-9P 854744-38-0P 854744-39-1P 854744-40-4P 854744-41-5P 854744-42-6P 854744-43-7P 854744-44-8P 854744-45-9P 854744-46-0P 854744-47-1P 854744-48-2P 854744-49-3P 854744-50-6P 854744-51-7P 854744-52-8P 854744-53-9P 854744-54-0P 854744-55-1P 854744-56-2P 854744-58-4P 854744-59-5P 854744-60-8P 854744-61-9P 854744-62-0P 854744-63-1P 854744-67-5P 854744-68-6P 854744-69-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(3-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-70-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(5-bromo-2-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-71-1P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[4-(1,2-dihydroxyethyl)phenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-72-2P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[[2-(hydroxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854744-73-3P, (2S)-N-[(1S,2R)-3-[[[3-(Acetylamino)-4-hydroxyphenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-74-4P 854744-75-5P

854744-76-6P 854744-78-8P 854744-79-9P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2,3-dihydro-1H-indol-5-yl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-80-2P, (2S)-N-[(1S,2R)-3-[[(2-Amino-4-methyl-1,3-thiazol-5-yl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-81-3P, (2S)-N-[(1S,2R)-3-[[[3-[(3-Aminopropanoyl)amino]-4-hydroxyphenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-82-4P, tert-Butyl [2-[3-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]anilino]-2-oxoethyl]carbamate 854744-83-5P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(5-formyl-2-furyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-84-6P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[5-[(E)-(hydroxyimino)methyl]-2-furyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-85-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[5-[(Z)-(hydroxyimino)methyl]-2-furyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854744-86-8P 854744-88-0P 854744-89-1P 854744-90-4P 854744-91-5P 854744-92-6P 854744-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**antiviral** agent; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 854744-94-8P 854744-95-9P 854744-96-0P 854744-97-1P 854744-98-2P 854744-99-3P 854745-00-9P 854745-01-0P 854745-02-1P 854745-03-2P 854745-04-3P 854745-06-5P 854745-07-6P 854745-08-7P 854745-09-8P 854745-10-1P 854745-11-2P 854745-12-3P 854745-13-4P 854745-14-5P 854745-15-6P 854745-16-7P 854745-17-8P 854745-18-9P 854745-19-0P 854745-20-3P 854745-21-4P 854745-22-5P 854745-23-6P 854745-24-7P 854745-25-8P 854745-26-9P 854745-27-0P 854745-28-1P 854745-29-2P 854745-30-5P 854745-31-6P 854745-32-7P 854745-33-8P 854745-34-9P 854746-46-6P, (2S)-N-[(1S,2R)-3-[[[4-[(E)-[[(3-Aminopropanoyl)oxy]imino]methyl]phenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-54-6P 854746-55-7P 854746-56-8P 854746-57-9P 854746-58-0P 854746-58-0P 854746-59-1P 854746-62-6P 854746-63-7P 854746-64-8P 854746-65-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[2-oxo-3-[(1,3-thiazol-2-yl)methyl]-1-imidazolidinyl]butanamide 854746-66-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[(5-ethyl-2-phenyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-67-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[(5-ethyl-2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-68-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[(2,5-dimethyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-69-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3,3-dimethyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-70-6P 854746-71-7P 854746-72-8P 854746-76-2P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-77-3P,

(2S)-N-[(1R,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-78-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-2-[3-[(2-isopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-79-5P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-isopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-80-8P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-isopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-81-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-2-[3-[(2-ethyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-82-0P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-ethyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-83-1P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-ethyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-84-2P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-ethyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-85-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-86-4P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-87-5P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-88-6P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-89-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-90-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,5-dichloro-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-91-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(5-nitro-3-thienyl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-92-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-[(3-pyridinylsulfonyl)amino]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-93-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-94-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-2-[3-[(2-cyclopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-95-5P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-cyclopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-96-6P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(2-cyclopropyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanamide 854746-97-7P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-ethyl-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-

2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-98-8P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-99-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-00-5P 854747-01-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(5-fluoro-4-hydroxy-2-methylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-02-7P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(5-chloro-4-hydroxy-2-methylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-03-8P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-chloro-4-hydroxy-5-methylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-04-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-[[(methylamino)sulfonyl]amino]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-05-0P, Ethyl [2-hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]phenyl]carbamate 854747-06-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-isopropylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-07-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-08-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3,5-dimethylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-09-4P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(5-nitro-3-thienyl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-10-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-nitro-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-11-8P, (2S)-N-[(1S,2R)-3-[[(4-Amino-3-hydroxyphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-12-9P 854747-13-0P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-(methylamino)phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-14-1P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[3-(dimethylamino)-4-hydroxyphenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-15-2P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[3-[[(ethylamino)carbonyl]amino]-4-hydroxyphenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-16-3P, Methyl [2-hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]phenyl]carbamate 854747-17-4P, Benzyl [2-hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]phenyl]carbamate 854747-18-5P, (2S)-N-[(1S,2R)-3-[[(1-Acetyl-2,3-dihydro-1H-indol-5-yl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-19-6P, (2S)-N-[(1S,2R)-1-Benzyl-

3-[[(2-chloro-4-hydroxy-5-methylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-20-9P, (2S)-N-[(1S,2R)-3-[[(3-Acetyl-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-21-0P, (2S)-N-[(1S,2R)-3-[[(2-Amino-1,3-thiazol-5-yl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-1-imidazolidinyl]butanamide 854747-22-1P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[2-oxo-3-[(3-quinolinyl)methyl]-1-imidazolidinyl]butanamide 854747-23-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(5-nitro-3-thienyl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-25-4P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[2-oxo-3-[(4-quinolinyl)methyl]-1-imidazolidinyl]butanamide 854747-26-5P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-(2-hydroxyethyl)phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-27-6P, (2S)-2-[3-[[2-(Acetylamino)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-3-[[(3-amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methylbutanamide 854747-28-7P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-cyano-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-29-8P, (2S,3S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxo-1-imidazolidinyl]pentanamide 854747-30-1P 854747-31-2P, (2S,3S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[(1H-benzimidazol-5-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanamide 854747-32-3P, (2S,3S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[2-oxo-3-[(2-quinolinyl)methyl]-1-imidazolidinyl]pentanamide 854747-33-4P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3,3-dimethyl-2-[2-oxo-3-[[2-(3-pyridinyl)-1,3-thiazol-4-yl]methyl]-1-imidazolidinyl]butanamide 854747-34-5P, (2S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3,3-dimethyl-2-[2-oxo-3-[[2-(3-pyridinyl)-1,3-thiazol-4-yl]methyl]-1-imidazolidinyl]butanamide 854747-35-6P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3,3-dimethylbutanamide 854747-36-7P, (2S,3S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]pentanamide 854747-37-8P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-chlorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-38-9P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-fluorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-39-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,4-dibromophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-40-3P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-41-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(1-

methyl-1H-imidazol-4-yl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-43-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-bromo-5-chloro-2-pyridinyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-46-9P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-fluorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-48-1P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(4-bromophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-50-5P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-chloro-4-fluorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-52-7P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,4-dimethoxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-54-9P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,4-dichlorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-57-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(2,4,6-trichlorophenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-59-4P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2-cyanophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-61-8P

, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-cyanophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-63-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2,5-dichloro-3-thienyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-65-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl(2-thienylsulfonyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-67-4P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2,4-dichlorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-69-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2,3-dichlorophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-70-9P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-72-1P 854747-73-2P, (2S)-N-[(1S,2R)-3-[[[4-(Acetylamino)-3-chlorophenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-75-4P, 2-Hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]benzoic acid 854747-77-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-fluoro-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-79-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl(5-isoquinolinylsulfonyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-81-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(3,4,5-trimethoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-83-4P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(3-chloro-4-methylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-85-6P,

(2S)-N-[(1S,2R)-1-Benzyl-3-[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-87-8P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-90-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl(phenylsulfonyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-92-5P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(5-bromo-2-methoxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-94-7P 854747-97-0P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[(2,3-dihydrobenzo[b]furan-5-yl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854747-99-2P 854748-01-9P, (2S)-N-[(1S,2R)-3-[(1,3-Benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-03-1P, (2S)-N-[(1S,2R)-3-[[(Benzo[b]furan-5-yl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-05-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl(3-pyridinylsulfonyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-07-5P, (2S)-N-[(1S,2R)-3-[[[2-(Acetylamino)-4-methyl-1,3-thiazol-5-yl]sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-09-7P 854748-11-1P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[5-[(Z)-[(benzyloxy)imino]methyl]-2-furyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-13-3P, Methyl 3-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]benzoate 854748-16-6P, (2S)-N-[(1S,2R)-3-[[(3-Acetylphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-18-8P 854748-22-4P, tert-Butyl [2-[2-hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]anilino]-2-oxoethyl]carbamate 854748-24-6P, (2S)-N-[(1S,2R)-1-Benzyl-3-[[[3-(formylamino)-4-hydroxyphenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-26-8P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-hydroxy-3-[(phenylacetyl)amino]phenyl]sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854748-28-0P, tert-Butyl [3-[2-hydroxy-5-[[[(2R,3S)-2-hydroxy-3-[[(2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanoyl]amino]-4-phenylbutyl](isobutyl)amino]sulfonyl]anilino]-3-oxopropyl]carbamate 854748-31-5P 854748-33-7P 854748-60-0P 854748-62-2P 854748-66-6P 854748-73-5P 854748-88-2P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-[3-[2-(isobutylamino)-2-oxoethyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854748-89-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[2-(4-morpholinyl)-2-oxoethyl]-2,4-dioxo-1-imidazolidinyl]butanamide 854748-90-6P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-(2-cyanobenzyl)-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854748-91-7P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-

methyl-2-[3-[(1-naphthyl)methyl]-2,4-dioxo-1-imidazolidinyl]butanamide 854748-92-8P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-(2-methoxy-5-nitrobenzyl)-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854748-95-1P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[3-(methoxymethyl)benzyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854748-97-3P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2,4-dioxo-1-imidazolidinyl]butanamide 854748-99-5P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-2,4-dioxo-1-imidazolidinyl]butanamide 854749-00-1P, (2S)-2-[3-(1,3-Benzodioxol-5-ylmethyl)-2,4-dioxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl]-3-methylbutanamide 854749-01-2P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-chlorophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-[3-[3-(hydroxymethyl)benzyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanamide 854749-03-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**antiviral** agent; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 3056-17-5, Stavudine 7481-89-2, Zalcitabine **25526-93-6**, Alovudine 29321-75-3, PRO 2000 30516-87-1, Zidovudine 69655-05-6, Didanosine 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134379-77-4, Reverset 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142632-32-4, Calanolide A 143491-54-7, Racivir 143491-57-0, Emtricitabine 145514-04-1, Amdoxovir 147127-20-6, Tenofovir 147318-81-8, KNI-272 149950-60-7, Emivirine 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD 3100 155213-67-5, Ritonavir 159519-65-0, Enfuvirtide 159989-64-7, Nelfinavir 160707-69-7, SPD 754 161814-49-9, Amprenavir 170020-61-8, FP 21399 171345-51-0, Zintevir 174022-42-5, PA-457 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 181785-84-2, Elvucitabine 186538-00-1, JE 2147 192725-17-0, Lopinavir 198904-31-3, Atazanavir 206361-99-1, TMC 114 206362-00-7, TMC 126 214287-88-4 214287-99-7, DPC 083 216863-66-0, L-756423 226700-79-4, Fosamprenavir 231957-54-3, MIV 150 251562-00-2, T-1249 269055-15-4, TMC-125 280571-30-4, S-1360 284661-68-3, DPC-681 284661-73-0, DPC-684 357263-13-9, BMS-806 370893-06-4, Schering C 376348-65-1, UK 427857 383198-58-1, PRO 542 394728-76-8, TMC 120 394730-30-4, SCH-D 410544-95-5, L-870810 410545-90-3, L-870812 461443-59-4, GW873140 674782-26-4, PRO 140
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 52350-85-3, Integrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, combination therapy; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 2913-97-5P, 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)acetaldehyde 16133-25-8P, 3-Pyridinesulfonyl chloride 24535-98-6P, 2-Chloro-4-hydroxy-5-methylbenzenesulfonyl Chloride 27685-90-1P, 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonyl Chloride 35338-02-4P, 3-Chloro-4-hydroxy-5-methylbenzenesulfonyl Chloride 69232-47-9P, (Acetyloxy)[4-(chlorosulfonyl)phenyl]methyl acetate 73956-15-7P 73956-16-8P, Ethyl 2-(diethoxymethyl)-1,3-thiazole-4-carboxylate 85642-13-3P, tert-Butyl ((1S)-2-amino-1-methyl-2-oxoethyl)carbamate 89226-13-1P, tert-Butyl (2-amino-2-

thioxoethyl)carbamate 108097-39-8P, 5-Chloro-4-hydroxy-2-methylbenzenesulfonyl Chloride 131148-62-4P, Ethyl 2-[(1S)-1-[(tert-butoxycarbonyl)amino]ethyl]-1,3-thiazole-4-carboxylate 135450-44-1P, 1-[6-(Chloromethyl)-2-pyridinyl]ethanone 141041-86-3P, tert-Butyl ((1S)-2-amino-1-methyl-2-thioxoethyl)carbamate 144163-81-5P, N-Methyl(2-methyl-1,3-thiazol-4-yl)methanamine 147682-51-7P, 4-Hydroxy-3-nitrobenzenesulfonyl Chloride 155269-58-2P 155269-59-3P, 6-[(Trityloxy)methyl]pyridine-2-carboxaldehyde 157567-12-9P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-(benzyloxy)-N-isobutylbenzenesulfonamide 157567-13-0P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutylbenzenesulfonamide 159005-71-7P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-methoxybenzenesulfonamide 159006-03-8P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]carbamate 160232-08-6P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-(isobutylamino)propyl]carbamate 162537-10-2P, Methyl (2S)-3-methyl-2-[[(4-nitrophenoxy)Carbonyl]amino]butanoate 163116-17-4P, tert-Butyl (2S,3S)-2-[(2-ethoxy-2-oxoethyl)amino]-3-methylpentanoate 165331-67-9P, (2R,3S)-3-Amino-1-azido-4-phenylbutan-2-ol 167011-40-7P, (2R,3S)-3-Amino-1-(isobutylamino)-4-phenyl-2-butanol 169280-56-2P, 4-Amino-N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-isobutylbenzenesulfonamide 183004-94-6P, tert-Butyl [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]carbamate 191226-98-9P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-nitrophenyl)sulfonyl]amino]propyl]carbamate 202817-20-7P, (2S)-3-Methyl-2-[[[methyl[(2-methyl-1,3-thiazol-4-yl)methyl]amino]carbonyl]amino]butanoic Acid 605653-52-9P, tert-Butyl [(1S,2R)-1-benzyl-3-[[(4-formylphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]carbamate 853893-93-3P, (2S)-3-Methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxoimidazolidin-1-yl]butanoic Acid 853893-94-4P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(isobutylamino)propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 853894-11-8P, tert-Butyl N-(2-hydroxyethyl)-N-[(2-methyl-1,3-thiazol-4-yl)methyl]carbamate 853894-12-9P, Methyl (2S)-3-methyl-2-[[2-[[(2-methyl-1,3-thiazol-4-yl)methyl]amino]ethyl]amino]butanoate 853894-13-0P, 2-[[(2-Methyl-1,3-thiazol-4-yl)methyl]amino]ethanol 854739-72-3P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-[(E)-(hydroxyimino)methyl]-N-isobutylbenzenesulfonamide 854739-73-4P, (2S,3S)-3-Methyl-2-[3-[(6-methyl-2-pyridinyl)methyl]-2-oxo-1-imidazolidinyl]pentanoic Acid 854739-74-5P, (2S)-3,3-Dimethyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxoimidazolidin-1-yl]butanoic Acid 854739-75-6P, (2S)-2-[3-[[2-[(Dimethylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoic Acid 854739-76-7P, (2S)-3-Methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-imidazol-1-yl]butanoic Acid 854741-04-1P, (2S)-2-[3-[(2-Ethyl-1,3-thiazol-4-yl)methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanoic Acid 854741-49-4P, Methyl (2S,3S)-3-methyl-2-[[(4-nitrophenoxy)Carbonyl]amino]pentanoate 854743-38-7P, 3-Amino-N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-4-chloro-N-isobutylbenzenesulfonamide 854743-39-8P, 3-Amino-N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutylbenzenesulfonamide 854743-40-1P, N-[5-[[((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)(isobutyl)amino]sulfonyl]-2-hydroxyphenyl]-1-methyl-1H-imidazole-4-sulfonamide 854743-41-2P, N-[5-[[((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)(isobutyl)amino]sulfonyl]-2-hydroxyphenyl]-3-pyridinesulfonamide 854743-42-3P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutyl-3-[(methylsulfonyl)amino]benzenesulfonamide 854743-43-4P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-3,5-dichloro-4-hydroxy-N-isobutylbenzenesulfonamide 854743-44-5P, N-((2R,3S)-3-Amino-2-

hydroxy-4-phenylbutyl)-3,5-dichloro-2-hydroxy-N-isobutylbenzenesulfonamide 854743-45-6P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutyl-3-methylbenzenesulfonamide 854743-46-7P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-5-fluoro-4-hydroxy-N-isobutyl-2-methylbenzenesulfonamide 854743-47-8P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-5-chloro-4-hydroxy-N-isobutyl-2-methylbenzenesulfonamide 854743-48-9P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-3-chloro-4-hydroxy-N-isobutyl-5-methylbenzenesulfonamide 854743-49-0P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-2-chloro-4-hydroxy-N-isobutyl-5-methylbenzenesulfonamide 854743-50-3P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutyl-3-[[(methylamino)sulfonyl]amino]benzenesulfonamide 854743-57-0P, 4-Amino-N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-3-hydroxy-N-isobutylbenzenesulfonamide 854745-35-0P, (Acetyloxy)[4-[[[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl](isobutyl)amino]sulfonyl]phenyl]methyl Acetate 854745-36-1P, tert-Butyl (2S,3S)-2-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]amino]-3-methylpentanoate 854745-37-2P, tert-Butyl (2S,3S)-2-[(2-aminoethyl)amino]-3-methylpentanoate 854745-38-3P, tert-Butyl (2S,3S)-3-methyl-2-[[2-[[(6-methyl-2-pyridinyl)methyl]amino]ethyl]amino]pentanoate 854745-39-4P, tert-Butyl (2S,3S)-3-methyl-2-[3-[(6-methyl-2-pyridinyl)methyl]-2-oxo-1-imidazolidinyl]pentanoate 854745-40-7P, N-(2,2-Dimethoxyethyl)-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]amine 854745-41-8P, 9H-Fluoren-9-ylmethyl N-(2,2-dimethoxyethyl)-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]carbamate 854745-42-9P 854745-43-0P, Methyl (2S)-2-[[2-[[(9H-fluoren-9-ylmethoxy)Carbonyl][(1-methyl-1H-benzimidazol-2-yl)methyl]amino]ethyl]amino]-3,3-dimethylbutanoate 854745-44-1P, Methyl (2S)-3,3-dimethyl-2-[3-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-oxoimidazolidin-1-yl]butanoate 854745-45-2P, tert-Butyl (2S)-2-[3-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoate 854745-46-3P, N-(2,2-Diethoxyethyl)-N-[(2-methyl-1,3-thiazol-4-yl)methyl]amine 854745-47-4P, Methyl (2S)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-imidazol-1-yl]butanoate 854745-48-5P, 2-(Diethoxymethyl)-1,3-thiazole-4-carboxaldehyde 854745-49-6P, tert-Butyl (2S)-2-[3-[[2-(diethoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoate 854745-51-0P, tert-Butyl (2S)-2-[3-[(2-formyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoate 854745-52-1P, tert-Butyl (2S)-3-methyl-2-[3-[[2-[(methylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanoate 854745-53-2P, tert-Butyl (2S)-2-[3-[[2-[[[(9H-fluoren-9-ylmethoxy)Carbonyl](methyl)amino]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoate 854745-54-3P, 9H-Fluoren-9-ylmethyl N-[[4-[[3-[(1S)-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]amino]Carbonyl]-2-methylpropyl]-2-oxo-1-imidazolidinyl]methyl]-1,3-thiazol-2-yl]methyl](methyl)Carbamate 854745-55-4P, (2S)-N-((1S,2R)-3-Azido-1-benzyl-2-hydroxypropyl)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxoimidazolidin-1-yl]butanamide 854745-56-5P, (2S)-N-((1S,2R)-3-Amino-1-benzyl-2-hydroxypropyl)-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxoimidazolidin-1-yl]butanamide 854745-57-6P 854745-58-7P 854745-59-8P, tert-Butyl (2S,3S)-2-[3-[[2-(diethoxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoate 854745-60-1P, tert-Butyl (2S,3S)-2-[3-[(2-formyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoate 854745-61-2P, tert-Butyl (2S,3S)-2-[3-[[2-(hydroxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoate 854745-62-3P, tert-Butyl (2S,3S)-3-methyl-2-[3-[[2-[[(methylsulfonyl)oxy]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]pentanoate 854745-63-4P, tert-Butyl

(2S,3S)-2-[3-[[2-(azidomethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoate 854745-64-5P, (2S,3S)-2-[3-[[2-[[[(9H-Fluoren-9-ylmethoxy)Carbonyl]amino]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoic Acid 854745-65-6P 854745-66-7P 854745-67-8P, tert-Butyl (2S,3S)-2-[3-[[2-[(isopropylamino)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoate 854745-68-9P, (2S,3S)-2-[3-[[2-[[[(9H-Fluoren-9-ylmethoxy)Carbonyl](isopropyl)amino]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylpentanoic Acid 854745-69-0P 854745-70-3P, tert-Butyl (2S,3S)-3-methyl-2-[2-oxo-3-[[6-[(trityloxy)methyl]pyridin-2-yl]methyl]imidazolidin-1-yl]pentanoate 854745-71-4P, (2S,3S)-3-Methyl-2-[2-oxo-3-[[6-[(trityloxy)methyl]pyridin-2-yl]methyl]imidazolidin-1-yl]pentanoic Acid 854745-72-5P 854745-73-6P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-2-[3-[[6-(hydroxymethyl)pyridin-2-yl]methyl]-2-oxoimidazolidin-1-yl]-3-methylpentanamide 854745-74-7P, (2S)-2-[3-[(6-Acetyl-2-pyridinyl)methyl]-2-oxo-1-imidazolidinyl]-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](isobutyl)amino]propyl]-3,3-dimethylbutanamide 854745-75-8P, tert-Butyl (2S,3S)-2-[(aminocarbonyl)(2-ethoxy-2-oxoethyl)amino]-3-methylpentanoate 854745-76-9P, tert-Butyl (2S,3S)-2-(2,4-dioxo-1-imidazolidinyl)-3-methylpentanoate 854745-77-0P, tert-Butyl (2S,3S)-3-methyl-2-[3-[(6-methyl-2-pyridinyl)methyl]-2,4-dioxo-1-imidazolidinyl]pentanoate 854745-79-2P 854745-80-5P, tert-Butyl (2S)-2-[(2-ethoxy-2-oxoethyl)amino]-3-methylbutanoate 854745-81-6P, tert-Butyl (2S)-2-(2,4-dioxo-1-imidazolidinyl)-3-methylbutanoate 854745-82-7P, tert-Butyl (2S)-2-[3-[(2-ethyl-1,3-thiazol-4-yl)methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanoate 854745-83-8P, tert-Butyl (2S)-2-[3-[[2-(diethoxymethyl)-1,3-thiazol-4-yl]methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanoate 854745-84-9P, tert-Butyl (2S)-2-[3-[(2-formyl-1,3-thiazol-4-yl)methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanoate 854745-85-0P, tert-Butyl (2S)-2-[3-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl]-2,4-dioxo-1-imidazolidinyl]-3-methylbutanoate 854745-87-2P 854745-88-3P 854745-89-4P, Methyl (2S,3S)-2-[[[[[2-[[(tert-butoxycarbonyl)amino]methyl]-1,3-thiazol-4-yl]methyl](methyl)amino]carbonyl]amino]-3-methylpentanoate 854745-90-7P, (2S,3S)-2-[[[[[2-[[(tert-Butoxycarbonyl)amino]methyl]-1,3-thiazol-4-yl]methyl](methyl)amino]carbonyl]amino]-3-methylpentanoic Acid 854745-91-8P 854745-92-9P, tert-Butyl [(1S)-1-[4-[(methylamino)methyl]-1,3-thiazol-2-yl]ethyl]carbamate 854745-93-0P, Methyl (2S,3S)-2-[[[[[2-[(1S)-1-[(tert-butoxycarbonyl)amino]ethyl]-1,3-thiazol-4-yl]methyl](methyl)amino]carbonyl]amino]-3-methylpentanoate 854745-94-1P 854745-95-2P, 1-[6-[(Methylamino)methyl]-2-pyridinyl]ethanone 854745-96-3P, tert-Butyl (2S,3S)-2-[[[[(6-acetyl-2-pyridinyl)methyl](methyl)amino]carbonyl]amino]-3-methylpentanoate 854745-97-4P, (2S,3S)-2-[[[[(6-Acetyl-2-pyridinyl)methyl](methyl)amino]carbonyl]amino]-3-methylpentanoic Acid 854745-98-5P 854745-99-6P, Hexahydrofuro[2,3-b]furan-3-yl 4-nitrophenyl carbonate 854746-00-2P, Methyl (2S)-2-[(chloroacetyl)amino]-3,3-dimethylbutanoate 854746-01-3P, Methyl (2S)-2-[2-[[(3-fluorobenzyl)amino]ethanoyl]amino]-3,3-dimethylbutanoate 854746-02-4P 854746-03-5P 854746-04-6P 854746-05-7P 854746-06-8P 854746-07-9P 854746-08-0P, tert-Butyl (2S)-2-[3-[[2-(hydroxymethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoate 854746-09-1P, tert-Butyl (2S)-3-methyl-2-[3-[[2-[[(methylsulfonyl)oxy]methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanoate 854746-10-4P, (2S)-2-[3-[[2-(Azidomethyl)-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]-3-methylbutanoic Acid 854746-12-6P, tert-Butyl (2S)-3-methyl-2-[3-[[2-[(methylsulfanyl)methyl]-1,3-thiazol-4-yl]methyl]-2-oxo-1-imidazolidinyl]butanoate 854746-13-7P, 9H-Fluoren-9-ylmethyl N-[[4-[[3-[(1S)-1-[[[(1S,2R)-1-

benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]amino]carbonyl]-2-methylpropyl]-2-oxo-1-imidazolidinyl]methyl]-1,3-thiazol-2-yl]methyl](methyl)Carbamate 854746-14-8P, 9H-Fluoren-9-ylmethyl [4-[[3-[(1S,2S)-1-[[[(1S,2R)-1-benzyl-3-[(cyclopentylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]amino]carbonyl]-2-methylbutyl]-2-oxo-1-imidazolidinyl]methyl]-1,3-thiazol-2-yl](methyl)carbamate 854746-15-9P, Benzyl [(1S)-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]amino]carbonyl]-3-hydroxypropyl]carbamate 854746-16-0P, 9H-Fluoren-9-ylmethyl N-[2-[[(1S)-1-[[[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]amino]carbonyl]-3-hydroxypropyl]amino]ethyl][(1-methyl-1H-benzimidazol-2-yl)methyl]carbamate 854746-17-1P, [3-[(1S)-1-[[[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]amino]carbonyl]-2-methylpropyl]-2,5-dioxo-1-imidazolidinyl]acetic acid 854746-18-2P 854746-19-3P, tert-Butyl [(1S,2R)-1-benzyl-3-[[(4-chloro-3-nitrophenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]carbamate 854746-20-6P, 4-(Benzyloxy)-3-nitrobenzenesulfonyl Chloride 854746-21-7P, tert-Butyl [(1S,2R)-1-benzyl-3-[[[4-(benzyloxy)-3-nitrophenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]carbamate 854746-22-8P 854746-23-9P 854746-24-0P 854746-25-1P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-hydroxy-3-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]sulfonyl](isobutyl)amino]propyl]carbamate 854746-26-2P 854746-27-3P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-hydroxy-3-[(3-pyridinylsulfonyl)amino]phenyl]sulfonyl](isobutyl)amino]propyl]carbamate 854746-28-4P 854746-29-5P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]sulfonyl](isobutyl)amino]propyl]carbamate 854746-30-8P, 4-(Benzyloxy)-3-methylbenzenesulfonyl Chloride 854746-31-9P 854746-32-0P, tert-Butyl [(1S,2R)-1-benzyl-3-[[[4-(benzyloxy)-3-methylphenyl]sulfonyl](isobutyl)amino]-2-hydroxypropyl]carbamate 854746-33-1P, 5-Fluoro-4-hydroxy-2-methylbenzenesulfonyl Chloride 854746-34-2P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[(4-hydroxy-3-nitrophenyl)sulfonyl](isobutyl)amino]propyl]carbamate 854746-35-3P 854746-36-4P, tert-Butyl [(1S,2R)-3-[[[3-amino-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl](isobutyl)amino]-1-benzyl-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-37-5P, tert-Butyl [(1S,2R)-1-benzyl-3-[N-isobutyl[[3-[[(methylamino)sulfonyl]amino]-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl]amino]-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-38-6P, tert-Butyl [(1S,2R)-1-benzyl-3-[[[3-[(ethoxycarbonyl)amino]-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl](isobutyl)amino]-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-39-7P 854746-40-0P, tert-Butyl [(1S,2R)-1-benzyl-3-[[[3-(dimethylamino)-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl](isobutyl)amino]-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-41-1P, tert-Butyl [(1S,2R)-1-benzyl-3-[[[3-[[(ethylamino)Carbonyl]amino]-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl](isobutyl)amino]-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-42-2P, tert-Butyl [(1S,2R)-1-benzyl-3-[N-isobutyl[[3-[(methoxycarbonyl)amino]-4-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]sulfonyl]amino]-2-[[2-(trimethylsilyl)ethoxy]methoxy]propyl]carbamate 854746-43-3P, Benzyl [5-[[[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-4-phenyl-2-[[2-(trimethylsilyl)ethoxy]methoxy]butyl](isobutyl)amino]sulfonyl]-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl]carbamate 854746-44-4P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)sulfonyl]amino]propyl]carbamate 854746-45-5P, tert-Butyl [(1S,2R)-1-benzyl-2-hydroxy-3-[[[4-(2-hydroxyethyl)phenyl]sulfonyl](isobutyl)amino]propyl]carbamate 854746-47-7P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(4-hydroxy-3-

nitrophenyl)sulfonyl](isobutyl)amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-48-8P, (2S)-N-[(1S,2R)-3-[[(3-Amino-4-hydroxyphenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-49-9P, (2S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(3-nitrophenyl)sulfonyl]amino]propyl]-3-methyl-2-[3-[(2-methyl-1,3-thiazol-4-yl)methyl]-2-oxo-1-imidazolidinyl]butanamide 854746-50-2P 854746-52-4P, (2S,3S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(isobutylamino)propyl]-3-methyl-2-[2-oxo-3-(3-pyridinylmethyl)-1-imidazolidinyl]pentanamide 854746-53-5P 854760-88-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 59-49-4, 2(3H)-Benzoxazolone 70-23-5, Ethyl bromopyruvate 78-81-9, Isobutylamine 88-75-5, 2-Nitrophenol 98-74-8, p-Nitrobenzenesulfonyl chloride 100-82-3, 3-Fluorobenzylamine 105-36-2, Ethyl bromoacetate 109-90-0, Ethyl isocyanate 121-51-7, 3-Nitrobenzenesulfonyl chloride 456-48-4, 3-Fluorobenzaldehyde 501-53-1, Benzyl chloroformate 615-74-7, 2-Chloro-5-methylphenol 636-73-7, 3-Pyridinesulfonic acid 645-36-3, Aminoacetaldehyde diethyl acetal 1122-71-0, 6-Methyl-2-pyridinemethanol 1122-72-1, 6-Methyl-2-pyridinecarboxaldehyde 1195-59-1, 2,6-Pyridinedimethanol 2258-42-6, Formic acetic anhydride 2633-67-2, 4-Vinylbenzenesulfonyl chloride 3012-80-4, 1-Methyl-2-formylbenzimidazole 3392-07-2 4070-48-8, (L)-Methyl valinate 4530-20-5, Boc-glycine 4533-96-4 4766-51-2 5306-98-9, 3-Chloro-6-methylphenol 6313-34-4 7134-04-5, O-Cresol-4-sulfonic acid 7693-46-1, 4-Nitrophenyl chloroformate 7764-95-6, Boc-(D)-alanine 10130-74-2, 3-Methoxybenzenesulfonyl chloride 13432-81-0, 3,5-Dichloro-4-hydroxybenzenesulfonyl chloride 13518-40-6 15761-38-3, Boc-L-alanine 18598-74-8, (L)-Methyl iso-leucinate hydrochloride 23378-88-3, 3,5-Dichloro-6-hydroxybenzenesulfonyl chloride 28920-43-6, 9H-Fluoren-9-ylmethyl chloroformate 30605-38-0, Dichloroacetone 32703-87-0 35677-89-5 39238-07-8, 4-Chloromethyl-2-methylthiazole 40516-60-7, 4-Chloromethyl-2-ethylthiazole 41057-04-9, 2-Nitrothiophene-3-carboxaldehyde 49584-26-1, p-Cyanobenzenesulfonyl chloride 53481-49-5 61189-99-9 62965-35-9 63038-27-7, (L)-tert-Leucine methyl ester hydrochloride 63762-79-8, 2-Fluoro-5-methylphenol 69320-89-4 69610-41-9, N-tert-Butoxycarbonyl-(L)-prolinal 76513-69-4, [2-(Trimethylsilyl)ethoxy]methyl chloride 85822-16-8, 4-Formylbenzenesulfonyl chloride 87001-32-9 98737-29-2 137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 854745-50-9 854746-51-3 854760-90-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 854743-51-4P, Ethyl [5-[[((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)(isobutyl)amino]sulfonyl]-2-hydroxyphenyl]carbamate 854743-52-5P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-hydroxy-N-isobutyl-3-(methylamino)benzenesulfonamide 854743-53-6P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-3-(dimethylamino)-4-hydroxy-N-isobutylbenzenesulfonamide 854743-54-7P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-3-[[(ethylamino)Carbonyl]amino]-4-hydroxy-N-isobutylbenzenesulfonamide 854743-55-8P, Methyl [5-[[((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)(isobutyl)amino]sulfonyl]-2-hydroxyphenyl]carbamate 854743-56-9P, Benzyl [5-[[((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)(isobutyl)amino]sulfonyl]-2-hydroxyphenyl]carbamate 854743-58-1P, N-((2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl)-4-(2-hydroxyethyl)-N-isobutylbenzenesulfonamide 854743-59-2P, N-((2R,3S)-3-Amino-2-

hydroxy-4-phenylbutyl)-N-isobutyl-4-[(methylsulfonyl)amino]benzene sulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

IT 854746-11-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of **HIV** protease inhibitors, in particular imidazolidine derivs.)

L82 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:527398 HCAPLUS Full-text
DOCUMENT NUMBER: 143:78485
TITLE: Preparation of amino acid derivatives as **HIV** protease inhibitors
INVENTOR(S): Degoey, David A.; Flentge, Charles A.; Flosi, William J.; Grampovnik, David J.; Kempf, Dale J.; Klein, Larry L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 204 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131017	A1	20050616	US 2003-733946	2003 1211
CA 2549098	AA	20050630	CA 2004-2549098	2004 1209
			<--	
WO 2005058841	A2	20050630	WO 2004-US41658	2004 1209
			<--	
WO 2005058841	A3	20060309		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1697344	A2	20060906	EP 2004-813910	2004 1209
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-733946 A 2003 1211
<--
WO 2004-US41658 W

OTHER SOURCE(S): MARPAT 143:78485

AB The invention relates to amino acid derivs. A- NHCHR6CHR5CHR4CHR3NHCOCHR2NHCO2R1 [A is an amino acid or acyl residue of defined structure; R1, R2, R3, R6 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl or heteroaryl; R4, R5 are H (not both), OH or substituted hydroxyl], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having **HIV** protease inhibitory activity. Thus, Me (1S,4R,6S,7S,10S)-7-benzyl- 1,10-di-tert-butyl-6-hydroxy-2,9,12-trioxo-4-[4-(2- pyridinyl)benzyl]-13-oxa-3,8,11-triazatetradec-1-ylcarbamate was prepared by a multistep procedure, which includes the reaction of intermediate tert-Bu (1S,2S,4R)-4-amino-1-benzyl-2-hydroxy-5-[4-(2-pyridinyl)phenyl]pentylcarbamate with N-protected L-tert-leucine. Compds. of the invention showed EC50 values 0.7-300 nM against wild-type **HIV**.

IT **25526-93-6**, Alovudine **92562-88-4**, MIV-210
129618-40-2, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-4709
ICS A61K031-4439; A61K031-427; C07D043-02; C07D417-02
INCL 514312000; 514341000; 546272700; 546153000; 514365000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): **1**, 7, **63**
ST amino acid peptide isostere prepn inhibitor **HIV** protease
IT **Antiviral** agents
Human
Human immunodeficiency virus
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT Amino acids, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(pseudopeptides; preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 144114-21-6, **Hiv** protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 854754-19-1P 854755-08-1P 854755-09-2P 854755-10-5P
854755-12-7P 854755-25-2P 854755-36-5P 854755-37-6P
854755-46-7P 854755-47-8P 854755-48-9P 854755-49-0P
854755-50-3P 854755-84-3P 854756-41-5P 854756-43-7P
854757-60-1P 854757-85-0P 854758-79-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)
IT 192725-55-6P 854754-01-1P 854754-05-5P 854754-12-4P
854754-23-7P 854754-28-2P 854754-31-7P 854754-34-0P
854754-36-2P 854754-42-0P 854754-48-6P 854754-49-7P
854754-53-3P 854754-60-2P 854754-64-6P 854754-65-7P
854754-71-5P 854754-72-6P 854754-76-0P 854754-79-3P
854754-80-6P 854754-82-8P 854755-01-4P 854755-03-6P
854755-04-7P 854755-06-9P 854755-14-9P 854755-21-8P
854755-26-3P 854755-30-9P 854755-31-0P 854755-35-4P
854755-38-7P 854755-45-6P 854755-51-4P 854755-54-7P
854755-57-0P 854755-61-6P 854755-65-0P 854755-69-4P
854755-72-9P 854755-73-0P 854755-74-1P 854755-75-2P
854755-76-3P 854755-77-4P 854755-81-0P 854755-82-1P
854755-86-5P 854755-91-2P 854755-99-0P 854756-01-7P
854756-05-1P 854756-09-5P 854756-11-9P 854756-21-1P
854756-33-5P 854756-35-7P 854756-37-9P 854756-39-1P
854756-45-9P 854756-56-2P 854756-58-4P 854756-63-1P
854756-68-6P 854756-70-0P 854756-75-5P 854756-80-2P
854756-88-0P 854756-94-8P 854757-02-1P 854757-04-3P
854757-06-5P 854757-08-7P 854757-10-1P 854757-32-7P
854757-34-9P 854757-38-3P 854757-40-7P 854757-49-6P
854757-56-5P 854757-62-3P 854757-68-9P 854757-70-3P
854757-72-5P 854757-76-9P 854757-82-7P 854757-87-2P
854758-00-2P 854758-04-6P 854758-13-7P 854758-17-1P
854758-29-5P 854758-32-0P 854758-41-1P 854758-48-8P
854758-49-9P 854758-54-6P 854758-57-9P 854758-58-0P
854758-61-5P 854758-64-8P 854758-67-1P 854758-71-7P
854758-78-4P 854758-85-3P 854758-86-4P 854758-90-0P

854758-93-3P 854758-96-6P 854758-97-7P 854758-98-8P
854758-99-9P 854759-00-5P 854759-01-6P 854759-02-7P
854759-03-8P 854759-04-9P 854759-05-0P 854759-06-1P
854759-07-2P 854759-08-3P 854759-09-4P 854759-10-7P
854759-11-8P 854759-12-9P 854759-13-0P 854759-14-1P
854759-15-2P 854759-16-3P 854759-17-4P 854759-18-5P
854759-19-6P 854759-20-9P 854759-21-0P 854759-22-1P
854759-23-2P 854759-24-3P 854759-25-4P 854759-26-5P
854759-27-6P 854759-28-7P 854759-29-8P 854759-30-1P
854759-33-4P 854759-35-6P 854759-38-9P 854759-40-3P
854759-42-5P 854759-46-9P 854759-47-0P 854759-48-1P
854759-49-2P 854759-51-6P 854759-52-7P 854759-53-8P
854759-54-9P 854759-55-0P 854759-56-1P 854759-57-2P
854759-58-3P 854759-59-4P 854759-60-7P 854759-61-8P
854759-62-9P 854759-63-0P 854759-64-1P 854759-65-2P
854759-67-4P 854759-69-6P 854759-72-1P 854759-77-6P
854759-79-8P 854759-81-2P 854759-83-4P 854759-85-6P
854759-87-8P 854759-89-0P 854759-90-3P 854759-92-5P
854759-93-6P 854759-94-7P 854759-95-8P 854759-97-0P
854759-98-1P 854760-00-2P 854760-01-3P 854760-03-5P
854760-05-7P 854760-06-8P 854760-07-9P 854760-09-1P
854760-10-4P 854760-13-7P 854760-17-1P 854760-19-3P
854760-22-8P 854760-24-0P 854760-25-1P 854760-26-2P
854760-27-3P 854760-28-4P 854760-29-5P 854760-30-8P
854760-31-9P 854760-32-0P 854760-33-1P 854760-34-2P
854760-35-3P 854760-36-4P 854760-37-5P 854760-38-6P
854760-39-7P 854760-40-0P 854760-42-2P 854760-43-3P
854760-44-4P 854760-45-5P 854760-46-6P 854760-47-7P
854760-48-8P 854760-49-9P 854760-50-2P 854760-51-3P
854760-52-4P 854760-53-5P 854760-54-6P 854760-55-7P
854760-56-8P 854760-57-9P 854760-61-5P 854760-65-9P
854760-66-0P 854760-67-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 854760-68-2P 854760-69-3P 854760-70-6P 854760-71-7P
854760-72-8P 854760-73-9P 854760-74-0P 854760-75-1P
854760-76-2P 854760-77-3P 854760-78-4P 854760-79-5P
854892-38-9P 854892-41-4P 854892-42-5P 854892-43-6P
854892-44-7P 854892-45-8P 854892-46-9P 854892-47-0P
854892-48-1P 854892-49-2P 854892-50-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 60-18-4, L-Tyrosine, reactions 62-55-5, Thioacetamide 70-23-5, Ethyl bromopyruvate 73-32-5, L-Isoleucine, reactions 98-80-6, Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 100-52-7, Benzaldehyde, reactions 105-36-2, Ethyl bromoacetate 105-53-3, Diethyl malonate 135-02-4, o Anisaldehyde 274-47-5, Imidazo[1,5-a]pyridine 500-22-1, 3-Pyridinecarboxaldehyde 529-20-4, o Tolualdehyde 534-07-6, 1 3 Dichloroacetone 552-89-6, 2-Nitrobenzaldehyde 563-83-7, Isobutyramide 589-15-1, 4-Bromobenzyl bromide 591-31-1, m Anisaldehyde 620-23-5, m Tolualdehyde 630-19-3, Trimethylacetaldehyde 701-99-5, Phenoxyacetyl chloride 1113-41-3, L-Penicillamine 1121-60-4, 2-Pyridinecarboxaldehyde 1122-71-0, 6-Methyl 2-pyridinemethanol 1122-72-1, 6-Methyl 2 pyridinecarboxaldehyde 1189-71-5, Chlorosulfonyl isocyanate 1452-77-3, 2-Pyridinecarboxamide 1589-82-8, Benzylmagnesium bromide 1730-25-2, Allylmagnesium bromide 3012-80-4, 1 Methyl 2 formylbenzimidazole 3430-13-5, 5-Bromo-2-methylpyridine 3510-66-5, 2-Bromo-5-methylpyridine 4363-93-3, 4-Quinolinecarboxaldehyde 4530-20-5 4621-66-3,

Thionicotinamide 4926-28-7, 2-Bromo 4 methylpyridine
5315-25-3, 2-Bromo-6-methylpyridine 5453-67-8, Dimethyl 2
6-pyridinedicarboxylate 5470-70-2, Methyl 6-methylnicotinate
6436-59-5 13335-71-2, 2,6-Dimethylphenoxyacetic acid
17997-47-6, 2 Tributylstannylpyridine 20859-02-3, L-tert Leucine
24015-97-2 24250-84-8, 4-Bromo L-phenylalanine 32939-32-5
37595-74-7, n-Phenyltrifluoromethanesulfonimide 40473-07-2,
2-Bromo 6 methoxypyridine 52199-24-3 65719-09-7, Methyl
2-methylnicotinate 69320-89-4 78795-02-5 78902-09-7,
Phthalimidoacetaldehyde diethyl acetal 98760-08-8 119483-45-3
162119-33-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease
inhibitors)

IT 2913-97-5P 5346-38-3P, 2-Pyridinecarbothioamide 13515-65-6P
15536-75-1P 19550-89-1P 20949-84-2P 39067-28-2P
39238-07-8P 39977-44-1P 53014-84-9P 56671-66-0P,
Imidazo[1,5-a]pyridine-3-carboxaldehyde 60032-57-7P
69950-65-8P 74761-39-0P 133047-44-6P 133047-45-7P
133047-46-8P 138745-99-0P 144163-81-5P 144163-85-9P
144163-88-2P 161772-80-1P 162537-11-3P 163116-17-4P
164014-94-2P 167556-64-1P 169870-02-4P 173838-60-3P
177748-39-9P 184679-13-8P 189195-41-3P 191481-72-8P
259807-95-9P 266306-18-7P 301652-23-3P 338462-91-2P
760938-66-7P 854739-74-5P 854741-49-4P 854745-36-1P
854745-37-2P 854745-39-4P 854745-40-7P 854745-41-8P
854745-42-9P 854745-75-8P 854745-76-9P 854745-77-0P
854745-79-2P 854753-93-8P 854753-94-9P 854753-96-1P
854753-97-2P 854753-98-3P 854753-99-4P 854754-00-0P
854754-02-2P 854754-03-3P 854754-04-4P 854754-06-6P
854754-07-7P 854754-08-8P 854754-09-9P 854754-11-3P
854754-14-6P 854754-15-7P 854754-16-8P 854754-17-9P
854754-20-4P 854754-21-5P 854754-22-6P 854754-24-8P
854754-26-0P 854754-27-1P 854754-29-3P 854754-30-6P
854754-32-8P 854754-33-9P 854754-35-1P 854754-37-3P
854754-38-4P 854754-40-8P 854754-41-9P 854754-43-1P
854754-45-3P 854754-46-4P 854754-47-5P 854754-50-0P
854754-52-2P 854754-54-4P 854754-56-6P 854754-58-8P
854754-59-9P 854754-61-3P 854754-63-5P 854754-66-8P
854754-67-9P 854754-68-0P 854754-70-4P 854754-73-7P
854754-75-9P 854754-78-2P 854754-81-7P 854754-83-9P
854754-84-0P 854754-85-1P 854754-86-2P 854754-87-3P
854754-88-4P 854754-89-5P 854754-90-8P 854754-91-9P
854754-92-0P 854754-93-1P 854754-94-2P 854754-95-3P
854754-96-4P 854754-97-5P 854754-98-6P 854754-99-7P
854755-00-3P 854755-02-5P 854755-05-8P 854755-07-0P
854755-23-0P 854755-27-4P 854755-29-6P 854755-32-1P
854755-34-3P 854755-39-8P 854755-40-1P 854755-41-2P
854755-42-3P 854755-44-5P 854755-52-5P 854755-53-6P
854755-55-8P 854755-56-9P 854755-58-1P 854755-60-5P
854755-62-7P 854755-64-9P 854755-66-1P 854755-68-3P
854755-70-7P 854755-71-8P 854755-78-5P 854755-79-6P
854755-80-9P 854755-83-2P 854755-85-4P 854755-87-6P
854755-88-7P 854755-89-8P 854755-90-1P 854755-92-3P
854755-93-4P 854755-95-6P 854755-97-8P 854756-03-9P
854756-07-3P 854756-13-1P 854756-15-3P 854756-17-5P
854756-19-7P 854756-25-5P 854756-27-7P 854756-29-9P
854756-31-3P 854756-48-2P 854756-50-6P 854756-52-8P
854756-54-0P 854756-61-9P 854756-66-4P 854756-73-3P
854756-78-8P 854756-82-4P 854756-84-6P 854756-86-8P
854756-90-4P 854756-92-6P 854756-96-0P 854756-98-2P
854757-00-9P 854757-12-3P 854757-14-5P 854757-16-7P
854757-18-9P 854757-20-3P 854757-22-5P 854757-24-7P
854757-26-9P 854757-28-1P 854757-30-5P 854757-36-1P
854757-42-9P 854757-44-1P 854757-47-4P 854757-51-0P
854757-54-3P 854757-58-7P 854757-64-5P 854757-66-7P
854757-74-7P 854757-78-1P 854757-80-5P 854757-90-7P

854757-91-8P 854757-93-0P 854757-94-1P 854757-95-2P
854757-97-4P 854757-99-6P 854758-02-4P 854758-09-1P
854758-11-5P 854758-15-9P 854758-20-6P 854758-22-8P
854758-23-9P 854758-24-0P 854758-25-1P 854758-26-2P
854758-27-3P 854758-28-4P 854758-30-8P 854758-31-9P
854758-33-1P 854758-34-2P 854758-35-3P 854758-36-4P
854758-37-5P 854758-38-6P 854758-40-0P 854758-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 854758-43-3P 854758-44-4P 854758-45-5P 854758-47-7P
854758-50-2P 854758-51-3P 854758-52-4P 854758-53-5P
854758-55-7P 854758-56-8P 854758-59-1P 854758-60-4P
854758-62-6P 854758-63-7P 854758-65-9P 854758-66-0P
854758-68-2P 854758-69-3P 854758-70-6P 854758-72-8P
854758-73-9P 854758-74-0P 854758-75-1P 854758-76-2P
854758-77-3P 854758-80-8P 854758-81-9P 854758-82-0P
854758-83-1P 854758-84-2P 854758-87-5P 854758-88-6P
854758-91-1P 854758-92-2P 854758-94-4P 854758-95-5P
854760-81-9P 854760-84-2P 854760-85-3P 854892-39-0P
854892-40-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 3056-17-5, Stavudine 7481-89-2, Zalcitabine **25526-93-6**, Alovudine 29321-75-3, PRO 2000 30516-87-1, Zidovudine 69655-05-6, Didanosine **92562-88-4**, MIV-210 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134379-77-4, D-D4FC 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142632-32-4, Calanolide A 143491-54-7, Racivir 143491-57-0, Emtricitabine 145514-04-1, Amdoxovir 147127-20-6, Tenofovir 147318-81-8, KNI-272 149950-60-7, Emivirine 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159519-65-0, Enfuvirtide 159989-64-7, Nelfinavir 160707-69-7, SPD754 161814-49-9, Amprenavir 170020-61-8, FP21399 171345-51-0, Zintevir 174022-42-5, PA-457 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 181785-84-2, Elvucitabine 186538-00-1, JE-2147 192725-17-0, Lopinavir 198904-31-3, Atazanavir 206361-99-1, TMC-114 206362-00-7, TMC-126 214287-88-4, DPC-961 214287-99-7, Dpc 083 216863-66-0, L-756423 226700-79-4, Fosamprenavir 231957-54-3, MIV-150 251562-00-2, T-1249 269055-15-4, TMC-125 280571-30-4, S-1360 284661-68-3, DPC-681 284661-73-0, DPC-684 357263-13-9, BMS-806 370893-06-4, Schering C 376348-65-1, UK-427857 383198-58-1, PRO 542 394728-76-8, TMC 120 394730-30-4, SCH-D 410544-95-5, L-870810 410545-90-3, L-870812 461443-59-4, GW873140 674782-26-4, PRO 140 854908-06-8, GW 5634
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 38870-89-2, Methoxyacetyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with ammonium acetate in preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 631-61-8, Ammonium acetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with methoxyacetyl chloride in preparation of amino acid derivs. as **HIV** protease inhibitors)

IT 7529-22-8, 4-Methylmorpholine 4 oxide
RL: RGT (Reagent); RACT (Reactant or reagent)
(sulfide oxidant; preparation of amino acid derivs. as **HIV** protease inhibitors)

L82 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:99157 HCAPLUS Full-text
DOCUMENT NUMBER: 142:170033
TITLE: Methods and compositions for the treatment or prevention of **human immunodeficiency virus** and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents
INVENTOR(S): Maziasz, Timothy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 172 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026902	A1	20050203	US 2004-769485	2004 0130
			<--	
PRIORITY APPLN. INFO.:			US 2003-443910P	P 2003 0131
			<--	

OTHER SOURCE(S): MARPAT 142:170033
AB The present invention provides compns. and methods for the treatment of **human immunodeficiency virus** (**HIV**) infection as well as **HIV** associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of **HIV** infection as well as **HIV** associated diseases and related disorders comprising the administration to a subject of an anti-**human immunodeficiency virus** agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.
IT **25526-93-6**, 3'-Fluoro-3'-deoxythymidine **41107-56-6**, 3'-Fluoro-2',3'-dideoxyuridine **51246-79-8**, 3'-Fluoro-2',3'-dideoxycytidine **87418-35-7** **92562-88-4**, 3'-Fluoro-2',3'-dideoxyguanosine **114753-53-6** **115249-86-0**, 2',3'-Dideoxy-3'-fluoro-5-bromouridine **119644-22-3**, 2',3'-Dideoxy-3'-fluoro-5-chlorouridine **119644-23-4** **124903-20-4** **127492-32-4** **129618-40-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 41107-56-6 HCAPLUS
CN Uridine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51246-79-8 HCAPLUS
CN Cytidine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 87418-35-7 HCAPLUS
CN Adenosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114753-53-6 HCAPLUS

CN Adenosine, 2-amino-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 115249-86-0 HCAPLUS
CN Uridine, 5-bromo-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-23-4 HCAPLUS
CN Uridine, 2',3'-dideoxy-3'-fluoro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 124903-20-4 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 127492-32-4 HCAPLUS
CN Cytidine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-55
ICS A61K031-54
INCL 514217000; 514226500
CC 1-5 (**Pharmacology**)
ST **HIV** infection related condition treatment cyclooxygenase 2 inhibitor **antiviral**
IT **AIDS** (disease)
(-related complex; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT CD4-positive T cell
T cell (lymphocyte)
(**HIV** infection reduces T-cells; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Sarcoma
(Kaposi's; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Cell proliferation
(T cell, proliferation inhibitor as virucide; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Muscle, disease
(ache; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT CD4 (antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist, as viral cellular entry inhibitor; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Cytotoxic agents
(antimetabolites, in treatment regimen; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Disease, animal
(arthropathy, aches; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Acyclonucleosides
Nucleosides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as anti-**HIV** agent; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Mycobacterium avium
(complex; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Meningitis
(cryptococcal; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Immunostimulants
(cyclooxygenase-2 inhibitor acts as an immunostimulant; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Joint, anatomical
(disease, aches; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT T cell (lymphocyte)
(helper cell, **HIV** infection reduces T-cells; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)
IT Infection
(herpes zoster; methods and compns. for treatment or prevention of **HIV** infection and related conditions using

cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Antibiotics
Antioxidants
Antitumor agents
Fungicides
Immunomodulators
Neoplasm
Protozoacides
Vaccines
(in treatment regimen; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Antibodies and Immunoglobulins
Cytokines
Hormones, animal, biological studies
Vitamins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in treatment regimen; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Cytomegalovirus
Human herpesvirus
(infection; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Glycosylation
(inhibitor, as viral assembly inhibitor; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT **AIDS** (disease)
Anti-**AIDS** agents
Combination chemotherapy
Diarrhea
Drug delivery systems
Fever and Hyperthermia
Gene therapy
Hepatitis
Human
Human immunodeficiency virus
Immunostimulation
Lymphoma
Seizures
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Natural products, pharmaceutical
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Antisense oligonucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Pneumonia
(pneumocystis carinii; methods and compns. for treatment or prevention of **HIV** infection and related conditions

using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Amines, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyamines, nonpolymeric, polyamine biosynthesis inhibitor as **HIV** inhibitor; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Viral RNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(processing inhibitor, as viral assembly inhibitor; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT T cell (lymphocyte)
(proliferation, proliferation inhibitor as virucide; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Skin, disease
(rash; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Lymph node, disease
(swelling; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Mouth, disease
(thrush; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Infection
(toxoplasmosis; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Infection
(viral; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(virion, antagonists as viral cellular entry inhibitor; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT Protein motifs
(zinc finger, inhibitor, as anti-**HIV** agent; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 30220-45-2
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(0; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 37205-61-1, Protease, inhibitor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as viral assembly inhibitor; methods and compns. for treatment

or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 15687-27-1, Ibuprofen
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in treatment regimen; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 9068-38-6, Reverse transcriptase 52350-85-3, Integrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor, as anti-**HIV** agent; methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 50-00-0, Formaldehyde, biological studies 111-30-8, Glutaral 548-04-9, Hypericin 2450-53-5, 3,5-Dicaffeoylquinic acid 6537-80-0 7770-78-7 13422-51-0, Hydroxocobalamin 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 33419-42-0 79831-76-8 113852-37-2, Cidofovir 126456-36-8 126456-38-0 127749-96-6 127749-99-9 127779-20-8 138483-63-3 139694-65-8 140196-60-7 141804-42-4 142762-74-1 143224-34-4 144142-67-6 144779-91-9 146654-21-9 147318-81-8 147384-69-8 148314-61-8 149267-24-3 151867-81-1 153353-79-8 159142-13-9 159878-27-0 159878-28-1 159989-65-8 160231-42-5 161186-50-1 161277-26-5 161277-30-1 161277-32-3 164514-52-7 165591-25-3 165591-39-9 168394-24-9 168899-54-5 169273-51-2 169273-55-6 173261-21-7 173828-55-2 174484-41-4 177932-89-7 179409-87-1 180463-16-5 180902-22-1 183854-24-2 188762-00-7 192725-17-0 244641-43-8 329900-75-6, Cyclooxygenase-2 834911-92-1 834911-93-2 834911-94-3 834911-95-4 834911-96-5 834911-97-6 834911-98-7 834911-99-8 834912-00-4 834912-01-5 834912-02-6 834912-03-7 834912-04-8 834912-05-9 834912-06-0 834912-07-1 834912-08-2 834912-09-3 834912-10-6 834912-11-7 834912-12-8 834912-13-9 834912-14-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 53-43-0, 3β-Hydroxyandrost-5-en-17-one 472-15-1 534-76-9 1077-28-7, 1,2-Dithiolane-3-pentanoic acid 1093-91-0, 16-α-Bromo-3-β-hydroxyandrost-5-en-17-one 6060-06-6 21967-41-9 41135-06-2, Inophyllum B 60857-08-1, 12-Deoxyphorbol-13-acetate 76663-53-1, 13-Hydroxyingenol-3-(2,3-dimethylbutanoate)-13-dodecanoate 102674-90-8 110042-95-0, Acemannan 134332-63-1 135383-02-7 137793-81-8 137893-48-2 138667-71-7 142632-32-4, Calanolide A 142632-33-5, Calanolide B 149572-31-6, Conocurvone 152187-38-7, Inophyllum P 155213-67-5, Ritonavir 165460-07-1 174022-42-5, 3-O-(3',3'-Dimethylsuccinyl)betulinic acid 184539-38-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 98-10-2D, Benzenesulfonamide, analogs and compds. 103-82-2D, Phenylacetic acid, derivs. 127-07-1, Hydroxyurea 129-46-4 254-04-6D, 2H-1-Benzopyran, compds. 254-04-6D, Benzopyran, compds. and analogs 2054-35-5D, analogs 3056-17-5 3112-85-4D, Methylsulfonylbenzene, analogs and compds. 3416-05-5, 3'-Deoxythymidine 4097-22-7, 2',3'-Dideoxyadenosine

4431-00-9, Aurintricarboxylic acid 7057-48-9 7481-88-1
7481-89-2, 2',3'-Dideoxycytidine 14665-52-2,
Bis(2-nitrophenyl)sulfone **25526-93-6**,
3'-Fluoro-3'-deoxythymidine 29828-28-2D, Dihydronaphthalene,
analogs 29968-14-7D, Dihydroquinoline, analogs 30516-87-1,
3'-Azido-3'-deoxythymidine 30516-87-1D, 3'-Azido-3'-
deoxythymidine, 5'alkylglycoside carbonates 31515-43-2,
2-Nitrophenyl phenyl sulfone 36791-04-5 **41107-56-6**,
3'-Fluoro-2',3'-dideoxyuridine **51246-79-8**,
3'-Fluoro-2',3'-dideoxycytidine 51803-78-2 53766-80-6,
2',3'-Didehydro-2',3'-dideoxyguanosine 63585-09-1,
Phosphonoformic acid trisodium salt 64224-21-1 66323-44-2
66323-46-4, 3'-Azido-2',3'-dideoxyguanosine 69655-05-6,
2',3'-Dideoxyinosine 71125-38-7 78794-60-2 79872-72-3
80937-31-1 84472-85-5, 3'-Azido-2',3'-dideoxyuridine
84472-89-9, 3'-Azido-2',3'-dideoxycytidine 85236-92-6,
3'-Azido-2',3'-dideoxy-5-iodouridine 85326-06-3,
2',3'-Dideoxyguanosine 85326-07-4, 6-Methyl-2',3'-
dideoxyadenosine 87190-74-7, 3'-Azido-2',3'-dideoxy-5-
fluorouridine 87190-79-2 87190-80-5 87190-84-9
87418-35-7 92562-88-4, 3'-Fluoro-2',3'-
dideoxyguanosine 93014-16-5, 4-(2-Methyl-4-phenyl-5-
oxazolyl)benzenesulfonamide 105380-83-4, 3'-Azido-2',3'-dideoxy-
5-ethyluridine 105784-82-5, 3'-Azido-2',3'-dideoxy-5-
bromouridine 106060-85-9 107036-62-4, 5-Fluoro-2',3'-
dideoxycytidine 107550-73-2 108441-50-5 108441-51-6,
3'-Azido-5-chloro-2',3'-dideoxyuridine 108895-46-1 109881-25-6
110142-99-9 110143-10-7 111495-90-0 111495-95-5
111495-96-6 111495-98-8 111496-01-6 114551-78-9
114753-53-6 115249-86-0, 2',3'-Dideoxy-3'-fluoro-
5-bromouridine 115913-79-6 116333-41-6 119555-47-4
119644-22-3, 2',3'-Dideoxy-3'-fluoro-5-chlorouridine
119644-23-4 120443-30-3 120503-30-2,
6-Dimethylaminopurine-2',3'-dideoxyriboside 120503-34-6
120503-35-7, N-Ethyl-2',3'-dideoxyadenosine 120826-45-1
121117-72-4 121135-52-2 121135-53-3 121353-93-3
123027-56-5 123663-49-0 124770-85-0 **124903-20-4**
125056-58-8 126062-18-8 126320-77-2 126347-69-1
127245-22-1 127492-31-3 **127492-32-4**
129618-40-2 130108-72-4 130108-73-5,
4'-Azido-2'-deoxyadenosine 130108-74-6, 4'-Azido-2'-
deoxyguanosine 130108-75-7, 4'-Azido-2'-deoxyuridine
130108-76-8, 4'-Azido-2'-deoxycytidine 130108-77-9,
4'-Azido-2'-deoxyinosine 130108-82-6, 4'-Azido-3'-deoxythymidine
130797-04-5 131293-25-9 131613-15-5 132235-73-5
132774-45-9 132796-66-8 132796-67-9 132796-68-0
132970-02-6 134379-77-4 134678-17-4, Epivir 135212-57-6
135525-66-5 135525-77-8 135560-41-7 135812-04-3
135812-34-9 136160-29-7 136160-30-0 136470-78-5, Ziagen
136816-75-6 136816-76-7 136816-96-1 136817-66-8
136891-12-8 137332-54-8 137945-48-3 138192-33-3
138226-12-7 139226-28-1 139418-97-6, 4'-Azido-5-chloro-2'-
deoxyuridine 139888-11-2, 4'-Cyanothymidine 141030-34-4
141030-55-9 141781-17-1 142102-79-2 143390-74-3
143491-57-0 143809-38-5 143809-39-6 144239-69-0
144433-06-7 145417-33-0 145514-01-8 145986-26-1
146739-86-8 147058-39-7 147362-57-0 147440-15-1
147584-54-1 147920-12-5 147920-13-6 147920-19-2
148311-89-1 148472-83-7, 5-Chloro-3-(phenylsulfonyl)indole-2-
carboxamide 149485-30-3 149485-98-3 149950-60-7
149950-61-8 150378-17-9, Indinavir 153562-59-5 153815-93-1
154598-52-4 158959-32-1, 1-[2-(4-Fluorophenyl)cyclopenten-1-yl]-
4-(methylsulfonyl)benzene 158959-33-2, 1-[2-(4-Fluoro-2-
methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene
158959-34-3, 1-[2-(4-Chlorophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 158959-35-4, 1-[2-(2,4-
Dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene

158959-37-6, 1-[2-(4-Trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene 158959-42-3, 1-[2-(4-Methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene 158959-43-4, 1-[2-(4-Fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene 158959-46-7, 4-[2-(4-Fluorophenyl)cyclopenten-1-yl]benzenesulfonamide 158959-47-8, 4-[2-(4-Chlorophenyl)cyclopenten-1-yl]benzenesulfonamide 158959-56-9, 4-[2-(4-Fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide 159429-69-3, 1-[2-(4-Methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene 159429-70-6, 1-[2-(4-Chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene 159499-99-7 159519-65-0, Enfuvirtide 159989-64-7, Nelfinavir 160705-95-3 160707-69-7 160707-70-0 160707-71-1 160963-01-9 162011-90-7 162054-19-5 163303-19-3 163303-25-1 163303-29-5 163303-38-6 163303-55-7 163451-80-7 165251-89-8 165328-42-7, 1-[2-(2,3-Difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene 165328-49-4, 4-[2-(4-Chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide 165328-51-8 168146-84-7 168299-83-0 168299-90-9 168433-84-9 169154-04-5 169154-07-8 169154-19-2 169154-24-9 169590-41-4, 4-[[5-(3-Fluoro-4-methoxyphenyl)-3-difluoromethyl]-1H-pyrazol-1-yl]benzenesulfonamide 169590-42-5 169902-71-0, 4-[2-(3-Chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide 169902-74-3, 4-[2-(3-Fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide 169902-75-4, 1-[2-(3-Chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene 169951-23-9 169951-24-0 169951-25-1 169951-27-3 169951-28-4 170569-31-0 170569-42-3 170569-50-3 170569-86-5, 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170569-87-6, 4-[5-Phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170569-88-7, 4-[5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170569-91-2, 4-[5-(4-Methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170570-05-5 170570-25-9 170570-29-3 170570-31-7 170570-32-8 170570-33-9 170571-71-8 171888-46-3 173776-67-5 174470-77-0 175676-91-2 175676-92-3 175677-05-1 175677-06-2 175677-07-3 175677-13-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

IT 175677-14-2 175883-05-3 175883-36-0 177560-19-9 177560-23-5 177560-29-1 177560-30-4 177560-34-8 177560-36-0 177560-38-2 177560-61-1 177577-60-5 177660-54-7 177660-55-8 177660-56-9 177660-67-2 177660-72-9 177660-73-0 177660-76-3 177660-77-4 177660-78-5 177660-80-9, 2-Methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine 177660-81-0 177660-85-4 177660-89-8 177660-92-3, 4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide 177660-94-5 177661-00-6 177661-01-7 177661-04-0 177661-06-2 177661-15-3 177661-17-5 177661-18-6 177661-19-7 177661-49-3 177662-22-5 177754-42-6 178870-32-1 178979-85-6 179382-91-3 180048-35-5 180302-52-7 181377-89-9 181377-90-2 181627-94-1 181627-96-3 181627-98-5 181628-00-2 181695-72-7 181695-81-8 181695-85-2 181696-18-4 181696-33-3 181809-58-5 181809-60-9 181809-63-2 183136-88-1 183610-65-3 185344-55-2 186804-50-2 186804-93-3, 4-[2-(2-Methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide 198470-84-7 201341-05-1 202138-50-9, Viread 202409-33-4 202409-52-7 204864-54-0 214287-88-4 215122-07-9 215122-12-6 215122-14-8 215122-18-2

215122-19-3 215122-20-6 215122-22-8 215122-24-0
215122-27-3 215122-28-4 215122-29-5 215122-30-8
215122-31-9 215122-32-0 215122-33-1 215122-35-3
215122-36-4 215122-37-5 215122-38-6 215122-39-7
215122-43-3 215122-44-4 215122-45-5 215122-46-6
215122-48-8 215122-49-9 215122-50-2 215122-51-3
215122-52-4 215122-53-5 215122-55-7 215122-56-8
215122-58-0 215122-59-1 215122-60-4 215122-61-5
215122-62-6 215122-63-7 215122-65-9 215122-70-6
215122-71-7 215122-74-0 215122-75-1 215122-76-2
215122-77-3 215123-03-8 215123-07-2 215123-08-3
215123-16-3 215123-48-1 215123-52-7 215123-60-7
215123-61-8, 6,8-Dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid 215123-64-1 215123-70-9 215123-77-6
215123-79-8 215123-80-1 215123-84-5 220991-20-8
264878-87-7 266320-83-6 467427-54-9 468067-63-2
477594-33-5 477594-34-6 631912-94-2 639785-67-4
725250-87-3 725250-88-4 834911-85-2 834911-86-3
834911-87-4 834911-88-5 834911-90-9 834911-91-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of **HIV** infection and related conditions using cyclooxygenase-2 selective inhibitors and **antiviral** agents)

L82 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:74120 HCAPLUS Full-text
DOCUMENT NUMBER: 142:176697
TITLE: Preparation of spiro compounds for the modulation of chemokine receptor activity
INVENTOR(S): Chan, Chun Kong; Zhang, Ming-Qiang; Moinet, Christophe; Proulx, Melanie; Reddy, Thumkunta Jagadeeswar; Courchesne, Marc
PATENT ASSIGNEE(S): Virochem Pharma Inc., Can.
SOURCE: PCT Int. Appl., 338 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007656	A1	20050127	WO 2004-CA1048	2004 0716
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005075326	A1	20050407	US 2004-893583	2004 0719
			<--	
PRIORITY APPLN. INFO.:			US 2003-487973P P	2003 0718

<--

OTHER SOURCE(S): MARPAT 142:176697
GI



I



II

AB The title compds. I [Y, Z and X = CH2, CO, CR4R5; W = H, alkyl, alkenyl, aryl, etc.; R1 = H, OH, alkyl, etc.; R2 = alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R3 = H, alkyl, alkenyl, alkynyl, aryl; R4, R5 = H, alkyl, alkenyl, alkynyl, aryl] and their pharmaceutically acceptable salts, useful for the modulation of CCR5 chemokine receptor activity and the treatment or prevention of diseases associated therewith, were prepared E.g., a multi-step synthesis of II.HCl, starting from tert-Bu 1-oxo-2,8-diaza- spiro[4.5]decane-8-carboxylate and 4-bromobenzyl bromide, was given. The compds. I have been found to have activity in binding to the CCR5 receptor, generally with an IC50 values of < 25 μM. Certain compds. I have also been tested in an assay for **HIV** activity, and generally having an IC50 values of < 1 μM.

IT **25526-93-6**, Alovudine **129618-40-2**, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of spiro compds. for treating diseases associated with CCR5 chemokine receptor activity in combination with other agents)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D471-10
ICS A61K031-437; A61P031-18
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, **63**
ST spiro compd prepn CCR5 chemokine receptor modulator **AIDS** ; diazaspirodecane prepn CCR5 chemokine receptor modulator **AIDS**
IT Vaccines
(**AIDS**, co-drug; preparation of spiro compds. for treating diseases associated with CCR5 chemokine receptor activity in combination with other agents)
IT Anti-**AIDS** agents
Anti-infective agents
Anti-inflammatory agents
Combination chemotherapy
Human
Immunomodulators
Immunosuppressants
(preparation of spiro compds. for the modulation of CCR5 chemokine receptor activity)
IT **AIDS** (disease)
Infection
Inflammation
(treating; preparation of spiro compds. for the modulation of CCR5 chemokine receptor activity)
IT Anti-**AIDS** agents
(vaccines, co-drug; preparation of spiro compds. for treating diseases associated with CCR5 chemokine receptor activity in combination with other agents)
IT 57-66-9, Probenecid 123-77-3, Azodicarbonamide 501-36-0, Resveratrol 3056-17-5, Stavudine 3416-05-5, 3'-Deoxythymidine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Foscarnet 7481-88-1 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin **25526-93-6**, Alovudine 28507-02-0, HE 2000 30516-87-1, Zidovudine 36791-04-5, Ribavirin 38640-92-5, Ampligen 59277-89-3, Acyclovir 69558-55-0, Thymopentin 69655-05-6, Didanosine 74817-61-1, Murabutide 82410-32-0, Ganciclovir 83869-56-1, Gm-csf 90803-92-2, Thymomodulin 123027-56-5, HEPT 126652-33-3 126652-38-8 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 141781-17-1D, TSAO, derivative 142632-32-4, (+)-Calanolide A 143491-54-7, Racivir 143491-57-0, Coviracil 145514-04-1, Amdoxovir 147127-20-6, Tenofovir 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, Amd3100 155213-67-5, Ritonavir 159519-65-0, t-20 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 165456-81-5, Combivir 170020-61-8, FP21399 174022-42-5, PA457 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 192725-17-0, Lopinavir 198904-31-3, Atazanavir 206361-99-1, Tmc114 213252-22-3, Reticulose 214287-99-7, Dpc083 226700-79-4, Fosamprenavir 231957-54-3, MIV 150 251562-00-2, t-1249 269055-15-4, TMc125 280571-30-4, s-1360 333994-00-6 357263-13-9, Bms-806 370893-06-4, Schering c 383198-58-1, PRO 542 394730-30-4, SCH-D 410544-95-5, 1-870810 410545-90-3, 1-870812 461443-59-4, Ak602 674782-26-4, PRO 140 675184-03-9, VX 385 690656-53-2, AMD 070
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of spiro compds. for treating diseases associated with CCR5 chemokine receptor activity in combination with other agents)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1016008 HCAPLUS Full-text
DOCUMENT NUMBER: 142:6507
TITLE: Preparation of naphthyridine integrase inhibitors
INVENTOR(S): Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101512	A2	20041125	WO 2004-US14814	2004 0512
			<--	
WO 2004101512	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622615	A2	20060208	EP 2004-751959	2004 0512
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:				
			US 2003-470059P	P 2003 0513
			<--	
			WO 2004-US14814	W 2004 0512

OTHER SOURCE(S): MARPAT 142:6507
GI



I

AB The title compds. [I; R1 = H, halo, alkyl, etc.; R2 = cycloalkyl, (un)substituted aryl, heterocyclyl; A = heterocycle; Q = alkyl, O, CO, SO2, etc.] that are **HIV** integrase inhibitors and therefore are useful in the inhibition of **HIV** replication, the prevention and/or treatment of infection by **HIV**, and in the treatment of **AIDS** and/or ARC, were prepared E.g., a multi-step synthesis of 7-(5-benzyl-4H-1,2,4- triazol-3-yl)-1,6-naphthyridin-8-ol, was given. The compds. I have anti-**HIV** activity in the range IC50 of 1-1000 nM. The pharmaceutical composition comprising the compound I is disclosed.

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
129618-40-2, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, **63**
ST naphthyridine prepn **HIV AIDS** ARC integrase inhibitor
IT **AIDS** (disease)
(-related complex; preparation of naphthyridine integrase inhibitors for treating **HIV** infection)
IT Interleukin 2
Trichosanthin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)
IT **AIDS** (disease)
Anti-**AIDS** agents
Human
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection)
IT Combination chemotherapy

Human immunodeficiency virus 1
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT Fluoropolymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT CD4 (antigen)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble CD4 and genetically engineered derivs. as co-drugs; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α, co-drug; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT 54-42-2, 2'-Deoxy-5-iodo-uridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, 1,1'-Azobis-formamide 616-91-1 3056-17-5, Stavudine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 30516-87-1, AZT 36791-04-5, Ribavirin 39809-25-1, Penciclovir 59277-89-3, Acyclovir 61512-21-8, Thymosin 69655-05-6, Didanosine 82410-32-0, Ganciclovir 83869-56-1, Granulocyte macrophage colony stimulating factor 104227-87-4, Famciclovir 113269-46-8, Oxetanocin-G 113852-37-2, HPMPC 124265-89-0, H 2G 124832-26-4, Valaciclovir 124930-59-2 127759-89-1, Lobucavir 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142340-99-6, Adefovir dipivoxil 142632-32-4, (+) Calanolide A 143491-54-7, FTC 145514-04-1, DAPD 147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159519-65-0, T-20 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 195156-77-5, ABT-606 198904-31-3, BMS-232632 201341-05-1, Bis-POC-PMPA 206361-99-1, TMC-114 213252-22-3, Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A 226700-79-4, GW 433908 251562-00-2, T-1249 269055-15-4, TMC-125 352234-06-1, AG 1776 383198-58-1, PRO 542 394728-76-8, TMC 120 714968-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT 52350-85-3, **HIV** integrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of **HIV**; preparation of naphthyridine integrase inhibitors for treating **HIV** infection in combination with other therapeutic agents)

IT 797786-45-9P 797786-54-0P 797786-77-7P 797788-49-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection)

IT 797786-32-4P 797786-33-5P 797786-34-6P 797786-35-7P
797786-36-8P 797786-37-9P 797786-38-0P 797786-39-1P
797786-40-4P 797786-41-5P 797786-42-6P 797786-43-7P

797786-44-8P 797786-46-0P 797786-47-1P 797786-48-2P
797786-49-3P 797786-50-6P 797786-51-7P 797786-52-8P
797786-53-9P 797786-55-1P 797786-56-2P 797786-57-3P
797786-58-4P 797786-59-5P 797786-60-8P 797786-61-9P
797786-62-0P 797786-63-1P 797786-64-2P 797786-65-3P
797786-66-4P 797786-67-5P 797786-68-6P 797786-69-7P
797786-70-0P 797786-71-1P 797786-72-2P 797786-73-3P
797786-74-4P 797786-75-5P 797786-76-6P 797786-78-8P
797786-79-9P 797786-80-2P 797786-81-3P 797786-82-4P
797786-83-5P 797786-84-6P 797786-85-7P 797786-86-8P
797786-87-9P 797786-88-0P 797786-89-1P 797786-90-4P
797786-91-5P 797786-92-6P 797786-93-7P 797786-94-8P
797786-95-9P 797786-96-0P 797786-97-1P 797786-98-2P
797786-99-3P 797787-00-9P 797787-01-0P 797787-02-1P
797787-03-2P 797787-04-3P 797787-05-4P 797787-06-5P
797787-07-6P 797787-08-7P 797787-09-8P 797787-10-1P
797787-11-2P 797787-12-3P 797787-14-5P 797787-15-6P
797787-16-7P 797787-17-8P 797787-18-9P 797787-19-0P
797787-20-3P 797787-21-4P 797787-22-5P 797787-23-6P
797787-24-7P 797787-25-8P 797787-26-9P 797787-27-0P
797787-28-1P 797787-29-2P 797787-30-5P 797787-31-6P
797787-32-7P 797787-33-8P 797787-34-9P 797787-35-0P
797787-36-1P 797787-37-2P 797787-38-3P 797787-39-4P
797787-40-7P 797787-41-8P 797787-42-9P 797787-43-0P
797787-44-1P 797787-45-2P 797787-46-3P 797787-47-4P
797787-48-5P 797787-49-6P 797787-50-9P 797787-51-0P
797787-52-1P 797787-53-2P 797787-54-3P 797787-55-4P
797787-56-5P 797787-57-6P 797787-58-7P 797787-59-8P
797787-60-1P 797787-61-2P 797787-62-3P 797787-63-4P
797787-64-5P 797787-65-6P 797787-66-7P 797787-67-8P
797787-68-9P 797787-69-0P 797787-70-3P 797787-71-4P
797787-72-5P 797787-73-6P 797787-74-7P 797787-75-8P
797787-76-9P 797787-77-0P 797787-78-1P 797787-79-2P
797787-81-6P 797787-82-7P 797787-84-9P 797787-86-1P
797787-87-2P 797787-88-3P 797787-89-4P 797787-90-7P
797787-91-8P 797787-92-9P 797787-93-0P 797787-94-1P
797787-95-2P 797787-96-3P 797787-97-4P 797787-98-5P
797787-99-6P 797788-00-2P 797788-01-3P 797788-02-4P
797788-04-6P 797788-06-8P 797788-07-9P 797788-08-0P
797788-09-1P 797788-10-4P 797788-11-5P 797788-12-6P
797788-13-7P 797788-14-8P 797788-15-9P 797788-16-0P
797788-17-1P 797788-18-2P 797788-45-5P 797788-46-6P
797788-47-7P 797788-48-8P 797788-50-2P 797788-51-3P
797790-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection)

IT 98-59-9, p-Toluenesulfonyl chloride 103-80-0, Phenyl acetyl chloride 104-94-9, p-Anisidine 109-01-3, N-Methylpiperazine 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 459-04-1, (4-Fluorophenyl)acetyl chloride 616-45-5, 2-Pyrrolidinone 937-39-3, Phenylacetic hydrazide 2645-02-5, Methyl N-[(4-methylphenyl)sulfonyl]glycinate 5625-67-2, Piperazin-2-one 6011-14-9, Aminoacetonitrile hydrochloride 25026-34-0, (4-Chlorophenyl)acetyl chloride 34624-38-9 34803-68-4, 1-(2-Pyrazinyl)piperazine 37441-50-2, 1,2-Thiazinane 1,1-dioxide 39890-43-2, N,N-Dimethyl-2-(1-piperazinyl)acetamide 54401-85-3, Ethyl pyridin-4-ylacetate 60075-23-2 66464-86-6 105184-38-1, (3,5-Difluorophenyl)acetic acid 118892-74-3, Isopropyl 3-(hydroxymethyl)pyridine-2-carboxylate 797788-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection)

IT 673-05-2P 3538-68-9P 7440-50-8DP, Copper, copper complex with hydroxynaphthyridine derivative 19730-99-5P 20228-87-9P,

N-(Cyanomethyl)-4-methylbenzenesulfonamide 20287-25-6P
34547-28-9P 39978-18-2P 57676-51-4P 69583-00-2P
341009-94-7P 410542-68-6P 410542-70-0P 410544-37-5P
410545-60-7P 410545-61-8P 797784-29-3P 797784-35-1P
797784-36-2P 797788-19-3P, Isopropyl 3-([(cyanomethyl)[(4-methylphenyl)sulfonyl]amino]methyl)pyridine-2-carboxylate
797788-20-6P, 8-Hydroxy-1,6-naphthyridine-7-carbonitrile
797788-21-7P 797788-22-8DP, copper complex 797788-22-8P
797788-23-9P 797788-24-0P 797788-25-1P 797788-26-2P
797788-27-3P 797788-29-5P 797788-30-8P 797788-31-9P
797788-32-0P 797788-33-1P 797788-34-2P 797788-35-3P
797788-36-4P 797788-37-5P 797788-38-6P 797788-39-7P
797788-40-0P 797788-41-1P 797788-42-2P 797788-43-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthyridine integrase inhibitors for treating **HIV** infection)

L82 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:857413 HCAPLUS Full-text
DOCUMENT NUMBER: 141:337774
TITLE: Pharmaceuticals containing a combination of nevirapine and an antiretroviral nucleoside
INVENTOR(S): Klaes, Heinz-Gerd; Mayers, Douglas Lytl; Valdez, Hernan; Koundourakis, Elena
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087169	A1	20041014	WO 2004-US8736	2004 0323
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1610797	A1	20060104	EP 2004-758183	2004 0323
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2004235780	A1	20041125	US 2004-809250	2004 0325
			<--	
PRIORITY APPLN. INFO.:			EP 2003-6996 A	2003 0327

<--		
EP 2003-16226	A	2003 0717
<--		
EP 2003-29526	A	2003 1220
<--		
WO 2004-US8736	W	2004 0323

OTHER SOURCE(S): MARPAT 141:337774

AB A pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprises a combination of nevirapine and at least 1 **antiviral** nucleoside, wherein the base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine or prodrug thereof. The **antiviral** nucleoside can be, e.g., alovudine. The nevirapine and the nucleoside are present in a synergistic ratio of 1:250 to 250:1.

IT **25526-93-6**, Alovudine **92562-88-4**
129618-40-2, Nevirapine **220750-46-9**
770723-01-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing combination of nevirapine and antiretroviral nucleoside)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 220750-46-9 HCAPLUS
CN L-Valine, ester with 2',3'-dideoxy-3'-fluoroguanosine 5'-(2-hydroxypropanoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 770723-01-8 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro-, mixt. with 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one (9CI) (CA INDEX NAME)

CM 1

CRN 129618-40-2
CMF C15 H14 N4 O



CM 2

CRN 25526-93-6
CMF C10 H13 F N2 O4

Absolute stereochemistry.



IC ICM A61K031-551
ICS A61K031-7068; A61K031-7072; A61K031-7076; A61K031-708; A61K045-06; A61P031-12; A61P031-18
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**
ST pharmaceutical **antiviral** combination nevirapine alovudine
IT **Human immunodeficiency virus 1**
Retroviridae
(infection; pharmaceuticals containing combination of nevirapine and antiretroviral nucleoside)
IT Anti-**AIDS** agents
Antiviral agents
Human
(pharmaceuticals containing combination of nevirapine and antiretroviral nucleoside)
IT **25526-93-6**, Alovudine **92562-88-4**
129618-40-2, Nevirapine **220750-46-9**
770723-01-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing combination of nevirapine and antiretroviral nucleoside)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:550533 HCAPLUS Full-text
DOCUMENT NUMBER: 141:82297
TITLE: Immunostimulatory nucleic acids for the treatment of disorders associated with microorganisms, for preventing antibiotic resistance and for treating and preventing warts
INVENTOR(S): Bratzler, Robert L.; Petersen, Deanna M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 54 pp., Cont. of U.S. Ser. No. 801,839, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004131628	A1	20040708	US 2003-666733	2003 0919
			<--	
PRIORITY APPLN. INFO.:			US 2000-187834P	P 2000 0308
			<--	

US 2001-801839 B1
2001
0308

<--

OTHER SOURCE(S): MARPAT 141:82297

AB The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an antimicrobial agent for the treatment or prevention of infectious disease associated with microorganisms in subjects, for preventing antibiotic resistance and for treating and preventing warts. The combination of drugs are administered in synergistic amts. or in various dosages or at various time schedules. The invention also relates to kits and compns. concerning the combination of drugs.

IT **25526-93-6**, Alovudine **129618-40-2**, Nevirapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory nucleic acids for treatment of disorders associated with microorganisms, preventing antibiotic resistance, and treating and preventing warts, and use with other agents)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K039-00
ICS A61K039-38
INCL 424184100
CC 1-5 (**Pharmacology**)
Section cross-reference(s): **63**

IT Allergy inhibitors
Anti-infective agents
Antibacterial agents
Antibacterial agents
Antibiotic resistance
Antibiotics
Antimicrobial agents
Antiviral agents
Drug delivery systems
Fungicides
Human
Immunostimulants

Infection
Parasiticides
Prophylaxis
Wart
(immunostimulatory nucleic acids for treatment of disorders associated with microorganisms, preventing antibiotic resistance, and treating and preventing warts, and use with other agents)

IT 15686-71-2, Cephalexin 16846-24-5, Josamycin 16915-79-0, Mequidox 17090-79-8, Monensin 17230-86-3, Carbenicillin Potassium 17692-15-8, Furazolium Tartrate 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 19561-70-7, Nifuratrone 19885-51-9, Aranotin 20685-78-3, Rolitetracycline Nitrate 21462-39-5, Clindamycin Hydrochloride 21593-23-7, Cephapirin 21638-36-8, Nifurimide 21649-57-0, Carbenicillin Phenyl Sodium 21736-83-4, Spectinomycin Hydrochloride 22373-78-0, Monensin Sodium 22573-93-9, Alexidine 22832-87-7, Miconazole Nitrate 22916-47-8, Miconazole 23067-13-2, Erythromycin Gluceptate 23155-02-4, Fosfomycin 23239-41-0, Cephacetrile sodium 23313-80-6, Epitetracycline Hydrochloride 23444-86-2, Suncillin Sodium 23593-75-1, Clotrimazole 23736-58-5, Cloxacillin Benzathine 24169-02-6, Econazole Nitrate 24356-60-3, Cephapirin Sodium 24390-14-5, Doxycycline Hyclate 24729-96-2, Clindamycin Phosphate 25389-94-0, Kanamycin Sulfate 25507-04-4, Clindamycin Palmitate Hydrochloride **25526-93-6**, Alovudine 25953-19-9, Cefazolin 26309-95-5, Pivampicillin Hydrochloride 26605-69-6, Carbenicillin Indanyl Sodium 26774-90-3, Epicillin 26786-84-5, Lomofungin 26787-78-0, Amoxicillin 27164-46-1, Cefazolin Sodium 27220-47-9, Econazole 27523-40-6, Isoconazole 27591-69-1, Tilorone Hydrochloride 27762-78-3, Kethoxal 27823-62-7, Chlortetracycline Bisulfate 27877-51-6, Tolindate 28069-65-0, Cuprimyxin 28088-64-4, Aminosalicylic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 29457-07-6, Ticarcillin Disodium 29984-33-6, Vidarabine Phosphate 30034-03-8, Cefamandole Sodium 30516-87-1, Zidovudine 31342-36-6, Chloramphenicol Pantothenate Complex 32385-11-8, Sisomicin 32886-97-8, Amdinocillin Pivoxil 32887-01-7, Amdinocillin 32986-56-4, Tobramycin 33564-30-6, Cefoxitin Sodium 34444-01-4, Cefamandole 35523-45-6, Fludalanine 35554-44-0, Enilconazole 35607-20-6, Avridine 35607-66-0, Cefoxitin 35834-26-5, Rosaramicin 36791-04-5, Ribavirin 36983-81-0, Fosfonet Sodium 37091-65-9, Azlocillin Sodium 37091-66-0, Azlocillin 37321-09-8, Apramycin 37332-99-3, Avoparcin 37517-28-5, Amikacin 37661-08-8, Bacampicillin Hydrochloride 38070-41-6, Tiodonium Chloride 38821-53-3, Cephradine 39030-72-3, Pivampicillin Pamoate 39809-25-1, Penciclovir 39831-55-5, Amikacin Sulfate 39878-70-1, Talampicillin Hydrochloride 40034-42-2, Rosoxacin 40966-79-8, Sarpicillin 41621-49-2, Ciclopirox Olamine 42057-22-7, Mezlocillin Sodium 42190-91-0, Pivampicillin Probenate 42540-40-9, Cefamandole Nafate 42835-25-6, Flumequine 43143-11-9, Bispyrithione Magsulfex 43169-50-2, Betamicin Sulfate 49842-07-1, Tobramycin Sulfate 50370-12-2, Cefadroxil 50838-36-3, Tolciclate 51022-98-1, Butirosin Sulfate 51481-65-3, Mezlocillin 51547-64-9, Rosaramicin stearate 51627-14-6, Cefatrizine 51627-20-4, Cefaparole 51762-05-1, Cefroxadine 52123-49-6, Cefazaflur Sodium 52152-93-9, Cefsulodin Sodium 53066-26-5, Lexithromycin 53179-09-2, Sisomicin Sulfate 53808-87-0, Tetroxoprim 53994-73-3, Cefaclor 55162-26-0, Pirbenicillin Sodium 55242-74-5, Oxifungin Hydrochloride 55242-77-8, Triafungin 55268-75-2, Cefuroxime 55298-68-5, Neomycin Palmitate 55694-87-6, Pentizidone Sodium 55852-84-1, Bacitracin Methylene Disalicylate 56093-45-9, Selenium Sulfide 56219-57-9, Arildone 56238-63-2, Cefuroxime Sodium 56391-57-2, Netilmicin Sulfate 56433-46-6, Cetocycline Hydrochloride 56585-33-2, Trimethoprim Sulfate 56689-42-0, Repromicin 56796-20-4, Cefmetazole 56796-39-5, Cefmetazole Sodium 58001-44-8, Clavulanic acid

58152-03-7, Isepamicin 58795-03-2, Apalcillin Sodium
58857-02-6, Ambruticin 59070-06-3, Ticarcillin Cresyl Sodium
59277-89-3, Acyclovir 59695-59-9, Cephalexin Hydrochloride
59703-84-3, Piperacillin Sodium 59733-86-7, Butikacin
59794-18-2, Paulomycin 59831-63-9, Doconazole 60207-31-0,
Azaconazole 60628-96-8, Bifonazole 60802-40-6, Rosaramicin
Sodium Phosphate 60925-61-3, Ceforanide 61036-62-2,
Teicoplanin 61270-78-8, Cefonicid Sodium 61318-90-9,
Sulconazole 61379-65-5, Rifapentine 61477-96-1, Piperacillin
62013-04-1, Dirithromycin 62587-73-9, Cefsulodin 62893-19-0,
Cefoperazone 62893-20-3, Cefoperazone Sodium 63198-97-0,
Viroxime 63527-52-6, Cefotaxime 63585-09-1, Foscarnet Sodium
64211-46-7, Oxiconazole Nitrate 64221-86-9, Imipenem
64221-86-9D, Imipenem, derivs. 64485-93-4, Cefotaxime Sodium
64544-07-6, Cefuroxime axetil 64872-77-1, Butoconazole Nitrate
64952-97-2, Moxalactam 65052-63-3, Cefetamet 65277-42-1,
Ketoconazole 65473-14-5, Naftifine Hydrochloride 65899-73-2,
Tioconazole 66148-78-5, Temocillin 66309-69-1, Cefotiam
Hydrochloride 66887-96-5, Propikacin 67337-44-4, Sarmoxicillin
67915-31-5, Terconazole 68401-82-1, Ceftizoxime Sodium
68693-30-1, Somantadine Hydrochloride 68902-57-8, Metioprim
69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69198-10-3,
Metronidazole Hydrochloride 69655-05-6, Didanosine 69657-51-8,
Acyclovir Sodium 69712-56-7, Cefotetan 70458-92-3, Pefloxacin
70458-95-6, Pefloxacin Mesylate 70458-96-7, Norfloxacin
70797-11-4, Cefpiramide 71002-10-3, Vidarabine Sodium Phosphate
71420-79-6 72275-67-3, Astromicin Sulfate 72301-78-1,
Zinviroxime. 72301-79-2, Enviroxime 72558-82-8, Ceftazidime
72559-06-9, Rifabutin 73334-05-1, Metronidazole Phosphate
73384-59-5, Ceftriaxone 73514-87-1, Fosarilate 73816-42-9,
Meclocycline Sulfosalicylate 74011-58-8, Enoxacin 74356-00-6,
Cefotetan Disodium 74578-69-1, Ceftriaxone Sodium 74849-93-7,
Cefpiramide Sodium 75738-58-8, Cefmenoxime Hydrochloride
76168-82-6, Ramoplanin 76470-66-1, Loracarbef 76497-13-7,
Sultamicillin 76610-84-9, Cefbuperazone 77146-42-0,
Chlorhexidine Phosphanilate 77181-69-2, Sorivudine 78040-85-4,
Coumermycin 78110-38-0, Aztreonam 78186-33-1, Fumoxicillin
78613-35-1, Amorolfine 78822-40-9, Pirlimycin Hydrochloride
78964-85-9, Fosfomycin Tromethamine 79350-37-1, Cefixime
79404-91-4, Cilofungin 79660-72-3, Fleroxacin 80168-44-1,
Zinoconazole Hydrochloride 80214-83-1, Roxithromycin
80621-81-4, Rifaximin 80883-55-2, Enviradene 81103-11-9,
Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
83038-87-3, Doxycycline Fosfatex 83200-96-8D, Carbapenem,
derivs. 83905-01-5, Azithromycin 84408-37-7, Desciclovir
84625-61-6, Itraconazole 84880-03-5, Cefpimizole 85287-61-2,
Cefpimizole Sodium 85721-33-1, Ciprofloxacin 86386-73-4,
Fluconazole 86393-37-5, Amifloxacin 86832-68-0, Carumonam
Sodium 87239-81-4, Cefpodoxime Proxetil 87495-31-6, Disoxaril
88036-80-0, Amifloxacin Mesylate 88040-23-7, Cefepime
90850-05-8, Gloximonam 90898-90-1, Oximonam 91161-71-6,
Terbinafine 91618-36-9, Ibafloxacin 91832-40-5, Cefdinir
92665-29-7, Cefprozil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(immunostimulatory nucleic acids for treatment of disorders
associated with microorganisms, preventing antibiotic resistance,
and treating and preventing warts, and use with other agents)

IT 93107-08-5, Ciprofloxacin Hydrochloride 94168-98-6, Rifametane
96036-03-2, Meropenem 96128-89-1, Erythromycin Acistrate
97519-39-6, Ceftibuten 97673-66-0, Trospectomycin Sulfate
98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin Hydrochloride
98753-19-6, Cefpirome Sulfate 100490-36-6, Tosufloxacin
100680-33-9, Cefuroxime Pivoxetil 101828-21-1, Butenafine
102426-96-0, Paldimycin 103060-53-3, Daptomycin 104227-87-4,
Famciclovir 104456-95-3, Cisconazole 105784-61-0, Temafloxacin
Hydrochloride 105956-99-8, Clinafloxacin hydrochloride

106941-25-7, Adefovir 107648-80-6, Cefepime Hydrochloride
107910-75-8, Ganciclovir Sodium 108319-06-8, Temafloxacin
110042-95-0, Acemannan 110588-57-3, Saperconazole 110871-86-8,
Sparfloxacin 112362-50-2, Dalfopristin 113102-19-5, Rifamexil
113852-37-2, Cidofovir 114394-67-1, Lomefloxacin Mesylate
117211-03-7, Cefetecol 120138-50-3, Quinupristin 120410-24-4,
Biapenem 120788-07-0, Sulopenem 124436-59-5, Pirodavir
124832-27-5, Valacyclovir Hydrochloride 127759-89-1, Lobucavir
127785-64-2, Basifungin **129618-40-2**, Nevirapine
132210-43-6, Cipamfylline 134678-17-4, Lamivudine 137487-62-8,
Alvircept Sudotox 138540-32-6, Atevirdine Mesylate
141611-76-9, Sanfetrinem Sodium 147221-93-0, Delavirdine
Mesylate 149845-06-7, Saquinavir Mesylate 151581-81-6,
Pradimicin 179463-17-3, MK 991 208538-73-2, FK 463
344414-75-1 645417-10-3, UK 292 645417-21-6, BAY 38-9502
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(immunostimulatory nucleic acids for treatment of disorders
associated with microorganisms, preventing antibiotic resistance,
and treating and preventing warts, and use with other agents)

L82 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534204 HCAPLUS Full-text
DOCUMENT NUMBER: 141:89006
TITLE: Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists
INVENTOR(S): Yang, Hanbiao; Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055016	A1	20040701	WO 2003-US39618	2003 1212 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296992	A1	20040709	AU 2003-296992	2003 1212 <--
EP 1569933	A1	20050907	EP 2003-813415	2003 1212 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006511552	T2	20060406	JP 2004-560830	

					2003 1212
			<--		
US 2006058284	A1	20060316	US 2005-538134		
					2005 0609
			<--		
PRIORITY APPLN. INFO.:			US 2002-433372P	P	
					2002 1213
			<--		
			WO 2003-US39618	W	
					2003 1212
			<--		

OTHER SOURCE(S): MARPAT 141:89006

GI



I



II



III

AB Title compds. I [R1 = (un)substituted-alkyl, -alkynyl, -cycloalkyl, -heterocyclyl, etc., or R1 and X taken together form a saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N that is fused to ring A; R2 = OH, halogen (un)substituted-alkyl, -alkoxy, -aryl, -heteroaryl, -cycloalkyl, etc., or two geminal R2s are optionally taken together to from a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, said fused or spiro ring optionally substituted; R3 = H, halo, cyano, trifluoromethyl, (un)substituted amino, acylamino, alkyl; R9 = H or oxo; X = C1-5 alkylene, optionally substituted with oxo, thioxo, -S(O)t where t = 1 or 2, halogen atoms, or alkyl and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, alkyl, alkenyl, etc.; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N; m = 0 or 1, n = 0-5;] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared via condensation of tert-Bu 3-(3,4-dichlorophenyl)-3-(3- oxopropyl)pyrrolidne-1-carboxylate (preparation given) with the amine III followed by deprotection and acylation with 2-furanoyl chloride. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly **HIV** infection).

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
119644-22-3 129618-40-2, BI-RG-587
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of pyrrolidine and azetidine derivs. as CCR5 antagonists)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D471-10
ICS A61K031-438; A61P031-00; A61P029-00; C07D235-00; C07D221-00
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 10, 63
ST pyrrolidine carboxylate triazaspirodecylalkyl prepn CCR5 antagonist **HIV** treatment
IT **AIDS** (disease)
Alzheimer's disease
Anti-**AIDS** agents
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Arteriosclerosis

Asthma
Drug interactions
Human
Human papillomavirus
Immune disease
Inflammation
Kidney, disease
Multiple sclerosis
Neoplasm
Prostate gland, neoplasm
Rheumatoid arthritis
Sjogren syndrome
Transplant rejection
Wound healing
(preparation of pyrrolidine and azetidine derivs. as CCR5 antagonists)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, Diazenedicarboxamide 127-07-1, Hydroxyurea 616-91-1, N-Acetylcysteine 3056-17-5, Stavudine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 15477-76-6D, Phosphonate, acyclic nucleoside derivs. 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 29706-85-2 30516-87-1, Zidovudine 39809-25-1 59277-89-3 61512-21-8, Thymosin 69655-05-6, Didanosine 82410-32-0 83869-56-1, GM-CSF 104227-87-4 113269-46-8 113852-37-2 **119644-22-3** 124265-89-0 124832-26-4 127759-89-1 127779-20-8, Saquinavir **129618-40-2**, BI-RG-587 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142340-99-6, Adefovir dipivoxil 142632-32-4, Calanolide A 143491-54-7, FTC 145514-04-1, Dapd 147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 195156-77-5 198904-31-3, BMS-232632 201341-05-1 213252-22-3, Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A 226700-79-4, Fosamprenavir 352234-06-1, AG-1776 383198-58-1, PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of pyrrolidine and azetidine derivs. as CCR5 antagonists)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534200 HCAPLUS Full-text
DOCUMENT NUMBER: 141:88928
TITLE: Preparation of indane compounds and analogs as CCR5 antagonists
INVENTOR(S): Youngman, Michael; Kazmierski, Wieslaw Mieczyslaw; Yang, Hanbiao; Aquino, Christopher Joseph
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

```
WO 2004055012          A1     20040701     WO 2003-US39975
                                                          2003
                                                          1212
                                                <--
     W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
         CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG,
         ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
         KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
         MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
         RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
         TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW,
         AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY,
         CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
         NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
         GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003300952          A1     20040709     AU 2003-300952
                                                          2003
                                                          1212
                                                <--
EP 1581530             A1     20051005     EP 2003-813460
                                                          2003
                                                          1212
                                                <--
     R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
         MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ,
         EE, HU, SK
JP 2006512339          T2     20060413     JP 2004-560887
                                                          2003
                                                          1212
                                                <--
US 2006047116          A1     20060302     US 2005-538183
                                                          2005
                                                          0609
                                                <--
PRIORITY APPLN. INFO.:                      US 2002-433378P      P
                                                          2002
                                                          1213
                                                <--
                                            WO 2003-US39975      W
                                                          2003
                                                          1212
                                                <--
OTHER SOURCE(S):       MARPAT 141:88928
GI
```



I



II

AB Title compds. I [R1 = (un)substituted saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring N and 0-4 addnl. heteroatoms selected from O, P, S or N, optionally attached through alkylene chain, (un)substituted-amide, etc.; R2 = OH, (un)substituted-alkyl, -alkoxy, -heteroaryl, etc., optionally two adjacent R2s taken together form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, or two geminal R2s optionally taken together from a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N, said fused or spiro ring being optionally substituted; R10 = H, halo, F3C, (un)substituted-aryl, etc., or two R10s may together form a 3-7 membered saturated, partially saturated, or aromatic carbocyclic ring, optionally containing one or more heteroatom selected from O, P, N, or S that is fused to depicted ring; X = (un)substituted- alkylene chain which optionally may have 0-3 heteroatoms selected from O, P, S or N; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N ; B = 4-7 membered saturated, partially saturated, or aromatic carbocyclic ring optionally containing 1-2 heteroatoms selected from O, P, S, or N; each Z maybe C or N (at least one Z = C) ; m = 1-3, n = 0-5, p = 0-4] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared by reaction of N-methyl(1-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8- azabicyclo[3.2.1]oct-8-yl]ethyl}-2,3-dihydro-1H-inden-1-yl)methanamine (preparation given) with 2-chlorophenylsulfonyl chloride. A preparative example utilizing combinatorial methods of synthesis is provided. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly **HIV** infection).

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
119644-22-3 129618-40-2, BI-RG-587
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of indane compds. and analogs as CCR5 antagonists)

RN 25526-93-6 HCAPLUS

CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D451-04
ICS C07D211-58; C07D471-10; C07D413-04; A61K031-439; A61P031-18
CC 25-23 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): **1**, 10, 27, **63**
ST indane deriv prepn CCR5 antagonist **HIV** treatment
IT **AIDS** (disease)
Alzheimer's disease
Anti-**AIDS** agents
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Arteriosclerosis
Asthma
Human
Human papillomavirus
Immune disease
Inflammation
Kidney, disease
Multiple sclerosis
Neoplasm
Prostate gland, neoplasm
Rheumatoid arthritis
Sjogren syndrome
Transplant rejection
Wound healing
(preparation of indane compds. and analogs as CCR5 antagonists)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole
123-77-3, Diazenedicarboxamide 127-07-1, Hydroxyurea 616-91-1,
N-Acetylcysteine 3056-17-5, Stavudine 4097-22-7,
2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid
6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7,
Erythropoietin 15477-76-6D, Phosphonate, acyclic nucleoside
derivs. 19771-63-2, Procysteine **25526-93-6**,
3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 29706-85-2
30516-87-1, Zidovudine 39809-25-1 59277-89-3 61512-21-8,
Thymosin 69655-05-6, Didanosine 82410-32-0 83869-56-1,
GM-CSF 104227-87-4 113269-46-8 113852-37-2
119644-22-3 124265-89-0 124832-26-4 127142-14-7
127759-89-1 127779-20-8, Saquinavir **129618-40-2**,
BI-RG-587 134678-17-4, Lamivudine 136470-78-5, Abacavir
136817-59-9, Delavirdine 142340-99-6, Adefovir dipivoxil
142632-32-4, Calanolide A 143491-54-7, FTC 145514-04-1, Dapd
147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0,
Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir
154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5,
Ritonavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir
170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4,
Tipranavir 178979-85-6, Capravirine 195156-77-5 198904-31-3,
BMS-232632 201341-05-1 213252-22-3, Reticulose 214287-99-7,
DPC-083 216863-66-0, MK-944A 226700-79-4, Fosamprenavir
352234-06-1, AG-1776 383198-58-1, PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of indane
compds. and analogs as CCR5 antagonists)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534199 HCAPLUS Full-text
DOCUMENT NUMBER: 141:89094
TITLE: Preparation of oxazine and morpholine derivatives as CCR5 antagonists
INVENTOR(S): Aquino, Christopher Joseph; Chong, Pek Yong; Duan, Maosheng; Kazmierski, Wieslaw Mieczyslaw
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055011	A1	20040701	WO 2003-US39740	2003 1212

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003300911	A1	20040709	AU 2003-300911	

2003
1212
<--
EP 1569931 A1 20050907 EP 2003-813436
2003
1212
<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006511555 T2 20060406 JP 2004-560858
2003
1212
<--
US 2006052595 A1 20060309 US 2005-538145
2005
0609
<--
PRIORITY APPLN. INFO.: US 2002-433410P P
2002
1213
<--
WO 2003-US39740 W
2003
1212
<--
OTHER SOURCE(S): MARPAT 141:89094
GI



I



II

AB Title compds. I [R1 = (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc., or R1 and X taken together from a saturated, partially saturated, or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N fused to ring A; R2 = OH, halo, (un)substituted-alkyl, -alkynyl, -heteroaryl, etc., optionally two adjacent R2s taken together form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, or two geminal R2s optionally taken together from a (un)substituted spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N, said fused or spiro ring being optionally substituted; X = (un)substituted-alkylene chain which optionally may have 0-3 heteroatoms selected from O, P, S or N; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N ; Ring B contains an oxygen atom in addition to depicted N; R3 = H, amine, CF3, halo, (un)substituted alkyl,

etc., Y = alkyl, alkenyl, alkynyl, carbonyl, thiocarbonyl, etc.; m = 0-1, n = 0-5] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared by reaction of [3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]acetaldehyde (preparation given) with 1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole dihydrochloride. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly **HIV** infection).

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
119644-22-3 129618-40-2, BI-RG-587
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of oxazine and morpholine derivs. as CCR5 antagonists)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D451-02
ICS C07D413-06; C07D413-14; C07D471-10; C07D417-14; A61K031-46; A61P031-18
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, 10, **63**

ST indane deriv prepn CCR5 antagonist **HIV** treatment

IT **AIDS** (disease)
Alzheimer's disease
Anti-**AIDS** agents
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Arteriosclerosis
Asthma
Human
Human papillomavirus
Immune disease
Inflammation
Kidney, disease
Multiple sclerosis
Neoplasm
Prostate gland, neoplasm
Rheumatoid arthritis
Sjogren syndrome
Transplant rejection
Wound healing
(preparation of oxazine and morpholine derivs. as CCR5 antagonists)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, Diazenedicarboxamide 127-07-1, Hydroxyurea 616-91-1, N-Acetylcysteine 3056-17-5, Stavudine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 15477-76-6D, Phosphonate, acyclic nucleoside derivs. 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 30516-87-1, Zidovudine 39809-25-1 59277-89-3 61512-21-8, Thymosin 69655-05-6, Didanosine 82410-32-0 83869-56-1, GM-CSF 104227-87-4 113269-46-8 113852-37-2 **119644-22-3** 124265-89-0 124832-26-4 124930-59-2 127759-89-1 127779-20-8, Saquinavir **129618-40-2**, BI-RG-587 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142340-99-6, Adefovir dipivoxil 142632-32-4, Calanolide A 143491-54-7, FTC 145514-04-1, DAPD 147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 195156-77-5 198904-31-3, BMS-232632 201341-05-1 213252-22-3, Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A 226700-79-4, Fosamprenavir 352234-06-1, AG-1776 383198-58-1, PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of oxazine and morpholine derivs. as CCR5 antagonists)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534198 HCAPLUS Full-text
DOCUMENT NUMBER: 141:88871
TITLE: Preparation of aminoalkylaryl cyclopropyl compounds as CCR5 antagonists
INVENTOR(S): Peckham, Jennifer Poole; Aquino, Christopher Joseph; Kazmierski, Wieslaw Mieczyslaw
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055010	A2	20040701	WO 2003-US39619	2003 1212
			<--	
WO 2004055010	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296993	A1	20040709	AU 2003-296993	2003 1212
			<--	
EP 1569934	A2	20050907	EP 2003-813416	2003 1212
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514950	T2	20060518	JP 2004-560831	2003 1212
			<--	
US 2006052408	A1	20060309	US 2005-538196	2005 0609
			<--	
PRIORITY APPLN. INFO.:			US 2002-433626P P	2002 1213
			<--	
			WO 2003-US39619 W	2003 1212
			<--	
OTHER SOURCE(S):	MARPAT 141:88871			
GI				



I



II

AB Title compds. I [R1 = (un)substituted saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N, optionally attached through alkylene chain, substituted-amine, -amide, etc.; R2 = OH, halogen (un)substituted-alkyl, -alkoxy, -aryl, -heteroaryl, -cycloalkyl, etc., optionally two adjacent R2s taken together form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, or two geminal R2s optionally taken together from a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N, said fused or spiro ring being optionally substituted; R10 = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, -heterocyclyl, -heteroaryl, or aryl; X = (un)substituted-alkylene chain which optionally may have 0-3 heteroatoms selected from O, P, S or N; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N ; m = 0-3, n = 0-5] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared by reaction of N-{[(1S,2R)-2-formyl-1- phenylcyclopropyl]methyl}-N-methylbenzenesulfonamide (preparation given) and 4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidine. Addnl. preparative examples utilizing combinatorial methods of synthesis are given. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly **HIV** infection).

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
119644-22-3 129618-40-2, BI-RG-587
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of aminoalkylaryl cyclopropane derivs. as CCR5 antagonists)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D413-00
CC 24-2 (Alicyclic Compounds)
Section cross-reference(s): **1**, 10, 27, **63**
ST cyclopropane aminoalkylaryl prepn CCR5 antagonist **HIV** treatment
IT **AIDS** (disease)
Alzheimer's disease
Anti-**AIDS** agents
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Arteriosclerosis
Asthma
Human
Human papillomavirus
Immune disease
Inflammation
Kidney, disease
Multiple sclerosis
Neoplasm
Prostate gland, neoplasm
Rheumatoid arthritis
Sjogren syndrome
Transplant rejection
Wound healing
(preparation of aminoalkylaryl cyclopropane derivs. as CCR5 antagonists)
IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, Diazenedicarboxamide 127-07-1, Hydroxyurea 616-91-1, N-Acetylcysteine 3056-17-5, Stavudine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 15477-76-6D, Phosphonate, acyclic nucleoside derivs. 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 30516-87-1,

Zidovudine 39809-25-1 59277-89-3 61512-21-8, Thymosin
69655-05-6, Didanosine 82410-32-0 83869-56-1, GM-CSF
104227-87-4 113269-46-8 113852-37-2 **119644-22-3**
124265-89-0 124832-26-4 127759-89-1 127779-20-8, Saquinavir
129618-40-2, BI-RG-587 134678-17-4, Lamivudine
136470-78-5, Abacavir 136817-59-9, Delavirdine 142340-99-6,
Adefovir dipivoxil 142632-32-4, Calanolide A 143491-54-7, FTC
145514-04-1, Dapd 147127-20-6, Tenofovir 147318-81-8, KNI-272
147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9,
Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100
155213-67-5, Ritonavir 159989-64-7, Nelfinavir 161814-49-9,
Amprenavir 170020-61-8, FP-21399 172293-43-5 174391-92-5,
Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine
195156-77-5 198904-31-3, BMS-232632 201341-05-1 213252-22-3,
Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A
226700-79-4, Fosamprenavir 352234-06-1, AG-1776 383198-58-1,
PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of
aminoalkylaryl cyclopropane derivs. as CCR5 antagonists)

L82 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534173 HCAPLUS Full-text
DOCUMENT NUMBER: 141:89016
TITLE: Preparation of benzimidazolylazabicyclooctylethylpiperidines as Ccr5 antagonists for the treatment of **HIV** infection
INVENTOR(S): Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph; Bifulco, Neil; Boros, Eric Eugene; Chauder, Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda, Felix, Jr.; Koble, Cecilia Suarez; Mclean, Ed Williams; Peckham, Jennifer Poole; Perkins, Angilique C.; Thompson, James Benjamin; Vanderwall, Dana
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; et al.; et al.
SOURCE: PCT Int. Appl., 859 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054974	A2	20040701	WO 2003-US39644	2003 1212
			<--	
WO 2004054974	A3	20040902		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509711	AA	20040701	CA 2003-2509711	2003 1212
			<--	

AU 2003300902	A1	20040709	AU 2003-300902	2003 1212 <--
EP 1569646	A2	20050907	EP 2003-813419	2003 1212 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017230	A	20051025	BR 2003-17230	2003 1212 <--
CN 1744899	A	20060308	CN 2003-80109628	2003 1212 <--
JP 2006511554	T2	20060406	JP 2004-560838	2003 1212 <--
NO 2005002739	A	20050819	NO 2005-2739	2005 0607 <--
PRIORITY APPLN. INFO.:			US 2002-433634P	P 2002 1213 <--
			WO 2003-US39644	W 2003 1212 <--

OTHER SOURCE(S): MARPAT 141:89016
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
*

AB Compds. I [R1 = (optionally substituted) alkyl, aryl, heteroaryl, carbocyclyl; R2 = H, (optionally substituted) alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroarylalkyl, heteroarylcycloalkyl, aralkylcarbonyl, heteroarylsulfinyl; R3 = H, halo, cyano, trifluoromethyl, (optionally substituted) amino, acylamino, alkyl; X = C1-5 alkylene, optionally substituted with oxo or thioxo groups or halogen atoms, and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, oxyalkylcarbonyl, sulfinyl, sulfonyl, oxycyanoimino, (optionally substituted) aminocarbonyl, carbonylamino, aminothiocarbonyl, oxyiminomethyl, thioiminomethyl, amino(cyanoimino)methyl, (cyanoimino)methyl, amino(acylimino)methyl, amino(sulfonylimino)methyl, amino(sulfinylimino)methyl, amino(alkoxyimino)methyl, amino(imino)methyl, (cyanoimino)methoxy, iminomethoxy, (cyanoimino)methanethiyl, alkylcarbonyloxy; A = saturated, partially saturated, or aromatic monocyclic ring with 5-6 atoms or a bicyclic ring with 8-10 members containing 0-5 nitrogen, oxygen, and/or sulfur atoms] such as II are prepared I are prepared as Ccr5 antagonists for the treatment of viral infections, (particularly **HIV** infection), related syndromes such as **AIDS**-related complex (ARC), progressive generalized lymphadenopathy, Kaposi's sarcoma, and neurol. conditions, and other diseases such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and immune-mediated disorders. The invention compds. have pIC50 values of ≥5 in assays for Ccr5 antagonism. Piperidineacetaldehyde III is prepared in four steps from 4-phenyl-4-piperidinecarbonitrile by protection of the piperidine with Boc anhydride, reduction of the nitrile with diisobutylaluminum hydride, Wittig olefination with

methoxymethylphosphonium chloride, and hydrolysis of the enol ether with catalytic p-toluenesulfonic acid monohydrate. The hydrochloride of endo-(benzimidazolyl)azabicyclooctane IV is prepared in five steps from tert-Bu endo-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate; reductive amination with benzylamine, reductive cleavage of the benzyl group by palladium-mediated hydrogenation, a nucleophilic aryl substitution reaction with 1-fluoro-2-nitrobenzene, reduction of the nitro group by hydrogenation over palladium on carbon, and treatment with tri-Et orthoacetate followed by treatment with hydrochloric acid in ethanol. Coupling of III and IV by reductive amination with sodium triacetoxyborohydride, cleavage of the Boc group with hydrochloric acid in dioxane, and acylation with pivaloyl chloride and triethylamine yields II.

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
119644-22-3 129618-40-2, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly **HIV** infection, and other diseases)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07D211-00
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, 10, **63**
ST benzimidazolylazabicyclooctylethylpiperidine prepn Ccr5 antagonist **HIV** treatment
IT **AIDS** (disease)
(-related complex; preparation of benzimidazolylazabicyclooctylethyl piperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Multiple sclerosis
(**AIDS**-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as multiple sclerosis)
IT Nervous system, disease
(**AIDS**-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Sarcoma
(Kaposi's; preparation of benzimidazolylazabicyclooctylethylpiperidi ne Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)
IT Mental and behavioral disorders
(dementia, **AIDS**-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Kidney
(excretion inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)
IT Envelope proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gp120env, antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)
IT Fusion, biological
(inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)
IT Lymph node, disease
(lymphadenopathy; preparation of benzimidazolylazabicyclooctylethylp iperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Anti-inflammatory agents
(nonsteroidal; preparation of benzimidazolylazabicyclooctylethylpipe ridine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)
IT Transport proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside transporter, inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)
IT **AIDS** (disease)
Anti-**AIDS** agents

(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)

IT CD4 (antigen)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly **HIV** infection, and other diseases)

IT Interleukin 2
Trichosanthin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly **HIV** infection, and other diseases)

IT Immunomodulators
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)

IT Acyclonucleosides
Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)

IT Purpura (disease)
(thrombocytopenic; preparation of benzimidazolylazabicyclooctylethyl piperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)

IT Infection
(viral; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infections)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly **HIV** infection, and other diseases)

IT 52350-85-3, Integrase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)

IT 9047-64-7, Ribonucleotide reductase 9068-38-6, Reverse transcriptase 144114-21-6, **HIV**-1 Protease
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly **HIV** infection)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, 1,1'-Azobisformamide 127-07-1, Hydroxyurea 616-91-1, N-Acetylcysteine 3056-17-5, Stavudine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 15477-76-6D, Phosphonate, nucleoside derivs. 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 29706-85-2 30516-87-1, AZT 39809-25-1, Penciclovir 59277-89-3, Acyclovir 61512-21-8, Thymosin 69655-05-6, 2',3'-Dideoxyinosine 82410-32-0, Ganciclovir 83869-56-1, GM-CSF 104227-87-4, Famciclovir 113269-46-8, Oxetanocin-G

113852-37-2, HPMPC **119644-22-3** 124265-89-0, H2G
124832-26-4, Valaciclovir 127142-14-7 127759-89-1, SQ-34514
127779-20-8, Saquinavir **129618-40-2**, Nevirapine
134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9,
Delavirdine 142340-99-6, Bis-POM PMEA 142632-32-4,
(+)-Calanolide A 143491-54-7, FTC 145514-04-1, DAPD
147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0,
Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir
154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5,
Ritonavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir
170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4,
Tipranavir 178979-85-6, Capravirine 195156-77-5, ABT-606
198904-31-3, BMS-232632 201341-05-1, Bis-POC-PMPA 213252-22-3,
Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A
226700-79-4, Fosamprenavir 352234-06-1, AG-1776 383198-58-1,
PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with
benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists
in the treatment of bacterial and viral infections,
particularly **HIV** infection, and other diseases)

L82 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531360 HCAPLUS Full-text
DOCUMENT NUMBER: 141:88873
TITLE: Preparation of heterocyclylalkyl substituted cyclohexyl compounds as CCR5 antagonists
INVENTOR(S): Duan, Maosheng; Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054581	A2	20040701	WO 2003-US39732	2003 1212
			<--	
WO 2004054581	A3	20050203		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297048	A1	20040709	AU 2003-297048	2003 1212
			<--	
EP 1569647	A2	20050907	EP 2003-813435	2003 1212
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ,				

EE, HU, SK				
JP 2006514646	T2	20060511	JP 2004-560857	2003 1212 <--
US 2006122166	A1	20060608	US 2005-538135	2005 0609 <--
PRIORITY APPLN. INFO.:			US 2002-433552P	P 2002 1213 <--
			WO 2003-US39732	W 2003 1212 <--

OTHER SOURCE(S): MARPAT 141:88873

GI



I



II

AB Title compds. I [R1 = (un)substituted saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N, optionally attached through alkylene chain, substituted-amine, -amide, etc.; R2 = OH, halogen (un)substituted-alkyl, -alkoxy, -aryl, -heteroaryl, -cycloalkyl, etc., optionally two adjacent R2s taken together form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, or two geminal R2s optionally taken together from a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N, said fused or spiro ring being optionally substituted; R10 = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, -heterocyclyl, -heteroaryl, or aryl; X = (un)substituted-alkylene chain which optionally may have 0-3 heteroatoms selected from O, P, S or N; A = saturated, partially saturated, or aromatic 4-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N ; m = 0 or 1, n = 0-5] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared by amidation of cis-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4- phenylcyclohexanamine (preparation given) with 3-(aminosulfonyl)-4- chlorobenzoic acid. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly **HIV** infection).

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
129618-40-2, BI-RG-587

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of heterocyclylalkyl substituted cyclohexanes derivs. as CCR5 antagonists)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-46
ICS A61K031-438; A61P031-18; A61P031-04; C07D451-02; C07D471-10; C07D333-52; C07D211-26; C07D401-04
CC 24-5 (Alicyclic Compounds)
Section cross-reference(s): **1**, 10, 27, **63**
ST cyclohexane heterocyclylalkyl prepn CCR5 antagonist **HIV** treatment
IT **AIDS** (disease)
Alzheimer's disease
Anti-**AIDS** agents
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Arteriosclerosis
Asthma
Human
Human papillomavirus
Immune disease
Inflammation
Kidney, disease
Multiple sclerosis
Neoplasm
Prostate gland, neoplasm
Rheumatoid arthritis
Sjogren syndrome
Transplant rejection

Wound healing
(preparation of heterocyclylalkyl substituted cyclohexanes derivs. as CCR5 antagonists)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, Diazenedicarboxamide 127-07-1, Hydroxyurea 616-91-1, N-Acetylcysteine 3056-17-5, Stavudine 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7, Erythropoietin 15477-76-6D, Phosphonate, acyclic nucleoside derivs. 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 30516-87-1, Zidovudine 39809-25-1 59277-89-3 61512-21-8, Thymosin 69655-05-6, Didanosine 82410-32-0 83869-56-1, GM-CSF 104227-87-4 113269-46-8 113852-37-2 124265-89-0 124832-26-4 127759-89-1 127779-20-8, Saquinavir **129618-40-2**, BI-RG-587 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142340-99-6, Adefovir dipivoxil 142632-32-4, Calanolide A 142739-72-8 143491-54-7, FTC 145514-04-1, Dapd 147127-20-6, Tenofovir 147318-81-8, KNI-272 147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir 154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 195156-77-5 198904-31-3, BMS-232632 201341-05-1 213252-22-3, Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A 226700-79-4, Fosamprenavir 352234-06-1, AG-1776 383198-58-1, PRO-542 714968-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for therapeutic administration; preparation of heterocyclylalkyl substituted cyclohexanes derivs. as CCR5 antagonists)

L82 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41226 HCAPLUS Full-text
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
			<--	
WO 2004004658	A3	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, ML, MR, NE, SN, TD, TG

CA 2491466	AA	20040115	CA 2003-2491466	2003 0709 <--
AU 2003265264	A1	20040123	AU 2003-265264	2003 0709 <--
US 2004077601	A1	20040422	US 2003-616694	2003 0709 <--
US 2005084490	A1	20050421	US 2003-616409	2003 0709 <--
EP 1578434	A2	20050928	EP 2003-763380	2003 0709 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006507352	T2	20060302	JP 2004-562634	2003 0709 <--
CN 1802090	A	20060712	CN 2003-821282	2003 0709 <--
CN 1826129	A	20060830	CN 2003-821281	2003 0709 <--

PRIORITY APPLN. INFO.:	US 2002-394856P	P	2002 0709 <--
	US 2002-414978P	P	2002 1001 <--
	US 2003-466435P	P	2003 0428 <--
	WO 2003-US21405	W	2003 0709 <--

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IT **25526-93-6**, Alovudine **92562-88-4**
129618-40-2, Nevirapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 92562-88-4 HCAPLUS
CN Guanosine, 2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K
CC 1-12 (**Pharmacology**)
Section cross-reference(s): 15
IT Actinomyces
Adenoviridae
Bacteroides
Borrelia
Campylobacter
Citrobacter
Clostridium difficile
Corynebacterium
Cytomegalovirus
Echinococcus

Enterobacter
Escherichia coli
Fasciola
Gardnerella
Haemophilus
Helicobacter pylori
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human papillomavirus
Hymenolepis
Klebsiella
Legionella
Listeria
Monkeypox virus
Necator americanus
Neisseria
Nocardia
Paragonimus
Pasteurella
Pneumocystis
Proteus (bacterium)
Pseudomonas
Respiratory syncytial virus
Rotavirus
Salmonella
Shigella
Spirillum
Spirochaeta
Streptobacillus
Streptococcus
Streptococcus pneumoniae
Taenia
Treponema
Trichomonas vaginalis
Trichuris trichiura
Trypanosoma brucei
Trypanosoma cruzi
(infection; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT Acute lymphocytic leukemia
Acute myeloid leukemia
Angiogenesis inhibitors
Anti-infective agents
Antibacterial agents
Antibacterial agents
Antibiotics
Antiemetics
Antimicrobial agents
Antitumor agents
Antiviral agents
Biliary tract, neoplasm
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Central nervous system, neoplasm
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Digestive tract, neoplasm
Drug delivery systems
Esophagus, neoplasm
Eye, neoplasm
Fungicides
Head and Neck

Head and Neck, neoplasm
Hodgkin's disease
Human
Immunodeficiency
Immunostimulants
Infection
Influenza A virus
Kidney, neoplasm
Larynx, neoplasm
Leprosy
Leukemia
Liver, neoplasm
Lymphoma
Malaria
Mammary gland, neoplasm
Melanoma
Mouth, neoplasm
Multiple myeloma
Multiple sclerosis
Mycosis
Nausea
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Parasiticides
Prostate gland, neoplasm
Radiotherapy
Respiratory system, neoplasm
Sarcoma
Skin, neoplasm
Staphylococcus
Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Tuberculosis
Tuberculostatics
Urinary system, neoplasm
Uterus, neoplasm
Vaccines
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 5980-31-4, Hexedine 6576-51-8, Stallimycin hydrochloride 6591-72-6, Penicillin v hydrabamine 6804-07-5, Carbadox 6981-18-6, Ormetoprim 6990-06-3, Fusidic acid 7054-25-3, Quinidine gluconate 7179-50-2, Oxytetracycline calcium 7481-89-2, Zalcitabine 7527-91-5, Acrisorcin 7542-37-2, Paromomycin 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 8017-57-0D, Trisulfapyrimidine, derivs. 8025-81-8, Spiramycin 8063-07-8, Kanamycin 8063-91-0, Mirincamycin hydrochloride 8064-90-2 8068-28-8, Colistimethate sodium 9001-06-3, Chitinase 9015-68-3, Asparaginase 9041-93-4, Bleomycin sulfate 10118-85-1, Lydimycin 10118-90-8, Minocycline 10500-82-0, Famotine hydrochloride 10540-97-3, Memotine hydrochloride 11006-76-1, Virginiamycin 11006-77-2, Statolon 11015-37-5, Bambermycin 11016-07-2, Fungimycin 11033-34-4, Steffimycin 11048-13-8, Nebramycin 11048-15-0, Kalafungin 11051-71-1, Avilamycin 11056-09-0, Ranimycin 11056-11-4, Biniramycin 11056-12-5, Cirolemycin 11056-13-6, Denofungin 11056-18-1, Scopafungin 11056-20-5, Zorbamycin 11078-21-0, Filipin 11096-49-4, Partricin 11096-79-0, Alamecin 11111-12-9, Cephalosporin 11121-32-7, Mepartricin 13292-46-1, Rifampin 13292-46-1D, Rifampin, derivs. 13392-28-4, Rimantadine 13411-16-0, Nifurpirinol 13463-41-7, Pyrithione zinc 13614-98-7, Minocycline hydrochloride 14088-71-2, Proclonol 14698-29-4, Oxolinic acid 15037-55-5, Ethonam nitrate 15176-29-1, Edoxudine 15318-45-3, Thiamphenicol

15475-56-6, Methotrexate sodium 15663-27-1, Cisplatin
15686-71-2, Cephalexin 16037-91-5, Stibogluconate sodium
16846-24-5, Josamycin 16915-79-0, Mequidox 17090-79-8,
Monensin 17230-86-3, Carbenicillin potassium 17692-15-8,
Furazolium tartrate 17784-12-2, Sulfacytine 18323-44-9,
Clindamycin 19387-91-8, Tinidazole 19561-70-7, Nifuratrone
19885-51-9, Aranotin 20685-78-3, Rolitetracycline nitrate
21462-39-5, Clindamycin hydrochloride 21593-23-7, Cephapirin
21638-36-8, Nifurimide 21649-57-0, Carbenicillin phenylsodium
21679-14-1, Fludarabine 21736-83-4, Spectinomycin hydrochloride
21738-42-1, Oxamniquine 22204-24-6, Pyrantel pamoate
22373-78-0, Monensin sodium 22484-64-6, Sulfanilate zinc
22573-93-9, Alexidine 22832-87-7, Miconazole nitrate
22916-38-7, Orconazole nitrate 22916-47-8, Miconazole
22994-85-0, Benznidazole 23067-13-2, Erythromycin gluceptate
23155-02-4, Fosfomycin 23214-92-8, Doxorubicin 23239-41-0,
Cephacetrile sodium 23256-30-6, Nifurtimox 23313-80-6,
Epitetracycline hydrochloride 23319-48-4, Megalomicin potassium
phosphate 23444-86-2, Suncillin sodium 23541-50-6,
Daunorubicin hydrochloride 23593-75-1, Clotrimazole
23736-58-5, Cloxacillin benzathine 24169-02-6, Econazole nitrate
24356-60-3, Cephapirin sodium 24390-14-5, Doxycycline hyclate
24729-96-2, Clindamycin phosphate 25316-40-9, Doxorubicin
hydrochloride 25389-94-0, Kanamycin sulfate 25507-04-4,
Clindamycin palmitate hydrochloride **25526-93-6**,
Alovudine 25953-19-9, Cefazolin 26309-95-5, Pivampicillin
hydrochloride 26605-69-6, Carbenicillinindanylsodium
26774-90-3, Epicillin 26786-84-5, Lomofungin 26787-78-0,
Amoxicillin 27164-46-1, Cefazolin sodium 27220-47-9, Econazole
27523-40-6, Isoconazole 27591-69-1, Tilorone hydrochloride
27762-78-3, Kethoxal 27823-62-7, Chlortetracycline bisulfate
27877-51-6, Tolindate 28069-65-0, Cuprimyxin 28088-64-4,
Aminosalicylic acid 28657-80-9, Cinoxacin 29342-05-0,
Ciclopirox 29457-07-6, Ticarcillin disodium 29767-20-2,
Teniposide 29984-33-6, Vidarabine phosphate 30034-03-8,
Cefamandole sodium 30516-87-1, Zidovudine 31342-36-6,
Chloramphenicol pantothenate complex 31431-39-7, Mebendazole
32385-11-8, Sisomicin 32886-97-8, Amdinocillin pivoxil
32887-01-7, Amdinocillin 32986-56-4, Tobramycin 33069-62-4,
Taxol 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium
34444-01-4, Cefamandole 35523-45-6, Fludalanine 35554-44-0,
Enilconazole 35607-20-6, Avridine 35607-66-0, Cefoxitin
35834-26-5, Rosaramicin 36791-04-5, Ribavirin 36983-81-0,
Fosfonet sodium 37091-65-9, Azlocillin sodium 37091-66-0,
Azlocillin 37321-09-8, Apramycin 37332-99-3, Avoparcin
37338-39-9 37517-28-5, Amikacin 37661-08-8, Bacampicillin
hydrochloride 38070-41-6, Tiodonium chloride 38821-53-3,
Cephradine 39030-72-3, Pivampicillin pamoate 39809-25-1,
Penciclovir 39831-55-5, Amikacin sulfate 39878-70-1,
Talampicillin hydrochloride 40034-42-2, Rosoxacin 40966-79-8,
Sarpicillin 41575-94-4, Carboplatin 41621-49-2, Ciclopirox
olamine 42057-22-7, Mezlocillin sodium 42190-91-0,
Pivampicillin probenate 42540-40-9, Cefamandole nafate
42835-25-6, Flumequine 43143-11-9, Bispyrithione magsulfex
43169-50-2, Betamicin sulfate 49620-13-5, Robustaflavone
49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil
50838-36-3, Tolciclate 51022-98-1, Butirosin sulfate
51481-64-2, Rosaramicin propionate 51481-65-3, Mezlocillin
51547-64-9, Rosaramicin stearate 51627-14-6, Cefatrizine
51627-20-4, Cefaparole 51762-05-1, Cefroxadine 52123-49-6,
Cefazaflur sodium 52152-93-9, Cefsulodin sodium 53066-26-5,
Lexithromycin 53179-09-2, Sisomicin sulfate 53230-10-7,
Mefloquine 53678-77-6, Muramyl dipeptide 53808-87-0,
Tetroxoprim 53910-25-1, Pentostatin 53994-73-3, Cefaclor
54965-21-8, Albendazole 55103-30-5, Rosaramicin butyrate
55162-26-0, Pirbenicillin sodium 55242-74-5, Oxifungin
hydrochloride 55242-77-8, Triafungin 55268-74-1, Praziquantel

55268-75-2, Cefuroxime 55298-68-5, Neomycin palmitate
55694-87-6, Pentizidone sodium 55852-84-1, Bacitracin methylene
disalicylate 56093-45-9, Selenium sulfide 56219-57-9, Arildone
56238-63-2, Cefuroxime sodium 56390-09-1, Epirubicin
hydrochloride 56391-57-2, Netilmicin sulfate 56433-46-6,
Cetocycline hydrochloride 56585-33-2, Trimethoprim sulfate
56689-42-0, Repromicin 56796-20-4, Cefmetazole 56796-39-5,
Cefmetazole sodium 57363-13-0, Droxacin sodium 57852-57-0,
Idarubicin hydrochloride 58001-44-8, Clavulanic acid
58152-03-7, Isepamicin 58795-03-2, Apalcillin sodium
58857-02-6, Ambruticin 58944-73-3, Sinefungin 59070-06-3,
Ticarcillin cresylsodium 59277-89-3, Acyclovir 59695-59-9,
Cephalexin hydrochloride 59703-84-3, Piperacillin sodium
59733-86-7, Butikacin 59794-18-2, Paulomycin 59831-63-9,
Doconazole 60207-31-0, Azaconazole 60628-96-8, Bifonazole
60802-40-6, Rosaramicin sodium phosphate 60925-61-3, Ceforanide
61036-62-2, Teicoplanin 61270-78-8, Cefonicid sodium
61318-91-0, Sulconazole nitrate 61379-65-5, Rifapentine
61477-96-1, Piperacillin 62013-04-1, Dirithromycin 62587-73-9,
Cefsulodin 62893-19-0, Cefoperazone 62893-20-3, Cefoperazone
sodium 62973-77-7, Parconazole hydrochloride 63198-97-0,
Viroxime
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine
boroproline compds. alone or in combination with other drugs,
antibodies, or antigens)

IT 63527-52-6, Cefotaxime 63585-09-1, Foscarnet sodium
64211-46-7, Oxiconazole nitrate 64221-86-9, Imipenem
64221-86-9D, Imipenem, derivs. 64485-93-4, Cefotaxime sodium
64544-07-6, Cefuroxime axetil 64872-77-1, Butoconazole nitrate
64952-97-2, Moxalactam 65025-62-9, (-)-Soulattrolide
65052-63-3, Cefetamet 65271-80-9, Mitoxantrone 65277-42-1,
Ketoconazole 65473-14-5, Naftifine hydrochloride 65899-73-2,
Tioconazole 66148-78-5, Temocillin 66309-69-1, Cefotiam
hydrochloride 66887-96-5, Propikacin 67337-44-4, Sarmoxicillin
67915-31-5, Terconazole 68401-82-1, Ceftizoxime sodium
68693-30-1, Somantadine hydrochloride 68902-57-8, Metioprim
69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69198-10-3,
Metronidazole hydrochloride 69402-03-5, Piridicillin sodium
69521-94-4, Thymosin α-1 69655-05-6, Didanosine
69657-51-8, Acyclovir sodium 69712-56-7, Cefotetan 69756-53-2,
Halofantrine 70052-12-9, Eflornithine 70288-86-7, Ivermectin
70458-92-3, Pefloxacin 70458-95-6, Pefloxacin mesylate
70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 71002-10-3,
Vidarabine sodium phosphate 71420-79-6 72275-67-3, Astromicin
sulfate 72301-78-1, Zinviroxime 72301-79-2, Enviroxime
72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73334-05-1,
Metronidazole phosphate 73384-59-5, Ceftriaxone 73514-87-1,
Fosarilate 73816-42-9, Meclocycline sulfosalicylate
74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium
74578-69-1, Ceftriaxone sodium 74682-62-5, Ticarcillin
monosodium 74849-93-7, Cefpiramide sodium 75738-58-8,
Cefmenoxime hydrochloride 76168-82-6, Ramoplanin 76470-66-1,
Loracarbef 76497-13-7, Sultamicillin 76610-84-9, Cefbuperazone
77146-42-0, Chlorhexidine phosphanilate 77181-69-2, Sorivudine
78040-85-4, Coumermycin 78110-38-0, Aztreonam 78186-33-1,
Fumoxicillin 78613-35-1, Amorolfine 78822-40-9, Pirlimycin
hydrochloride 78964-85-9, Fosfomycin tromethamine 79350-37-1,
Cefixime 79404-91-4, Cilofungin 79660-72-3, Fleroxacin
80168-44-1, Zinoconazole hydrochloride 80214-83-1, Roxithromycin
80621-81-4, Rifaximin 80883-55-2, Enviradene 81103-11-9,
Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
83038-87-3, Doxycycline fosfatex 83200-96-8D, Carbapenem,
derivs. 83905-01-5, Azithromycin 84408-37-7, Desciclovir
84625-61-6, Itraconazole 84880-03-5, Cefpimizole 85287-61-2,

Cefpimizole sodium 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 86832-68-0, Carumonam sodium 87239-81-4, Cefpodoxime proxetil 87495-31-6, Disoxaril 87806-31-3, Porfimer sodium 88036-80-0, Amifloxacin mesylate 88040-23-7, Cefepime 90849-08-4, Oximonam sodium 90850-05-8, Gloximonam 90898-90-1, Oximonam 91161-71-6, Terbinafine 91618-36-9, Ibafloxacin 91832-40-5, Cefdinir **92562-88-4** 92665-29-7, Cefprozil 93107-08-5, Ciprofloxacin hydrochloride 94088-85-4, Doxycycline calcium 94168-98-6, Rifametane 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96128-89-1, Erythromycin acistrate 97519-39-6, Ceftibuten 97673-66-0, Trospectomycin sulfate 97682-44-5, Irinotecan 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin hydrochloride 98753-19-6, Cefpirome sulfate 100234-70-6, Resorcinomycin A 100490-36-6, Tosufloxacin 100680-33-9, Cefuroxime pivoxetil 101828-21-1, Butenafine 102426-96-0, Paldimycin 103060-53-3, Daptomycin 104227-87-4, Famciclovir 104456-95-3, Cisconazole 105784-61-0, Temafloxacin hydrochloride 105956-99-8, Clinafloxacin hydrochloride 106941-25-7, Adefovir 107648-80-6, Cefepime hydrochloride 107910-75-8, Ganciclovir sodium 108319-06-8, Temafloxacin 110042-95-0, Acemannan 110588-57-3, Saperconazole 110871-86-8, Sparfloxacin 110942-02-4, Aldesleukin 112362-50-2, Dalfopristin 113102-19-5, Rifamexil 113852-37-2, Cidofovir 114394-67-1, Lomefloxacin mesylate 114977-28-5, Taxotere 117091-64-2, Etoposide phosphate 117211-03-7, Cefetecol 119413-54-6, Topotecan hydrochloride 120138-50-3, Quinupristin 120410-24-4, Biapenem 120788-07-0, Sulopenem 122111-03-9, Gemcitabine hydrochloride 124436-59-5, Pirodavir 124832-27-5, Valacyclovir hydrochloride 125317-39-7, Vinorelbine tartrate 127464-60-2, Vascular endothelial growth factor 127759-89-1, Lobucavir 127779-20-8, Saquinavir 127785-64-2, Basifungin **129618-40-2**, Nevirapine 130167-69-0, Pegaspargase 132210-43-6, Cipamfylline 134678-17-4, Lamivudine 136817-59-9, Delavirdine 137487-62-8, Alvircept sudotox 138540-32-6, Atevirdine mesylate 139442-47-0, LFM-A 12 141611-76-9, Sanfetrinem sodium 142217-69-4, Entecavir 142340-99-6, Adefovir dipivoxil 142632-32-4, (+)Calanolide A 143491-57-0, Emtricitabine 147221-93-0, Delavirdine mesylate 149845-06-7, Saquinavir mesylate 150378-17-9, Indinavir 150572-30-8 151581-81-6, Pradimicin 152121-44-3 152923-56-3, Daclizumab 154598-52-4, Efavirenz 155213-67-5, Ritonavir 156586-89-9, Panorex 159989-64-7, Nelfinavir 163252-36-6, Clevudine 163661-45-8, (-)-Calanolide A 164301-51-3, CNI-1493 167869-21-8, PD98059 170277-31-3, Infliximab 174722-31-7, Rituxan 179463-17-3, MK 991 180288-69-1, Herceptin 183319-69-9, Tarceva 184475-35-2, Iressa 185243-69-0, Etanercept 187029-72-7, (-)-7,8-Dihydrosoulattrolide 188039-54-5, Palivizumab 205923-56-4, IMC-C225 206181-63-7, Zevalin 208538-73-2, FK 463 208921-02-2, Tositumomab 211555-05-4, WHI-P97 213327-37-8, Oregovomab 216503-57-0, Campath 216503-58-1, Mitumomab 216974-75-3, Avastin 220578-59-6, Mylotarg 339150-51-5, CeaVac 339150-82-2, LymphoCide 339151-95-0, MDX-22 339151-96-1, MDX-447 339152-71-5, MDX-210 339286-23-6, Gliomab-H 339286-24-7, GNI-250 339526-30-6, MDX-220 478159-64-7, 2C3 645405-72-7 645405-73-8 645416-54-2, AG 1458 645417-10-3, UK 292 645417-21-6, BAY 38-9502 646031-42-7, Celogovab 646032-07-7, Zamyl

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

L82 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5729 HCAPLUS Full-text
DOCUMENT NUMBER: 138:56191

TITLE: Preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides

INVENTOR(S): Chu, Chung K.; Otto, Michael J.; Shi, Junxing; Schinazi, Raymond F.; Choi, Yongseok; Gumina, Giuseppe; Chong, Youhoon; et al.

PATENT ASSIGNEE(S): Pharmasset Ltd., Barbados; University of Georgia Research Foundation, Inc.; Emory University

SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000200	A2	20030103	WO 2002-US20245	20020624
			<--	
WO 2003000200	A3	20040902		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451745	AA	20030103	CA 2002-2451745	20020624
			<--	
EP 1478322	A2	20041124	EP 2002-756310	20020624
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005503358	T2	20050203	JP 2003-506646	20020624
			<--	
CN 1599744	A	20050323	CN 2002-816455	20020624
			<--	
US 2005119286	A1	20050602	US 2002-179612	20020624
			<--	
US 6949522	B2	20050927		
BR 2002010594	A	20051101	BR 2002-10594	20020624
			<--	
PRIORITY APPLN. INFO.:			US 2001-300356P P	20010622
			<--	

US 2001-305386P P 20010713
<--
WO 2002-US20245 W 20020624
<--

OTHER SOURCE(S): MARPAT 138:56191
GI



I

AB The present invention includes compds. and compns. of β-halo-nucleosides I wherein: R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; X is O, S, SO2 or CH2; Y is fluoro, chloro, bromo or iodo; and B is a purine or pyrimidine base that may optionally be substituted, as well as methods to treat **HIV**, HBV or abnormal cellular proliferation comprising administering said compds. or compns. Thus, (-)-1-[(1S,4R)-2,3-dideoxy-2,3-didehydro-2-fluoro-4-thio-β-D-ribofuranosyl]-cytosine was prepared and tested in vitro as **antiviral** agent. Preferred examples of **antiviral** agents can be used in combination or alternation with other known **antiviral** agents for **HIV** therapy. Use of the any one of the pharmaceutical compns. for the treatment and/or prophylaxis of an **HIV** infection or an abnormal cellular proliferation in a host.

IT **125362-05-2P 396653-01-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

RN 125362-05-2 HCAPLUS
CN Cytidine, 2',3'-didehydro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396653-01-3 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5S)-4-fluoro-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **129618-40-2**, Nevirapine **181623-96-1**
181785-94-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 181623-96-1 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[4-fluoro-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 181785-94-4 HCAPLUS
CN Cytidine, 2',3'-didehydro-2',3'-dideoxy-3',5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **184700-37-6P 395075-16-8P 395075-17-9P**
395075-18-0P 395075-19-1P 395075-20-4P
395075-21-5P 479035-81-9P 479035-82-0P
479035-84-2P 479035-85-3P 479035-86-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

RN 184700-37-6 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4,4-difluorotetrahydro-5-(hydroxymethyl)-2-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 395075-16-8 HCAPLUS
CN 2-Furanmethanol, 3,3-difluorotetrahydro-5-methoxy-, benzoate, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 395075-17-9 HCAPLUS
CN 2-Furanmethanol, 5-(acetyloxy)-3,3-difluorotetrahydro-, benzoate, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395075-18-0 HCAPLUS
CN Benzamide, N-[1-[(2S,5S)-5-[(benzoyloxy)methyl]-4,4-difluorotetrahydro-2-furanyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 395075-19-1 HCAPLUS
CN Benzamide, N-[1-[(2R,5S)-5-[(benzoyloxy)methyl]-4,4-difluorotetrahydro-2-furanyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 395075-20-4 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2S,5S)-4,4-difluorotetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 395075-21-5 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-4,4-difluorotetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 479035-81-9 HCAPLUS
CN 2-Furanmethanol, 5-(acetyloxy)-3,3-difluorotetrahydro-, benzoate, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479035-82-0 HCAPLUS
CN Benzamide, N-[1-[(2R,5R)-5-[(benzoyloxy)methyl]-4,4-difluorotetrahydro-2-furanyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 479035-84-2 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(5S)-5-[(benzoyloxy)methyl]-4,4-difluorotetrahydro-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479035-85-3 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5S)-4,4-difluorotetrahydro-5-(hydroxymethyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 479035-86-4 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-4,4-difluorotetrahydro-5-(hydroxymethyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **396653-02-4P 479035-87-5P 479035-88-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
RN 396653-02-4 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-4-fluoro-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 479035-87-5 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5S)-4-fluoro-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 479035-88-6 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-4-fluoro-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K
CC 33-9 (Carbohydrates)
Section cross-reference(s): **1**, **63**
ST human **antiviral** nucleoside prodrug **AIDS** cytotoxicity prepn cellular proliferation
IT Cell proliferation
(inhibition; preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT Anti-**AIDS** agents
Antiviral agents
Cytotoxic agents
Cytotoxicity
Hepatitis B virus
Human
Human immunodeficiency virus 1
Therapy
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT Nucleosides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT Drug delivery systems
(prodrugs; preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT Infection
(viral; preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT 9026-93-1, Adenosine deaminase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT **125362-05-2P** 165399-47-3P 166249-15-6P
396653-01-3P 398133-37-4P 476210-28-3P 476210-30-7P
476210-37-4P 479036-01-6P 479036-12-9P 479036-22-1P
479036-23-2P 479036-25-4P 479036-26-5P 479036-38-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)
IT 3056-17-5, D4T 7481-89-2, DDC 30516-87-1, AZT 39809-25-1, Penciclovir 59277-89-3, Acyclovir 69655-05-6, DDI 104227-87-4, Famciclovir 118353-05-2, Carbovir 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 136470-78-5, Abacavir 143491-54-7, FTC 145440-12-6 145514-01-8 145514-04-1 149950-60-7, MKC-442 150378-17-9, Indinavir 154598-52-4, DMP-266 163252-36-6, L-FMAU 177932-89-7, DMP-450

181623-96-1 181785-94-4 182967-46-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

IT 609-06-3, L-Xylose 15186-48-8 26661-13-2 34837-55-3, Benzeneselenenyl bromide 137719-21-2 169736-17-8 180675-22-3 212954-52-4 367491-78-9 479036-27-6 479036-29-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

IT 68660-45-7P 145887-01-0P 145887-10-1P 145887-11-2P
171721-11-2P **184700-37-6P** 395075-12-4P 395075-13-5P
395075-14-6P 395075-15-7P **395075-16-8P**
395075-17-9P 395075-18-0P 395075-19-1P
395075-20-4P 395075-21-5P 398133-29-4P
398133-32-9P 398133-34-1P 398133-35-2P 398133-36-3P
476209-84-4P 476209-86-6P 476209-92-4P 476209-94-6P
476210-00-1P 476210-02-3P 476210-04-5P 476210-06-7P
476210-09-0P 476210-11-4P 476210-22-7P 476210-24-9P
476210-26-1P 476210-32-9P 476210-33-0P 476210-34-1P
476210-35-2P 476210-39-6P 476210-45-4P 476210-47-6P
479035-76-2P 479035-77-3P 479035-78-4P 479035-79-5P
479035-80-8P **479035-81-9P 479035-82-0P**
479035-83-1P **479035-84-2P 479035-85-3P**
479035-86-4P 479035-89-7P 479035-90-0P 479035-91-1P
479035-92-2P 479035-93-3P 479035-94-4P 479035-95-5P
479035-96-6P 479035-98-8P 479036-13-0P 479036-14-1P
479036-15-2P 479036-16-3P 479036-17-4P 479036-18-5P
479036-19-6P 479036-20-9P 479036-21-0P 479036-30-1P
479036-31-2P 479036-32-3P 479036-40-3P 479036-41-4P
479036-42-5P 479036-43-6P 479036-44-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

IT **396653-02-4P** 398133-33-0P **479035-87-5P**
479035-88-6P 479036-03-8P 479036-05-0P 479036-28-7P
479036-39-0P 479036-45-8P 479036-46-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, **antiviral** activity, and cytotoxicity of β-2'- and 3'-halo-nucleosides)

L82 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:695941 HCAPLUS Full-text
DOCUMENT NUMBER: 137:232453
TITLE: Preparation of substituted benzophenones as inhibitors of reverse transcriptase
INVENTOR(S): Chan, Joseph Howing
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070470	A2	20020912	WO 2002-US6037	20020228
			<--	
WO 2002070470	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

```
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
            GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
            MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
            VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT,
            BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
            NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
            ML, MR, NE, SN, TD, TG
    CA 2439820          AA    20020912    CA 2002-2439820
                                                              2002
                                                              0228
                                                 <--
    EP 1363877          A2    20031126    EP 2002-723265
                                                              2002
                                                              0228
                                                 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
            MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    BR 2002007752       A     20040323    BR 2002-7752
                                                              2002
                                                              0228
                                                 <--
    CN 1494528          A     20040505    CN 2002-805882
                                                              2002
                                                              0228
                                                 <--
    NZ 527864           A     20040528    NZ 2002-527864
                                                              2002
                                                              0228
                                                 <--
    JP 2004525914       T2    20040826    JP 2002-569791
                                                              2002
                                                              0228
                                                 <--
    ZA 2003006549       A     20041122    ZA 2003-6549
                                                              2003
                                                              0821
                                                 <--
    NO 2003003857       A     20031027    NO 2003-3857
                                                              2003
                                                              0901
                                                 <--
    US 2004122064       A1    20040624    US 2004-469104
                                                              2004
                                                              0205
                                                 <--
    US 6995283          B2    20060207
    US 2006009651       A1    20060112    US 2005-223634
                                                              2005
                                                              0909
                                                 <--
PRIORITY APPLN. INFO.:                      US 2001-272953P     P
                                                              2001
                                                              0302
                                                 <--
                                            WO 2002-US6037      W
                                                              2002
                                                              0228
                                                 <--
                                            US 2004-469104      A3
                                                              2004
                                                              0205

OTHER SOURCE(S):        MARPAT 137:232453
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
*

AB Title compds. I [R1 = ≥1 substituent chosen from halo, CF3, alkyl, aminoalkyl, alkoxy, CN, NO2, NH2, thioalkoxy, etc.; R2 = H, halo, alkyl, NO2, NH2, alkylamino, CF3, alkoxy; R3 = OH, halo, CF3, NO2, alkyl; R4 = sulfonamido, sulfonylimino, etc.;] were prepared For instance, 3,5-dichlorobromobenzene was metalated (MTBE, n-BuLi, -50°) and acylated with the N,2-dimethoxy-N-methyl-5-chlorobenzamide and the resulting benzophenone converted to II. II was converted to III in 5 steps. Polymorphic forms of sodium, choline, calcium, magnesium, ethanolamine and triethylamine salts of III were prepared and characterized. Oral bioavailability and solubility parameters were determined for III and polymorphic salt forms thereof. Compds. of the present invention have anti-**HIV** activity and deliver compds. that have anti- **HIV** activity in the range IC50 = 1-1000 nM against wild type and mutant viruses.

IT **25526-93-6**, 3'-Deoxy-3'-fluorothymidine
129618-40-2, Nevirapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of substituted benzophenones as inhibitors of reverse transcriptase)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM C07C311-51
ICS C07D295-14; C07C311-53; C07C311-46; C07D207-16; A61K031-18; A61P031-18

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): **1**

IT **AIDS** (disease)
Anti-**AIDS** agents
Antiviral agents
Human
(preparation of substituted benzophenones as inhibitors of reverse

transcriptase)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole 123-77-3, 1,1'-Azobis-formamide 616-91-1, NAC 3056-17-5, d4T 4097-22-7, 2',3'-Dideoxyadenosine 4428-95-9, Phosphonoformic acid 6493-05-6, Pentoxifylline 7481-89-2, 2',3'-Dideoxycytidine 11096-26-7, Erythropoietin 19771-63-2, Procysteine **25526-93-6**, 3'-Deoxy-3'-fluorothymidine 29321-75-3, PRO-2000 30516-87-1, AZT 36791-04-5, Ribavirin 39809-25-1, Penciclovir 59277-89-3, Acyclovir 61512-21-8, Thymosin 69655-05-6, 2',3'-Dideoxyinosine 82410-32-0, Ganciclovir 83869-56-1, Granulocyte macrophage colony stimulating factor 104227-87-4, Famciclovir 106941-25-7, Adefovir 113269-46-8, Oxetanocin-G 113852-37-2, HPMPC 124265-89-0, H 2G 124832-26-4, Valaciclovir 127759-89-1, SQ-34514 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 132077-80-6 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 142632-32-4, (+)-Calanolide A 143491-54-7, FTC 145514-04-1, DAPD 147127-20-6, Tenofovir 147318-81-8, KNI-272 149950-60-7, MKC-442 150378-17-9, Indinavir 155148-31-5, AMD-3100 155213-67-5, Ritonavir 159519-65-0, T-20 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399 174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6, Capravirine 195156-77-5, ABT 606 198904-31-3, BMS-232632 201341-05-1, Bis-POC-PMPA 213252-22-3, Reticulose 214287-99-7, DPC-083 216863-66-0, MK-944A 251562-00-2, T-1249 269055-15-4, TMC-125 352234-06-1, AG-1776 383198-58-1, PRO-542 394728-76-8, TMC-120
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of substituted benzophenones as inhibitors of reverse transcriptase)

L82 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:521462 HCAPLUS Full-text
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
			<--	
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
AU 2002219472	A1	20020716	AU 2002-219472	20020102
			<--	
EP 1351678	A2	20031015	EP 2002-727007	20020102
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				

MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004092583 A1 20040513 US 2004-250535
2004
0102
<--
PRIORITY APPLN. INFO.: IE 2001-2 A
2001
0102
<--
WO 2002-IE1 W
2002
0102
<--

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, **antiviral**, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **25526-93-6**, Alovudine **129618-40-2**, Nevirapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-00
CC 1-6 (**Pharmacology**)
Section cross-reference(s): **10**, **63**

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug targeting to **HIV** infected cells using; incensole and furanogermacrens and compds. as antitumor and

antimicrobial agents)
IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp120env, drug targeting to **HIV** infected cells using antibodies to; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp160env, drug targeting to **HIV** infected cells using antibodies to; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT Adrenal gland, neoplasm
Anti-**AIDS** agents
Anti-infective agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antidiarrheals
Antitumor agents
B-cell leukemia
Bladder, neoplasm
Brain, neoplasm
Burn
Central nervous system, neoplasm
Drug delivery systems
Enterococcus faecalis
Hairy cell leukemia
Hematopoietic neoplasm
Hodgkin's disease
Human
Leukemia
Leukemia
Lymphoma
Mammary gland, neoplasm
Melanoma
Monocytic leukemia
Mouth, neoplasm
Multiple myeloma
Myeloid leukemia
Myelomonocytic leukemia
Neoplasm
Newborn
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Sarcoma
Staphylococcus aureus
Stomach, neoplasm
T-cell leukemia
Testis, neoplasm
(incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT **Antiviral** agents
(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT **Human immunodeficiency virus**
(targeting to cells infected with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT 144114-21-6, **HIV**-1 Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT 54-05-7, Chloroquine 54-42-2, Idoxuridine 60-54-8, Tetracycline 69-74-9, Cytarabine Hydrochloride 70-00-8,

Trifluridine 80-08-0, Dapsone 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 443-48-1, Metronidazole 494-79-1, Melarsoprol 665-66-7, Amantadine Hydrochloride 1501-84-4, Rimantadine Hydrochloride 1910-68-5, Methisazone 3056-17-5, d4T 3736-81-0, Diloxanide furoate 5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2 9004-70-0, HE-2000 10500-82-0, Famotine Hydrochloride 10540-97-3, Memotine Hydrochloride 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC 19387-91-8, Tinidazole 19885-51-9, Aranotin 22994-85-0, Benznidazole 23256-30-6, Nifurtimox **25526-93-6**, Alovudine 27591-69-1, Tilorone Hydrochloride 27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin 36983-81-0, Fosfonet Sodium 37338-39-9 39809-25-1, Penciclovir 51867-87-9 53230-10-7, Mefloquine 56219-57-9, Arildone 59277-89-3, Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium 63968-64-9D, Artemisinin, derivs. 68693-30-1, Somantadine Hydrochloride 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69655-05-6, DdI 69657-51-8, Acyclovir Sodium 69756-53-2, Halofantrine 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 73514-87-1, Fosarilate 77181-69-2, Sorivudine 80883-55-2, Enviradene 82410-32-0, Ganciclovir 84408-37-7, Desciclovir 85087-20-3, Doxycycline 87495-31-6, Disoxaril 95233-18-4, Atovaquone 100817-46-7, Stibogluconic acid 104227-87-4, Famciclovir 106362-32-7, Peptide T 106941-25-7, PMEA 107910-75-8, Ganciclovir Sodium 110042-95-0, Acemannan 110143-10-7, Lodenosine 113852-37-2, Cidofovir 124436-59-5, Pirodavir 124832-27-5, Valacyclovir Hydrochloride 127759-89-1, Lobucavir 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 132210-43-6, Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir 136817-59-9, Delavirdine 137487-62-8, Alvircept Sudotox 138540-32-6, Atevirdine Mesylate 141204-94-6, Co-artemether 142340-99-6 142632-32-4, Calanolide A 143491-57-0, Coviracil 145514-04-1, DAPD 147127-20-6, Tenofovir 147221-93-0, Delavirdine Mesylate 147318-81-8, KNI-272 147362-57-0, Loviride 149845-06-7, Saquinavir Mesylate 149950-60-7, Emivirine 150378-17-9, Indinavir 153127-49-2, ALX40-4C 154598-52-4, DMP 266 155148-31-5, AMD 3100 155213-67-5, Ritonavir 156879-70-8 159519-65-0, Pentafuside 159989-64-7, Nelfinavir 163451-80-7 170020-61-8, FP-21399 174484-41-4, Tipranavir 177932-89-7, DMP-450 178979-85-6, AG 1549 185220-03-5, PNU142721 192725-17-0, ABT-378 214287-88-4, DPC961 216863-66-0, L-756423 251562-00-2, T-1249 383198-56-9, BW 141 383198-57-0, BMS-232630 383198-58-1, PRO 542

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

L82 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:935354 HCAPLUS Full-text

DOCUMENT NUMBER: 136:64094

TITLE: The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites, and precursors thereof in the treatment of viral infections

INVENTOR(S): Prendergast, Patrick Thomas

PATENT ASSIGNEE(S): Kotze, Gavin Salomon, S. Afr.

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097749	A2	20011227	WO 2001-IB1101	20010622
			<--	
WO 2001097749	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001074383	A5	20020102	AU 2001-74383	20010622
			<--	
PRIORITY APPLN. INFO.:			IE 2000-511 A	20000623
			<--	
			IE 2001-275 A	20010321
			<--	
			WO 2001-IB1101 W	20010622
			<--	

AB The invention discloses the use of synthetic, non-hormonal 21-aminosteroids, derivs., metabolites, and precursors thereof in the treatment of viral infections, particularly hepatitis and retroviral infection by **HIV**. Synthetic non-hormonal 21-aminosteroids are disclosed for use in the prophylaxis and therapy of hepatitis viral infections. These compds. can be administered alone or in combination with conventional **antiviral** agents.

IT **25526-93-6**, Alovudine **129618-40-2**, Nevirapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K
CC 1-5 (**Pharmacology**)
ST **antiviral** aminosteroid hepatitis virus **HIV**
IT **AIDS** (disease)
(**AIDS**-related syndromes; aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)
IT Animal virus
Anti-**AIDS** agents
Antiviral agents
Border disease virus 1
Bovine diarrhea virus
Cachexia
Classical swine fever virus
Cytomegalovirus
Drug delivery systems
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis delta virus
Hepatitis virus
Herpesviridae
Human herpesvirus 4
Human immunodeficiency virus
Immunomodulators
Newborn
Retroviridae
(aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)
IT 54-42-2, Idoxuridine 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 127-07-1, Hydroxyurea 665-66-7, Amantadine hydrochloride 1501-84-4, Rimantadine hydrochloride 1910-68-5, Methisazone 2751-09-9, Triacetyloleandomycin 3056-17-5, d4T 5536-17-4, Vidarabine 7481-89-2, DdC 9004-70-0, HE-2000 10500-82-0, Famotine hydrochloride 10540-97-3 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC 19885-51-9, Aranotin **25526-93-6**, Alovudine 27591-69-1, Tilorone hydrochloride 27762-78-3, Kethoxal 29984-33-6, Vidarabine phosphate 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin 36983-81-0, Fosfonet sodium 39809-25-1, Penciclovir 56219-57-9, Arildone 59277-89-3, Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet sodium 65277-42-1, Ketoconazole 68693-30-1 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69655-05-6, DdI 69657-51-8, Acyclovir sodium 71002-10-3 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 73514-87-1, Fosarilate 77181-69-2, Sorivudine 80883-55-2, Enviradene 82410-32-0, Ganciclovir 84408-37-7, Desciclovir 87495-31-6, Disoxaril 104227-87-4, Famciclovir 106362-32-7, Peptide T 106941-25-7, PMEA 107910-75-8, Ganciclovir sodium 110042-95-0, Acemannan 110101-66-1, Tirilazad 110101-66-1D, Tirilazad, metabolites 110101-67-2, Tirilazad mesylate 110143-10-7, Lodenosine 113852-37-2, Cidofovir 124436-59-5, Pirodavir 124832-27-5, Valacyclovir hydrochloride 127759-89-1, Lobucavir 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 132210-43-6, Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir

136817-59-9, Delavirdine 137487-62-8, Alvircept sudotox
138540-32-6, Atevirdine mesylate 142340-99-6 142632-32-4,
Calanolide A 143491-57-0, BW 1592 145514-04-1, DAPD
147127-20-6, Tenofovir 147221-93-0, Delavirdine mesylate
147318-81-8, KNI-272 147362-57-0, Loviride 149845-06-7,
Saquinavir mesylate 149950-60-7, Emivirine 150378-17-9,
Indinavir 153127-49-2, ALX40-4C 154598-52-4, DMP 266
155148-31-5, AMD 3100 155213-67-5, Ritonavir 157744-31-5
157744-31-5D, metabolites 159519-65-0, Pentafuside
159989-64-7, Nelfinavir 162758-91-0 162758-91-0D, metabolites
163451-80-7, HBY097 170020-61-8, FP-21399 174484-41-4,
Tipranavir 177180-81-3 177180-81-3D, metabolites 177180-82-4
177180-82-4D, metabolites 177932-89-7, DMP-450 178979-85-6, AG
1549 185220-03-5, PNU142721 192725-17-0, ABT-378
214287-88-4, DPC 961 216863-66-0, L-756423 251562-00-2, T-1249
383198-55-8, Naragin 383198-56-9, BW 141 383198-57-0, BMS
232630 383198-58-1, PRO 542
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(aminosteroids, derivs., metabolites, and precursors for
treatment of viral infection, and use with other agents)

L82 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:795684 HCAPLUS Full-text
DOCUMENT NUMBER: 132:35990
TITLE: Multibinding inhibitors of **HIV** reverse transcriptase
INVENTOR(S): Mammen, Mathai; Oare, David; Griffin, John H.; Aggen, James
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964048	A1	19991216	WO 1999-US12774	1999 0608
			<--	
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6288234	B1	20010911	US 1999-325662	1999 0604
			<--	
SG 106036	A1	20040930	SG 1999-2845	1999 0607
			<--	
AT 322910	E	20060415	AT 1999-928455	1999 0607
			<--	
CA 2316999	AA	19991216	CA 1999-2316999	1999

0608
<--
AU 9945517 A1 19991230 AU 1999-45517
1999
0608
<--
EP 1003541 A1 20000531 EP 1999-928454
1999
0608
<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
SG 80631 A1 20010522 SG 1999-2719
1999
0608
<--
SG 90053 A1 20020723 SG 1999-2944
1999
0608
<--
US 6566509 B1 20030520 US 1999-327899
1999
0608
<--
ZA 2000004086 A 20010810 ZA 2000-4086
2000
0810
<--
ZA 2000004558 A 20011130 ZA 2000-4558
2000
0831
<--
ZA 2000004559 A 20020402 ZA 2000-4559
2000
0831
<--
US 2002028943 A1 20020307 US 2001-760827
2001
0117
<--
US 2004023290 A1 20040205 US 2002-161279
2002
0603
<--
US 2003176670 A1 20030918 US 2002-330381
2002
1227
<--
PRIORITY APPLN. INFO.: US 1998-88448P P
1998
0608
<--
US 1998-93072P P
1998
0716
<--
US 1999-325662 A3
1999
0604
<--
US 1999-327899 A1
1999
0608
<--
US 1999-328071 B1
1999
0608

<--
WO 1999-US12774 W
1999
0608
<--
US 2000-502938 A1
2000
0211
<--

AB Novel **human immunodeficiency virus** (**HIV**) reverse transcriptase inhibitors that act as multibinding agents, LpXq [where L = at least one nucleoside reverse transcriptase inhibitor and at least one non-nucleoside reverse transcriptase inhibitor; X = a linker; p = 2-10; q = 1-20; linker lengths range from 2-100 Å], are disclosed. Combinatorial arrays, methods of synthesis, and methods of assaying the dimeric and multimeric compds. are also embodied by the invention. A number of divalent prophetic examples, each derived from one nucleoside reverse transcriptase inhibitor ligand and one non-nucleoside reverse transcriptase inhibitor ligand and a difunctional linker, are given. Compds. of the invention inhibit **HIV** replication in vivo (no data). The multibinding compds. have increased potency over currently available inhibitors and provide improved biol. and/or therapeutic effects compared to the aggregate of the unlinked ligands due to their multibinding properties (no data). Nucleoside reverse transcriptase ligands may include 5'-deoxy analogs of zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, adefovir, raluridine, oral PMPA prodrug, azidouridine, IVX-E-59, emtricitabine, and lodenosine. Non-nucleoside reverse transcriptase ligands may include nevirapine, delavirdine, efavirenz, MKC-442, loviride, S-1153, talviraline, calanolide A, and tivirapine.

IT **119644-22-3DP**, Raluridine, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of **129618-40-2DP** , Nevirapine, dimeric and multimeric multibinding derivs. of
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of multibinding inhibitors of **HIV** reverse transcriptase)

RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K038-00
ICS A61K039-00; A61K039-44; A61K039-395; A61K051-00; C07K002-00; C07K004-00; G01N033-53; G01N033-543; G01N033-566; A01N057-34; C12P019-38
CC 33-9 (Carbohydrates)
Section cross-reference(s): **1**, **63**
ST dimeric multimeric multibinding **HIV** reverse transcriptase inhibitor prepn; combinatorial array multibinding **human immunodeficiency virus** reverse transcriptase inhibitor
IT Structure-activity relationship
(ligand-binding; preparation of multibinding inhibitors of **HIV** reverse transcriptase)
IT Anti-**AIDS** agents
Antiviral agents
Combinatorial library
Drug delivery systems
Drug screening
(preparation of multibinding inhibitors of **HIV** reverse transcriptase)
IT Nucleosides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of multibinding inhibitors of **HIV** reverse transcriptase)
IT 9068-38-6, Reverse transcriptase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of multibinding inhibitors of **HIV** reverse transcriptase)
IT 3056-17-5P, Stavudine 7481-89-2P, Zalcitabine 30516-87-1P, Zidovudine 69655-05-6P, Didanosine 106941-25-7P, Adefovir 107021-12-5P 110143-10-7P, Lodenosine **119644-22-3DP**, Raluridine, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of 121135-53-3DP, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of **129618-40-2DP**, Nevirapine, dimeric and multimeric multibinding derivs. of 134678-17-4DP, Lamivudine, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of 136470-78-5DP, Abacavir, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of 136817-59-9DP, Delavirdine, dimeric and multimeric multibinding derivs. of 137332-54-8DP, Tivirapine, dimeric and multimeric multibinding derivs. of 142632-32-4DP, Calanolide A, dimeric and multimeric multibinding derivs. of 143491-57-0DP, Emtricitabine, dimeric and multimeric multibinding derivs. of 5'-deoxy analogs of 147362-57-0DP, Loviride, dimeric and multimeric multibinding derivs. of 149950-60-7DP, MKC-442, dimeric and multimeric multibinding derivs. of 154598-52-4DP, Efavirenz, dimeric and multimeric multibinding derivs. of 163451-80-7DP, Talviraline, dimeric and multimeric multibinding derivs. of 178979-85-6DP, S 1153, dimeric and multimeric multibinding derivs. of
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of multibinding inhibitors of **HIV** reverse transcriptase)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:205535 HCAPLUS Full-text

DOCUMENT NUMBER: 124:306324
TITLE: Rapid screening of antiretroviral combinations
AUTHOR(S): St. Clair, Marty; Pennington, Kevin N.; Rooney, James; Barry, David W.
CORPORATE SOURCE: Department Virology, Burroughs Wellcome Co., Research Triangle Park, NC, 27709-4498, USA
SOURCE: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (**1995**), 10(Suppl. 1), S24-S27
CODEN: JDSRET; ISSN: 1077-9450
PUBLISHER: Lippincott-Raven
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An in-vitro assay was designed to ascertain the inhibitory action of drug combinations on **HIV**-infected MT4 cells, allowing rapid evaluation of those that may be of use in the clinic. Manipulation of this system also provides data on the efficacy of drugs under conditions of high viral load and against resistant strains.

IT **119644-22-3**, 935U83 **129618-40-2**, Nevirapine
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(screening of antiretroviral combinations including)

RN 119644-22-3 HCAPLUS
CN Uridine, 5-chloro-2',3'-dideoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



CC 1-1 (**Pharmacology**)
ST retrovirus inhibitor combination screening; **HIV** inhibitor combination screening; **human immunodeficiency virus** inhibitor combination screening; virucide retro combination screening
IT 7481-89-2, DdC 30516-87-1, Zidovudine 69655-05-6, DdI **119644-22-3**, 935U83 127779-20-8, Saquinavir **129618-40-2**, Nevirapine 134678-17-4, 3TC
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(screening of antiretroviral combinations including)

L82 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:526821 HCAPLUS Full-text
DOCUMENT NUMBER: 122:274069
TITLE: Use of tumor necrosis factor inhibitors together with **antiviral** agents, and therapeutic compositions thereof, against **HIV** infection
INVENTOR(S): Andrulis, Peter J., Jr.; Angres, Issac
PATENT ASSIGNEE(S): Andrulis Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504525	A2	19950216	WO 1994-US8741	1994 0803
			<--	
WO 9504525	A3	19950601		
W: AU, CA, CN, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9473763	A1	19950228	AU 1994-73763	1994 0803
			<--	
EP 712310	A1	19960522	EP 1994-922777	1994 0803
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6001828	A	19991214	US 1997-956277	1997 1023
			<--	
PRIORITY APPLN. INFO.:			US 1993-101752 A	1993 0804
			<--	
			WO 1994-US8741 W	1994 0803
			<--	
			US 1995-462034 B1	1995 0605
			<--	

AB A pharmaceutical composition for treating **HIV** infection comprises (a) a tumor necrosis factor inhibitor (e.g. thalidomide, pentoxifylline, xanthine derivs.); (b) a compound selected from a reverse transcriptase inhibitor (e.g. AZT, ddI, ddC), a protease inhibitor, a gene inhibitor, a myristoylation inhibitor, a cell-virus binding inhibitor, a LTR promoter site inhibitor, ribosome inactivators, a platelet aggregation inhibitor, and propylactic and therapeutic **HIV** vaccine, and (c) a pharmaceutical inert nontoxic carrier. A capsule formulation contains e.g. pentoxifylline and AZT.

IT **25526-93-6 129618-40-2**, BI-RG-587
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)

RN 25526-93-6 HCAPLUS
CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



IC ICM A61K031-00
ICS A61K031-52; A61K031-445
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**
ST **HIV** infection TNF inhibitor **antiviral**
combination; reverse transcriptase inhibitor TNF inhibitor
HIV; capsule pentoxifylline AZT **HIV** infection
treatment
IT Phospholipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AC2; tumor necrosis factor inhibitor-**antiviral** agent
combination for **HIV** infection treatment)
IT Vaccines
(**HIV**; tumor necrosis factor inhibitor-
antiviral agent combination for **HIV** infection
treatment)
IT Animal cell
Virus
(cell-virus binding inhibitors; tumor necrosis factor
inhibitor-**antiviral** agent combination for **HIV**
infection treatment)
IT Ribosome
(inactivators; tumor necrosis factor inhibitor-
antiviral agent combination for **HIV** infection
treatment)
IT Gene, microbial
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; tumor necrosis factor inhibitor-**antiviral**
agent combination for **HIV** infection treatment)
IT Blood platelet aggregation inhibitors
Virucides and Virustats
(tumor necrosis factor inhibitor-**antiviral** agent
combination for **HIV** infection treatment)
IT Pharmaceutical dosage forms
(capsules, tumor necrosis factor inhibitor-**antiviral**
agent combination for **HIV** infection treatment)

IT Virus, animal
(human immunodeficiency, tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(long terminal repeat, promoter site, inhibitors; tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)
IT Acylation
(myristoylation, inhibitors; tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)
IT Lymphokines and Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tumor necrosis factor, inhibitors; tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)
IT 9068-38-6, Reverse transcriptase 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)
IT 50-35-1, Thalidomide 69-89-6D, Xanthine, derivs. 3416-05-5
6493-05-6, Pentoxifylline 7481-89-2 **25526-93-6**
30516-87-1, AZT 30516-87-1D, AZT, lipophilic prodrugs
69655-05-6, DdI 126320-77-2, R-82150 **129618-40-2**,
BI-RG-587 134680-32-3 135525-77-8, L697639 139339-45-0
162786-04-1 162786-05-2 162786-06-3 162786-07-4
162786-08-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor necrosis factor inhibitor-**antiviral** agent combination for **HIV** infection treatment)

=> => d que stat l79
L2 8 SEA FILE=REGISTRY ABB=ON PLU=ON (129618-40-2/BI OR 144114-21-6/BI OR 220750-46-9/BI OR 25526-93-6/BI OR 52350-85-3/BI OR 770723-01-8/BI OR 9068-38-6/BI OR 92562-88-4/BI)
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON 220750-46-9/RN
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 92562-88-4/RN
L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON 25526-93-6/RN
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L18 1733 SEA FILE=REGISTRY SSS FUL L16
L19 STR



Page 1-A

7

Page 1-B



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE
L20 STR



Page 1-A



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE

L23	1142	SEA FILE=REGISTRY SUB=L18 SSS FUL L20
L24	2	SEA FILE=REGISTRY SUB=L18 SSS FUL L19
L25	4	SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND L23
L27	54	SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?CYTIDIN?/CNS
L28	36	SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND 1/F NOT (1-5/CL OR 1-5/BR OR 2-5/F)
L29	9	SEA FILE=REGISTRY ABB=ON PLU=ON L28 AND 3/N AND 3/O
L30	2	SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND C9H12FN3O3/MF
L31	6	SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?FLUOROADENOSIN?/CNS
L32	1	SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND C10 H12 F N5 O2/MF
L33	4	SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L34	49	SEA FILE=HCAPLUS ABB=ON PLU=ON L4
L35	292	SEA FILE=HCAPLUS ABB=ON PLU=ON L5
L36	39	SEA FILE=HCAPLUS ABB=ON PLU=ON L30
L37	35	SEA FILE=HCAPLUS ABB=ON PLU=ON L32
L38	338	SEA FILE=HCAPLUS ABB=ON PLU=ON (L33 OR L34 OR L35 OR L36 OR L37)
L39	315	SEA FILE=HCAPLUS ABB=ON PLU=ON L25
L40	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L24

```
L41          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23
L42          835 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18
L43          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L44            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  129618-40-2/RN
L45         1501 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L44
L46           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L42
L47           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L43
L48           30 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L38
L49           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L46 OR L47 OR L48)
L50              QUE  ABB=ON  PLU=ON  PHARMAC?/SC,SX
L51           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L49 AND L50
L52        57456 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ANTIVIRAL OR ANTI(A)VI
                 RAL
L53           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L52
L55        35862 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HUMAN IMMUNODEFICIENCY
                  VIRUS?/CT
L56           20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 AND L51
L57              QUE  ABB=ON  PLU=ON  HUMAN(W)IMMUNODEFICIEN?(W)VIRUS? O
                 R HIV OR AIDS
L58           32 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L57
L59           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 OR L53 OR L56 OR
                 L58
L60           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L59 AND 1907-2003/PY,P
                 RY
L61          145 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L62          133 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L63          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  L18
L64          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L61 OR L62 OR L63)
L65         1381 SEA FILE=BIOSIS ABB=ON  PLU=ON  L44
L66            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L65 AND L64
L67            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L66 AND (L52 OR L57)
L68          274 SEA FILE=EMBASE ABB=ON  PLU=ON  L18
L69         5710 SEA FILE=EMBASE ABB=ON  PLU=ON  L44
L70           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L68 AND L69
L71           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L70 AND (L52 OR L57)
L72           17 SEA FILE=EMBASE ABB=ON  PLU=ON  L71 AND 1907-2003/PY
L73          125 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L74          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  L18
L75          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L73 OR L74)
L76         1183 SEA FILE=MEDLINE ABB=ON  PLU=ON  L44
L77            1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L75 AND L76
L78           43 DUP REM L60 L67 L72 L77 (1 DUPLICATE REMOVED)
L79            2 SEA FILE=BIOSIS L78


=> d l79 1-2 ibib abs hit hitind

L79  ANSWER 1 OF 2  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation
     on STN
ACCESSION NUMBER:    1994:387261  BIOSIS  Full-text
DOCUMENT NUMBER:     PREV199497400261
TITLE:               Present and future of the human
                     immunodeficiency virus (
                     HIV) reverse transcriptase inhibitors.
AUTHOR(S):           Juarez Gimenez, J. C.; Sanz Pamplona, S.; Flores,
                     G.; Montoro Ronsano, J. B.; Altisent Roca, C.
CORPORATE SOURCE:    Servicio de Farmacia, Unidad de Hemofilia, Hosp.
                     Gen. Valle de Hebron, Barcelona, Spain
SOURCE:              Farmacia Clinica, (1994) Vol. 11, No. 3, pp.
                     255-258, 260-266.
                     CODEN: FACLE2. ISSN: 0212-6583.
DOCUMENT TYPE:       Article
                     General Review; (Literature Review)
```

LANGUAGE: Spanish
ENTRY DATE: Entered STN: 14 Sep 1994
Last Updated on STN: 15 Sep 1994

AB Since the identification of the **human immunodeficiency virus** (**HIV**) the schedules for the treatment of **AIDS** and other opportunist infections have undergone considerable modification in the course of the last few times. In this study we review the principal clinical trials, the mechanism of action and of resistances of the 2,3'-dideoxynucleoside analog antiretroviral drugs, such as Zidovudine (ZDV), Didanosine (ddI), Dideoxycitidine (ddC), Estavudine (d4T), Alovudine (FLT) and 3-TC, and the reverse transcriptase (RT) inhibitor non-nucleosides, such as Foscarnet, TIBO and derivates, Bispiperazines, L drugs and Nevirapine. We describe current treatment strategies according to the patients' immunological and clinical conditions.

TI Present and future of the **human immunodeficiency virus** (**HIV**) reverse transcriptase inhibitors.

AB Since the identification of the **human immunodeficiency virus** (**HIV**) the schedules for the treatment of **AIDS** and other opportunist infections have undergone considerable modification in the course of the last few times. In this study we review the principal clinical trials, the mechanism of action and of resistances of the 2,3'-dideoxynucleoside analog antiretroviral drugs, such as Zidovudine (ZDV), Didanosine (ddI), Dideoxycitidine (ddC), Estavudine (d4T), Alovudine (FLT) and 3-TC, and the reverse transcriptase (RT) inhibitor non-nucleosides, such as Foscarnet, TIBO and derivates, Bispiperazines, L drugs and Nevirapine. We describe current treatment strategies according to the patients' immunological and clinical conditions.

IT Miscellaneous Descriptors
ALOVUDINE; **ANTIVIRAL**-DRUG; DIDANOSINE; DIDEOXYCYTIDINE; ESTAVUDINE; FOSCARNET; NEVIRAPINE; PHARMACODYNAMICS; ZIDOVUDINE

RN 30516-87-1 (ZIDOVUDINE)
69655-05-6 (DIDANOSINE)
7481-89-2 (DIDEOXYCYTIDINE)
25526-93-6 (ALOVUDINE)
4428-95-9 (FOSCARNET)
129618-40-2 (NEVIRAPINE)

CC Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - Chemical and physical 10806
Pathology - Therapy 12512
Pharmacology - Drug metabolism and metabolic stimulators 22003
Pharmacology - Clinical pharmacology 22005
Medical and clinical microbiology - Virology 36006
Chemotherapy - Antiviral agents 38506

IT Major Concepts
Enzymology (Biochemistry and Molecular Biophysics); Infection; Pharmacology

IT Chemicals & Biochemicals
ZIDOVUDINE; DIDANOSINE; DIDEOXYCYTIDINE; ALOVUDINE; FOSCARNET; NEVIRAPINE

IT Miscellaneous Descriptors
ALOVUDINE; **ANTIVIRAL**-DRUG; DIDANOSINE; DIDEOXYCYTIDINE; ESTAVUDINE; FOSCARNET; NEVIRAPINE; PHARMACODYNAMICS; ZIDOVUDINE

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

ORGN Classifier
Retroviridae 03305
Super Taxa
DNA and RNA Reverse Transcribing Viruses; Viruses; Microorganisms
Organism Name
Retroviridae

Taxa Notes
DNA and RNA Reverse Transcribing Viruses, Microorganisms, Viruses
RN 30516-87-1 (ZIDOVUDINE)
69655-05-6 (DIDANOSINE)
7481-89-2 (DIDEOXYCYTIDINE)
25526-93-6 (ALOVUDINE)
4428-95-9 (FOSCARNET)
129618-40-2 (NEVIRAPINE)

L79 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:58467 BIOSIS Full-text
DOCUMENT NUMBER: PREV199344024117
TITLE: New antiretroviral agents in clinical development.
AUTHOR(S): Flexner, Charles
CORPORATE SOURCE: Div. Clin. Pharmacol., Dep. Med., Johns Hopkins Univ. Sch. Med., Baltimore, Md. 21205, USA
SOURCE: Current Opinion in Infectious Diseases, (1992) Vol. 5, No. 6, pp. 798-805.
ISSN: 0951-7375.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jan 1993
Last Updated on STN: 17 Mar 1993
IT Miscellaneous Descriptors
ACQUIRED IMMUNODEFICIENCY SYNDROME; ALOVUDINE; ANTIRETROVIRAL TOXINS; **ANTIVIRAL**-DRUG; CD4-PSEUDOMONAS EXOTOXIN; COMPOUND Q; CYTOKINES; CYTOPROTECTANTS; DIDANOSINE; DIETHYLDITHIOCARBAMATE; DRUG LICENSING; INTERFERONS; INTERLEUKIN-2; INTERLEUKIN-4; L697661; N=ACETYLCYSTEINE; NEVIRAPINE; NON- NUCLEOSIDE INHIBITORS; NUCLEOSIDE ANALOGUES; PROCYSTEINE; PROTEASE INHIBITORS; RECOMBINANT HUMAN CD4-IMMUNOGLOBULIN G; REVERSE TRANSCRIPTASE INHIBITORS; R82913; STAVUDINE; TAT INHIBITOR; TETRAHYDROIMIDAZOBENZODIAZEPINTHIONE; U-87201E; VACCINES; ZALCITABINE; ZIDOVUDINE; 2' 3'=DIDEOXY-3'-THIACYTIDINE
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGN Classifier
Retroviridae 03305
Super Taxa
DNA and RNA Reverse Transcribing Viruses; Viruses; Microorganisms
Organism Name
human immunodeficiency virus
Taxa Notes
DNA and RNA Reverse Transcribing Viruses, Microorganisms, Viruses
RN 30516-87-1 (ZIDOVUDINE)
69655-05-6 (DIDANOSINE)
7481-89-2 (ZALCITABINE)
25526-93-6 (ALOVUDINE)
3056-17-5 (STAVUDINE)
126347-69-1 (R82913)
129618-40-2 (NEVIRAPINE)
135525-78-9 (L697661)
37205-61-1 (PROTEASE INHIBITORS)
23526-02-5 (EXOTOXIN)
616-91-1 (N-ACETYLCYSTEINE)

147-84-2 (DIETHYLDITHIOCARBAMATE)
CC General biology - Institutions, administration and legislation 00508
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Biochemistry studies - Proteins, peptides and amino acids 10064
Biochemistry studies - Carbohydrates 10068
Replication, transcription, translation 10300
Enzymes - Physiological studies 10808
Metabolism - Nucleic acids, purines and pyrimidines 13014
Blood - Blood, lymphatic and reticuloendothelial pathologies 15006
Blood - Lymphatic tissue and reticuloendothelial system 15008
Endocrine - General 17002
Pharmacology - Clinical pharmacology 22005
Pharmacology - Blood and hematopoietic agents 22008
Pharmacology - Immunological processes and allergy 22018
Toxicology - General and methods 22501
Genetics of bacteria and viruses 31500
Virology - Animal host viruses 33506
Immunology - Immunopathology, tissue immunology 34508
Medical and clinical microbiology - Virology 36006
Chemotherapy - Antiviral agents 38506
IT Major Concepts
Clinical Endocrinology (Human Medicine, Medical Sciences); Infection; Pharmacology
IT Chemicals & Biochemicals
ZIDOVUDINE; DIDANOSINE; ZALCITABINE; ALOVUDINE; STAVUDINE; R82913; NEVIRAPINE; L697661; PROTEASE INHIBITORS; EXOTOXIN; N-ACETYLCYSTEINE; DIETHYLDITHIOCARBAMATE
IT Miscellaneous Descriptors
ACQUIRED IMMUNODEFICIENCY SYNDROME; ALOVUDINE; ANTIRETROVIRAL TOXINS; **ANTIVIRAL**-DRUG; CD4-PSEUDOMONAS EXOTOXIN; COMPOUND Q; CYTOKINES; CYTOPROTECTANTS; DIDANOSINE; DIETHYLDITHIOCARBAMATE; DRUG LICENSING; INTERFERONS; INTERLEUKIN-2; INTERLEUKIN-4; L697661; N=ACETYLCYSTEINE; NEVIRAPINE; NON- NUCLEOSIDE INHIBITORS; NUCLEOSIDE ANALOGUES; PROCYSTEINE; PROTEASE INHIBITORS; RECOMBINANT HUMAN CD4-IMMUNOGLOBULIN G; REVERSE TRANSCRIPTASE INHIBITORS; R82913; STAVUDINE; TAT INHIBITOR; TETRAHYDROIMIDAZOBENZODIAZEPINTHIONE; U-87201E; VACCINES; ZALCITABINE; ZIDOVUDINE; 2' 3'=DIDEOXY-3'-THIACYTIDINE
GT USA (North America, Nearctic region)
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGN Classifier
Retroviridae 03305
Super Taxa
DNA and RNA Reverse Transcribing Viruses; Viruses; Microorganisms
Organism Name
human immunodeficiency virus
Taxa Notes
DNA and RNA Reverse Transcribing Viruses, Microorganisms, Viruses
RN 30516-87-1 (ZIDOVUDINE)
69655-05-6 (DIDANOSINE)
7481-89-2 (ZALCITABINE)
25526-93-6 (ALOVUDINE)
3056-17-5 (STAVUDINE)
126347-69-1 (R82913)

129618-40-2 (NEVIRAPINE)
135525-78-9 (L697661)
37205-61-1 (PROTEASE INHIBITORS)
23526-02-5 (EXOTOXIN)
616-91-1 (N-ACETYLCYSTEINE)
147-84-2 (DIETHYLDITHIOCARBAMATE)

=> => d que stat l80
L2 8 SEA FILE=REGISTRY ABB=ON PLU=ON (129618-40-2/BI OR 144114-21-6/BI OR 220750-46-9/BI OR 25526-93-6/BI OR 52350-85-3/BI OR 770723-01-8/BI OR 9068-38-6/BI OR 92562-88-4/BI)
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON 220750-46-9/RN
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 92562-88-4/RN
L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON 25526-93-6/RN
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L18 1733 SEA FILE=REGISTRY SSS FUL L16
L19 STR



Page 1-A

7

Page 1-B



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE
L20 STR



Page 1-A



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE

L23 1142 SEA FILE=REGISTRY SUB=L18 SSS FUL L20
L24 2 SEA FILE=REGISTRY SUB=L18 SSS FUL L19
L25 4 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND L23
L27 54 SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?CYTIDIN?/CNS
L28 36 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND 1/F NOT (1-5/CL OR 1-5/BR OR 2-5/F)
L29 9 SEA FILE=REGISTRY ABB=ON PLU=ON L28 AND 3/N AND 3/O
L30 2 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND C9H12FN3O3/MF
L31 6 SEA FILE=REGISTRY ABB=ON PLU=ON L23 AND ?FLUOROADENOSIN?/CNS
L32 1 SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND C10 H12 F N5 O2/MF
L33 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L34 49 SEA FILE=HCAPLUS ABB=ON PLU=ON L4
L35 292 SEA FILE=HCAPLUS ABB=ON PLU=ON L5
L36 39 SEA FILE=HCAPLUS ABB=ON PLU=ON L30
L37 35 SEA FILE=HCAPLUS ABB=ON PLU=ON L32
L38 338 SEA FILE=HCAPLUS ABB=ON PLU=ON (L33 OR L34 OR L35 OR L36 OR L37)
L39 315 SEA FILE=HCAPLUS ABB=ON PLU=ON L25
L40 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L24
L41 697 SEA FILE=HCAPLUS ABB=ON PLU=ON L23
L42 835 SEA FILE=HCAPLUS ABB=ON PLU=ON L18
L43 697 SEA FILE=HCAPLUS ABB=ON PLU=ON (L38 OR L39 OR L40 OR L41)
L44 1 SEA FILE=REGISTRY ABB=ON PLU=ON 129618-40-2/RN
L45 1501 SEA FILE=HCAPLUS ABB=ON PLU=ON L44
L46 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L45 AND L42
L47 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L45 AND L43
L48 30 SEA FILE=HCAPLUS ABB=ON PLU=ON L45 AND L38
L49 33 SEA FILE=HCAPLUS ABB=ON PLU=ON (L46 OR L47 OR L48)
L50 QUE ABB=ON PLU=ON PHARMAC?/SC,SX
L51 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L49 AND L50
L52 57456 SEA FILE=HCAPLUS ABB=ON PLU=ON ANTIVIRAL OR ANTI(A)VIRAL
L53 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L51 AND L52
L55 35862 SEA FILE=HCAPLUS ABB=ON PLU=ON HUMAN IMMUNODEFICIENCY VIRUS?/CT
L56 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L55 AND L51
L57 QUE ABB=ON PLU=ON HUMAN(W)IMMUNODEFICIEN?(W)VIRUS? OR HIV OR AIDS
L58 32 SEA FILE=HCAPLUS ABB=ON PLU=ON L51 AND L57
L59 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L51 OR L53 OR L56 OR L58
L60 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L59 AND 1907-2003/PY,PRY
L61 145 SEA FILE=BIOSIS ABB=ON PLU=ON (L38 OR L39 OR L40 OR L41)
L62 133 SEA FILE=BIOSIS ABB=ON PLU=ON (L33 OR L34 OR L35 OR L36 OR L37)
L63 147 SEA FILE=BIOSIS ABB=ON PLU=ON L18
L64 147 SEA FILE=BIOSIS ABB=ON PLU=ON (L61 OR L62 OR L63)
L65 1381 SEA FILE=BIOSIS ABB=ON PLU=ON L44
L66 2 SEA FILE=BIOSIS ABB=ON PLU=ON L65 AND L64
L67 2 SEA FILE=BIOSIS ABB=ON PLU=ON L66 AND (L52 OR L57)
L68 274 SEA FILE=EMBASE ABB=ON PLU=ON L18
L69 5710 SEA FILE=EMBASE ABB=ON PLU=ON L44
L70 30 SEA FILE=EMBASE ABB=ON PLU=ON L68 AND L69
L71 30 SEA FILE=EMBASE ABB=ON PLU=ON L70 AND (L52 OR L57)
L72 17 SEA FILE=EMBASE ABB=ON PLU=ON L71 AND 1907-2003/PY
L73 125 SEA FILE=MEDLINE ABB=ON PLU=ON (L33 OR L34 OR L35 OR L36 OR L37)
L74 155 SEA FILE=MEDLINE ABB=ON PLU=ON L18
L75 155 SEA FILE=MEDLINE ABB=ON PLU=ON (L73 OR L74)
L76 1183 SEA FILE=MEDLINE ABB=ON PLU=ON L44

L77 1 SEA FILE=MEDLINE ABB=ON PLU=ON L75 AND L76
L78 43 DUP REM L60 L67 L72 L77 (1 DUPLICATE REMOVED)
L80 16 SEA FILE=EMBASE L78

=> d l80 1-16 iall hit hitind

L80 ANSWER 1 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003246602 EMBASE Full-text
TITLE: Update on prescribing errors with HAART.
AUTHOR: Faragon J.J.; Lesar T.S.
CORPORATE SOURCE: J.J. Faragon, Department of Pharmacy, Albany College of Pharmacy, Albany, NY, United States
SOURCE: AIDS Reader, (1 Jun 2003) Vol. 13, No. 6, pp. 268-270+274-278. .
Refs: 39
ISSN: 1053-0894 CODEN: AIREFO
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 3 Jul 2003
Last Updated on STN: 3 Jul 2003

ABSTRACT: Medication-prescribing errors associated with HAART may lead to treatment failure, development of resistance, or drug toxicity.
Reports have described HAART-related medication-prescribing errors; the causes of these errors are often multifactorial and include lack of knowledge about **HIV** treatments, complexity of regimens, and soundalike/look-alike names of medications. Clinicians caring for ***HIV*** -infected patients should be aware of the potential for prescribing errors associated with HAART and employ strategies to prevent them.

CONTROLLED TERM: Medical Descriptors:
*highly active antiretroviral therapy
prescription
treatment failure
medical practice
Human immunodeficiency virus infection: DT, drug therapy
drug nomenclature
human
review
Drug Descriptors:
antiretrovirus agent: CB, drug combination
antiretrovirus agent: DT, drug therapy
antiretrovirus agent: PR, pharmaceutics
antiretrovirus agent: PO, oral drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PR, pharmaceutics
proteinase inhibitor: PO, oral drug administration
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: PR, pharmaceutics
nevirapine: DT, drug therapy
nelfinavir: CB, drug combination
nelfinavir: DT, drug therapy
nelfinavir: PO, oral drug administration

zidovudine: CB, drug combination
zidovudine: DT, drug therapy
didanosine: CB, drug combination
didanosine: DT, drug therapy
didanosine: PR, pharmaceutics
zalcitabine: CB, drug combination
zalcitabine: DT, drug therapy
stavudine: CB, drug combination
stavudine: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
abacavir: DT, drug therapy
tenofovir: DT, drug therapy
delavirdine: DT, drug therapy
efavirenz: DT, drug therapy
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: PR, pharmaceutics
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: DT, drug therapy
indinavir: CB, drug combination
indinavir: DT, drug therapy
amprenavir: DO, drug dose
amprenavir: DT, drug therapy
lopinavir: CB, drug combination
lopinavir: DT, drug therapy
enfuvirtide: DT, drug therapy
amdoxovir: DT, drug therapy
dpc 817: DT, drug therapy
3' fluorothymidine: DT, drug therapy
racivir: DT, drug therapy
emtricitabine: DT, drug therapy
capravirine: DT, drug therapy
tipranavir: DT, drug therapy
amprenavir phosphate: DT, drug therapy
tmc 125: DT, drug therapy
unindexed drug
unclassified drug
tenofovir disoproxil
lopinavir plus ritonavir

CAS REGISTRY NO.: (proteinase inhibitor) 37205-61-1; (nevirapine) **129618-40-2**; (nelfinavir) 159989-64-7, 159989-65-8; (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (abacavir) 136470-78-5, 188062-50-2; (tenofovir) 147127-19-3, 147127-20-6; (delavirdine) 136817-59-9; (efavirenz) 154598-52-4; (saquinavir) 127779-20-8, 149845-06-7; (ritonavir) 155213-67-5; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (amprenavir) 161814-49-9; (lopinavir) 192725-17-0; (enfuvirtide) 159519-65-0; (3' fluorothymidine) **25526-93-6**; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (capravirine) 178979-85-6; (tipranavir) 174484-41-4; (amprenavir phosphate) 226700-79-4, 226700-80-7, 226700-81-8; (tenofovir disoproxil) 202138-50-9

CHEMICAL NAME: Dpc 817; Fuzeon; Kaletra; Agenerase; Crixivan; Norvir; Fortovase; Invirase; Sustiva; Rescriptor; Viread; Ziagen; Epivir; Zerit; Hivid; Videx; Retrovir; Viracept; Viramune

SO AIDS Reader, (1 Jun 2003) Vol. 13, No. 6, pp. 268-270+274-278. .
Refs: 39
ISSN: 1053-0894 CODEN: AIREFO

AB Medication-prescribing errors associated with HAART may lead to treatment failure, development of resistance, or drug toxicity. Reports have described HAART-related

medication-prescribing errors; the causes of these errors are often multifactorial and include lack of knowledge about **HIV** treatments, complexity of regimens, and soundalike/look-alike names of medications. Clinicians caring for **HIV**-infected patients should be aware of the potential for prescribing errors associated with HAART and employ strategies to prevent them.

CT Medical Descriptors:
*highly active antiretroviral therapy
prescription
treatment failure
medical practice
Human immunodeficiency virus infection: DT, drug therapy
drug nomenclature
human
review
Drug Descriptors:
antiretrovirus agent: CB, drug combination
antiretrovirus agent: DT, drug therapy
antiretrovirus agent: PR, pharmaceutics
antiretrovirus agent: PO, oral drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PR, pharmaceutics
proteinase inhibitor: PO, oral drug administration
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: PR, pharmaceutics
nevirapine: DT, drug therapy
nelfinavir: CB, drug combination
nelfinavir: DT, drug therapy
nelfinavir: PO, oral drug administration
zidovudine: CB, drug combination
zidovudine: DT, drug therapy
didanosine: CB, drug combination
didanosine: DT, drug therapy
didanosine: PR, pharmaceutics
zalcitabine: CB, drug combination
zalcitabine: DT, drug therapy
stavudine: CB, drug combination
stavudine: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
abacavir: DT, drug therapy
tenofovir: DT, drug therapy
delavirdine: DT, drug therapy
efavirenz: DT, drug therapy
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: PR, pharmaceutics
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: DT, drug therapy
indinavir: CB, drug combination
indinavir: DT, drug therapy
amprenavir: DO, drug dose
amprenavir: DT, drug therapy
lopinavir: CB, drug combination
lopinavir: DT, drug therapy
enfuvirtide: DT, drug therapy
amdoxovir: DT, drug therapy
dpc 817: DT, drug therapy
3' fluorothymidine: DT, drug therapy
racivir: DT, drug therapy
emtricitabine: DT, drug therapy
capravirine: DT, drug therapy
tipranavir: DT, drug therapy
amprenavir phosphate: DT, drug therapy

tmc 125: DT, drug therapy
unindexed drug
unclassified drug
tenofovir disoproxil
lopinavir plus ritonavir

RN (proteinase inhibitor) 37205-61-1; (nevirapine) **129618-40-2**; (nelfinavir) 159989-64-7, 159989-65-8; (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (abacavir) 136470-78-5, 188062-50-2; (tenofovir) 147127-19-3, 147127-20-6; (delavirdine) 136817-59-9; (efavirenz) 154598-52-4; (saquinavir) 127779-20-8, 149845-06-7; (ritonavir) 155213-67-5; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (amprenavir) 161814-49-9; (lopinavir) 192725-17-0; (enfuvirtide) 159519-65-0; (3' fluorothymidine) **25526-93-6**; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (capravirine) 178979-85-6; (tipranavir) 174484-41-4; (amprenavir phosphate) 226700-79-4, 226700-80-7, 226700-81-8; (tenofovir disoproxil) 202138-50-9

CT Medical Descriptors:
*highly active antiretroviral therapy
prescription
treatment failure
medical practice
Human immunodeficiency virus infection: DT, drug therapy
drug nomenclature
human
review
Drug Descriptors:
antiretrovirus agent: CB, drug combination
antiretrovirus agent: DT, drug therapy
antiretrovirus agent: PR, pharmaceutics
antiretrovirus agent: PO, oral drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PR, pharmaceutics
proteinase inhibitor: PO, oral drug administration
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: PR, pharmaceutics
nevirapine: DT, drug therapy
nelfinavir: CB, drug combination
nelfinavir: DT, drug therapy
nelfinavir: PO, oral drug administration
zidovudine: CB, drug combination
zidovudine: DT, drug therapy
didanosine: CB, drug combination
didanosine: DT, drug therapy
didanosine: PR, pharmaceutics
zalcitabine: CB, drug combination
zalcitabine: DT, drug therapy
stavudine: CB, drug combination
stavudine: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
abacavir: DT, drug therapy
tenofovir: DT, drug therapy
delavirdine: DT, drug therapy
efavirenz: DT, drug therapy
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: PR, pharmaceutics
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: DT, drug therapy
indinavir: CB, drug combination

indinavir: DT, drug therapy
amprenavir: DO, drug dose
amprenavir: DT, drug therapy
lopinavir: CB, drug combination
lopinavir: DT, drug therapy
enfuvirtide: DT, drug therapy
amdoxovir: DT, drug therapy
dpc 817: DT, drug therapy
3' fluorothymidine: DT, drug therapy
racivir: DT, drug therapy
emtricitabine: DT, drug therapy
capravirine: DT, drug therapy
tipranavir: DT, drug therapy
amprenavir phosphate: DT, drug therapy
tmc 125: DT, drug therapy
unindexed drug
unclassified drug
tenofovir disoproxil
lopinavir plus ritonavir

RN (proteinase inhibitor) 37205-61-1; (nevirapine) **129618-40-2**; (nelfinavir) 159989-64-7, 159989-65-8; (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (abacavir) 136470-78-5, 188062-50-2; (tenofovir) 147127-19-3, 147127-20-6; (delavirdine) 136817-59-9; (efavirenz) 154598-52-4; (saquinavir) 127779-20-8, 149845-06-7; (ritonavir) 155213-67-5; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (amprenavir) 161814-49-9; (lopinavir) 192725-17-0; (enfuvirtide) 159519-65-0; (3' fluorothymidine) **25526-93-6**; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (capravirine) 178979-85-6; (tipranavir) 174484-41-4; (amprenavir phosphate) 226700-79-4, 226700-80-7, 226700-81-8; (tenofovir disoproxil) 202138-50-9

CN Dpc 817; Fuzeon; Kaletra; Agenerase; Crixivan; Norvir; Fortovase; Invirase; Sustiva; Rescriptor; Viread; Ziagen; Epivir; Zerit; Hivid; Videx; Retrovir; Viracept; Viramune

L80 ANSWER 2 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003109626 EMBASE Full-text
TITLE: **HIV** DART 2002: Frontiers in drug development for antiretroviral therapies: 15-19 December 2002, Naples, FL, USA.
AUTHOR: Wainberg M.A.
CORPORATE SOURCE: M.A. Wainberg, McGill University, AIDS Centre, Jewish General Hospital, Montreal, Que., Canada. mark.wainberg@mcgill.ca
SOURCE: IDrugs, (1 Feb 2003) Vol. 6, No. 2, pp. 110-113. . ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
026 Immunology, Serology and Transplantation
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 27 Mar 2003
Last Updated on STN: 27 Mar 2003

ABSTRACT: In general, this was an excellent conference that presented considerable new information on **antiviral** drug development in the field of **HIV** disease. It included information on new targets as well as information on compounds that are already relatively advanced in clinical development. There is a consensus that the field of **HIV** disease requires novel agents that will hopefully achieve greater durability in regard to suppression of ongoing viral

replication as well as greater efficacy at prevention of sequestration of latent virus in reservoir tissues. There is little doubt that important new developments will take place in years ahead that will make an important difference to patient well being.

CONTROLLED TERM: Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
***Human immunodeficiency virus infection: PC, prevention**
***Human immunodeficiency virus infection: DR, drug resistance**
human
clinical trial
nonhuman
Human immunodeficiency virus
virus pathogenesis
drug information
drug targeting
virus replication
drug efficacy
highly active antiretroviral therapy
drug structure
drug bioavailability
tissue distribution
drug effect
drug toxicity: SI, side effect
dose response
drug design
virus strain
virus mutation
drug binding
antiviral activity
immunotherapy
virus load
virus resistance
drug potentiation
conference paper

CONTROLLED TERM: Drug Descriptors:
*antiretrovirus agent: PK, pharmacokinetics
*antiretrovirus agent: PD, pharmacology
*antiretrovirus agent: DT, drug therapy
*antiretrovirus agent: PO, oral drug administration
*antiretrovirus agent: AE, adverse drug reaction
*antiretrovirus agent: DV, drug development
*antiretrovirus agent: AN, drug analysis
*antiretrovirus agent: CT, clinical trial
*antiretrovirus agent: CM, drug comparison
*antiretrovirus agent: CB, drug combination
*antiretrovirus agent: VA, intravaginal drug administration
*antiretrovirus agent: SC, subcutaneous drug administration
*antiretrovirus agent: IT, drug interaction
enfuvirtide: PD, pharmacology
enfuvirtide: DT, drug therapy
enfuvirtide: AN, drug analysis
enfuvirtide: DV, drug development
enfuvirtide: PO, oral drug administration
enfuvirtide: PK, pharmacokinetics
enfuvirtide: SC, subcutaneous drug administration
enfuvirtide: CT, clinical trial
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): PO, oral drug administration

1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): PD, pharmacology
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): AE, adverse drug reaction
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): DO, drug dose
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): AN, drug analysis
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): DV, drug development
ak 602: PK, pharmacokinetics
ak 602: AN, drug analysis
ak 602: PO, oral drug administration
ak 602: DV, drug development
ak 602: DT, drug therapy
RNA directed DNA polymerase inhibitor: DV, drug development
RNA directed DNA polymerase inhibitor: PD, pharmacology
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: VA, intravaginal drug administration
RNA directed DNA polymerase inhibitor: CM, drug comparison
proteinase inhibitor: DV, drug development
proteinase inhibitor: PD, pharmacology
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: VA, intravaginal drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose
proteinase inhibitor: AN, drug analysis
proteinase inhibitor: IT, drug interaction
tmc 125: DV, drug development
tmc 125: PD, pharmacology
tmc 125: CT, clinical trial
tmc 125: DT, drug therapy
tmc 125: VA, intravaginal drug administration
tmc 114: DV, drug development
tmc 114: PD, pharmacology
tmc 114: CT, clinical trial
tmc 114: DT, drug therapy
tmc 114: VA, intravaginal drug administration
cytidine derivative: PD, pharmacology
cytidine derivative: DV, drug development
dpc 817: DV, drug development
dpc 817: PD, pharmacology
lamivudine: PD, pharmacology
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: DT, drug therapy
zidovudine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
nevirapine: CT, clinical trial
stavudine: PD, pharmacology
stavudine: CM, drug comparison
stavudine: DT, drug therapy
stavudine: CT, clinical trial
virus vaccine: DT, drug therapy
virus vaccine: PD, pharmacology

virus vaccine: TP, topical drug administration
immunomodulating agent: CT, clinical trial
immunomodulating agent: DT, drug therapy
3' fluorothymidine: CT, clinical trial
3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: AN, drug analysis
3' fluorothymidine: DV, drug development
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: CB, drug combination
tipranavir: CB, drug combination
tipranavir: PD, pharmacology
tipranavir: AN, drug analysis
tipranavir: DV, drug development
tipranavir: DT, drug therapy
tipranavir: IT, drug interaction
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: PD, pharmacology
ritonavir: DT, drug therapy
ritonavir: IT, drug interaction
racivir: PK, pharmacokinetics
racivir: PD, pharmacology
racivir: AE, adverse drug reaction
amprenavir: PD, pharmacology
amprenavir: DT, drug therapy
ach 126443: PD, pharmacology
polyinosinic polycytidylic acid: DT, drug therapy
polyinosinic polycytidylic acid: CT, clinical trial
nucleoside analog: DT, drug therapy
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: AN, drug analysis
nucleoside analog: DV, drug development
nucleoside analog: AE, adverse drug reaction
nucleoside analog: PK, pharmacokinetics
nucleoside analog: CM, drug comparison
efavirenz: PD, pharmacology
efavirenz: DT, drug therapy
dermavir: DT, drug therapy
dermavir: TP, topical drug administration
dermavir: PD, pharmacology
unclassified drug
reverset
t 649

CAS REGISTRY NO.: (enfuvirtide) 159519-65-0; (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5; (proteinase inhibitor) 37205-61-1; (lamivudine) 134678-17-4, 134680-32-3; (zidovudine) 30516-87-1; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (3' fluorothymidine) **25526-93-6**; (tipranavir) 174484-41-4; (ritonavir) 155213-67-5; (amprenavir) 161814-49-9; (polyinosinic polycytidylic acid) 24939-03-5, 26301-44-0; (efavirenz) 154598-52-4

CHEMICAL NAME: (1) Amd 3100; (2) Ak 602; (3) Tmc 125; (4) Tmc 114; (5) Dpc 817; (6) Reverset; (7) Dpc 817; (8) Reverset; (9) Racivir; (10) Dpc 817; (11) Racivir; (12) Reverset; (13) U 140690; (14) Fuzeon; (15) T 649; (16) Fuzeon; (17) T 649; (18) Ach 126443; (19) Ak 602; (20) Miv 310; (21) Dermavir

COMPANY NAME: (1) Anormed; (2) Ono; (4) Tibotec Virco; (6) Bristol Myers Squibb; (9) Emory University; (12) Pharmasset; (13) Boehringer Ingelheim; (15) Hoffmann La Roche; (17) Trimeris; (18) Achillion (United States); (19) Kumamoto University; (20) Medivir; (21) Research Institute for Genetic and Human Therapy

TI **HIV** DART 2002: Frontiers in drug development for antiretroviral therapies: 15-19 December 2002, Naples, FL, USA.

SO IDrugs, (1 Feb 2003) Vol. 6, No. 2, pp. 110-113. .
ISSN: 1369-7056 CODEN: IDRUFN

AB In general, this was an excellent conference that presented considerable new information on **antiviral** drug development in the field of **HIV** disease. It included information on new targets as well as information on compounds that are already relatively advanced in clinical development. There is a consensus that the field of **HIV** disease requires novel agents that will hopefully achieve greater durability in regard to suppression of ongoing viral replication as well as greater efficacy at prevention of sequestration of latent virus in reservoir tissues. There is little doubt that important new developments will take place in years ahead that will make an important difference to patient well being.

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
***Human immunodeficiency virus infection: PC, prevention**
***Human immunodeficiency virus infection: DR, drug resistance**
human
clinical trial
nonhuman
Human immunodeficiency virus
virus pathogenesis
drug information
drug targeting
virus replication
drug efficacy
highly active antiretroviral therapy
drug structure
drug bioavailability
tissue distribution
drug effect
drug toxicity: SI, side effect
dose response
drug design
virus strain
virus mutation
drug binding
antiviral activity
immunotherapy
virus load
virus resistance
drug potentiation
conference paper

CT Drug Descriptors:
*antiretrovirus agent: PK, pharmacokinetics
*antiretrovirus agent: PD, pharmacology
*antiretrovirus agent: DT, drug therapy
*antiretrovirus agent: PO, oral drug administration
*antiretrovirus agent: AE, adverse drug reaction
*antiretrovirus agent: DV, drug development
*antiretrovirus agent: AN, drug analysis
*antiretrovirus agent: CT, clinical trial
*antiretrovirus agent: CM, drug comparison
*antiretrovirus agent: CB, drug combination
*antiretrovirus agent: VA, intravaginal drug administration
*antiretrovirus agent: SC, subcutaneous drug administration
*antiretrovirus agent: IT, drug interaction
enfuvirtide: PD, pharmacology
enfuvirtide: DT, drug therapy
enfuvirtide: AN, drug analysis
enfuvirtide: DV, drug development
enfuvirtide: PO, oral drug administration
enfuvirtide: PK, pharmacokinetics
enfuvirtide: SC, subcutaneous drug administration
enfuvirtide: CT, clinical trial
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11

tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): PO, oral drug administration
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): PD, pharmacology
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): AE, adverse drug reaction
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DO, drug dose
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): AN, drug analysis
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DV, drug development
ak 602: PK, pharmacokinetics
ak 602: AN, drug analysis
ak 602: PO, oral drug administration
ak 602: DV, drug development
ak 602: DT, drug therapy
RNA directed DNA polymerase inhibitor: DV, drug development
RNA directed DNA polymerase inhibitor: PD, pharmacology
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: VA, intravaginal drug administration
RNA directed DNA polymerase inhibitor: CM, drug comparison
proteinase inhibitor: DV, drug development
proteinase inhibitor: PD, pharmacology
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: VA, intravaginal drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose
proteinase inhibitor: AN, drug analysis
proteinase inhibitor: IT, drug interaction
tmc 125: DV, drug development
tmc 125: PD, pharmacology
tmc 125: CT, clinical trial
tmc 125: DT, drug therapy
tmc 125: VA, intravaginal drug administration
tmc 114: DV, drug development
tmc 114: PD, pharmacology
tmc 114: CT, clinical trial
tmc 114: DT, drug therapy
tmc 114: VA, intravaginal drug administration
cytidine derivative: PD, pharmacology
cytidine derivative: DV, drug development
dpc 817: DV, drug development
dpc 817: PD, pharmacology
lamivudine: PD, pharmacology
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: DT, drug therapy
zidovudine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
nevirapine: CT, clinical trial
stavudine: PD, pharmacology
stavudine: CM, drug comparison
stavudine: DT, drug therapy
stavudine: CT, clinical trial
virus vaccine: DT, drug therapy
virus vaccine: PD, pharmacology
virus vaccine: TP, topical drug administration
immunomodulating agent: CT, clinical trial
immunomodulating agent: DT, drug therapy
3' fluorothymidine: CT, clinical trial

3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: AN, drug analysis
3' fluorothymidine: DV, drug development
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: CB, drug combination
tipranavir: CB, drug combination
tipranavir: PD, pharmacology
tipranavir: AN, drug analysis
tipranavir: DV, drug development
tipranavir: DT, drug therapy
tipranavir: IT, drug interaction
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: PD, pharmacology
ritonavir: DT, drug therapy
ritonavir: IT, drug interaction
racivir: PK, pharmacokinetics
racivir: PD, pharmacology
racivir: AE, adverse drug reaction
amprenavir: PD, pharmacology
amprenavir: DT, drug therapy
ach 126443: PD, pharmacology
polyinosinic polycytidylic acid: DT, drug therapy
polyinosinic polycytidylic acid: CT, clinical trial
nucleoside analog: DT, drug therapy
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: AN, drug analysis
nucleoside analog: DV, drug development
nucleoside analog: AE, adverse drug reaction
nucleoside analog: PK, pharmacokinetics
nucleoside analog: CM, drug comparison
efavirenz: PD, pharmacology
efavirenz: DT, drug therapy
dermavir: DT, drug therapy
dermavir: TP, topical drug administration
dermavir: PD, pharmacology
unclassified drug
reverset
t 649

RN (enfuvirtide) 159519-65-0; (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5; (proteinase inhibitor) 37205-61-1; (lamivudine) 134678-17-4, 134680-32-3; (zidovudine) 30516-87-1; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (3' fluorothymidine) **25526-93-6**; (tipranavir) 174484-41-4; (ritonavir) 155213-67-5; (amprenavir) 161814-49-9; (polyinosinic polycytidylic acid) 24939-03-5, 26301-44-0; (efavirenz) 154598-52-4

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
***Human immunodeficiency virus infection: PC, prevention**
***Human immunodeficiency virus infection: DR, drug resistance**
human
clinical trial
nonhuman
Human immunodeficiency virus
virus pathogenesis
drug information
drug targeting
virus replication
drug efficacy
highly active antiretroviral therapy
drug structure
drug bioavailability
tissue distribution
drug effect

drug toxicity: SI, side effect
dose response
drug design
virus strain
virus mutation
drug binding
antiviral activity
immunotherapy
virus load
virus resistance
drug potentiation
conference paper
CT Drug Descriptors:
*antiretrovirus agent: PK, pharmacokinetics
*antiretrovirus agent: PD, pharmacology
*antiretrovirus agent: DT, drug therapy
*antiretrovirus agent: PO, oral drug administration
*antiretrovirus agent: AE, adverse drug reaction
*antiretrovirus agent: DV, drug development
*antiretrovirus agent: AN, drug analysis
*antiretrovirus agent: CT, clinical trial
*antiretrovirus agent: CM, drug comparison
*antiretrovirus agent: CB, drug combination
*antiretrovirus agent: VA, intravaginal drug administration
*antiretrovirus agent: SC, subcutaneous drug administration
*antiretrovirus agent: IT, drug interaction
enfuvirtide: PD, pharmacology
enfuvirtide: DT, drug therapy
enfuvirtide: AN, drug analysis
enfuvirtide: DV, drug development
enfuvirtide: PO, oral drug administration
enfuvirtide: PK, pharmacokinetics
enfuvirtide: SC, subcutaneous drug administration
enfuvirtide: CT, clinical trial
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): PO, oral drug administration
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): PD, pharmacology
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): AE, adverse drug reaction
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DO, drug dose
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): AN, drug analysis
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DV, drug development
ak 602: PK, pharmacokinetics
ak 602: AN, drug analysis
ak 602: PO, oral drug administration
ak 602: DV, drug development
ak 602: DT, drug therapy
RNA directed DNA polymerase inhibitor: DV, drug development
RNA directed DNA polymerase inhibitor: PD, pharmacology
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: DT, drug therapy
RNA directed DNA polymerase inhibitor: VA, intravaginal drug
administration
RNA directed DNA polymerase inhibitor: CM, drug comparison
proteinase inhibitor: DV, drug development
proteinase inhibitor: PD, pharmacology
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: VA, intravaginal drug administration
proteinase inhibitor: CB, drug combination
proteinase inhibitor: DO, drug dose

proteinase inhibitor: AN, drug analysis
proteinase inhibitor: IT, drug interaction
tmc 125: DV, drug development
tmc 125: PD, pharmacology
tmc 125: CT, clinical trial
tmc 125: DT, drug therapy
tmc 125: VA, intravaginal drug administration
tmc 114: DV, drug development
tmc 114: PD, pharmacology
tmc 114: CT, clinical trial
tmc 114: DT, drug therapy
tmc 114: VA, intravaginal drug administration
cytidine derivative: PD, pharmacology
cytidine derivative: DV, drug development
dpc 817: DV, drug development
dpc 817: PD, pharmacology
lamivudine: PD, pharmacology
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: DT, drug therapy
zidovudine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
nevirapine: CT, clinical trial
stavudine: PD, pharmacology
stavudine: CM, drug comparison
stavudine: DT, drug therapy
stavudine: CT, clinical trial
virus vaccine: DT, drug therapy
virus vaccine: PD, pharmacology
virus vaccine: TP, topical drug administration
immunomodulating agent: CT, clinical trial
immunomodulating agent: DT, drug therapy
3' fluorothymidine: CT, clinical trial
3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: AN, drug analysis
3' fluorothymidine: DV, drug development
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: CB, drug combination
tipranavir: CB, drug combination
tipranavir: PD, pharmacology
tipranavir: AN, drug analysis
tipranavir: DV, drug development
tipranavir: DT, drug therapy
tipranavir: IT, drug interaction
ritonavir: CB, drug combination
ritonavir: DO, drug dose
ritonavir: PD, pharmacology
ritonavir: DT, drug therapy
ritonavir: IT, drug interaction
racivir: PK, pharmacokinetics
racivir: PD, pharmacology
racivir: AE, adverse drug reaction
amprenavir: PD, pharmacology
amprenavir: DT, drug therapy
ach 126443: PD, pharmacology
polyinosinic polycytidylic acid: DT, drug therapy
polyinosinic polycytidylic acid: CT, clinical trial
nucleoside analog: DT, drug therapy
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: AN, drug analysis
nucleoside analog: DV, drug development
nucleoside analog: AE, adverse drug reaction
nucleoside analog: PK, pharmacokinetics
nucleoside analog: CM, drug comparison

efavirenz: PD, pharmacology
efavirenz: DT, drug therapy
dermavir: DT, drug therapy
dermavir: TP, topical drug administration
dermavir: PD, pharmacology
unclassified drug
reverset
t 649

RN (enfuvirtide) 159519-65-0; (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5; (proteinase inhibitor) 37205-61-1; (lamivudine) 134678-17-4, 134680-32-3; (zidovudine) 30516-87-1; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (3' fluorothymidine) **25526-93-6**; (tipranavir) 174484-41-4; (ritonavir) 155213-67-5; (amprenavir) 161814-49-9; (polyinosinic polycytidylic acid) 24939-03-5, 26301-44-0; (efavirenz) 154598-52-4

CN (1) Amd 3100; (2) Ak 602; (3) Tmc 125; (4) Tmc 114; (5) Dpc 817; (6) Reverset; (7) Dpc 817; (8) Reverset; (9) Racivir; (10) Dpc 817; (11) Racivir; (12) Reverset; (13) U 140690; (14) Fuzeon; (15) T 649; (16) Fuzeon; (17) T 649; (18) Ach 126443; (19) Ak 602; (20) Miv 310; (21) Dermavir

CO (1) Anormed; (2) Ono; (4) Tibotec Virco; (6) Bristol Myers Squibb; (9) Emory University; (12) Pharmasset; (13) Boehringer Ingelheim; (15) Hoffmann La Roche; (17) Trimeris; (18) Achillion (United States); (19) Kumamoto University; (20) Medivir; (21) Research Institute for Genetic and Human Therapy

L80 ANSWER 3 OF 16 EMBASE

ACCESSION NUMBER: 2000237078 EMBASE Full-text
TITLE: Amprenavir: A new **human immunodeficiency virus** type 1 protease inhibitor.
AUTHOR: Fung H.B.; Kirschenbaum H.L.; Hameed R.
CORPORATE SOURCE: Dr. H.B. Fung, Pharmacy Service, Bronx VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, United States
SOURCE: Clinical Therapeutics, (2000) Vol. 22, No. 5, pp. 549-572. .
Refs: 68
ISSN: 0149-2918 CODEN: CLTHDG
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jul 2000
Last Updated on STN: 20 Jul 2000

ABSTRACT: Objective: This paper reviews the pharmacologic properties and clinical usefulness of amprenavir, a new **human** ***immunodeficiency*** **virus** type 1 (**HIV**-1) protease inhibitor. Background: Amprenavir, the most recent ***HIV*** -1 protease inhibitor to receive marketing approval from the US Food and Drug Administration, is a potent competitive inhibitor of ***HIV*** -1 protease and a relatively weak inhibitor of **HIV** -2 protease. Inhibition of the **HIV**-I protease enzyme results in immature and noninfectious viral particles. Amprenavir is rapidly absorbed following oral administration. The time to peak concentration (T(max)) in adults is between 1 and 2 hours, the area under the plasma concentration versus time curve is roughly proportional to the dose, the half-life is .apprx.8 hours, and the volume of distribution is .apprx.430 L. The T(max) in children 4 to 12 years of age is between 1.1 and 1.4 hours. The bioavailability of the solution is 86% relative to the capsule formulation. It is metabolized by the cytochrome P-450 isozyme CYP3A4 and to a lesser extent by CYP2D6 and CYP2C9. Methods:

We searched MEDLINE® (1966 to January 2000), AIDSLINE® (1980 to January 2000), International Pharmaceutical Abstracts (1970 to January 2000), PharmaProjects (January 2000 version), and web sites of major ***HIV*** /acquired immunodeficiency syndrome conferences for appropriate published references (1996 to February 2000). Results: Data reported to date indicate that amprenavir is efficacious in the treatment of **HIV** disease in patients with primary **HIV** infection, antiretroviral-naive patients, protease inhibitor-naive patients, protease inhibitor-experienced patients, and pediatric patients. Adverse effects were usually of early onset (range, 2 to 21 days) and transient (range, 3 to 46 days), although the incidence of metabolic abnormalities such as lipodystrophy, hyperlipidemia, and diabetes mellitus has not yet been defined. Amprenavir should be avoided in patients with a known sulfonamide allergy. Concomitant use of other medications that are CYP3A4 inducers or inhibitors should be done cautiously and only if the potential benefit clearly outweighs potential risk. The dose should be reduced in patients with significant hepatic impairment (Child-Pugh score, ≥5). Amprenavir probably should not be administered with rifabutin, rifampin, astemizole, midazolam, triazolam, bepridil, dihydroergotamine, ergotamine, or cisapride. The recommended adult dose is 1200 mg twice daily. For patients between 4 and 12 years of age or between 13 and 16 years of age who weigh <50 kg, the recommended dosage of the capsule form is 20 mg/kg (22.5 mg/kg for oral solution) twice daily or 15 mg/kg (17 mg/kg for oral solution) 3 times a day to a maximum dose of 2400 mg (2800 mg for oral solution). Patients should not take vitamin E supplements because amprenavir is formulated with a large amount of vitamin E (109 IU/capsule and 46 IU/mL oral solution) to improve oral absorption. Amprenavir may be administered with or without food, but a high-fat meal (>67 g fat) should be avoided. Conclusions: Published clinical data are limited, but amprenavir appears to be efficacious and generally well tolerated in patients with ***HIV*** infection. Pharmacoeconomic data are not yet available. The introduction of amprenavir appears to be important, since it provides an additional treatment option as a component of both initial and salvage combination therapies for patients with **HIV**.

CONTROLLED TERM: Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
*acquired immune deficiency syndrome: DT, drug therapy
Human immunodeficiency virus 1
metabolic disorder: SI, side effect
drug structure
drug mechanism
IC 50
antiviral activity
drug metabolism
food drug interaction
antibiotic resistance
drug efficacy
drug induced disease: SI, side effect
drug tolerability
drug contraindication
practice guideline
treatment planning
human
clinical trial
review

CONTROLLED TERM: Drug Descriptors:
*amprenavir: AE, adverse drug reaction
*amprenavir: CT, clinical trial
*amprenavir: AD, drug administration
*amprenavir: AN, drug analysis
*amprenavir: CB, drug combination

*amprenavir: CM, drug comparison
*amprenavir: CR, drug concentration
*amprenavir: DO, drug dose
*amprenavir: IT, drug interaction
*amprenavir: DT, drug therapy
*amprenavir: PK, pharmacokinetics
*amprenavir: PD, pharmacology
*amprenavir: PO, oral drug administration
*proteinase inhibitor: AE, adverse drug reaction
*proteinase inhibitor: CT, clinical trial
*proteinase inhibitor: AD, drug administration
*proteinase inhibitor: AN, drug analysis
*proteinase inhibitor: CB, drug combination
*proteinase inhibitor: CM, drug comparison
*proteinase inhibitor: CR, drug concentration
*proteinase inhibitor: DO, drug dose
*proteinase inhibitor: IT, drug interaction
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: PK, pharmacokinetics
*proteinase inhibitor: PD, pharmacology
*proteinase inhibitor: PO, oral drug administration
abacavir: CT, clinical trial
abacavir: CB, drug combination
abacavir: CM, drug comparison
abacavir: DO, drug dose
abacavir: IT, drug interaction
abacavir: DT, drug therapy
clarithromycin: IT, drug interaction
efavirenz: CT, clinical trial
efavirenz: CB, drug combination
efavirenz: DO, drug dose
efavirenz: IT, drug interaction
efavirenz: DT, drug therapy
indinavir: AE, adverse drug reaction
indinavir: CT, clinical trial
indinavir: CB, drug combination
indinavir: CM, drug comparison
indinavir: DO, drug dose
indinavir: IT, drug interaction
indinavir: DT, drug therapy
indinavir: PD, pharmacology
ketoconazole: IT, drug interaction
lamivudine: AE, adverse drug reaction
lamivudine: CT, clinical trial
lamivudine: CB, drug combination
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
lamivudine: IT, drug interaction
lamivudine: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nelfinavir: CM, drug comparison
nelfinavir: DO, drug dose
nelfinavir: IT, drug interaction
nelfinavir: DT, drug therapy
nelfinavir: PD, pharmacology
rifabutin: IT, drug interaction
rifampicin: IT, drug interaction
ritonavir: CT, clinical trial
ritonavir: CB, drug combination
ritonavir: CM, drug comparison
ritonavir: DO, drug dose
ritonavir: IT, drug interaction
ritonavir: DT, drug therapy
ritonavir: PD, pharmacology
saquinavir: CT, clinical trial
saquinavir: CB, drug combination

saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: IT, drug interaction
saquinavir: DT, drug therapy
saquinavir: PD, pharmacology
zidovudine: AE, adverse drug reaction
zidovudine: CT, clinical trial
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: IT, drug interaction
zidovudine: DT, drug therapy
RNA directed DNA polymerase inhibitor: AE, adverse drug reaction
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: CM, drug comparison
RNA directed DNA polymerase inhibitor: DO, drug dose
RNA directed DNA polymerase inhibitor: IT, drug interaction
RNA directed DNA polymerase inhibitor: DT, drug therapy
amitriptyline: IT, drug interaction
amitriptyline: PD, pharmacology
imipramine: IT, drug interaction
imipramine: PD, pharmacology
propranolol: IT, drug interaction
propranolol: PD, pharmacology
pethidine: IT, drug interaction
pethidine: PD, pharmacology
didanosine: IT, drug interaction
raluridine: IT, drug interaction
emtricitabine: IT, drug interaction
nevirapine: AE, adverse drug reaction
nevirapine: CT, clinical trial
nevirapine: CB, drug combination
nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: CB, drug combination
stavudine: CM, drug comparison
stavudine: DT, drug therapy
sulfonamide
sulfonylurea derivative
probenecid
acetazolamide
thiazide diuretic agent
unindexed drug

CAS REGISTRY NO.: (amprenavir) 161814-49-9; (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (clarithromycin) 81103-11-9; (efavirenz) 154598-52-4; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (ketoconazole) 65277-42-1; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (rifabutin) 72559-06-9; (rifampicin) 13292-46-1; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8, 149845-06-7; (zidovudine) 30516-87-1; (amitriptyline) 50-48-6, 549-18-8; (imipramine) 113-52-0, 50-49-7; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (pethidine) 28097-96-3, 50-13-5, 57-42-1; (didanosine) 69655-05-6; (raluridine)

119644-22-3; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (probenecid) 57-66-9; (acetazolamide) 1424-27-7, 59-66-5

CHEMICAL NAME: (1) Agenerase; Vx 478; 141w94; 935u83; 524w91
COMPANY NAME: (1) Vertex (United States)

TI Amprenavir: A new **human immunodeficiency virus** type 1 protease inhibitor.

SO Clinical Therapeutics, (2000) Vol. 22, No. 5, pp. 549-572. .
Refs: 68
ISSN: 0149-2918 CODEN: CLTHDG

AB Objective: This paper reviews the pharmacologic properties and clinical usefulness of amprenavir, a new **human immunodeficiency virus** type 1 (**HIV**-1) protease inhibitor. Background: Amprenavir, the most recent **HIV**-1 protease inhibitor to receive marketing approval from the US Food and Drug Administration, is a potent competitive inhibitor of **HIV**-1 protease and a relatively weak inhibitor of **HIV**-2 protease. Inhibition of the **HIV**-I protease enzyme results in immature and noninfectious viral particles. Amprenavir is rapidly absorbed following oral administration. The time to peak concentration (T(max)) in adults is between 1 and 2 hours, the area under the plasma concentration versus time curve is roughly proportional to the dose, the half-life is .apprx.8 hours, and the volume of distribution is .apprx.430 L. The T(max) in children 4 to 12 years of age is between 1.1 and 1.4 hours. The bioavailability of the solution is 86% relative to the capsule formulation. It is metabolized by the cytochrome P-450 isozyme CYP3A4 and to a lesser extent by CYP2D6 and CYP2C9. Methods: We searched MEDLINE® (1966 to January 2000), AIDSLINE® (1980 to January 2000), International Pharmaceutical Abstracts (1970 to January 2000), PharmaProjects (January 2000 version), and web sites of major **HIV**/acquired immunodeficiency syndrome conferences for appropriate published references (1996 to February 2000). Results: Data reported to date indicate that amprenavir is efficacious in the treatment of **HIV** disease in patients with primary **HIV** infection, antiretroviral-naive patients, protease inhibitor-naive patients, protease inhibitor-experienced patients, and pediatric patients. Adverse effects were usually of early onset (range, 2 to 21 days) and transient (range, 3 to 46 days), although the incidence of metabolic abnormalities such as lipodystrophy, hyperlipidemia, and diabetes mellitus has not yet been defined. Amprenavir should be avoided in patients with a known sulfonamide allergy. Concomitant use of other medications that are CYP3A4 inducers or inhibitors should be done cautiously and only if the potential benefit clearly outweighs potential risk. The dose should be reduced in patients with significant hepatic impairment (Child-Pugh score, ≥5). Amprenavir probably should not be administered with rifabutin, rifampin, astemizole, midazolam, triazolam, bepridil, dihydroergotamine, ergotamine, or cisapride. The recommended adult dose is 1200 mg twice daily. For patients between 4 and 12 years of age or between 13 and 16 years of age who weigh <50 kg, the recommended dosage of the capsule form is 20 mg/kg (22.5 mg/kg for oral solution) twice daily or 15 mg/kg (17 mg/kg for oral solution) 3 times a day to a maximum dose of 2400 mg (2800 mg for oral solution). Patients should not take vitamin E supplements because amprenavir is formulated with a large amount of vitamin E (109 IU/capsule and 46 IU/mL oral solution) to improve oral absorption. Amprenavir may be administered with or without food, but a high-fat meal (>67 g fat) should be avoided. Conclusions: Published clinical data are limited, but amprenavir appears to be efficacious and generally well tolerated in patients with **HIV** infection. Pharmacoeconomic data are not yet available. The introduction of amprenavir appears to be important, since it provides an additional treatment option as a component of both initial and salvage combination therapies for patients with **HIV**.

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
*acquired immune deficiency syndrome: DT, drug therapy
Human immunodeficiency virus 1
metabolic disorder: SI, side effect
drug structure
drug mechanism
IC 50
antiviral activity
drug metabolism
food drug interaction
antibiotic resistance
drug efficacy

drug induced disease: SI, side effect
drug tolerability
drug contraindication
practice guideline
treatment planning
human
clinical trial
review

CT Drug Descriptors:
*amprenavir: AE, adverse drug reaction
*amprenavir: CT, clinical trial
*amprenavir: AD, drug administration
*amprenavir: AN, drug analysis
*amprenavir: CB, drug combination
*amprenavir: CM, drug comparison
*amprenavir: CR, drug concentration
*amprenavir: DO, drug dose
*amprenavir: IT, drug interaction
*amprenavir: DT, drug therapy
*amprenavir: PK, pharmacokinetics
*amprenavir: PD, pharmacology
*amprenavir: PO, oral drug administration
*proteinase inhibitor: AE, adverse drug reaction
*proteinase inhibitor: CT, clinical trial
*proteinase inhibitor: AD, drug administration
*proteinase inhibitor: AN, drug analysis
*proteinase inhibitor: CB, drug combination
*proteinase inhibitor: CM, drug comparison
*proteinase inhibitor: CR, drug concentration
*proteinase inhibitor: DO, drug dose
*proteinase inhibitor: IT, drug interaction
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: PK, pharmacokinetics
*proteinase inhibitor: PD, pharmacology
*proteinase inhibitor: PO, oral drug administration
abacavir: CT, clinical trial
abacavir: CB, drug combination
abacavir: CM, drug comparison
abacavir: DO, drug dose
abacavir: IT, drug interaction
abacavir: DT, drug therapy
clarithromycin: IT, drug interaction
efavirenz: CT, clinical trial
efavirenz: CB, drug combination
efavirenz: DO, drug dose
efavirenz: IT, drug interaction
efavirenz: DT, drug therapy
indinavir: AE, adverse drug reaction
indinavir: CT, clinical trial
indinavir: CB, drug combination
indinavir: CM, drug comparison
indinavir: DO, drug dose
indinavir: IT, drug interaction
indinavir: DT, drug therapy
indinavir: PD, pharmacology
ketoconazole: IT, drug interaction
lamivudine: AE, adverse drug reaction
lamivudine: CT, clinical trial
lamivudine: CB, drug combination
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
lamivudine: IT, drug interaction
lamivudine: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nelfinavir: CM, drug comparison
nelfinavir: DO, drug dose

nelfinavir: IT, drug interaction
nelfinavir: DT, drug therapy
nelfinavir: PD, pharmacology
rifabutin: IT, drug interaction
rifampicin: IT, drug interaction
ritonavir: CT, clinical trial
ritonavir: CB, drug combination
ritonavir: CM, drug comparison
ritonavir: DO, drug dose
ritonavir: IT, drug interaction
ritonavir: DT, drug therapy
ritonavir: PD, pharmacology
saquinavir: CT, clinical trial
saquinavir: CB, drug combination
saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: IT, drug interaction
saquinavir: DT, drug therapy
saquinavir: PD, pharmacology
zidovudine: AE, adverse drug reaction
zidovudine: CT, clinical trial
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: IT, drug interaction
zidovudine: DT, drug therapy
RNA directed DNA polymerase inhibitor: AE, adverse drug reaction
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: CM, drug comparison
RNA directed DNA polymerase inhibitor: DO, drug dose
RNA directed DNA polymerase inhibitor: IT, drug interaction
RNA directed DNA polymerase inhibitor: DT, drug therapy
amitriptyline: IT, drug interaction
amitriptyline: PD, pharmacology
imipramine: IT, drug interaction
imipramine: PD, pharmacology
propranolol: IT, drug interaction
propranolol: PD, pharmacology
pethidine: IT, drug interaction
pethidine: PD, pharmacology
didanosine: IT, drug interaction
raluridine: IT, drug interaction
emtricitabine: IT, drug interaction
nevirapine: AE, adverse drug reaction
nevirapine: CT, clinical trial
nevirapine: CB, drug combination
nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: CB, drug combination
stavudine: CM, drug comparison
stavudine: DT, drug therapy
sulfonamide
sulfonylurea derivative
probenecid
acetazolamide
thiazide diuretic agent
unindexed drug

RN (amprenavir) 161814-49-9; (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (clarithromycin) 81103-11-9; (efavirenz) 154598-52-4; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (ketoconazole) 65277-42-1; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (rifabutin) 72559-06-9; (rifampicin) 13292-46-1; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8, 149845-06-7; (zidovudine) 30516-87-1;

(amitriptyline) 50-48-6, 549-18-8; (imipramine) 113-52-0, 50-49-7; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (pethidine) 28097-96-3, 50-13-5, 57-42-1; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (probenecid) 57-66-9; (acetazolamide) 1424-27-7, 59-66-5

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
*acquired immune deficiency syndrome: DT, drug therapy
Human immunodeficiency virus 1
metabolic disorder: SI, side effect
drug structure
drug mechanism
IC 50
antiviral activity
drug metabolism
food drug interaction
antibiotic resistance
drug efficacy
drug induced disease: SI, side effect
drug tolerability
drug contraindication
practice guideline
treatment planning
human
clinical trial
review

CT Drug Descriptors:
*amprenavir: AE, adverse drug reaction
*amprenavir: CT, clinical trial
*amprenavir: AD, drug administration
*amprenavir: AN, drug analysis
*amprenavir: CB, drug combination
*amprenavir: CM, drug comparison
*amprenavir: CR, drug concentration
*amprenavir: DO, drug dose
*amprenavir: IT, drug interaction
*amprenavir: DT, drug therapy
*amprenavir: PK, pharmacokinetics
*amprenavir: PD, pharmacology
*amprenavir: PO, oral drug administration
*proteinase inhibitor: AE, adverse drug reaction
*proteinase inhibitor: CT, clinical trial
*proteinase inhibitor: AD, drug administration
*proteinase inhibitor: AN, drug analysis
*proteinase inhibitor: CB, drug combination
*proteinase inhibitor: CM, drug comparison
*proteinase inhibitor: CR, drug concentration
*proteinase inhibitor: DO, drug dose
*proteinase inhibitor: IT, drug interaction
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: PK, pharmacokinetics
*proteinase inhibitor: PD, pharmacology
*proteinase inhibitor: PO, oral drug administration
abacavir: CT, clinical trial
abacavir: CB, drug combination
abacavir: CM, drug comparison
abacavir: DO, drug dose
abacavir: IT, drug interaction
abacavir: DT, drug therapy
clarithromycin: IT, drug interaction
efavirenz: CT, clinical trial
efavirenz: CB, drug combination
efavirenz: DO, drug dose
efavirenz: IT, drug interaction
efavirenz: DT, drug therapy

indinavir: AE, adverse drug reaction
indinavir: CT, clinical trial
indinavir: CB, drug combination
indinavir: CM, drug comparison
indinavir: DO, drug dose
indinavir: IT, drug interaction
indinavir: DT, drug therapy
indinavir: PD, pharmacology
ketoconazole: IT, drug interaction
lamivudine: AE, adverse drug reaction
lamivudine: CT, clinical trial
lamivudine: CB, drug combination
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
lamivudine: IT, drug interaction
lamivudine: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nelfinavir: CM, drug comparison
nelfinavir: DO, drug dose
nelfinavir: IT, drug interaction
nelfinavir: DT, drug therapy
nelfinavir: PD, pharmacology
rifabutin: IT, drug interaction
rifampicin: IT, drug interaction
ritonavir: CT, clinical trial
ritonavir: CB, drug combination
ritonavir: CM, drug comparison
ritonavir: DO, drug dose
ritonavir: IT, drug interaction
ritonavir: DT, drug therapy
ritonavir: PD, pharmacology
saquinavir: CT, clinical trial
saquinavir: CB, drug combination
saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: IT, drug interaction
saquinavir: DT, drug therapy
saquinavir: PD, pharmacology
zidovudine: AE, adverse drug reaction
zidovudine: CT, clinical trial
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: IT, drug interaction
zidovudine: DT, drug therapy
RNA directed DNA polymerase inhibitor: AE, adverse drug reaction
RNA directed DNA polymerase inhibitor: CT, clinical trial
RNA directed DNA polymerase inhibitor: CB, drug combination
RNA directed DNA polymerase inhibitor: CM, drug comparison
RNA directed DNA polymerase inhibitor: DO, drug dose
RNA directed DNA polymerase inhibitor: IT, drug interaction
RNA directed DNA polymerase inhibitor: DT, drug therapy
amitriptyline: IT, drug interaction
amitriptyline: PD, pharmacology
imipramine: IT, drug interaction
imipramine: PD, pharmacology
propranolol: IT, drug interaction
propranolol: PD, pharmacology
pethidine: IT, drug interaction
pethidine: PD, pharmacology
didanosine: IT, drug interaction
raluridine: IT, drug interaction
emtricitabine: IT, drug interaction
nevirapine: AE, adverse drug reaction
nevirapine: CT, clinical trial
nevirapine: CB, drug combination

nevirapine: CM, drug comparison
nevirapine: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: CB, drug combination
stavudine: CM, drug comparison
stavudine: DT, drug therapy
sulfonamide
sulfonylurea derivative
probenecid
acetazolamide
thiazide diuretic agent
unindexed drug

RN (amprenavir) 161814-49-9; (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (clarithromycin) 81103-11-9; (efavirenz) 154598-52-4; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (ketoconazole) 65277-42-1; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (rifabutin) 72559-06-9; (rifampicin) 13292-46-1; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8, 149845-06-7; (zidovudine) 30516-87-1; (amitriptyline) 50-48-6, 549-18-8; (imipramine) 113-52-0, 50-49-7; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (pethidine) 28097-96-3, 50-13-5, 57-42-1; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (probenecid) 57-66-9; (acetazolamide) 1424-27-7, 59-66-5

CN (1) Agenerase; Vx 478; 141w94; 935u83; 524w91

CO (1) Vertex (United States)

L80 ANSWER 4 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000220779 EMBASE Full-text
TITLE: Predictive value of treatment effects in SIV/SHIV infections in monkeys.
AUTHOR: Bottiger D.; Oberg B.
CORPORATE SOURCE: D. Bottiger, Medivir AB, Lunastigen 7, S-141 44 Huddinge, Stockholm, Sweden. bo.oberg@medivir.se
SOURCE: Current Opinion in Anti-infective Investigational Drugs, (2000) Vol. 2, No. 3, pp. 255-264.
Refs: 86
ISSN: 1464-8458 CODEN: COADFY
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 13 Jul 2000
Last Updated on STN: 13 Jul 2000

ABSTRACT: Monkeys infected with simian immunodeficiency virus (SIV) or hybrids between SIV and **HIV** are excellent models in the efforts to develop new therapies against **HIV/AIDS**. The clinical effect against **HIV** of a certain compound and dose can be predicted by the use of a few infected animals while cell culture models may give misleading results. Increasingly complicated treatment combinations and many different resistant **HIV** strains make it important to use predictive models before entering clinical trials. SIV/SHIV-infected monkeys offer such a model.

CONTROLLED TERM: Medical Descriptors:
*virus infection: ET, etiology
*virus infection: DT, drug therapy
human
clinical trial
nonhuman
animal model

experimental model
monkey
Simian immunodeficiency virus
Human immunodeficiency virus
treatment outcome
virus gene
antiviral activity
dose response
drug efficacy
drug effect
drug screening
review

CONTROLLED TERM: Drug Descriptors:
*antivirus agent: DT, drug therapy
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: IM, intramuscular drug administration
*antivirus agent: CT, clinical trial
*antivirus agent: CB, drug combination
zidovudine: DT, drug therapy
zidovudine: DV, drug development
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: DV, drug development
zalcitabine: CM, drug comparison
zalcitabine: DO, drug dose
stavudine: DT, drug therapy
stavudine: DV, drug development
stavudine: CM, drug comparison
stavudine: DO, drug dose
lamivudine: DT, drug therapy
lamivudine: DV, drug development
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: DV, drug development
3' fluorothymidine: CM, drug comparison
3' fluorothymidine: DO, drug dose
2',3' dideoxy 3' fluorouridine: DT, drug therapy
2',3' dideoxy 3' fluorouridine: DV, drug development
2',3' dideoxy 3' fluorouridine: CM, drug comparison
2',3' dideoxy 3' fluorouridine: DO, drug dose
2',3' dideoxyguanosine: DT, drug therapy
2',3' dideoxyguanosine: DV, drug development
2',3' dideoxyguanosine: CM, drug comparison
2',3' dideoxyguanosine: DO, drug dose
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DT, drug therapy
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DV, drug development
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: CM, drug comparison
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DO, drug dose
2'3' dideoxy 3' hydroxymethylcytosine: DT, drug therapy
2'3' dideoxy 3' hydroxymethylcytosine: DV, drug development

2'3' dideoxy 3' hydroxymethylcytosine: CM, drug comparison
2'3' dideoxy 3' hydroxymethylcytosine: DO, drug dose
cytosine derivative: DT, drug therapy
cytosine derivative: DV, drug development
cytosine derivative: CM, drug comparison
cytosine derivative: DO, drug dose
nevirapine: DT, drug therapy
nevirapine: DV, drug development
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nevirapine: DO, drug dose
trovirdine: DT, drug therapy
trovirdine: DV, drug development
trovirdine: CM, drug comparison
trovirdine: CT, clinical trial
trovirdine: DO, drug dose
foscarnet: DT, drug therapy
foscarnet: DV, drug development
foscarnet: DO, drug dose
adefovir: DT, drug therapy
adefovir: DV, drug development
adefovir: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonomethoxypropyl)adenine: DV, drug development
9 (2 phosphonomethoxypropyl)adenine: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: CT, clinical trial
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DO, drug dose
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: CT, clinical trial
hydroxyurea: DT, drug therapy
hydroxyurea: DO, drug dose
hydroxyurea: DV, drug development
thalidomide: DT, drug therapy
thalidomide: CT, clinical trial
thalidomide: DV, drug development
cyclosporin A: DT, drug therapy
cyclosporin A: CT, clinical trial
cyclosporin A: DV, drug development
soluble CD4 antigen: DV, drug development
soluble CD4 antigen: IM, intramuscular drug administration
soluble CD4 antigen: CT, clinical trial
soluble CD4 antigen: DT, drug therapy
recombinant alpha interferon: DT, drug therapy
recombinant alpha interferon: CB, drug combination
recombinant alpha interferon: DV, drug development
unclassified drug
ddl
gcv
flt
flg
f2g
2',3' dideoxy 3' hydroxymethylcytidine

fcu
6 cl ddg
aciclovir

CAS REGISTRY NO.: (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (2',3' dideoxy 3' fluorouridine) **41107-56-6**; (2',3' dideoxyguanosine) 85326-06-3; (9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine) 105868-85-7; (nevirapine) **129618-40-2**; (trovirdine) 148311-89-1, 149488-17-5; (foscarnet) 4428-95-9; (adefovir) 106941-25-7; (9 (2 phosphonomethoxypropyl)adenine) 147127-19-3, 147127-20-6; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (hydroxyurea) 127-07-1; (thalidomide) 50-35-1; (cyclosporin A) 59865-13-3, 63798-73-2; (aciclovir) 59277-89-3

CHEMICAL NAME: (1) Ddl; (2) D4T; (3) AZT; (4) Ddc; (5) Gcv; (6) 3TC; (7) Flt; (8) Flg; (9) F2g; (10) Bea 005; (11) U 75875; Fcu; 6 cl ddg; Acv

COMPANY NAME: (2) Bristol Myers Squibb; (3) Glaxo; (5) Hoffmann La Roche; (6) Biochem Pharma; (7) American Cyanamid; (10) Medivir; (11) Pharmacia Upjohn; Boehringer Ingelheim; Astra Zeneca; Rega

SO Current Opinion in Anti-infective Investigational Drugs, (2000) Vol. 2, No. 3, pp. 255-264. .
Refs: 86
ISSN: 1464-8458 CODEN: COADFY

AB Monkeys infected with simian immunodeficiency virus (SIV) or hybrids between SIV and **HIV** are excellent models in the efforts to develop new therapies against **HIV/ AIDS**. The clinical effect against **HIV** of a certain compound and dose can be predicted by the use of a few infected animals while cell culture models may give misleading results. Increasingly complicated treatment combinations and many different resistant **HIV** strains make it important to use predictive models before entering clinical trials. SIV/SHIV-infected monkeys offer such a model.

CT Medical Descriptors:
*virus infection: ET, etiology
*virus infection: DT, drug therapy
human
clinical trial
nonhuman
animal model
experimental model
monkey
Simian immunodeficiency virus
Human immunodeficiency virus
treatment outcome
virus gene
antiviral activity
dose response
drug efficacy
drug effect
drug screening
review

CT Drug Descriptors:
*antivirus agent: DT, drug therapy
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: IM, intramuscular drug administration
*antivirus agent: CT, clinical trial
*antivirus agent: CB, drug combination
zidovudine: DT, drug therapy
zidovudine: DV, drug development
zidovudine: CM, drug comparison

zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: DV, drug development
zalcitabine: CM, drug comparison
zalcitabine: DO, drug dose
stavudine: DT, drug therapy
stavudine: DV, drug development
stavudine: CM, drug comparison
stavudine: DO, drug dose
lamivudine: DT, drug therapy
lamivudine: DV, drug development
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: DV, drug development
3' fluorothymidine: CM, drug comparison
3' fluorothymidine: DO, drug dose
2',3' dideoxy 3' fluorouridine: DT, drug therapy
2',3' dideoxy 3' fluorouridine: DV, drug development
2',3' dideoxy 3' fluorouridine: CM, drug comparison
2',3' dideoxy 3' fluorouridine: DO, drug dose
2',3' dideoxyguanosine: DT, drug therapy
2',3' dideoxyguanosine: DV, drug development
2',3' dideoxyguanosine: CM, drug comparison
2',3' dideoxyguanosine: DO, drug dose
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DT, drug therapy
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DV, drug development
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: CM, drug comparison
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DO, drug dose
2'3' dideoxy 3' hydroxymethylcytosine: DT, drug therapy
2'3' dideoxy 3' hydroxymethylcytosine: DV, drug development
2'3' dideoxy 3' hydroxymethylcytosine: CM, drug comparison
2'3' dideoxy 3' hydroxymethylcytosine: DO, drug dose
cytosine derivative: DT, drug therapy
cytosine derivative: DV, drug development
cytosine derivative: CM, drug comparison
cytosine derivative: DO, drug dose
nevirapine: DT, drug therapy
nevirapine: DV, drug development
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nevirapine: DO, drug dose
trovirdine: DT, drug therapy
trovirdine: DV, drug development
trovirdine: CM, drug comparison
trovirdine: CT, clinical trial
trovirdine: DO, drug dose
foscarnet: DT, drug therapy
foscarnet: DV, drug development
foscarnet: DO, drug dose
adefovir: DT, drug therapy
adefovir: DV, drug development
adefovir: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonomethoxypropyl)adenine: DV, drug development
9 (2 phosphonomethoxypropyl)adenine: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: CT, clinical trial
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2

isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DO, drug dose
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: CT, clinical trial
hydroxyurea: DT, drug therapy
hydroxyurea: DO, drug dose
hydroxyurea: DV, drug development
thalidomide: DT, drug therapy
thalidomide: CT, clinical trial
thalidomide: DV, drug development
cyclosporin A: DT, drug therapy
cyclosporin A: CT, clinical trial
cyclosporin A: DV, drug development
soluble CD4 antigen: DV, drug development
soluble CD4 antigen: IM, intramuscular drug administration
soluble CD4 antigen: CT, clinical trial
soluble CD4 antigen: DT, drug therapy
recombinant alpha interferon: DT, drug therapy
recombinant alpha interferon: CB, drug combination
recombinant alpha interferon: DV, drug development
unclassified drug
ddl
gcv
flt
flg
f2g
2',3' dideoxy 3' hydroxymethylcytidine
fcu
6 cl ddg
aciclovir

RN (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (2',3' dideoxy 3' fluorouridine) **41107-56-6**; (2',3' dideoxyguanosine) 85326-06-3; (9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine) 105868-85-7; (nevirapine) **129618-40-2**; (trovirdine) 148311-89-1, 149488-17-5; (foscarnet) 4428-95-9; (adefovir) 106941-25-7; (9 (2 phosphonomethoxypropyl)adenine) 147127-19-3, 147127-20-6; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (hydroxyurea) 127-07-1; (thalidomide) 50-35-1; (cyclosporin A) 59865-13-3, 63798-73-2; (aciclovir) 59277-89-3

CT Medical Descriptors:
*virus infection: ET, etiology
*virus infection: DT, drug therapy
human
clinical trial
nonhuman
animal model
experimental model
monkey
Simian immunodeficiency virus
Human immunodeficiency virus
treatment outcome
virus gene
antiviral activity
dose response
drug efficacy
drug effect
drug screening
review

CT Drug Descriptors:

*antivirus agent: DT, drug therapy
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: IM, intramuscular drug administration
*antivirus agent: CT, clinical trial
*antivirus agent: CB, drug combination
zidovudine: DT, drug therapy
zidovudine: DV, drug development
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: DV, drug development
zalcitabine: CM, drug comparison
zalcitabine: DO, drug dose
stavudine: DT, drug therapy
stavudine: DV, drug development
stavudine: CM, drug comparison
stavudine: DO, drug dose
lamivudine: DT, drug therapy
lamivudine: DV, drug development
lamivudine: CM, drug comparison
lamivudine: DO, drug dose
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: DV, drug development
3' fluorothymidine: CM, drug comparison
3' fluorothymidine: DO, drug dose
2',3' dideoxy 3' fluorouridine: DT, drug therapy
2',3' dideoxy 3' fluorouridine: DV, drug development
2',3' dideoxy 3' fluorouridine: CM, drug comparison
2',3' dideoxy 3' fluorouridine: DO, drug dose
2',3' dideoxyguanosine: DT, drug therapy
2',3' dideoxyguanosine: DV, drug development
2',3' dideoxyguanosine: CM, drug comparison
2',3' dideoxyguanosine: DO, drug dose
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DT, drug therapy
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DV, drug development
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: CM, drug comparison
9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine: DO, drug dose
2'3' dideoxy 3' hydroxymethylcytosine: DT, drug therapy
2'3' dideoxy 3' hydroxymethylcytosine: DV, drug development
2'3' dideoxy 3' hydroxymethylcytosine: CM, drug comparison
2'3' dideoxy 3' hydroxymethylcytosine: DO, drug dose
cytosine derivative: DT, drug therapy
cytosine derivative: DV, drug development
cytosine derivative: CM, drug comparison
cytosine derivative: DO, drug dose
nevirapine: DT, drug therapy
nevirapine: DV, drug development
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nevirapine: DO, drug dose
trovirdine: DT, drug therapy
trovirdine: DV, drug development
trovirdine: CM, drug comparison
trovirdine: CT, clinical trial
trovirdine: DO, drug dose
foscarnet: DT, drug therapy
foscarnet: DV, drug development
foscarnet: DO, drug dose
adefovir: DT, drug therapy
adefovir: DV, drug development

adefovir: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonomethoxypropyl)adenine: DV, drug development
9 (2 phosphonomethoxypropyl)adenine: DO, drug dose
9 (2 phosphonomethoxypropyl)adenine: CT, clinical trial
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DO, drug dose
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: CT, clinical trial
hydroxyurea: DT, drug therapy
hydroxyurea: DO, drug dose
hydroxyurea: DV, drug development
thalidomide: DT, drug therapy
thalidomide: CT, clinical trial
thalidomide: DV, drug development
cyclosporin A: DT, drug therapy
cyclosporin A: CT, clinical trial
cyclosporin A: DV, drug development
soluble CD4 antigen: DV, drug development
soluble CD4 antigen: IM, intramuscular drug administration
soluble CD4 antigen: CT, clinical trial
soluble CD4 antigen: DT, drug therapy
recombinant alpha interferon: DT, drug therapy
recombinant alpha interferon: CB, drug combination
recombinant alpha interferon: DV, drug development
unclassified drug
ddl
gcv
flt
f1g
f2g
2',3' dideoxy 3' hydroxymethylcytidine
fcu
6 cl ddg
aciclovir

RN (zidovudine) 30516-87-1; (didanosine) 69655-05-6; (zalcitabine) 7481-89-2; (stavudine) 3056-17-5; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (2',3' dideoxy 3' fluorouridine) **41107-56-6**; (2',3' dideoxyguanosine) 85326-06-3; (9 [4 hydroxy 2 (hydroxymethyl)butyl]guanine) 105868-85-7; (nevirapine) **129618-40-2**; (trovirdine) 148311-89-1, 149488-17-5; (foscarnet) 4428-95-9; (adefovir) 106941-25-7; (9 (2 phosphonomethoxypropyl)adenine) 147127-19-3, 147127-20-6; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (hydroxyurea) 127-07-1; (thalidomide) 50-35-1; (cyclosporin A) 59865-13-3, 63798-73-2; (aciclovir) 59277-89-3

CN (1) Ddl; (2) D4T; (3) AZT; (4) Ddc; (5) Gcv; (6) 3TC; (7) Flt; (8) Flg; (9) F2g; (10) Bea 005; (11) U 75875; Fcu; 6 cl ddg; Acv

CO (2) Bristol Myers Squibb; (3) Glaxo; (5) Hoffmann La Roche; (6) Biochem Pharma; (7) American Cyanamid; (10) Medivir; (11) Pharmacia Upjohn; Boehringer Ingelheim; Astra Zeneca; Rega

L80 ANSWER 5 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000102461 EMBASE Full-text
TITLE: Current **antiviral** agents FactFile: 1999-2000 update. 5th edition: Part II -

Human immunodeficiency viruses.

AUTHOR: Kinchington D.; Gee S.; Balzarini J.; Gait M.; De Clercq E.; Field H.J.

CORPORATE SOURCE: D. Kinchington, Intemational Antiviral News, International Medical Press, 125 High Holborn, London WC1V 6QA, United Kingdom. iavn@intmedpress.com

SOURCE: International Antiviral News, (2000) Vol. 8, No. 1, pp. 4-21. .
Refs: 121
ISSN: 0965-2310 CODEN: IANWEL

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 6 Apr 2000
Last Updated on STN: 6 Apr 2000

ABSTRACT: This FactFile is again an expandedand updated version of the fourth edition,which appeared in October 1998. Part I of the update, which was published in 7:7, covers agents mainly active against herpes, hepatitis and respiratory viruses.The entries are limited to key ***antiviral*** agents that have undergone or are about to undergo at least Phase I clinical evaluation. Some originally promising compounds whose clinical development or use has been suspended are also included.

CONTROLLED TERM: Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
Human immunodeficiency virus 1
Human immunodeficiency virus 2
human
review
Drug Descriptors:
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): PD, pharmacology
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one: DT, drug therapy
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one: PD, pharmacology
3' azido 2',3' dideoxy 5 methylcytidine: DT, drug therapy
3' azido 2',3' dideoxy 5 methylcytidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: PD, pharmacology
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: DT, drug therapy
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: PD, pharmacology
a 77003: DT, drug therapy
a 77003: PD, pharmacology
abacavir: DT, drug therapy
abacavir: PD, pharmacology
adefovir dipivoxil: DT, drug therapy
adefovir dipivoxil: PD, pharmacology

adefovir: DT, drug therapy
adefovir: PD, pharmacology
amprenavir: DT, drug therapy
amprenavir: PD, pharmacology
atevirdine mesylate: DT, drug therapy
atevirdine mesylate: PD, pharmacology
behenyl alcohol: DT, drug therapy
behenyl alcohol: PD, pharmacology
castanospermine 6 butyrate: DT, drug therapy
castanospermine 6 butyrate: PD, pharmacology
delavirdine: DT, drug therapy
delavirdine: PD, pharmacology
didanosine: DT, drug therapy
didanosine: PD, pharmacology
efavirenz: DT, drug therapy
efavirenz: PD, pharmacology
emivirine: DT, drug therapy
emivirine: PD, pharmacology
emtricitabine: DT, drug therapy
emtricitabine: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: PD, pharmacology
hydroxyurea: DT, drug therapy
hydroxyurea: PD, pharmacology
hypericin: DT, drug therapy
hypericin: PD, pharmacology
indinavir: DT, drug therapy
indinavir: PD, pharmacology
kynostatin 272: DT, drug therapy
kynostatin 272: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: PD, pharmacology
talviraline: DT, drug therapy
talviraline: PD, pharmacology
trecovirsen: DT, drug therapy
trecovirsen: PD, pharmacology
zintevir: DT, drug therapy
zintevir: PD, pharmacology
foscarnet sodium
lamivudine
isis 5320
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone

CAS REGISTRY NO.: (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5; (1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one) 177932-89-7; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' fluorothymidine) **25526-93-6**; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (a 77003) 134878-17-4; (abacavir) 136470-78-5, 188062-50-2; (adefovir dipivoxil) 142340-99-6; (adefovir) 106941-25-7; (amprenavir) 161814-49-9; (atevirdine mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9, 141117-12-6; (delavirdine) 136817-59-9; (didanosine) 69655-05-6; (efavirenz) 154598-52-4; (emivirine) 149950-60-7; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (foscarnet) 4428-95-9; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (kynostatin 272) 147318-81-8; (nevirapine) **129618-40-2** ; (talviraline) 163451-80-7; (trecovirsen) 170274-79-0; (zintevir) 171345-51-0; (foscarnet sodium) 63585-09-1; (lamivudine) 134678-17-4,

134680-32-3; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9

CHEMICAL NAME: (1) Ziagen; (2) Alovudine; (3) Preveon; (4) Amd 3100; (5) Agenerase; (6) Ar 177; (7) Cs 92; (8) Rescriptor; (9) Dmp 323; (10) Videx; (11) Dmp 450; (12) Coactinon; (13) Foscavir; (14) Sustiva; (15) Coviracil; (16) GEM 91; (18) Hydrea; (19) Hby 097; (20) Vimrxyn; (21) Crixivan; (22) Kni 272; (23) Epivir; (24) Isis 5320; (26) L 697661; (27) Viramune

COMPANY NAME: (2) Lederle; (3) Gilead; (4) Anormed; (5) Verla Pharma; (6) Aronex; (8) Pharmacia Upjohn; (12) Mitsubishi; (13) Astra; (14) Du Pont Merck; (15) Triangle; (16) Hybridon; (17) Bristol Myers Squibb; (18) Bristol; (20) Nexell p; (22) Kyoto; (23) Glaxo Wellcome; (24) Isis; (25) Merck and Co; (26) Merck; (27) Roxane lab

TI Current **antiviral** agents FactFile: 1999-2000 update. 5th edition: Part II - **Human immunodeficiency viruses.**

SO International Antiviral News, (2000) Vol. 8, No. 1, pp. 4-21. .
Refs: 121
ISSN: 0965-2310 CODEN: IANWEL

AB This FactFile is again an expandedand updated version of the fourth edition,which appeared in October 1998. Part I of the update, which was published in 7:7, covers agents mainly active against herpes, hepatitis and respiratory viruses.The entries are limited to key **antiviral** agents that have undergone or are about to undergo at least Phase I clinical evaluation. Some originally promising compounds whose clinical development or use has been suspended are also included.

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
Human immunodeficiency virus 1
Human immunodeficiency virus 2
human
review
Drug Descriptors:
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane): PD, pharmacology
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one: DT, drug therapy
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one: PD, pharmacology
3' azido 2',3' dideoxy 5 methylcytidine: DT, drug therapy
3' azido 2',3' dideoxy 5 methylcytidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: PD, pharmacology
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: DT, drug therapy
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: PD, pharmacology
a 77003: DT, drug therapy
a 77003: PD, pharmacology
abacavir: DT, drug therapy
abacavir: PD, pharmacology
adefovir dipivoxil: DT, drug therapy
adefovir dipivoxil: PD, pharmacology
adefovir: DT, drug therapy
adefovir: PD, pharmacology
amprenavir: DT, drug therapy
amprenavir: PD, pharmacology
atevirdine mesylate: DT, drug therapy
atevirdine mesylate: PD, pharmacology

behenyl alcohol: DT, drug therapy
behenyl alcohol: PD, pharmacology
castanospermine 6 butyrate: DT, drug therapy
castanospermine 6 butyrate: PD, pharmacology
delavirdine: DT, drug therapy
delavirdine: PD, pharmacology
didanosine: DT, drug therapy
didanosine: PD, pharmacology
efavirenz: DT, drug therapy
efavirenz: PD, pharmacology
emivirine: DT, drug therapy
emivirine: PD, pharmacology
emtricitabine: DT, drug therapy
emtricitabine: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: PD, pharmacology
hydroxyurea: DT, drug therapy
hydroxyurea: PD, pharmacology
hypericin: DT, drug therapy
hypericin: PD, pharmacology
indinavir: DT, drug therapy
indinavir: PD, pharmacology
kynostatin 272: DT, drug therapy
kynostatin 272: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: PD, pharmacology
talviraline: DT, drug therapy
talviraline: PD, pharmacology
trecovirsen: DT, drug therapy
trecovirsen: PD, pharmacology
zintevir: DT, drug therapy
zintevir: PD, pharmacology
foscarnet sodium
lamivudine
isis 5320
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone

RN (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5; (1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one) 177932-89-7; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' fluorothymidine) **25526-93-6**; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (a 77003) 134878-17-4; (abacavir) 136470-78-5, 188062-50-2; (adefovir dipivoxil) 142340-99-6; (adefovir) 106941-25-7; (amprenavir) 161814-49-9; (atevirdine mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9, 141117-12-6; (delavirdine) 136817-59-9; (didanosine) 69655-05-6; (efavirenz) 154598-52-4; (emivirine) 149950-60-7; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (foscarnet) 4428-95-9; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (kynostatin 272) 147318-81-8; (nevirapine) **129618-40-2**; (talviraline) 163451-80-7; (trecovirsen) 170274-79-0; (zintevir) 171345-51-0; (foscarnet sodium) 63585-09-1; (lamivudine) 134678-17-4, 134680-32-3; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9

CT Medical Descriptors:
***Human immunodeficiency virus infection: DT, drug therapy**
Human immunodeficiency virus 1
Human immunodeficiency virus 2
human
review
Drug Descriptors:
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology

1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): DT, drug therapy
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane): PD, pharmacology
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6
dihydroxy 1h 1,3 diazepin 2 one: DT, drug therapy
1,3 bis(3 aminobenzyl) 4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6
dihydroxy 1h 1,3 diazepin 2 one: PD, pharmacology
3' azido 2',3' dideoxy 5 methylcytidine: DT, drug therapy
3' azido 2',3' dideoxy 5 methylcytidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
3' fluorothymidine: PD, pharmacology
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4
(hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: DT, drug therapy
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4
(hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one: PD, pharmacology
a 77003: DT, drug therapy
a 77003: PD, pharmacology
abacavir: DT, drug therapy
abacavir: PD, pharmacology
adefovir dipivoxil: DT, drug therapy
adefovir dipivoxil: PD, pharmacology
adefovir: DT, drug therapy
adefovir: PD, pharmacology
amprenavir: DT, drug therapy
amprenavir: PD, pharmacology
atevirdine mesylate: DT, drug therapy
atevirdine mesylate: PD, pharmacology
behenyl alcohol: DT, drug therapy
behenyl alcohol: PD, pharmacology
castanospermine 6 butyrate: DT, drug therapy
castanospermine 6 butyrate: PD, pharmacology
delavirdine: DT, drug therapy
delavirdine: PD, pharmacology
didanosine: DT, drug therapy
didanosine: PD, pharmacology
efavirenz: DT, drug therapy
efavirenz: PD, pharmacology
emivirine: DT, drug therapy
emivirine: PD, pharmacology
emtricitabine: DT, drug therapy
emtricitabine: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: PD, pharmacology
hydroxyurea: DT, drug therapy
hydroxyurea: PD, pharmacology
hypericin: DT, drug therapy
hypericin: PD, pharmacology
indinavir: DT, drug therapy
indinavir: PD, pharmacology
kynostatin 272: DT, drug therapy
kynostatin 272: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: PD, pharmacology
talviraline: DT, drug therapy
talviraline: PD, pharmacology
trecovirsen: DT, drug therapy
trecovirsen: PD, pharmacology
zintevir: DT, drug therapy
zintevir: PD, pharmacology
foscarnet sodium
lamivudine
isis 5320
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl
2(1h) pyridone
RN (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane)) 155148-31-5; (1,3 bis(3 aminobenzyl)

4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1h 1,3 diazepin 2 one) 177932-89-7; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' fluorothymidine) **25526-93-6**; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (a 77003) 134878-17-4; (abacavir) 136470-78-5, 188062-50-2; (adefovir dipivoxil) 142340-99-6; (adefovir) 106941-25-7; (amprenavir) 161814-49-9; (atevirdine mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9, 141117-12-6; (delavirdine) 136817-59-9; (didanosine) 69655-05-6; (efavirenz) 154598-52-4; (emivirine) 149950-60-7; (emtricitabine) 137530-41-7, 143491-54-7, 143491-57-0; (foscarnet) 4428-95-9; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6, 180683-37-8; (kynostatin 272) 147318-81-8; (nevirapine) **129618-40-2**; (talviraline) 163451-80-7; (trecovirsen) 170274-79-0; (zintevir) 171345-51-0; (foscarnet sodium) 63585-09-1; (lamivudine) 134678-17-4, 134680-32-3; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9

CN (1) Ziagen; (2) Alovudine; (3) Preveon; (4) Amd 3100; (5) Agenerase; (6) Ar 177; (7) Cs 92; (8) Rescriptor; (9) Dmp 323; (10) Videx; (11) Dmp 450; (12) Coactinon; (13) Foscavir; (14) Sustiva; (15) Coviracil; (16) GEM 91; (18) Hydrea; (19) Hby 097; (20) Vimrxyn; (21) Crixivan; (22) Kni 272; (23) Epivir; (24) Isis 5320; (26) L 697661; (27) Viramune

CO (2) Lederle; (3) Gilead; (4) Anormed; (5) Verla Pharma; (6) Aronex; (8) Pharmacia Upjohn; (12) Mitsubishi; (13) Astra; (14) Du Pont Merck; (15) Triangle; (16) Hybridon; (17) Bristol Myers Squibb; (18) Bristol; (20) Nexell p; (22) Kyoto; (23) Glaxo Wellcome; (24) Isis; (25) Merck and Co; (26) Merck; (27) Roxane lab

L80 ANSWER 6 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 97305371 EMBASE Full-text
DOCUMENT NUMBER: 1997305371
TITLE: Current **antiviral** agents FactFile. 3rd Edition: Part II - **Human immunodeficiency viruses**.
AUTHOR: Kinchington D.; Balzarini J.; Field H.J.
SOURCE: International Antiviral News, (1997) Vol. 5, No. 9, pp. 161-174. .
Refs: 100
ISSN: 0965-2310 CODEN: IANWEL
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Oct 1997
Last Updated on STN: 23 Oct 1997
CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus**
blood toxicity: SI, side effect
clinical trial
drug structure
human
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
short survey
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5

ethyl 6 methyl 2(1h) pyridone
3' azido 2',3' dideoxy 5 methylcytidine
3' azido 2',3' dideoxyuridine
3' fluorothymidine
3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one
6 benzyl 1 ethoxymethyl 5 isopropyluracil
a 77003
a 80987
adefovir
adefovir dipivoxil
atevirdine mesylate
behenyl alcohol
castanospermine 6 butyrate
delavirdine
diamide
didanosine
foscarnet sodium
hydroxyurea
hypericin
indinavir
kynostatin 272
lamivudine
lobucavir
loviride
nelfinavir
nevirapine
ritonavir
unindexed drug

CAS REGISTRY NO.: (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione) 163451-80-7; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (a 77003) 134878-17-4; (adefovir) 106941-25-7; (adefovir dipivoxil) 142340-99-6; (atevirdine mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (diamide) 10465-78-8; (didanosine) 69655-05-6; (foscarnet sodium) 63585-09-1; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (kynostatin 272) 147318-81-8; (lamivudine) 134678-17-4, 134680-32-3; (lobucavir) 126062-18-8, 127759-89-1; (loviride) 147362-57-0; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (ritonavir) 155213-67-5

CHEMICAL NAME: (1) A 77003; (2) A 80987; (3) Norvir; (4) Epivir; (5) Cs 92; (6) 524w91; (7) Videx; (8) Dmp 323; (9) Foscavir; (10) Crixivan; (11) L 697661; (12) Hby 097; (13) Hydrea; (14) Kni 272; (15) Mdl 28574; (16) Mkc 442; (17) Lidakol; (18) Viracept; (19) Viramune

COMPANY NAME: (3) Abbott; (4) Glaxo; (6) Triangle; (7) Bristol myers squibb; (8) Du pont merck; (9) Astra; (11) Merck; (12) Hoechst; (13) Squibb; (14) Kyoto; (15)

Marion merrell dow; (16) Mitsubishi; (17) Lidak; (18) Agouron; (19) Roxane; Gilead; Hubriphar; Isis; Johnson matthey; Aronex; Ciba geigy; Scotia; Hybridon; Janssen; Pharmacia upjohn; National institute of health; National cancer institute; Japan energy; Procept; Takeda

TI Current **antiviral** agents FactFile. 3rd Edition: Part II - **Human immunodeficiency viruses.**

SO International Antiviral News, (1997) Vol. 5, No. 9, pp. 161-174. .
Refs: 100
ISSN: 0965-2310 CODEN: IANWEL

CT Medical Descriptors:
***human immunodeficiency virus**
blood toxicity: SI, side effect
clinical trial
drug structure
human
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
short survey
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone
3' azido 2',3' dideoxy 5 methylcytidine
3' azido 2',3' dideoxyuridine
3' fluorothymidine
3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one
6 benzyl 1 ethoxymethyl 5 isopropyluracil
a 77003
a 80987
adefovir
adefovir dipivoxil
atevirdine mesylate
behenyl alcohol
castanospermine 6 butyrate
delavirdine
diamide
didanosine
foscarnet sodium
hydroxyurea
hypericin
indinavir
kynostatin 272
lamivudine
lobucavir
loviride
nelfinavir
nevirapine
ritonavir
unindexed drug

RN (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione) 163451-80-7; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (a 77003) 134878-17-4; (adefovir)

106941-25-7; (adefovir dipivoxil) 142340-99-6; (atevirdine mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (diamide) 10465-78-8; (didanosine) 69655-05-6; (foscarnet sodium) 63585-09-1; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (kynostatin 272) 147318-81-8; (lamivudine) 134678-17-4, 134680-32-3; (lobucavir) 126062-18-8, 127759-89-1; (loviride) 147362-57-0; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (ritonavir) 155213-67-5

CT Medical Descriptors:
***human immunodeficiency virus**
blood toxicity: SI, side effect
clinical trial
drug structure
human
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
short survey
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone
3' azido 2',3' dideoxy 5 methylcytidine
3' azido 2',3' dideoxyuridine
3' fluorothymidine
3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione
4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one
6 benzyl 1 ethoxymethyl 5 isopropyluracil
a 77003
a 80987
adefovir
adefovir dipivoxil
atevirdine mesylate
behenyl alcohol
castanospermine 6 butyrate
delavirdine
diamide
didanosine
foscarnet sodium
hydroxyurea
hypericin
indinavir
kynostatin 272
lamivudine
lobucavir
loviride
nelfinavir
nevirapine
ritonavir
unindexed drug

RN (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxy 5 methylcytidine) 87190-79-2; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (3,4 dihydro 4 isopropoxycarbonyl 6 methoxy 3 (methylthiomethyl) 2(1h) quinoxalinethione) 163451-80-7; (4,7 dibenzyl 2,3,4,5,6,7 hexahydro 5,6 dihydroxy 1,3 bis[4 (hydroxymethyl)benzyl] 2h 1,3 diazepin 2 one) 151867-81-1; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (a 77003) 134878-17-4; (adefovir) 106941-25-7; (adefovir dipivoxil) 142340-99-6; (atevirdine

mesylate) 138540-32-6; (behenyl alcohol) 30303-65-2; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (diamide) 10465-78-8; (didanosine) 69655-05-6; (foscarnet sodium) 63585-09-1; (hydroxyurea) 127-07-1; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (kynostatin 272) 147318-81-8; (lamivudine) 134678-17-4, 134680-32-3; (lobucavir) 126062-18-8, 127759-89-1; (loviride) 147362-57-0; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (ritonavir) 155213-67-5

CN (1) A 77003; (2) A 80987; (3) Norvir; (4) Epivir; (5) Cs 92; (6) 524w91; (7) Videx; (8) Dmp 323; (9) Foscavir; (10) Crixivan; (11) L 697661; (12) Hby 097; (13) Hydrea; (14) Kni 272; (15) Mdl 28574; (16) Mkc 442; (17) Lidakol; (18) Viracept; (19) Viramune

CO (3) Abbott; (4) Glaxo; (6) Triangle; (7) Bristol myers squibb; (8) Du pont merck; (9) Astra; (11) Merck; (12) Hoechst; (13) Squibb; (14) Kyoto; (15) Marion merrell dow; (16) Mitsubishi; (17) Lidak; (18) Agouron; (19) Roxane; Gilead; Hubriphar; Isis; Johnson matthey; Aronex; Ciba geigy; Scotia; Hybridon; Janssen; Pharmacia upjohn; National institute of health; National cancer institute; Japan energy; Procept; Takeda

L80 ANSWER 7 OF 16 EMBASE

ACCESSION NUMBER: 96248921 EMBASE Full-text
DOCUMENT NUMBER: 1996248921
TITLE: What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of **human immunodeficiency virus** type 1 (**HIV**-1) infections?.
AUTHOR: De Clercq E.
CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universite Leuven, Minderbroedersstraat 10,B-3000 Leuven, Belgium
SOURCE: Reviews in Medical Virology, (1996) Vol. 6, No. 2, pp. 97-117. .
ISSN: 1052-9276 CODEN: RMVIEW
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Oct 1996
Last Updated on STN: 15 Oct 1996
CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: ET, etiology**
***human immunodeficiency virus infection: DT, drug therapy**
*virus infection: PC, prevention
*virus infection: ET, etiology
*virus infection: DT, drug therapy
drug conformation
drug potentiation
drug resistance
drug structure
human
human immunodeficiency virus 1
nonhuman
review
simian virus
structure activity relation
virus inhibition
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside derivative: DT, drug therapy

*acyclic nucleoside: DT, drug therapy
*nucleoside derivative: DT, drug therapy
*proteinase inhibitor: DT, drug therapy
*rna directed dna polymerase inhibitor: AN, drug analysis
*rna directed dna polymerase inhibitor: DT, drug therapy
abacavir: DT, drug therapy
abacavir: DV, drug development
2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: DV, drug development
zalcitabine: DT, drug therapy
zalcitabine: IT, drug interaction
zalcitabine: CB, drug combination
didanosine: DT, drug therapy
didanosine: CB, drug combination
didanosine: IT, drug interaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: AN, drug analysis
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: CB, drug combination
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: IT, drug interaction
raluridine: DV, drug development
raluridine: DT, drug therapy
6 benzyl 1 ethoxymethyl 5 isopropyluracil: AN, drug analysis
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: IT, drug interaction
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: CB, drug combination
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: AN, drug analysis
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: DV, drug development
9 (2 phosphonylmethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonylmethoxypropyl)adenine: DV, drug development
adefovir: DT, drug therapy
adefovir: DV, drug development
anilide: DV, drug development
anilide: AN, drug analysis
benzimidazole derivative: DV, drug development
benzimidazole derivative: AN, drug analysis
delavirdine: CB, drug combination
delavirdine: AN, drug analysis
delavirdine: IT, drug interaction
diazepine derivative: AN, drug analysis
diazepine derivative: DV, drug development
dipivoxil: DT, drug therapy
dipivoxil: DV, drug development
lamivudine: DT, drug therapy
loviride: DV, drug development
loviride: AN, drug analysis
trovirdine: AN, drug analysis
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: IT, drug interaction

nevirapine: AN, drug analysis
oxathiin derivative: AN, drug analysis
oxathiin derivative: DV, drug development
quinoxaline derivative: DV, drug development
quinoxaline derivative: AN, drug analysis
stavudine: DT, drug therapy
trovirdine: DV, drug development
unindexed drug
zidovudine: DT, drug therapy
zidovudine: IT, drug interaction
zidovudine: CB, drug combination
unclassified drug

CAS REGISTRY NO.: (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone) 135525-71-2; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 137332-54-8; (adefovir) 106941-25-7; (delavirdine) 136817-59-9; (lamivudine) 134678-17-4, 134680-32-3; (loviride) 147362-57-0; (trovirdine) 148311-89-1, 149488-17-5; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trovirdine) 148311-89-1, 149488-17-5; (zidovudine) 30516-87-1

CHEMICAL NAME: 935u83; 524w91; 1592u89; Bi rg 587; L 696229; L 697661; R 86183; Mkc 442; U 90152; R 89439; Ly 300046

TI What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of **human immunodeficiency virus** type 1 (**HIV**-1) infections?.

SO Reviews in Medical Virology, (1996) Vol. 6, No. 2, pp. 97-117. .
ISSN: 1052-9276 CODEN: RMVIEW

CT Medical Descriptors:
***human immunodeficiency virus infection: ET, etiology**
***human immunodeficiency virus infection: DT, drug therapy**
*virus infection: PC, prevention
*virus infection: ET, etiology
*virus infection: DT, drug therapy
drug conformation
drug potentiation
drug resistance
drug structure
human
human immunodeficiency virus 1
nonhuman
review
simian virus
structure activity relation
virus inhibition
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside derivative: DT, drug therapy
*acyclic nucleoside: DT, drug therapy
*nucleoside derivative: DT, drug therapy
*proteinase inhibitor: DT, drug therapy
*rna directed dna polymerase inhibitor: AN, drug analysis
*rna directed dna polymerase inhibitor: DT, drug therapy
abacavir: DT, drug therapy
abacavir: DV, drug development

2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: DV, drug development
zalcitabine: DT, drug therapy
zalcitabine: IT, drug interaction
zalcitabine: CB, drug combination
didanosine: DT, drug therapy
didanosine: CB, drug combination
didanosine: IT, drug interaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: AN, drug analysis
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: CB, drug combination
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: IT, drug interaction
raluridine: DV, drug development
raluridine: DT, drug therapy
6 benzyl 1 ethoxymethyl 5 isopropyluracil: AN, drug analysis
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: IT, drug interaction
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: CB, drug combination
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: AN, drug analysis
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: DV, drug development
9 (2 phosphonylmethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonylmethoxypropyl)adenine: DV, drug development
adefovir: DT, drug therapy
adefovir: DV, drug development
anilide: DV, drug development
anilide: AN, drug analysis
benzimidazole derivative: DV, drug development
benzimidazole derivative: AN, drug analysis
delavirdine: CB, drug combination
delavirdine: AN, drug analysis
delavirdine: IT, drug interaction
diazepine derivative: AN, drug analysis
diazepine derivative: DV, drug development
dipivoxil: DT, drug therapy
dipivoxil: DV, drug development
lamivudine: DT, drug therapy
loviride: DV, drug development
loviride: AN, drug analysis
trovirdine: AN, drug analysis
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: IT, drug interaction
nevirapine: AN, drug analysis
oxathiin derivative: AN, drug analysis
oxathiin derivative: DV, drug development
quinoxaline derivative: DV, drug development
quinoxaline derivative: AN, drug analysis
stavudine: DT, drug therapy
trovirdine: DV, drug development
unindexed drug
zidovudine: DT, drug therapy
zidovudine: IT, drug interaction
zidovudine: CB, drug combination
unclassified drug

RN (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7,

143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone) 135525-71-2; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 137332-54-8; (adefovir) 106941-25-7; (delavirdine) 136817-59-9; (lamivudine) 134678-17-4, 134680-32-3; (loviride) 147362-57-0; (trovirdine) 148311-89-1, 149488-17-5; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trovirdine) 148311-89-1, 149488-17-5; (zidovudine) 30516-87-1

CT Medical Descriptors:
***human immunodeficiency virus infection: ET, etiology**
***human immunodeficiency virus infection: DT, drug therapy**
*virus infection: PC, prevention
*virus infection: ET, etiology
*virus infection: DT, drug therapy
drug conformation
drug potentiation
drug resistance
drug structure
human
human immunodeficiency virus 1
nonhuman
review
simian virus
structure activity relation
virus inhibition
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside derivative: DT, drug therapy
*acyclic nucleoside: DT, drug therapy
*nucleoside derivative: DT, drug therapy
*proteinase inhibitor: DT, drug therapy
*rna directed dna polymerase inhibitor: AN, drug analysis
*rna directed dna polymerase inhibitor: DT, drug therapy
abacavir: DT, drug therapy
abacavir: DV, drug development
2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: DV, drug development
zalcitabine: DT, drug therapy
zalcitabine: IT, drug interaction
zalcitabine: CB, drug combination
didanosine: DT, drug therapy
didanosine: CB, drug combination
didanosine: IT, drug interaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: AN, drug analysis
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: CB, drug combination
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone: IT, drug interaction
raluridine: DV, drug development
raluridine: DT, drug therapy
6 benzyl 1 ethoxymethyl 5 isopropyluracil: AN, drug analysis
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: IT, drug interaction
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: CB, drug combination
8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: AN, drug analysis

8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione: DV, drug development
9 (2 phosphonylmethoxypropyl)adenine: DT, drug therapy
9 (2 phosphonylmethoxypropyl)adenine: DV, drug development
adefovir: DT, drug therapy
adefovir: DV, drug development
anilide: DV, drug development
anilide: AN, drug analysis
benzimidazole derivative: DV, drug development
benzimidazole derivative: AN, drug analysis
delavirdine: CB, drug combination
delavirdine: AN, drug analysis
delavirdine: IT, drug interaction
diazepine derivative: AN, drug analysis
diazepine derivative: DV, drug development
dipivoxil: DT, drug therapy
dipivoxil: DV, drug development
lamivudine: DT, drug therapy
loviride: DV, drug development
loviride: AN, drug analysis
trovirdine: AN, drug analysis
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: IT, drug interaction
nevirapine: AN, drug analysis
oxathiin derivative: AN, drug analysis
oxathiin derivative: DV, drug development
quinoxaline derivative: DV, drug development
quinoxaline derivative: AN, drug analysis
stavudine: DT, drug therapy
trovirdine: DV, drug development
unindexed drug
zidovudine: DT, drug therapy
zidovudine: IT, drug interaction
zidovudine: CB, drug combination
unclassified drug

RN (proteinase inhibitor) 37205-61-1; (abacavir) 136470-78-5, 188062-50-2; (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3 [2 (2 benzoxazolyl)ethyl] 5 ethyl 6 methyl 2(1h) pyridone) 135525-71-2; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (8 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 137332-54-8; (adefovir) 106941-25-7; (delavirdine) 136817-59-9; (lamivudine) 134678-17-4, 134680-32-3; (loviride) 147362-57-0; (trovirdine) 148311-89-1, 149488-17-5; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trovirdine) 148311-89-1, 149488-17-5; (zidovudine) 30516-87-1

CN 935u83; 524w91; 1592u89; Bi rg 587; L 696229; L 697661; R 86183; Mkc 442; U 90152; R 89439; Ly 300046

L80 ANSWER 8 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 96238338 EMBASE Full-text
DOCUMENT NUMBER: 1996238338
TITLE: **AIDS** research highlights.
AUTHOR: Graul A.I.
SOURCE: Drug News and Perspectives, (1996) Vol. 9, No. 6, pp. 380-384. .
ISSN: 0214-0934 CODEN: DNPEED
COUNTRY: Spain
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 004 Microbiology
006 Internal Medicine

030 Pharmacology
037 Drug Literature Index

LANGUAGE: English

ENTRY DATE: Entered STN: 1 Oct 1996
Last Updated on STN: 1 Oct 1996

CONTROLLED TERM: Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
clinical research
clinical trial
conference paper
human
nonhuman
phase 1 clinical trial
phase 2 clinical trial
virus replication
Drug Descriptors:
***anti human immunodeficiency virus agent: DT, drug therapy**
***human immunodeficiency virus vaccine: DT, drug therapy**
***human immunodeficiency virus vaccine: CT, clinical trial**
*integrase: EC, endogenous compound
*monoclonal antibody
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: DT, drug therapy
didanosine: CB, drug combination
didanosine: CT, clinical trial
didanosine: DT, drug therapy
3 aminobenzamide: PD, pharmacology
3 aminobenzamide: CB, drug combination
raluridine: DT, drug therapy
raluridine: CB, drug combination
raluridine: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CB, drug combination
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: DT, drug therapy
acetylcysteine: CB, drug combination
acetylcysteine: PD, pharmacology
boromycin: PD, pharmacology
castanospermine 6 butyrate: CT, clinical trial
castanospermine 6 butyrate: DT, drug therapy
delavirdine: CT, clinical trial
delavirdine: DT, drug therapy
glycoprotein gp 120: EC, endogenous compound
gramicidin: PD, pharmacology
indinavir: CT, clinical trial
indinavir: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
lamivudine: CT, clinical trial
mdl 28574a
nelfinavir: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nevirapine: CT, clinical trial

nevirapine: DT, drug therapy
nevirapine: CB, drug combination
nonoxinol 9: DT, drug therapy
nonoxinol 9: CT, clinical trial
pentafuside: PD, pharmacology
pro 2000: DT, drug therapy
pro 2000: CT, clinical trial
ritonavir: DT, drug therapy
ritonavir: CT, clinical trial
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
spv 30: DT, drug therapy
spv 30: CT, clinical trial
stavudine: DT, drug therapy
stavudine: CT, clinical trial
stavudine: CB, drug combination
transactivator protein: EC, endogenous compound
unindexed drug
zidovudine: DT, drug therapy
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
t 20
unclassified drug

CAS REGISTRY NO.: (proteinase inhibitor) 37205-61-1; (didanosine) 69655-05-6; (3 aminobenzamide) 3544-24-9; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (acetylcysteine) 616-91-1; (boromycin) 34524-20-4; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (gramicidin) 1405-97-6; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (nonoxinol 9) 96827-50-8; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CHEMICAL NAME: (1) Invirase; (2) Norvir; (3) Crixivan; (4) Retrovir; (5) Mkc 442; (6) 935u83; (7) Mdl 28574a; (8) Spv 30; (9) Pro 2000; T 20

COMPANY NAME: (1) Hoffmann la roche; (2) Abbott; (3) Merck and co; (5) Mitsubishi; (6) Glaxo; (7) Hoechst; (8) Arkopharma (France); (9) Procept

TI **AIDS** research highlights.

SO Drug News and Perspectives, (1996) Vol. 9, No. 6, pp. 380-384. .
ISSN: 0214-0934 CODEN: DNPEED

CT Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
clinical research
clinical trial
conference paper
human
nonhuman
phase 1 clinical trial
phase 2 clinical trial
virus replication
Drug Descriptors:
***anti human immunodeficiency virus agent: DT, drug therapy**
***human immunodeficiency virus vaccine: DT, drug therapy**
***human immunodeficiency virus vaccine: CT, clinical trial**
*integrase: EC, endogenous compound
*monoclonal antibody
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: DT, drug therapy

didanosine: CB, drug combination
didanosine: CT, clinical trial
didanosine: DT, drug therapy
3 aminobenzamide: PD, pharmacology
3 aminobenzamide: CB, drug combination
raluridine: DT, drug therapy
raluridine: CB, drug combination
raluridine: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CB, drug combination
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: DT, drug therapy
acetylcysteine: CB, drug combination
acetylcysteine: PD, pharmacology
boromycin: PD, pharmacology
castanospermine 6 butyrate: CT, clinical trial
castanospermine 6 butyrate: DT, drug therapy
delavirdine: CT, clinical trial
delavirdine: DT, drug therapy
glycoprotein gp 120: EC, endogenous compound
gramicidin: PD, pharmacology
indinavir: CT, clinical trial
indinavir: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
lamivudine: CT, clinical trial
mdl 28574a
nelfinavir: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nevirapine: CT, clinical trial
nevirapine: DT, drug therapy
nevirapine: CB, drug combination
nonoxinol 9: DT, drug therapy
nonoxinol 9: CT, clinical trial
pentafuside: PD, pharmacology
pro 2000: DT, drug therapy
pro 2000: CT, clinical trial
ritonavir: DT, drug therapy
ritonavir: CT, clinical trial
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
spv 30: DT, drug therapy
spv 30: CT, clinical trial
stavudine: DT, drug therapy
stavudine: CT, clinical trial
stavudine: CB, drug combination
transactivator protein: EC, endogenous compound
unindexed drug
zidovudine: DT, drug therapy
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
t 20
unclassified drug

RN (proteinase inhibitor) 37205-61-1; (didanosine) 69655-05-6; (3 aminobenzamide) 3544-24-9; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (acetylcysteine) 616-91-1; (boromycin) 34524-20-4; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (gramicidin) 1405-97-6; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (nonoxinol 9) 96827-50-8; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CT Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity

clinical research
clinical trial
conference paper
human
nonhuman
phase 1 clinical trial
phase 2 clinical trial
virus replication
Drug Descriptors:
***anti human immunodeficiency virus agent: DT, drug therapy**
***human immunodeficiency virus vaccine: DT, drug therapy**
***human immunodeficiency virus vaccine: CT, clinical trial**
*integrase: EC, endogenous compound
*monoclonal antibody
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: CT, clinical trial
*rna directed dna polymerase inhibitor: DT, drug therapy
didanosine: CB, drug combination
didanosine: CT, clinical trial
didanosine: DT, drug therapy
3 aminobenzamide: PD, pharmacology
3 aminobenzamide: CB, drug combination
raluridine: DT, drug therapy
raluridine: CB, drug combination
raluridine: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CB, drug combination
6 benzyl 1 ethoxymethyl 5 isopropyluracil: CT, clinical trial
6 benzyl 1 ethoxymethyl 5 isopropyluracil: DT, drug therapy
acetylcysteine: CB, drug combination
acetylcysteine: PD, pharmacology
boromycin: PD, pharmacology
castanospermine 6 butyrate: CT, clinical trial
castanospermine 6 butyrate: DT, drug therapy
delavirdine: CT, clinical trial
delavirdine: DT, drug therapy
glycoprotein gp 120: EC, endogenous compound
gramicidin: PD, pharmacology
indinavir: CT, clinical trial
indinavir: DT, drug therapy
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
lamivudine: CT, clinical trial
mdl 28574a
nelfinavir: DT, drug therapy
nelfinavir: CT, clinical trial
nelfinavir: CB, drug combination
nevirapine: CT, clinical trial
nevirapine: DT, drug therapy
nevirapine: CB, drug combination
nonoxinol 9: DT, drug therapy
nonoxinol 9: CT, clinical trial
pentafuside: PD, pharmacology
pro 2000: DT, drug therapy
pro 2000: CT, clinical trial
ritonavir: DT, drug therapy
ritonavir: CT, clinical trial
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
spv 30: DT, drug therapy
spv 30: CT, clinical trial
stavudine: DT, drug therapy
stavudine: CT, clinical trial
stavudine: CB, drug combination
transactivator protein: EC, endogenous compound
unindexed drug
zidovudine: DT, drug therapy

zidovudine: CB, drug combination
zidovudine: CT, clinical trial
t 20
unclassified drug

RN (proteinase inhibitor) 37205-61-1; (didanosine) 69655-05-6; (3 aminobenzamide) 3544-24-9; (raluridine) **119644-22-3**; (6 benzyl 1 ethoxymethyl 5 isopropyluracil) 149950-60-7; (acetylcysteine) 616-91-1; (boromycin) 34524-20-4; (castanospermine 6 butyrate) 121104-96-9; (delavirdine) 136817-59-9; (gramicidin) 1405-97-6; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nelfinavir) 159989-64-7, 159989-65-8; (nevirapine) **129618-40-2**; (nonoxinol 9) 96827-50-8; (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CN (1) Invirase; (2) Norvir; (3) Crixivan; (4) Retrovir; (5) Mkc 442; (6) 935u83; (7) Mdl 28574a; (8) Spv 30; (9) Pro 2000; T 20

CO (1) Hoffmann la roche; (2) Abbott; (3) Merck and co; (5) Mitsubishi; (6) Glaxo; (7) Hoechst; (8) Arkopharma (France); (9) Procept

L80 ANSWER 9 OF 16 EMBASE

ACCESSION NUMBER: 96212034 EMBASE Full-text
DOCUMENT NUMBER: 1996212034
TITLE: [Adverse effects of antiretrovirals]. EFECTOS ADVERSOS DE LOS ANTIRRETROVIRALES.
AUTHOR: Salinas Rosillo C.; Arias Munoz M.J.; Fernandez Figares D.
CORPORATE SOURCE: Servicio Farmacia, Hospital Clinico San Cecilio,Granada, Spain
SOURCE: Farmacia Clinica, (1996) Vol. 13, No. 5, pp. 328-336. .
ISSN: 0212-6583 CODEN: FACLE2
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: Spanish
SUMMARY LANGUAGE: English; Spanish

ABSTRACT: The therapeutic arsenal of drugs currently used for the treatment of **human immunodeficiency virus** is continually growing in order to try and offset both the high number of resistances that have appeared and their adverse effects. Depending on their mechanism of action they may be divided into inverse transcriptase inhibitors, protease inhibitors recently approved by the FDA such as saquinavir and ritonavir, and transcription and translation inhibitors at all levels of the virus biological cycle. In this study we give prime consideration to their adverse effects, both in the case of authorized drugs and ones currently being researched.

CONTROLLED TERM: Medical Descriptors:
*adverse drug reaction: SI, side effect
*virus infection: DR, drug resistance
drug mechanism
drug resistance
human
immune deficiency
review
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*ritonavir: AE, adverse drug reaction
*saquinavir: AE, adverse drug reaction
zalcitabine: AE, adverse drug reaction
didanosine: AE, adverse drug reaction
3' fluorothymidine: AE, adverse drug reaction
acetylcysteine: AE, adverse drug reaction

alpha interferon: AE, adverse drug reaction
delavirdine: AE, adverse drug reaction
foscarnet: AE, adverse drug reaction
interleukin 2: AE, adverse drug reaction
lamivudine: AE, adverse drug reaction
n butyldeoxynojirimycin: AE, adverse drug reaction
nevirapine: AE, adverse drug reaction
stavudine: AE, adverse drug reaction
trichosanthin: AE, adverse drug reaction
zidovudine: AE, adverse drug reaction

CAS REGISTRY NO.: (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6**; (acetylcysteine) 616-91-1; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (interleukin 2) 85898-30-2; (lamivudine) 134678-17-4, 134680-32-3; (n butyldeoxynojirimycin) 72599-27-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1

CHEMICAL NAME: Glq 223

SO Farmacia Clinica, (1996) Vol. 13, No. 5, pp. 328-336. .
ISSN: 0212-6583 CODEN: FACLE2

AB The therapeutic arsenal of drugs currently used for the treatment of **human immunodeficiency virus** is continually growing in order to try and offset both the high number of resistances that have appeared and their adverse effects. Depending on their mechanism of action they may be divided into inverse transcriptase inhibitors, protease inhibitors recently approved by the FDA such as saquinavir and ritonavir, and transcription and translation inhibitors at all levels of the virus biological cycle. In this study we give prime consideration to their adverse effects, both in the case of authorized drugs and ones currently being researched.

RN (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6**; (acetylcysteine) 616-91-1; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (interleukin 2) 85898-30-2; (lamivudine) 134678-17-4, 134680-32-3; (n butyldeoxynojirimycin) 72599-27-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1

CT Medical Descriptors:
*adverse drug reaction: SI, side effect
*virus infection: DR, drug resistance
drug mechanism
drug resistance
human
immune deficiency
review
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*ritonavir: AE, adverse drug reaction
*saquinavir: AE, adverse drug reaction
zalcitabine: AE, adverse drug reaction
didanosine: AE, adverse drug reaction
3' fluorothymidine: AE, adverse drug reaction
acetylcysteine: AE, adverse drug reaction
alpha interferon: AE, adverse drug reaction
delavirdine: AE, adverse drug reaction
foscarnet: AE, adverse drug reaction
interleukin 2: AE, adverse drug reaction
lamivudine: AE, adverse drug reaction
n butyldeoxynojirimycin: AE, adverse drug reaction
nevirapine: AE, adverse drug reaction
stavudine: AE, adverse drug reaction
trichosanthin: AE, adverse drug reaction
zidovudine: AE, adverse drug reaction

RN (ritonavir) 155213-67-5; (saquinavir) 127779-20-8; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6**; (acetylcysteine) 616-91-1; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (interleukin 2) 85898-30-2;

(lamivudine) 134678-17-4, 134680-32-3; (n butyldeoxynojirimycin) 72599-27-0; (nevirapine) **129618-40-2**; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1
CN Glq 223

L80 ANSWER 10 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 96130491 EMBASE Full-text
DOCUMENT NUMBER: 1996130491
TITLE: New initiatives in combination antiretroviral chemotherapy.
AUTHOR: Rooney J.F.; Warwick J.C.; Elkins M.M.; St. Clair M.H.; Barry D.W.
CORPORATE SOURCE: Department of Infectious Diseases, Burroughs Wellcome Co.,Research Triangle Park, NC, United States
SOURCE: Advances in Experimental Medicine and Biology, (1996) Vol. 394, pp. 373-382. .
ISSN: 0065-2598 CODEN: AEMBAP
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 004 Microbiology
006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 29 May 1996
Last Updated on STN: 29 May 1996
CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
clinical protocol
clinical trial
conference paper
controlled study
drug choice
drug efficacy
human
human immunodeficiency virus
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
priority journal
treatment outcome
virus inhibition
Drug Descriptors:
***anti human immunodeficiency virus agent: PD, pharmacology**
***anti human immunodeficiency virus agent: CB, drug combination**
***anti human immunodeficiency virus agent: CM, drug comparison**
***anti human immunodeficiency virus agent: CT, clinical trial**
***anti human immunodeficiency virus agent: DV, drug development**
***anti human immunodeficiency virus agent: DT, drug therapy**
2',3' dideoxy 5 fluoro 3' thiacytidine: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: PD, pharmacology
zalcitabine: DT, drug therapy
zalcitabine: CT, clinical trial

zalcitabine: CB, drug combination
zalcitabine: CM, drug comparison
didanosine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: CM, drug comparison
didanosine: CB, drug combination
raluridine: PD, pharmacology
raluridine: CT, clinical trial
raluridine: DT, drug therapy
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: CT, clinical trial
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: PD, pharmacology
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: DT, drug therapy
abacavir: PD, pharmacology
abacavir: DT, drug therapy
abacavir: CT, clinical trial
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
lamivudine: CT, clinical trial
lamivudine: DT, drug therapy
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: DT, drug therapy
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PD, pharmacology
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: CM, drug comparison
saquinavir: CT, clinical trial
tucaresol: CT, clinical trial
tucaresol: PD, pharmacology
tucaresol: DT, drug therapy
zidovudine: DT, drug therapy
zidovudine: CM, drug comparison
zidovudine: CB, drug combination
zidovudine: CT, clinical trial

CAS REGISTRY NO.: (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide) 161814-49-9; (abacavir) 136470-78-5, 188062-50-2; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (proteinase inhibitor) 37205-61-1; (saquinavir) 127779-20-8; (tucaresol) 84290-27-7; (zidovudine) 30516-87-1

CHEMICAL NAME: (1) Bw 935u83; (2) Bw 524w91; (3) Bw 589c80; (4) Vx 478; (5) Bw 1592u89; (6) Bw 141w94

COMPANY NAME: (4) Vertex; (6) Burroughs wellcome

SO Advances in Experimental Medicine and Biology, (1996) Vol. 394, pp. 373-382. .
ISSN: 0065-2598 CODEN: AEMBAP

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
clinical protocol

clinical trial
conference paper
controlled study
drug choice
drug efficacy
human
human immunodeficiency virus
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
priority journal
treatment outcome
virus inhibition
Drug Descriptors:
***anti human immunodeficiency virus agent: PD, pharmacology**
***anti human immunodeficiency virus agent: CB, drug combination**
***anti human immunodeficiency virus agent: CM, drug comparison**
***anti human immunodeficiency virus agent: CT, clinical trial**
***anti human immunodeficiency virus agent: DV, drug development**
***anti human immunodeficiency virus agent: DT, drug therapy**
2',3' dideoxy 5 fluoro 3' thiacytidine: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: PD, pharmacology
zalcitabine: DT, drug therapy
zalcitabine: CT, clinical trial
zalcitabine: CB, drug combination
zalcitabine: CM, drug comparison
didanosine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: CM, drug comparison
didanosine: CB, drug combination
raluridine: PD, pharmacology
raluridine: CT, clinical trial
raluridine: DT, drug therapy
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: CT, clinical trial
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: PD, pharmacology
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: DT, drug therapy
abacavir: PD, pharmacology
abacavir: DT, drug therapy
abacavir: CT, clinical trial
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
lamivudine: CT, clinical trial
lamivudine: DT, drug therapy
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: DT, drug therapy
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PD, pharmacology
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: CM, drug comparison

saquinavir: CT, clinical trial
tucaresol: CT, clinical trial
tucaresol: PD, pharmacology
tucaresol: DT, drug therapy
zidovudine: DT, drug therapy
zidovudine: CM, drug comparison
zidovudine: CB, drug combination
zidovudine: CT, clinical trial

RN (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide) 161814-49-9; (abacavir) 136470-78-5, 188062-50-2; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (proteinase inhibitor) 37205-61-1; (saquinavir) 127779-20-8; (tucaresol) 84290-27-7; (zidovudine) 30516-87-1

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
clinical protocol
clinical trial
conference paper
controlled study
drug choice
drug efficacy
human
human immunodeficiency virus
phase 1 clinical trial
phase 2 clinical trial
phase 3 clinical trial
priority journal
treatment outcome
virus inhibition
Drug Descriptors:
***anti human immunodeficiency virus agent: PD, pharmacology**
***anti human immunodeficiency virus agent: CB, drug combination**
***anti human immunodeficiency virus agent: CM, drug comparison**
***anti human immunodeficiency virus agent: CT, clinical trial**
***anti human immunodeficiency virus agent: DV, drug development**
***anti human immunodeficiency virus agent: DT, drug therapy**
2',3' dideoxy 5 fluoro 3' thiacytidine: CT, clinical trial
2',3' dideoxy 5 fluoro 3' thiacytidine: DT, drug therapy
2',3' dideoxy 5 fluoro 3' thiacytidine: PD, pharmacology
zalcitabine: DT, drug therapy
zalcitabine: CT, clinical trial
zalcitabine: CB, drug combination
zalcitabine: CM, drug comparison
didanosine: CT, clinical trial
didanosine: DT, drug therapy
didanosine: CM, drug comparison
didanosine: CB, drug combination
raluridine: PD, pharmacology
raluridine: CT, clinical trial
raluridine: DT, drug therapy
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: CT, clinical trial
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: PD, pharmacology
4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide: DT, drug

therapy
abacavir: PD, pharmacology
abacavir: DT, drug therapy
abacavir: CT, clinical trial
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
lamivudine: CT, clinical trial
lamivudine: DT, drug therapy
nevirapine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CT, clinical trial
nucleoside analog: PD, pharmacology
nucleoside analog: CT, clinical trial
nucleoside analog: DT, drug therapy
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PD, pharmacology
saquinavir: CB, drug combination
saquinavir: DT, drug therapy
saquinavir: CM, drug comparison
saquinavir: CT, clinical trial
tucaresol: CT, clinical trial
tucaresol: PD, pharmacology
tucaresol: DT, drug therapy
zidovudine: DT, drug therapy
zidovudine: CM, drug comparison
zidovudine: CB, drug combination
zidovudine: CT, clinical trial

RN (2',3' dideoxy 5 fluoro 3' thiacytidine) 137530-41-7, 143491-54-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (4 amino n [2 hydroxy 4 phenyl 3 (tetrahydrofuran 3 yloxycarbonylamino)butyl] n isobutylbenzenesulfonamide) 161814-49-9; (abacavir) 136470-78-5, 188062-50-2; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (proteinase inhibitor) 37205-61-1; (saquinavir) 127779-20-8; (tucaresol) 84290-27-7; (zidovudine) 30516-87-1

CN (1) Bw 935u83; (2) Bw 524w91; (3) Bw 589c80; (4) Vx 478; (5) Bw 1592u89; (6) Bw 141w94

CO (4) Vertex; (6) Burroughs wellcome

L80 ANSWER 11 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 96071473 EMBASE Full-text
DOCUMENT NUMBER: 1996071473
TITLE: Rapid screening of antiretroviral combinations.
AUTHOR: St. Clair M.; Pennington K.N.; Rooney J.; Barry D.W.
CORPORATE SOURCE: Department of Virology, Burroughs Wellcome Co., 3030 Cornwallis Road,Res. Triangle Park, NC 27709-4498, United States
SOURCE: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, (1995) Vol. 10, No. SUPPL. 1, pp. S24-S27.
ISSN: 1077-9450 CODEN: JDSRET
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 Mar 1996
Last Updated on STN: 19 Mar 1996

ABSTRACT: Increasing evidence supports the view that therapy with combinations of antiretroviral drugs provides greater and more

sustained benefits in the treatment of **HIV** infection than either monotherapy or sequential therapy. As the number of licensed and developmental antiretroviral agents grows, in vitro analysis is increasingly being used to aid in the selection of effective combinations. An assay has been designed to ascertain the inhibitory action of drug combinations on **HIV**-infected MT4 cells, allowing rapid evaluation of those that may be of use in the clinic. Manipulation of this system also provides data on the efficacy of drugs under conditions of high viral load and against resistant strains, providing valuable information for the treatment of antiretroviral-experienced patients with advanced disease.

CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
article
concentration response
controlled study
drug choice
drug efficacy
drug screening
human
human cell
in vitro study
priority journal
Drug Descriptors:
*antivirus agent: CB, drug combination
*antivirus agent: CM, drug comparison
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
didanosine: DT, drug therapy
didanosine: DO, drug dose
didanosine: CM, drug comparison
didanosine: CB, drug combination
didanosine: PD, pharmacology
raluridine: CM, drug comparison
raluridine: DO, drug dose
raluridine: DT, drug therapy
raluridine: PD, pharmacology
foscarnet: DT, drug therapy
indinavir: CB, drug combination
indinavir: DO, drug dose
indinavir: PD, pharmacology
indinavir: DT, drug therapy
indinavir: CM, drug comparison
interferon: DT, drug therapy
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
lamivudine: DO, drug dose
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CB, drug combination
nevirapine: DO, drug dose
nevirapine: PD, pharmacology
ribavirin: DT, drug therapy
saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: DT, drug therapy

saquinavir: PD, pharmacology
saquinavir: CB, drug combination
stavudine: DT, drug therapy
zidovudine: PD, pharmacology
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy

CAS REGISTRY NO.: (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (foscarnet) 4428-95-9; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CHEMICAL NAME: (1) Mk 639; (2) L 735524; 935u83

COMPANY NAME: (2) Merck

SO Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, (1995) Vol. 10, No. SUPPL. 1, pp. S24-S27. .
ISSN: 1077-9450 CODEN: JDSRET

AB Increasing evidence supports the view that therapy with combinations of antiretroviral drugs provides greater and more sustained benefits in the treatment of **HIV** infection than either monotherapy or sequential therapy. As the number of licensed and developmental antiretroviral agents grows, in vitro analysis is increasingly being used to aid in the selection of effective combinations. An assay has been designed to ascertain the inhibitory action of drug combinations on **HIV** -infected MT4 cells, allowing rapid evaluation of those that may be of use in the clinic. Manipulation of this system also provides data on the efficacy of drugs under conditions of high viral load and against resistant strains, providing valuable information for the treatment of antiretroviral-experienced patients with advanced disease.

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
article
concentration response
controlled study
drug choice
drug efficacy
drug screening
human
human cell
in vitro study
priority journal
Drug Descriptors:
*antivirus agent: CB, drug combination
*antivirus agent: CM, drug comparison
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
didanosine: DT, drug therapy
didanosine: DO, drug dose
didanosine: CM, drug comparison
didanosine: CB, drug combination
didanosine: PD, pharmacology
raluridine: CM, drug comparison
raluridine: DO, drug dose
raluridine: DT, drug therapy
raluridine: PD, pharmacology
foscarnet: DT, drug therapy
indinavir: CB, drug combination
indinavir: DO, drug dose
indinavir: PD, pharmacology

indinavir: DT, drug therapy
indinavir: CM, drug comparison
interferon: DT, drug therapy
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
lamivudine: DO, drug dose
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CB, drug combination
nevirapine: DO, drug dose
nevirapine: PD, pharmacology
ribavirin: DT, drug therapy
saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: DT, drug therapy
saquinavir: PD, pharmacology
saquinavir: CB, drug combination
stavudine: DT, drug therapy
zidovudine: PD, pharmacology
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy

RN (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (foscarnet) 4428-95-9; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
antiviral activity
article
concentration response
controlled study
drug choice
drug efficacy
drug screening
human
human cell
in vitro study
priority journal
Drug Descriptors:
*antivirus agent: CB, drug combination
*antivirus agent: CM, drug comparison
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
didanosine: DT, drug therapy
didanosine: DO, drug dose
didanosine: CM, drug comparison
didanosine: CB, drug combination
didanosine: PD, pharmacology
raluridine: CM, drug comparison
raluridine: DO, drug dose
raluridine: DT, drug therapy
raluridine: PD, pharmacology
foscarnet: DT, drug therapy
indinavir: CB, drug combination
indinavir: DO, drug dose

indinavir: PD, pharmacology
indinavir: DT, drug therapy
indinavir: CM, drug comparison
interferon: DT, drug therapy
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
lamivudine: DO, drug dose
lamivudine: CM, drug comparison
lamivudine: CB, drug combination
nevirapine: DT, drug therapy
nevirapine: CM, drug comparison
nevirapine: CB, drug combination
nevirapine: DO, drug dose
nevirapine: PD, pharmacology
ribavirin: DT, drug therapy
saquinavir: CM, drug comparison
saquinavir: DO, drug dose
saquinavir: DT, drug therapy
saquinavir: PD, pharmacology
saquinavir: CB, drug combination
stavudine: DT, drug therapy
zidovudine: PD, pharmacology
zidovudine: CB, drug combination
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy

RN (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (raluridine) **119644-22-3**; (foscarnet) 4428-95-9; (indinavir) 150378-17-9, 157810-81-6; (lamivudine) 134678-17-4, 134680-32-3; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (saquinavir) 127779-20-8; (stavudine) 3056-17-5; (zidovudine) 30516-87-1

CN (1) Mk 639; (2) L 735524; 935u83

CO (2) Merck

L80 ANSWER 12 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 94295946 EMBASE Full-text
DOCUMENT NUMBER: 1994295946
TITLE: Agents for treating **human immunodeficiency virus** infection.
AUTHOR: Acosta E.P.; Fletcher C.V.
CORPORATE SOURCE: Department of Pharmacy Practice, University of Minnesota, 7-115 Health Sciences Unit, 308 Harvard Street, S.E.,Minneapolis, MN 55455, United States
SOURCE: American Journal of Hospital Pharmacy, (1994) Vol. 51, No. 18, pp. 2251-2267+2286-2287. .
ISSN: 0002-9289 CODEN: AJHPA
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 Oct 1994
Last Updated on STN: 19 Oct 1994

ABSTRACT: The replicative cycle of the **human** ***immunodeficiency*** **virus (HIV)** is reviewed,
and currently used and investigational agents directed against the virus are discussed. The first step in the replication of **HIV** is selective binding of the envelope glycoprotein to CD4 receptors located on T lymphocytes. The virion is then uncoated within the cytoplasm, yielding viral genomic RNA. Reverse transcriptase uses the viral RNA as a template to form single-stranded DNA, which is duplicated to form proviral DNA through the activity of ribonuclease H.

Host RNA polymerases transcribe the integrated proviral DNA into messenger RNA, and there is subsequent translation to viral proteins. After translation, further modification of precursor polyproteins is necessary to produce functional peptides. The assembled virus then buds from the cell surface and invades other cells. Targets of drug intervention in the replicative cycle include (1) binding and entry, (2) reverse transcriptase, (3) transcription and translation, and (4) viral maturation and budding. Inhibitors of binding and entry include recombinant soluble CD4, immunoadhesins, peptide T, and hypericin. Nucleoside reverse-transcriptase inhibitors include zidovudine, didanosine, zalcitabine, and stavudine. Foscarnet, tetrahydroimidazobenzo-diazepinthione compounds, and nevirapine are some non-nucleoside reverse-transcriptase inhibitors. Inhibitors of transcription and translation include antagonists of the tat gene and GLQ223. Castanospermine, N-butyldeoxynojirimycin, and protease inhibitors interfere with viral maturation and budding. Drug combinations that have been or are being investigated include zidovudine plus interferon alfa, zidovudine plus zalcitabine, and zidovudine plus didanosine. Four agents currently have approved labeling for use against **HIV** infection: zidovudine, didanosine, zalcitabine, and stavudine. Monotherapy with zidovudine remains the treatment of first choice. Although progress has been made in developing drug therapies for **HIV** infection, more selective and more potent drugs are urgently needed. The best approach at present is to optimize the use of available agents, continue to investigate new therapies, and educate the public about prevention.

CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: DT, drug therapy**
anemia: SI, side effect
blood toxicity: SI, side effect
diarrhea: SI, side effect
drug design
drug mechanism
flatulence: SI, side effect
human
kidney disease: SI, side effect
neutropenia: SI, side effect
pancreatitis: SI, side effect
peripheral neuropathy: SI, side effect
priority journal
review
virus replication
virus transcription
Drug Descriptors:
*3' fluorothymidine: PD, pharmacology
*3' fluorothymidine: DO, drug dose
*3' fluorothymidine: AE, adverse drug reaction
*3' fluorothymidine: CT, clinical trial
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: PD, pharmacology
*antivirus agent: DT, drug therapy
*lamivudine: CT, clinical trial
zalcitabine: PD, pharmacology
zalcitabine: CT, clinical trial
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: PK, pharmacokinetics
didanosine: PD, pharmacology
didanosine: CT, clinical trial
didanosine: CB, drug combination
didanosine: DO, drug dose

didanosine: AE, adverse drug reaction
didanosine: DT, drug therapy
didanosine: PK, pharmacokinetics
9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine
alpha interferon: CB, drug combination
azidouridine: DT, drug therapy
azidouridine: PD, pharmacology
castanospermine: PK, pharmacokinetics
castanospermine: AE, adverse drug reaction
castanospermine: CT, clinical trial
castanospermine: DO, drug dose
castanospermine: PD, pharmacology
cd4 antigen: PD, pharmacology
cd4 antigen: CT, clinical trial
delavirdine
foscarnet: DO, drug dose
foscarnet: PD, pharmacology
foscarnet: PK, pharmacokinetics
foscarnet: DT, drug therapy
foscarnet: AE, adverse drug reaction
glycoprotein gp 120: EC, endogenous compound
hypericin: CT, clinical trial
hypericin: PD, pharmacology
immunoadhesin: DT, drug therapy
immunoadhesin: CT, clinical trial
immunoadhesin: PD, pharmacology
indinavir
n butyldeoxynojirimycin: PK, pharmacokinetics
n butyldeoxynojirimycin: CT, clinical trial
n butyldeoxynojirimycin: AE, adverse drug reaction
n butyldeoxynojirimycin: DO, drug dose
n butyldeoxynojirimycin: PD, pharmacology
saquinavir: CT, clinical trial
nevirapine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: DO, drug dose
nevirapine: CB, drug combination
peptide t: CT, clinical trial
peptide t: PD, pharmacology
r 18893
rna directed dna polymerase: EC, endogenous compound
sc 49483
telinavir
stavudine: PD, pharmacology
stavudine: PK, pharmacokinetics
stavudine: DO, drug dose
stavudine: CT, clinical trial
stavudine: DT, drug therapy
tibo derivative: PD, pharmacology
trichosanthin: CT, clinical trial
trichosanthin: DO, drug dose
trichosanthin: PD, pharmacology
trichosanthin: DT, drug therapy
trichosanthin: PK, pharmacokinetics
zidovudine: PD, pharmacology
zidovudine: PK, pharmacokinetics
zidovudine: DT, drug therapy
zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
zidovudine: AE, adverse drug reaction

l 735525
unclassified drug

CAS REGISTRY NO.: (3' fluorothymidine) **25526-93-6**; (lamivudine) 134678-17-4, 134680-32-3; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 126347-69-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (castanospermine) 79831-76-8; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (n butyldeoxynojirimycin) 72599-27-0; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (rna directed dna polymerase) 37213-50-6, 9068-38-6; (telinavir) 143224-34-4; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1

CHEMICAL NAME: (1) Glq 223; (2) Sc 52151; (3) L 735525; Ro 24 7429; Sc 49483; L 735524; Ro 31 8959; R 82913; R 18893; Sc 48334

COMPANY NAME: (1) Genelabs; (2) Searle; (3) Merck; Upjohn; Bristol myers squibb; Burroughs wellcome; Astra; Glaxo; Boehringer ingelheim; Hoffmann la roche

TI Agents for treating **human immunodeficiency virus** infection.

SO American Journal of Hospital Pharmacy, (1994) Vol. 51, No. 18, pp. 2251-2267+2286-2287.
ISSN: 0002-9289 CODEN: AJHPA

AB The replicative cycle of the **human immunodeficiency virus** (**HIV**) is reviewed, and currently used and investigational agents directed against the virus are discussed. The first step in the replication of **HIV** is selective binding of the envelope glycoprotein to CD4 receptors located on T lymphocytes. The virion is then uncoated within the cytoplasm, yielding viral genomic RNA. Reverse transcriptase uses the viral RNA as a template to form single-stranded DNA, which is duplicated to form proviral DNA through the activity of ribonuclease H. Host RNA polymerases transcribe the integrated proviral DNA into messenger RNA, and there is subsequent translation to viral proteins. After translation, further modification of precursor polyproteins is necessary to produce functional peptides. The assembled virus then buds from the cell surface and invades other cells. Targets of drug intervention in the replicative cycle include (1) binding and entry, (2) reverse transcriptase, (3) transcription and translation, and (4) viral maturation and budding. Inhibitors of binding and entry include recombinant soluble CD4, immunoadhesins, peptide T, and hypericin. Nucleoside reverse-transcriptase inhibitors include zidovudine, didanosine, zalcitabine, and stavudine. Foscarnet, tetrahydroimidazobenzo-diazepinthione compounds, and nevirapine are some non-nucleoside reverse-transcriptase inhibitors. Inhibitors of transcription and translation include antagonists of the tat gene and GLQ223. Castanospermine, N-butyldeoxynojirimycin, and protease inhibitors interfere with viral maturation and budding. Drug combinations that have been or are being investigated include zidovudine plus interferon alfa, zidovudine plus zalcitabine, and zidovudine plus didanosine. Four agents currently have approved labeling for use against **HIV** infection: zidovudine, didanosine, zalcitabine, and stavudine. Monotherapy with zidovudine remains the treatment of first choice. Although progress has been made in developing drug therapies for **HIV** infection, more selective and more potent drugs are urgently needed. The best approach at present is to optimize the use of available agents, continue to investigate new therapies, and educate the public about prevention.

CT Medical Descriptors:
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: DT, drug therapy**
anemia: SI, side effect
blood toxicity: SI, side effect
diarrhea: SI, side effect
drug design
drug mechanism
flatulence: SI, side effect
human
kidney disease: SI, side effect

neutropenia: SI, side effect
pancreatitis: SI, side effect
peripheral neuropathy: SI, side effect
priority journal
review
virus replication
virus transcription
Drug Descriptors:
*3' fluorothymidine: PD, pharmacology
*3' fluorothymidine: DO, drug dose
*3' fluorothymidine: AE, adverse drug reaction
*3' fluorothymidine: CT, clinical trial
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: PD, pharmacology
*antivirus agent: DT, drug therapy
*lamivudine: CT, clinical trial
zalcitabine: PD, pharmacology
zalcitabine: CT, clinical trial
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: PK, pharmacokinetics
didanosine: PD, pharmacology
didanosine: CT, clinical trial
didanosine: CB, drug combination
didanosine: DO, drug dose
didanosine: AE, adverse drug reaction
didanosine: DT, drug therapy
didanosine: PK, pharmacokinetics
9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine
alpha interferon: CB, drug combination
azidouridine: DT, drug therapy
azidouridine: PD, pharmacology
castanospermine: PK, pharmacokinetics
castanospermine: AE, adverse drug reaction
castanospermine: CT, clinical trial
castanospermine: DO, drug dose
castanospermine: PD, pharmacology
cd4 antigen: PD, pharmacology
cd4 antigen: CT, clinical trial
delavirdine
foscarnet: DO, drug dose
foscarnet: PD, pharmacology
foscarnet: PK, pharmacokinetics
foscarnet: DT, drug therapy
foscarnet: AE, adverse drug reaction
glycoprotein gp 120: EC, endogenous compound
hypericin: CT, clinical trial
hypericin: PD, pharmacology
immunoadhesin: DT, drug therapy
immunoadhesin: CT, clinical trial
immunoadhesin: PD, pharmacology
indinavir
n butyldeoxynojirimycin: PK, pharmacokinetics
n butyldeoxynojirimycin: CT, clinical trial
n butyldeoxynojirimycin: AE, adverse drug reaction
n butyldeoxynojirimycin: DO, drug dose
n butyldeoxynojirimycin: PD, pharmacology
saquinavir: CT, clinical trial
nevirapine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: DO, drug dose

nevirapine: CB, drug combination
peptide t: CT, clinical trial
peptide t: PD, pharmacology
r 18893
rna directed dna polymerase: EC, endogenous compound
sc 49483
telinavir
stavudine: PD, pharmacology
stavudine: PK, pharmacokinetics
stavudine: DO, drug dose
stavudine: CT, clinical trial
stavudine: DT, drug therapy
tibo derivative: PD, pharmacology
trichosanthin: CT, clinical trial
trichosanthin: DO, drug dose
trichosanthin: PD, pharmacology
trichosanthin: DT, drug therapy
trichosanthin: PK, pharmacokinetics
zidovudine: PD, pharmacology
zidovudine: PK, pharmacokinetics
zidovudine: DT, drug therapy
zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
zidovudine: AE, adverse drug reaction
l 735525
unclassified drug

RN (3' fluorothymidine) **25526-93-6**; (lamivudine) 134678-17-4, 134680-32-3; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 126347-69-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (castanospermine) 79831-76-8; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (n butyldeoxynojirimycin) 72599-27-0; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (rna directed dna polymerase) 37213-50-6, 9068-38-6; (telinavir) 143224-34-4; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1

CT Medical Descriptors:
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: DT, drug therapy**
anemia: SI, side effect
blood toxicity: SI, side effect
diarrhea: SI, side effect
drug design
drug mechanism
flatulence: SI, side effect
human
kidney disease: SI, side effect
neutropenia: SI, side effect
pancreatitis: SI, side effect
peripheral neuropathy: SI, side effect
priority journal
review
virus replication
virus transcription
Drug Descriptors:
*3' fluorothymidine: PD, pharmacology
*3' fluorothymidine: DO, drug dose
*3' fluorothymidine: AE, adverse drug reaction
*3' fluorothymidine: CT, clinical trial
*antivirus agent: DV, drug development
*antivirus agent: DO, drug dose
*antivirus agent: PD, pharmacology
*antivirus agent: DT, drug therapy

*lamivudine: CT, clinical trial
zalcitabine: PD, pharmacology
zalcitabine: CT, clinical trial
zalcitabine: CB, drug combination
zalcitabine: DO, drug dose
zalcitabine: DT, drug therapy
zalcitabine: PK, pharmacokinetics
didanosine: PD, pharmacology
didanosine: CT, clinical trial
didanosine: CB, drug combination
didanosine: DO, drug dose
didanosine: AE, adverse drug reaction
didanosine: DT, drug therapy
didanosine: PK, pharmacokinetics
9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine
alpha interferon: CB, drug combination
azidouridine: DT, drug therapy
azidouridine: PD, pharmacology
castanospermine: PK, pharmacokinetics
castanospermine: AE, adverse drug reaction
castanospermine: CT, clinical trial
castanospermine: DO, drug dose
castanospermine: PD, pharmacology
cd4 antigen: PD, pharmacology
cd4 antigen: CT, clinical trial
delavirdine
foscarnet: DO, drug dose
foscarnet: PD, pharmacology
foscarnet: PK, pharmacokinetics
foscarnet: DT, drug therapy
foscarnet: AE, adverse drug reaction
glycoprotein gp 120: EC, endogenous compound
hypericin: CT, clinical trial
hypericin: PD, pharmacology
immunoadhesin: DT, drug therapy
immunoadhesin: CT, clinical trial
immunoadhesin: PD, pharmacology
indinavir
n butyldeoxynojirimycin: PK, pharmacokinetics
n butyldeoxynojirimycin: CT, clinical trial
n butyldeoxynojirimycin: AE, adverse drug reaction
n butyldeoxynojirimycin: DO, drug dose
n butyldeoxynojirimycin: PD, pharmacology
saquinavir: CT, clinical trial
nevirapine: CT, clinical trial
nevirapine: PD, pharmacology
nevirapine: DT, drug therapy
nevirapine: DO, drug dose
nevirapine: CB, drug combination
peptide t: CT, clinical trial
peptide t: PD, pharmacology
r 18893
rna directed dna polymerase: EC, endogenous compound
sc 49483
telinavir
stavudine: PD, pharmacology
stavudine: PK, pharmacokinetics
stavudine: DO, drug dose
stavudine: CT, clinical trial
stavudine: DT, drug therapy
tibo derivative: PD, pharmacology
trichosanthin: CT, clinical trial
trichosanthin: DO, drug dose
trichosanthin: PD, pharmacology

trichosanthin: DT, drug therapy
trichosanthin: PK, pharmacokinetics
zidovudine: PD, pharmacology
zidovudine: PK, pharmacokinetics
zidovudine: DT, drug therapy
zidovudine: DO, drug dose
zidovudine: CB, drug combination
zidovudine: CT, clinical trial
zidovudine: AE, adverse drug reaction
l 735525
unclassified drug

RN (3' fluorothymidine) **25526-93-6**; (lamivudine) 134678-17-4, 134680-32-3; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (9 chloro 4,5,6,7 tetrahydro 5 methyl 6 (3 methyl 2 butenyl)imidazo[4,5,1 jk][1,4]benzodiazepine 2(1h) thione) 126347-69-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (castanospermine) 79831-76-8; (delavirdine) 136817-59-9; (foscarnet) 4428-95-9; (hypericin) 548-04-9; (indinavir) 150378-17-9, 157810-81-6; (n butyldeoxynojirimycin) 72599-27-0; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (rna directed dna polymerase) 37213-50-6, 9068-38-6; (telinavir) 143224-34-4; (stavudine) 3056-17-5; (trichosanthin) 60318-52-7; (zidovudine) 30516-87-1

CN (1) Glq 223; (2) Sc 52151; (3) L 735525; Ro 24 7429; Sc 49483; L 735524; Ro 31 8959; R 82913; R 18893; Sc 48334

CO (1) Genelabs; (2) Searle; (3) Merck; Upjohn; Bristol myers squibb; Burroughs wellcome; Astra; Glaxo; Boehringer ingelheim; Hoffmann la roche

L80 ANSWER 13 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93275483 EMBASE Full-text
DOCUMENT NUMBER: 1993275483
TITLE: [**Antiviral** drugs].
WIRKUNG ANTIVIRALER SUBSTANZEN.
AUTHOR: Rubsamen-Waigmann H.; Pfutzner A.; Biesert L.
CORPORATE SOURCE: Chemotherapeutisches, Forschungsinstitut, Paul-Ehrlich-Strasse 42-44,60596 Frankfurt, Germany
SOURCE: Immunitat und Infektion, (1993) Vol. 21, No. 4, pp. 106-110. .
ISSN: 0340-1162 CODEN: IMINDI
COUNTRY: Germany
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 004 Microbiology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: German
SUMMARY LANGUAGE: English; German
ENTRY DATE: Entered STN: 17 Oct 1993
Last Updated on STN: 17 Oct 1993
CONTROLLED TERM: Medical Descriptors:
***antiviral activity**
***human immunodeficiency virus infection: DT, drug therapy**
human
inhalational drug administration
intravenous drug administration
oral drug administration
short survey
topical drug administration
virus infection
Drug Descriptors:
*antivirus agent: PD, pharmacology
*antivirus agent: DV, drug development
*antivirus agent: CM, drug comparison
*zidovudine: PD, pharmacology

*zidovudine: CM, drug comparison
*zidovudine: DV, drug development
lamivudine: DV, drug development
2',3' dideoxyadenosine: DV, drug development
zalcitabine: DV, drug development
didanosine: DV, drug development
3' fluorothymidine: DV, drug development
a 75925: DV, drug development
aciclovir: DT, drug therapy
alpha interferon: DV, drug development
amantadine: DT, drug therapy
bay 946: DV, drug development
castanospermine: DV, drug development
dextran sulfate: DV, drug development
foscarnet: DV, drug development
ganciclovir: DT, drug therapy
hypericin: DV, drug development
idoxuridine: DT, drug therapy
saquinavir: DV, drug development
nevirapine: DV, drug development
ribavirin: DV, drug development
ribavirin: DT, drug therapy
rimantadine: DT, drug therapy
sr 41476: DV, drug development
trifluridine: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
unindexed drug
vidarabine: DT, drug therapy
unclassified drug

CAS REGISTRY NO.: (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (2',3' dideoxyadenosine) 4097-22-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6**; (aciclovir) 59277-89-3; (amantadine) 665-66-7, 768-94-5; (castanospermine) 79831-76-8; (dextran sulfate) 9011-18-1, 9042-14-2; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (hypericin) 548-04-9; (idoxuridine) 54-42-2; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (rimantadine) 13392-28-4, 1501-84-4; (trifluridine) 70-00-8; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (vidarabine) 2006-02-2, 5536-17-4

CHEMICAL NAME: Retrovir; U 75875; Ro 31 8959; Bch 189; Nevirapine; A 75925; Sr 41476

TI [**Antiviral** drugs].
WIRKUNG ANTIVIRALER SUBSTANZEN.

SO Immunitat und Infektion, (1993) Vol. 21, No. 4, pp. 106-110. .
ISSN: 0340-1162 CODEN: IMINDI

CT Medical Descriptors:
***antiviral activity**
***human immunodeficiency virus infection: DT, drug therapy**
human
inhalational drug administration
intravenous drug administration
oral drug administration
short survey
topical drug administration
virus infection
Drug Descriptors:
*antivirus agent: PD, pharmacology
*antivirus agent: DV, drug development
*antivirus agent: CM, drug comparison

*zidovudine: PD, pharmacology
*zidovudine: CM, drug comparison
*zidovudine: DV, drug development
lamivudine: DV, drug development
2',3' dideoxyadenosine: DV, drug development
zalcitabine: DV, drug development
didanosine: DV, drug development
3' fluorothymidine: DV, drug development
a 75925: DV, drug development
aciclovir: DT, drug therapy
alpha interferon: DV, drug development
amantadine: DT, drug therapy
bay 946: DV, drug development
castanospermine: DV, drug development
dextran sulfate: DV, drug development
foscarnet: DV, drug development
ganciclovir: DT, drug therapy
hypericin: DV, drug development
idoxuridine: DT, drug therapy
saquinavir: DV, drug development
nevirapine: DV, drug development
ribavirin: DV, drug development
ribavirin: DT, drug therapy
rimantadine: DT, drug therapy
sr 41476: DV, drug development
trifluridine: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
unindexed drug
vidarabine: DT, drug therapy
unclassified drug

RN (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (2',3' dideoxyadenosine) 4097-22-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6**; (aciclovir) 59277-89-3; (amantadine) 665-66-7, 768-94-5; (castanospermine) 79831-76-8; (dextran sulfate) 9011-18-1, 9042-14-2; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (hypericin) 548-04-9; (idoxuridine) 54-42-2; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (rimantadine) 13392-28-4, 1501-84-4; (trifluridine) 70-00-8; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (vidarabine) 2006-02-2, 5536-17-4

CT Medical Descriptors:
***antiviral activity**
***human immunodeficiency virus infection: DT, drug therapy**
human
inhalational drug administration
intravenous drug administration
oral drug administration
short survey
topical drug administration
virus infection
Drug Descriptors:
*antivirus agent: PD, pharmacology
*antivirus agent: DV, drug development
*antivirus agent: CM, drug comparison
*zidovudine: PD, pharmacology
*zidovudine: CM, drug comparison
*zidovudine: DV, drug development
lamivudine: DV, drug development
2',3' dideoxyadenosine: DV, drug development
zalcitabine: DV, drug development
didanosine: DV, drug development
3' fluorothymidine: DV, drug development
a 75925: DV, drug development

aciclovir: DT, drug therapy
alpha interferon: DV, drug development
amantadine: DT, drug therapy
bay 946: DV, drug development
castanospermine: DV, drug development
dextran sulfate: DV, drug development
foscarnet: DV, drug development
ganciclovir: DT, drug therapy
hypericin: DV, drug development
idoxuridine: DT, drug therapy
saquinavir: DV, drug development
nevirapine: DV, drug development
ribavirin: DV, drug development
ribavirin: DT, drug therapy
rimantadine: DT, drug therapy
sr 41476: DV, drug development
trifluridine: DT, drug therapy
1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide: DV, drug development
unindexed drug
vidarabine: DT, drug therapy
unclassified drug

RN (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (2',3' dideoxyadenosine) 4097-22-7; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3' fluorothymidine) **25526-93-6** ; (aciclovir) 59277-89-3; (amantadine) 665-66-7, 768-94-5; (castanospermine) 79831-76-8; (dextran sulfate) 9011-18-1, 9042-14-2; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (hypericin) 548-04-9; (idoxuridine) 54-42-2; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (ribavirin) 36791-04-5; (rimantadine) 13392-28-4, 1501-84-4; (trifluridine) 70-00-8; (1 (naphthoxyacetyl)histidyl(5 amino 6 cyclohexyl 3,4 dihydroxy 2 isopropylhexanoyl)isoleucine n (2 pyridylmethyl)amide) 112190-24-6; (vidarabine) 2006-02-2, 5536-17-4

CN Retrovir; U 75875; Ro 31 8959; Bch 189; Nevirapine; A 75925; Sr 41476

L80 ANSWER 14 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93168878 EMBASE Full-text
DOCUMENT NUMBER: 1993168878
TITLE: Challenges in the therapy of **HIV** infection.
AUTHOR: Yarchoan R.; Mitsuya H.; Broder S.
CORPORATE SOURCE: Retroviral Diseases Section, National Cancer Institute, National Institutes of Health,Bethesda, MD 20892, United States
SOURCE: Trends in Pharmacological Sciences, (1993) Vol. 14, No. 5, pp. 196-202. .
ISSN: 0165-6147 CODEN: TPHSDY
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jul 1993
Last Updated on STN: 11 Jul 1993

ABSTRACT: Drugs that inhibit **human immunodeficiency** ***virus*** (**HIV**) replication have been shown to have clinical utility in patients with **HIV** infection. However, the immunological improvement induced by available anti-**HIV** therapies in patients with acquired immune deficiency syndrome (***AIDS***) is incomplete and transient. Explanations for this may

include immunological barriers to complete reconstitution, low therapeutic indices of the available drugs, and the development of viral resistance. An understanding of these processes, as discussed here by Robert Yarchoan and colleagues, may provide important leads for the development of improved therapy for **AIDS**.

CONTROLLED TERM: Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus**
*immune response
*virus infection: DT, drug therapy
drug development
drug resistance
human
human cell
human tissue
mouse
nonhuman
opportunistic infection: CO, complication
priority journal
review
thymus
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside: PD, pharmacology
*2',3' dideoxynucleoside: DT, drug therapy
*2',3' dideoxynucleoside: CM, drug comparison
*2',3' dideoxynucleoside: DV, drug development
*2',3' dideoxynucleoside: AN, drug analysis
*aspartic proteinase inhibitor: DV, drug development
*cytokine: EC, endogenous compound
*enzyme inhibitor: DV, drug development
***human immunodeficiency virus vaccine: DV, drug development**
*virus vaccine: DV, drug development
lamivudine: DV, drug development
stavudine: DV, drug development
zalcitabine: DV, drug development
zalcitabine: AN, drug analysis
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
didanosine: PD, pharmacology
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DT, drug therapy
didanosine: AN, drug analysis
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3' fluorothymidine: DV, drug development
alpha interferon: DT, drug therapy
antisense oligodeoxynucleotide: DV, drug development
complementary rna: DV, drug development
interleukin 6: EC, endogenous compound
nevirapine: DV, drug development
tumor necrosis factor alpha: EC, endogenous compound
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: AN, drug analysis
zidovudine: DT, drug therapy
zidovudine: DV, drug development

CAS REGISTRY NO.: (lamivudine) 134678-17-4, 134680-32-3; (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine)

69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' fluorothymidine) **25526-93-6**; (nevirapine) **129618-40-2**; (zidovudine) 30516-87-1

CHEMICAL NAME: L 697661

TI Challenges in the therapy of **HIV** infection.

SO Trends in Pharmacological Sciences, (1993) Vol. 14, No. 5, pp. 196-202. .
ISSN: 0165-6147 CODEN: TPHSDY

AB Drugs that inhibit **human immunodeficiency virus** (**HIV**) replication have been shown to have clinical utility in patients with **HIV** infection. However, the immunological improvement induced by available anti- **HIV** therapies in patients with acquired immune deficiency syndrome (**AIDS**) is incomplete and transient. Explanations for this may include immunological barriers to complete reconstitution, low therapeutic indices of the available drugs, and the development of viral resistance. An understanding of these processes, as discussed here by Robert Yarchoan and colleagues, may provide important leads for the development of improved therapy for **AIDS**.

CT Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus**
*immune response
*virus infection: DT, drug therapy
drug development
drug resistance
human
human cell
human tissue
mouse
nonhuman
opportunistic infection: CO, complication
priority journal
review
thymus
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside: PD, pharmacology
*2',3' dideoxynucleoside: DT, drug therapy
*2',3' dideoxynucleoside: CM, drug comparison
*2',3' dideoxynucleoside: DV, drug development
*2',3' dideoxynucleoside: AN, drug analysis
*aspartic proteinase inhibitor: DV, drug development
*cytokine: EC, endogenous compound
*enzyme inhibitor: DV, drug development
***human immunodeficiency virus vaccine: DV, drug development**
*virus vaccine: DV, drug development
lamivudine: DV, drug development
stavudine: DV, drug development
zalcitabine: DV, drug development
zalcitabine: AN, drug analysis
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
didanosine: PD, pharmacology
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DT, drug therapy
didanosine: AN, drug analysis
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3' fluorothymidine: DV, drug development
alpha interferon: DT, drug therapy
antisense oligodeoxynucleotide: DV, drug development
complementary rna: DV, drug development
interleukin 6: EC, endogenous compound
nevirapine: DV, drug development

tumor necrosis factor alpha: EC, endogenous compound
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: AN, drug analysis
zidovudine: DT, drug therapy
zidovudine: DV, drug development

RN (lamivudine) 134678-17-4, 134680-32-3; (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' fluorothymidine) **25526-93-6**; (nevirapine) **129618-40-2**; (zidovudine) 30516-87-1

CT Medical Descriptors:
*acquired immune deficiency syndrome: DT, drug therapy
***human immunodeficiency virus**
*immune response
*virus infection: DT, drug therapy
drug development
drug resistance
human
human cell
human tissue
mouse
nonhuman
opportunistic infection: CO, complication
priority journal
review
thymus
virus replication
Drug Descriptors:
*2',3' dideoxynucleoside: PD, pharmacology
*2',3' dideoxynucleoside: DT, drug therapy
*2',3' dideoxynucleoside: CM, drug comparison
*2',3' dideoxynucleoside: DV, drug development
*2',3' dideoxynucleoside: AN, drug analysis
*aspartic proteinase inhibitor: DV, drug development
*cytokine: EC, endogenous compound
*enzyme inhibitor: DV, drug development
***human immunodeficiency virus vaccine: DV, drug development**
*virus vaccine: DV, drug development
lamivudine: DV, drug development
stavudine: DV, drug development
zalcitabine: DV, drug development
zalcitabine: AN, drug analysis
zalcitabine: CM, drug comparison
zalcitabine: DT, drug therapy
zalcitabine: PD, pharmacology
didanosine: PD, pharmacology
didanosine: DV, drug development
didanosine: CM, drug comparison
didanosine: DT, drug therapy
didanosine: AN, drug analysis
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: DV, drug development
3' fluorothymidine: DV, drug development
alpha interferon: DT, drug therapy
antisense oligodeoxynucleotide: DV, drug development
complementary rna: DV, drug development
interleukin 6: EC, endogenous compound
nevirapine: DV, drug development
tumor necrosis factor alpha: EC, endogenous compound
zidovudine: PD, pharmacology
zidovudine: CM, drug comparison
zidovudine: AN, drug analysis
zidovudine: DT, drug therapy
zidovudine: DV, drug development

RN (lamivudine) 134678-17-4, 134680-32-3; (stavudine) 3056-17-5;

(zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' fluorothymidine) **25526-93-6**; (nevirapine) **129618-40-2**; (zidovudine) 30516-87-1
CN L 697661

L80 ANSWER 15 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 93098981 EMBASE Full-text
DOCUMENT NUMBER: 1993098981
TITLE: Future therapies in the management of critically ill **AIDS** patients.
AUTHOR: Torres R.A.; Franke-Ruta G.; Barr M.R.
CORPORATE SOURCE: AIDS Center, St Vincent's Hospital Medical Center, 153 West 12th Street,New York, NY 10012, United States
SOURCE: Critical Care Clinics, (1993) Vol. 9, No. 1, pp. 153-176. .
ISSN: 0749-0704 CODEN: CCCLEH
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 May 1993
Last Updated on STN: 16 May 1993

ABSTRACT: The advent of **antiviral** therapy for **HIV** infection and anti-infective agents for the treatment and prophylaxis of Pneumocystis carinii pneumonia has had a significant impact on the survival and quality of life of persons with **AIDS** and associated conditions. This article discusses zidovudine and other ***antiviral*** therapies for **HIV** infection, as well as some of the new treatment and prophylactic strategies to manage opportunistic infections which can ameliorate the course of advanced ***HIV*** infection in patients who may require critical care.

CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: TH, therapy**
abdominal pain: SI, side effect
acquired immune deficiency syndrome
antiviral activity
bacterial infection: DT, drug therapy
bacterial infection: CO, complication
blood toxicity: SI, side effect
bone marrow toxicity: SI, side effect
cryptococcus neoformans
drowsiness: SI, side effect
drug mixture
headache: SI, side effect
herpes virus
human
human cytomegalovirus
mycobacteriosis: DT, drug therapy
mycobacterium intracellulare avium
mycotic meningitis: DT, drug therapy
nausea: SI, side effect
neurotoxicity: SI, side effect
nonhuman
opportunistic infection: DT, drug therapy
oral drug administration

pancreatitis: SI, side effect
pneumocystis carinii pneumonia: CO, complication
pneumocystis carinii pneumonia: DT, drug therapy
review
survival rate
toxoplasma gondii
toxoplasmosis: DT, drug therapy
vomiting: SI, side effect

CONTROLLED TERM: Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: DO, drug dose
stavudine: DT, drug therapy
zalcitabine: CM, drug comparison
zalcitabine: CT, clinical trial
zalcitabine: DO, drug dose
zalcitabine: AE, adverse drug reaction
zalcitabine: DT, drug therapy
didanosine: CT, clinical trial
didanosine: DO, drug dose
didanosine: DT, drug therapy
didanosine: AE, adverse drug reaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5
ethyl 6 methyl 2(1h) pyridone: DT, drug therapy
3' azido 2',3' dideoxyuridine: DT, drug therapy
3' azido 2',3' dideoxyuridine: AE, adverse drug
reaction
3' azido 2',3' dideoxyuridine: CT, clinical trial
3' fluorothymidine: CT, clinical trial
3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: DO, drug dose
3' fluorothymidine: DT, drug therapy
amikacin: DT, drug therapy
amikacin: CB, drug combination
amikacin: CT, clinical trial
ciprofloxacin: CT, clinical trial
ciprofloxacin: DT, drug therapy
ciprofloxacin: CB, drug combination
corticosteroid: CB, drug combination
corticosteroid: DT, drug therapy
cotrimoxazole: CM, drug comparison
cotrimoxazole: CB, drug combination
cotrimoxazole: CT, clinical trial
cotrimoxazole: AE, adverse drug reaction
cotrimoxazole: DT, drug therapy
cytidine derivative: DO, drug dose
cytidine derivative: CT, clinical trial
cytidine derivative: DT, drug therapy
erythropoietin: DT, drug therapy
erythropoietin: DV, drug development
ethambutol: DT, drug therapy
ethambutol: CT, clinical trial
ethambutol: CB, drug combination
foscarnet: DT, drug therapy
foscarnet: CM, drug comparison
foscarnet: CT, clinical trial
ganciclovir: CM, drug comparison
ganciclovir: CT, clinical trial
ganciclovir: DT, drug therapy
granulocyte colony stimulating factor: DV, drug
development
granulocyte colony stimulating factor: DT, drug
therapy
granulocyte macrophage colony stimulating factor:

DT, drug therapy
granulocyte macrophage colony stimulating factor: DV, drug development
interferon: DV, drug development
interferon: DT, drug therapy
interferon: CT, clinical trial
interleukin 2: DT, drug therapy
interleukin 2: DV, drug development
methisoprinol: DT, drug therapy
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
nevirapine: DT, drug therapy
nucleoside analog: AE, adverse drug reaction
nucleoside analog: DT, drug therapy
nucleoside analog: DO, drug dose
nucleoside analog: CT, clinical trial
pentamidine: CM, drug comparison
pentamidine: DT, drug therapy
pentamidine: AE, adverse drug reaction
pentamidine: CT, clinical trial
pentoxifylline: DT, drug therapy
pentoxifylline: DV, drug development
proteinase inhibitor: DT, drug therapy
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: AE, adverse drug reaction
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: CT, clinical trial
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: DT, drug therapy
atevirdine mesylate: CT, clinical trial
atevirdine mesylate: DO, drug dose
atevirdine mesylate: DT, drug therapy
unindexed drug: CT, clinical trial
unindexed drug: DV, drug development
unindexed drug: DT, drug therapy
zidovudine: AE, adverse drug reaction
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy

CAS REGISTRY NO.: (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (amikacin) 37517-28-5, 39831-55-5; (ciprofloxacin) 85721-33-1; (cotrimoxazole) 8064-90-2; (erythropoietin) 11096-26-7; (ethambutol) 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (interleukin 2) 85898-30-2; (methisoprinol) 36703-88-5; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (pentamidine) 100-33-4; (pentoxifylline) 6493-05-6; (proteinase inhibitor) 37205-61-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (atevirdine mesylate) 138540-32-6; (zidovudine) 30516-87-1

TI Future therapies in the management of critically ill **AIDS** patients.

SO Critical Care Clinics, (1993) Vol. 9, No. 1, pp. 153-176. .
ISSN: 0749-0704 CODEN: CCCLEH

AB The advent of **antiviral** therapy for **HIV** infection and anti-infective agents for the treatment and prophylaxis of Pneumocystis carinii pneumonia has had a significant

impact on the survival and quality of life of persons with **AIDS** and associated conditions. This article discusses zidovudine and other **antiviral** therapies for **HIV** infection, as well as some of the new treatment and prophylactic strategies to manage opportunistic infections which can ameliorate the course of advanced **HIV** infection in patients who may require critical care.

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: TH, therapy**
abdominal pain: SI, side effect
acquired immune deficiency syndrome
antiviral activity
bacterial infection: DT, drug therapy
bacterial infection: CO, complication
blood toxicity: SI, side effect
bone marrow toxicity: SI, side effect
cryptococcus neoformans
drowsiness: SI, side effect
drug mixture
headache: SI, side effect
herpes virus
human
human cytomegalovirus
mycobacteriosis: DT, drug therapy
mycobacterium intracellulare avium
mycotic meningitis: DT, drug therapy
nausea: SI, side effect
neurotoxicity: SI, side effect
nonhuman
opportunistic infection: DT, drug therapy
oral drug administration
pancreatitis: SI, side effect
pneumocystis carinii pneumonia: CO, complication
pneumocystis carinii pneumonia: DT, drug therapy
review
survival rate
toxoplasma gondii
toxoplasmosis: DT, drug therapy
vomiting: SI, side effect

CT Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: DO, drug dose
stavudine: DT, drug therapy
zalcitabine: CM, drug comparison
zalcitabine: CT, clinical trial
zalcitabine: DO, drug dose
zalcitabine: AE, adverse drug reaction
zalcitabine: DT, drug therapy
didanosine: CT, clinical trial
didanosine: DO, drug dose
didanosine: DT, drug therapy
didanosine: AE, adverse drug reaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: DT, drug therapy
3' azido 2',3' dideoxyuridine: DT, drug therapy
3' azido 2',3' dideoxyuridine: AE, adverse drug reaction
3' azido 2',3' dideoxyuridine: CT, clinical trial
3' fluorothymidine: CT, clinical trial
3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: DO, drug dose
3' fluorothymidine: DT, drug therapy
amikacin: DT, drug therapy
amikacin: CB, drug combination

amikacin: CT, clinical trial
ciprofloxacin: CT, clinical trial
ciprofloxacin: DT, drug therapy
ciprofloxacin: CB, drug combination
corticosteroid: CB, drug combination
corticosteroid: DT, drug therapy
cotrimoxazole: CM, drug comparison
cotrimoxazole: CB, drug combination
cotrimoxazole: CT, clinical trial
cotrimoxazole: AE, adverse drug reaction
cotrimoxazole: DT, drug therapy
cytidine derivative: DO, drug dose
cytidine derivative: CT, clinical trial
cytidine derivative: DT, drug therapy
erythropoietin: DT, drug therapy
erythropoietin: DV, drug development
ethambutol: DT, drug therapy
ethambutol: CT, clinical trial
ethambutol: CB, drug combination
foscarnet: DT, drug therapy
foscarnet: CM, drug comparison
foscarnet: CT, clinical trial
ganciclovir: CM, drug comparison
ganciclovir: CT, clinical trial
ganciclovir: DT, drug therapy
granulocyte colony stimulating factor: DV, drug development
granulocyte colony stimulating factor: DT, drug therapy
granulocyte macrophage colony stimulating factor: DT, drug therapy
granulocyte macrophage colony stimulating factor: DV, drug development
interferon: DV, drug development
interferon: DT, drug therapy
interferon: CT, clinical trial
interleukin 2: DT, drug therapy
interleukin 2: DV, drug development
methisoprinol: DT, drug therapy
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
nevirapine: DT, drug therapy
nucleoside analog: AE, adverse drug reaction
nucleoside analog: DT, drug therapy
nucleoside analog: DO, drug dose
nucleoside analog: CT, clinical trial
pentamidine: CM, drug comparison
pentamidine: DT, drug therapy
pentamidine: AE, adverse drug reaction
pentamidine: CT, clinical trial
pentoxifylline: DT, drug therapy
pentoxifylline: DV, drug development
proteinase inhibitor: DT, drug therapy
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: AE, adverse drug reaction
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: CT, clinical trial
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: DT, drug therapy
atevirdine mesylate: CT, clinical trial
atevirdine mesylate: DO, drug dose
atevirdine mesylate: DT, drug therapy
unindexed drug: CT, clinical trial
unindexed drug: DV, drug development
unindexed drug: DT, drug therapy
zidovudine: AE, adverse drug reaction
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy
RN (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine)

69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (amikacin) 37517-28-5, 39831-55-5; (ciprofloxacin) 85721-33-1; (cotrimoxazole) 8064-90-2; (erythropoietin) 11096-26-7; (ethambutol) 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (interleukin 2) 85898-30-2; (methisoprinol) 36703-88-5; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (pentamidine) 100-33-4; (pentoxifylline) 6493-05-6; (proteinase inhibitor) 37205-61-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (atevirdine mesylate) 138540-32-6; (zidovudine) 30516-87-1

CT Medical Descriptors:

***human immunodeficiency virus infection: DT, drug therapy**
***human immunodeficiency virus infection: PC, prevention**
***human immunodeficiency virus infection: TH, therapy**
abdominal pain: SI, side effect
acquired immune deficiency syndrome
antiviral activity
bacterial infection: DT, drug therapy
bacterial infection: CO, complication
blood toxicity: SI, side effect
bone marrow toxicity: SI, side effect
cryptococcus neoformans
drowsiness: SI, side effect
drug mixture
headache: SI, side effect
herpes virus
human
human cytomegalovirus
mycobacteriosis: DT, drug therapy
mycobacterium intracellulare avium
mycotic meningitis: DT, drug therapy
nausea: SI, side effect
neurotoxicity: SI, side effect
nonhuman
opportunistic infection: DT, drug therapy
oral drug administration
pancreatitis: SI, side effect
pneumocystis carinii pneumonia: CO, complication
pneumocystis carinii pneumonia: DT, drug therapy
review
survival rate
toxoplasma gondii
toxoplasmosis: DT, drug therapy
vomiting: SI, side effect

CT Drug Descriptors:

*antivirus agent: AE, adverse drug reaction
*antivirus agent: DO, drug dose
*antivirus agent: DT, drug therapy
stavudine: AE, adverse drug reaction
stavudine: CT, clinical trial
stavudine: DO, drug dose
stavudine: DT, drug therapy
zalcitabine: CM, drug comparison
zalcitabine: CT, clinical trial
zalcitabine: DO, drug dose
zalcitabine: AE, adverse drug reaction
zalcitabine: DT, drug therapy
didanosine: CT, clinical trial
didanosine: DO, drug dose
didanosine: DT, drug therapy
didanosine: AE, adverse drug reaction
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone: DT, drug therapy

3' azido 2',3' dideoxyuridine: DT, drug therapy
3' azido 2',3' dideoxyuridine: AE, adverse drug reaction
3' azido 2',3' dideoxyuridine: CT, clinical trial
3' fluorothymidine: CT, clinical trial
3' fluorothymidine: AE, adverse drug reaction
3' fluorothymidine: DO, drug dose
3' fluorothymidine: DT, drug therapy
amikacin: DT, drug therapy
amikacin: CB, drug combination
amikacin: CT, clinical trial
ciprofloxacin: CT, clinical trial
ciprofloxacin: DT, drug therapy
ciprofloxacin: CB, drug combination
corticosteroid: CB, drug combination
corticosteroid: DT, drug therapy
cotrimoxazole: CM, drug comparison
cotrimoxazole: CB, drug combination
cotrimoxazole: CT, clinical trial
cotrimoxazole: AE, adverse drug reaction
cotrimoxazole: DT, drug therapy
cytidine derivative: DO, drug dose
cytidine derivative: CT, clinical trial
cytidine derivative: DT, drug therapy
erythropoietin: DT, drug therapy
erythropoietin: DV, drug development
ethambutol: DT, drug therapy
ethambutol: CT, clinical trial
ethambutol: CB, drug combination
foscarnet: DT, drug therapy
foscarnet: CM, drug comparison
foscarnet: CT, clinical trial
ganciclovir: CM, drug comparison
ganciclovir: CT, clinical trial
ganciclovir: DT, drug therapy
granulocyte colony stimulating factor: DV, drug development
granulocyte colony stimulating factor: DT, drug therapy
granulocyte macrophage colony stimulating factor: DT, drug therapy
granulocyte macrophage colony stimulating factor: DV, drug development
interferon: DV, drug development
interferon: DT, drug therapy
interferon: CT, clinical trial
interleukin 2: DT, drug therapy
interleukin 2: DV, drug development
methisoprinol: DT, drug therapy
saquinavir: DT, drug therapy
saquinavir: CT, clinical trial
nevirapine: DT, drug therapy
nucleoside analog: AE, adverse drug reaction
nucleoside analog: DT, drug therapy
nucleoside analog: DO, drug dose
nucleoside analog: CT, clinical trial
pentamidine: CM, drug comparison
pentamidine: DT, drug therapy
pentamidine: AE, adverse drug reaction
pentamidine: CT, clinical trial
pentoxifylline: DT, drug therapy
pentoxifylline: DV, drug development
proteinase inhibitor: DT, drug therapy
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: AE, adverse drug reaction
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: CT, clinical trial
[7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine: DT, drug therapy
atevirdine mesylate: CT, clinical trial
atevirdine mesylate: DO, drug dose

atevirdine mesylate: DT, drug therapy
unindexed drug: CT, clinical trial
unindexed drug: DV, drug development
unindexed drug: DT, drug therapy
zidovudine: AE, adverse drug reaction
zidovudine: CM, drug comparison
zidovudine: DO, drug dose
zidovudine: DT, drug therapy
RN (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (3' azido 2',3' dideoxyuridine) 84472-85-5; (3' fluorothymidine) **25526-93-6**; (amikacin) 37517-28-5, 39831-55-5; (ciprofloxacin) 85721-33-1; (cotrimoxazole) 8064-90-2; (erythropoietin) 11096-26-7; (ethambutol) 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; (foscarnet) 4428-95-9; (ganciclovir) 82410-32-0; (interleukin 2) 85898-30-2; (methisoprinol) 36703-88-5; (saquinavir) 127779-20-8; (nevirapine) **129618-40-2**; (pentamidine) 100-33-4; (pentoxifylline) 6493-05-6; (proteinase inhibitor) 37205-61-1; ([7 chloro 5 (1h pyrrol 2 yl) 3h benzo[e][1,4]diazepin 2 yl]methylamine) 139339-45-0; (atevirdine mesylate) 138540-32-6; (zidovudine) 30516-87-1

L80 ANSWER 16 OF 16 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 92257016 EMBASE Full-text
DOCUMENT NUMBER: 1992257016
TITLE: [Present and near future of anti-**HIV** therapy].
ANTI-**HIV**-BEHANDELING, HEDEN EN NABIJE TOEKOMST.
AUTHOR: Danner S.A.; Lange J.M.A.; Cooper D.A.
CORPORATE SOURCE: Academisch Medisch Centrum, Afdeling Interne Zaken, Meibergdreef 9,1105 AZ Amsterdam, Netherlands
SOURCE: Nederlands Tijdschrift voor Geneeskunde, (1992) Vol. 136, No. 31, pp. 1496-1500. .
ISSN: 0028-2162 CODEN: NETJAN
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: Dutch
ENTRY DATE: Entered STN: 20 Sep 1992
Last Updated on STN: 20 Sep 1992
CONTROLLED TERM: Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
drug efficacy
drug resistance
human
review
Drug Descriptors:
*stavudine: DT, drug therapy
*stavudine: PD, pharmacology
*zalcitabine: CB, drug combination
*zalcitabine: PD, pharmacology
*zalcitabine: DT, drug therapy
*didanosine: PD, pharmacology
*didanosine: DT, drug therapy
*didanosine: CB, drug combination
*antivirus agent: DV, drug development
*antivirus agent: DT, drug therapy
*antivirus agent: CM, drug comparison
*granulocyte colony stimulating factor: CB, drug

combination
*granulocyte colony stimulating factor: DT, drug therapy
*nucleoside: DT, drug therapy
*nucleoside: CB, drug combination
*zidovudine: CB, drug combination
*zidovudine: DO, drug dose
*zidovudine: DT, drug therapy
*zidovudine: PD, pharmacology
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
11 cyclopropyl 5,6 dihydro 4 methyl 11h pyrido[3,2 b]pyrido[3,2 e][1,4]diazepin 6 one
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: PD, pharmacology
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DT, drug therapy
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DV, drug development
3' fluorothymidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
adefovir: DV, drug development
adefovir: DT, drug therapy
adefovir: PD, pharmacology
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: DV, drug development
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: PD, pharmacology
alpha interferon: DT, drug therapy
alpha interferon: CB, drug combination
complementary rna: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: CB, drug combination
granulocyte macrophage colony stimulating factor: CB, drug combination
granulocyte macrophage colony stimulating factor: DT, drug therapy
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: DV, drug development
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: PD, pharmacology
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone
ribavirin: PD, pharmacology
7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one
tibo derivative: PD, pharmacology
tibo derivative: DV, drug development
nevirapine
unclassified drug

CAS REGISTRY NO.: (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (adefovir) 106941-25-7; (foscarnet) 4428-95-9; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (ribavirin) 36791-04-5; (7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one) 30195-30-3; (nevirapine) **129618-40-2**

CHEMICAL NAME: Bi rg 587; L 697661; Ro 5 3335

TI [Present and near future of anti-**HIV** therapy].
ANTI-**HIV**-BEHANDELING, HEDEN EN NABIJE TOEKOMST.

SO Nederlands Tijdschrift voor Geneeskunde, (1992) Vol. 136, No. 31, pp. 1496-1500. .
ISSN: 0028-2162 CODEN: NETJAN

CT Medical Descriptors:

***human immunodeficiency virus infection: DT, drug therapy**
drug efficacy
drug resistance
human
review
Drug Descriptors:
*stavudine: DT, drug therapy
*stavudine: PD, pharmacology
*zalcitabine: CB, drug combination
*zalcitabine: PD, pharmacology
*zalcitabine: DT, drug therapy
*didanosine: PD, pharmacology
*didanosine: DT, drug therapy
*didanosine: CB, drug combination
*antivirus agent: DV, drug development
*antivirus agent: DT, drug therapy
*antivirus agent: CM, drug comparison
*granulocyte colony stimulating factor: CB, drug combination
*granulocyte colony stimulating factor: DT, drug therapy
*nucleoside: DT, drug therapy
*nucleoside: CB, drug combination
*zidovudine: CB, drug combination
*zidovudine: DO, drug dose
*zidovudine: DT, drug therapy
*zidovudine: PD, pharmacology
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
11 cyclopropyl 5,6 dihydro 4 methyl 11h pyrido[3,2 b]pyrido[3,2 e][1,4]diazepin 6 one
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: PD, pharmacology
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DT, drug therapy
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DV, drug development
3' fluorothymidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
adefovir: DV, drug development
adefovir: DT, drug therapy
adefovir: PD, pharmacology
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: DV, drug development
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: PD, pharmacology
alpha interferon: DT, drug therapy
alpha interferon: CB, drug combination
complementary rna: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: CB, drug combination
granulocyte macrophage colony stimulating factor: CB, drug combination
granulocyte macrophage colony stimulating factor: DT, drug therapy
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: DV, drug development
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: PD, pharmacology
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone
ribavirin: PD, pharmacology
7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one
tibo derivative: PD, pharmacology
tibo derivative: DV, drug development
nevirapine
unclassified drug
RN (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine) 69655-05-6; (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (adefovir) 106941-25-7; (foscarnet) 4428-95-9; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone)

135525-78-9; (ribavirin) 36791-04-5; (7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one) 30195-30-3; (nevirapine) **129618-40-2**

CT Medical Descriptors:
***human immunodeficiency virus infection: DT, drug therapy**
drug efficacy
drug resistance
human
review
Drug Descriptors:
*stavudine: DT, drug therapy
*stavudine: PD, pharmacology
*zalcitabine: CB, drug combination
*zalcitabine: PD, pharmacology
*zalcitabine: DT, drug therapy
*didanosine: PD, pharmacology
*didanosine: DT, drug therapy
*didanosine: CB, drug combination
*antivirus agent: DV, drug development
*antivirus agent: DT, drug therapy
*antivirus agent: CM, drug comparison
*granulocyte colony stimulating factor: CB, drug combination
*granulocyte colony stimulating factor: DT, drug therapy
*nucleoside: DT, drug therapy
*nucleoside: CB, drug combination
*zidovudine: CB, drug combination
*zidovudine: DO, drug dose
*zidovudine: DT, drug therapy
*zidovudine: PD, pharmacology
lamivudine: PD, pharmacology
lamivudine: DT, drug therapy
11 cyclopropyl 5,6 dihydro 4 methyl 11h pyrido[3,2 b]pyrido[3,2 e][1,4]diazepin 6 one
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: PD, pharmacology
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DT, drug therapy
2,6 diamino 9 (3 fluoro 2 phosphonomethoxypropyl)purine: DV, drug development
3' fluorothymidine: PD, pharmacology
3' fluorothymidine: DT, drug therapy
adefovir: DV, drug development
adefovir: DT, drug therapy
adefovir: PD, pharmacology
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: DV, drug development
9 [3 fluoro 2 (phosphonomethoxy)propyl]adenine: PD, pharmacology
alpha interferon: DT, drug therapy
alpha interferon: CB, drug combination
complementary rna: PD, pharmacology
foscarnet: DT, drug therapy
foscarnet: CB, drug combination
granulocyte macrophage colony stimulating factor: CB, drug combination
granulocyte macrophage colony stimulating factor: DT, drug therapy
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: DV, drug development
imidazo[4,5,1 jk] 1,4 benzodiazepine derivative: PD, pharmacology
3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone
ribavirin: PD, pharmacology
7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one
tibo derivative: PD, pharmacology
tibo derivative: DV, drug development
nevirapine
unclassified drug

RN (stavudine) 3056-17-5; (zalcitabine) 7481-89-2; (didanosine)

69655-05-6; (zidovudine) 30516-87-1; (lamivudine) 134678-17-4, 134680-32-3; (3' fluorothymidine) **25526-93-6**; (adefovir) 106941-25-7; (foscarnet) 4428-95-9; (3 [(4,7 dichloro 2 benzoxazolylmethyl)amino] 5 ethyl 6 methyl 2(1h) pyridone) 135525-78-9; (ribavirin) 36791-04-5; (7 chloro 1,3 dihydro 5 (2 pyrrolyl) 2h 1,4 benzodiazepin 2 one) 30195-30-3; (nevirapine) **129618-40-2**

CN Bi rg 587; L 697661; Ro 5 3335

=> => d que stat l81

L2 8 SEA FILE=REGISTRY ABB=ON PLU=ON (129618-40-2/BI OR 144114-21-6/BI OR 220750-46-9/BI OR 25526-93-6/BI OR 52350-85-3/BI OR 770723-01-8/BI OR 9068-38-6/BI OR 92562-88-4/BI)

L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON 220750-46-9/RN

L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 92562-88-4/RN

L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON 25526-93-6/RN

L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L18 1733 SEA FILE=REGISTRY SSS FUL L16

L19 STR



Page 1-A

7

Page 1-B



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

STEREO ATTRIBUTES: NONE
L20 STR



Page 1-A



Page 2-A
VAR G1=7/17/27/36/51/65/72/84
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 87

```
STEREO ATTRIBUTES: NONE
L23         1142 SEA FILE=REGISTRY SUB=L18 SSS FUL L20
L24            2 SEA FILE=REGISTRY SUB=L18 SSS FUL L19
L25            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND L23
L27           54 SEA FILE=REGISTRY ABB=ON  PLU=ON  L23 AND ?CYTIDIN?/CNS

L28           36 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND 1/F NOT
                 (1-5/CL OR 1-5/BR OR 2-5/F)
L29            9 SEA FILE=REGISTRY ABB=ON  PLU=ON  L28 AND 3/N AND 3/O
L30            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 AND  C9H12FN3O3/M
                 F
L31            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L23 AND ?FLUOROADENOS
                 IN?/CNS
L32            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L31 AND C10 H12 F N5
                 O2/MF
L33            4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3
L34           49 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4
L35          292 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5
L36           39 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L30
L37           35 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L32
L38          338 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L39          315 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L25
L40            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L24
L41          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23
L42          835 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18
L43          697 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L44            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  129618-40-2/RN
L45         1501 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L44
L46           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L42
L47           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L43
L48           30 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 AND L38
L49           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L46 OR L47 OR L48)
L50               QUE  ABB=ON  PLU=ON  PHARMAC?/SC,SX
L51           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L49 AND L50
L52        57456 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ANTIVIRAL OR ANTI(A)VI
                 RAL
L53           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L52
L55        35862 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HUMAN IMMUNODEFICIENCY
                  VIRUS?/CT
L56           20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 AND L51
L57               QUE  ABB=ON  PLU=ON  HUMAN(W)IMMUNODEFICIEN?(W)VIRUS? O
                 R HIV OR AIDS
L58           32 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 AND L57
L59           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 OR L53 OR L56 OR
                 L58
L60           24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L59 AND 1907-2003/PY,P
                 RY
L61          145 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L38 OR L39 OR L40 OR
                 L41)
L62          133 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L63          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  L18
L64          147 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L61 OR L62 OR L63)
L65         1381 SEA FILE=BIOSIS ABB=ON  PLU=ON  L44
L66            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L65 AND L64
L67            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  L66 AND (L52 OR L57)
L68          274 SEA FILE=EMBASE ABB=ON  PLU=ON  L18
L69         5710 SEA FILE=EMBASE ABB=ON  PLU=ON  L44
L70           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L68 AND L69
L71           30 SEA FILE=EMBASE ABB=ON  PLU=ON  L70 AND (L52 OR L57)
L72           17 SEA FILE=EMBASE ABB=ON  PLU=ON  L71 AND 1907-2003/PY
L73          125 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR
                 L36 OR L37)
L74          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  L18
L75          155 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L73 OR L74)
```

```
L76        1183 SEA FILE=MEDLINE ABB=ON  PLU=ON  L44
L77           1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L75 AND L76
L78          43 DUP REM L60 L67 L72 L77 (1 DUPLICATE REMOVED)
L81           1 SEA FILE=MEDLINE L78


=> d l81 1 ibib abs hit hitind

L81  ANSWER 1 OF 1     MEDLINE on STN
ACCESSION NUMBER:    1999128283     MEDLINE  Full-text
DOCUMENT NUMBER:     PubMed ID: 9927728
TITLE:               Molecular basis for the enantioselectivity of HIV-1
                     reverse transcriptase: role of the 3'-hydroxyl
                     group of the L-(beta)-ribose in chiral
                     discrimination between D- and L-enantiomers of
                     deoxy- and dideoxy-nucleoside triphosphate analogs.
AUTHOR:              Maga G; Amacker M; Hubscher U; Gosselin G; Imbach J
                     L; Mathe C; Faraj A; Sommadossi J P; Spadari S
CORPORATE SOURCE:    Institute of Biochemical and Evolutionary Genetics,
                     National Research Council, I-27100, Pavia, Italy..
                     maga@igbe.pv.cnr.it
SOURCE:              Nucleic acids research, (1999 Feb 15) Vol. 27, No.
                     4, pp. 972-8.
                     Journal code: 0411011. ISSN: 0305-1048.
PUB. COUNTRY:        ENGLAND: United Kingdom
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals; AIDS
ENTRY MONTH:         199904
ENTRY DATE:          Entered STN: 26 Apr 1999
                     Last Updated on STN: 26 Apr 1999
                     Entered Medline: 13 Apr 1999
```

AB In order to identify the basis for the relaxed enantio-selectivity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and to evaluate possible cross-resistance patterns between L-nucleoside-, D-nucleoside- and non-nucleoside RT inhibitors, to be utilised in anti-HIV-1 combination therapy, we applied an in vitro approach based on the utilisation of six recom-binant HIV-1 RT mutants containing single amino acid substitutions known to confer Nevirapine resistance in treated patients. The mutants were compared on different RNA/DNA and DNA/DNA substrates to the wild type (wt) enzyme for their sensitivity towards inhibition by the D- and L-enantiomers of 2'-deoxy- and 2',3'-dideoxynucleoside triphosphate analogs. The results showed that the 3'-hydroxyl group of the L-(beta)-2'-deoxyribose moiety caused an unfavourable steric hindrance with critic residues in the HIV-1 RT active site and this steric barrier was increased by the Y181I mutation. Elimination of the 3'-hydroxyl group removed this hindrance and significantly improved binding to the HIV-1 RT wt and to the mutants. These results demonstrate the critical role of both the tyrosine 181 of RT and the 3'-position of the sugar ring, in chiral discrimination between D- and L-nucleoside triphosphates. Moreover, they provide an important rationale for the combination of D- and L-(beta)-dideoxynucleoside analogs with non-nucleoside RT inhibitors in anti-HIV chemotherapy, since non- nucleosideinhibitors resistance mutations did not confer cross-resistance to dideoxynucleoside analogs.

RN **129618-40-2 (Nevirapine)**; 2056-98-6 (2'-deoxycytidine 5'-triphosphate); 30516-87-1 (Zidovudine); 3352-57-6 (Hydroxyl Radical); 365-08-2 (thymidine 5'-triphosphate); **40026-13-9 (3'-fluorothymidine-5'-triphosphate)**; 50-69-1 (Ribose); 55520-40-6 (Tyrosine); 73-32-5 (Isoleucine); 9007-49-2 (DNA); 92586-35-1 (3'-azido-3'-deoxythymidine 5'-triphosphate)

CT *Anti-HIV Agents: ME, metabolism
Anti-HIV Agents: PD, pharmacology
Carbohydrates
Catalysis
DNA: BI, biosynthesis
Deoxycytosine Nucleotides: ME, metabolism
Deoxycytosine Nucleotides: PD, pharmacology
Deoxyribonucleosides: ME, metabolism
Deoxyribonucleosides: PD, pharmacology
*Dideoxynucleosides: ME, metabolism